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BENZOIC ACID ANALOGS AS INHIBITORS 
OF STAT PROTEIN 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
2 
261-269; Turkson, J.; et al. J. Biol. Chem. 2001, 276, 4S443-
4S4SS; Siddiquee, K.; et al. Proc. Natl. Acad. Sci. U.S.A. 
2007, 104, 7391-7396.; Turkson, J.; et al. Mo!. Cancer. Ther. 
2004, 3, 1S33-1S42; and Turkson, J.; et al. J. Biol. Chem. 
5 200S, 280, 32979-32988), 
This invention was made with government support under 
grant numbers CA106439 and CA12886S awarded by the 10 
National Cancer Institute of the National Institutes of Health. 
inhibition of STAT3 activation or disruption of dimeriza-
tion induces cancer cell death and tumor regression. How 
aberrant STAT3 is regulated for meeting the tumor-specific 
requirements in malignant cells remains undefined. There 
have been no studies into defining the molecular details of 
how malignant cells regulate aberrant STAT3 and how this 
The United States government has certain rights in the inven-
tion. 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
regulation changes upon STAT3 inhibition prior to the onset 
of phenotypic changes, although knowing these events will 
facilitate efforts in modulating aberrant STAT3 for managing 
15 human cancers. Small-molecule STAT3 inhibitors thus pro-
vide tools for probing the molecular dynamics of the cellular 
processing ofSTAT3 to understand STAT3's role as a signal-
ing intermediate and a molecular mediator of the events lead-This application is a National Phase Application of Inter-
national Application No. PCT/US2011/046340, filed Aug. 2, 
2011, which claims priority to U.S. Patent Application No. 20 
61/369,796, filedAug. 2, 2010, and U.S. Patent Application 
No. 61/422,046, filed Dec. 10, 2010, the entire contents of 
which are incorporated herein fully by this reference. 
ing to carcinogenesis and malignant progression. 
Stats signaling, like Stat3 signaling, is transiently activated 
in normal cells and is deactivated by a number of different 
cytosolic and nuclear regulators, including phosphatases, 
SOCS, PIAS, and proteasomal degradation. 1 Like Stat3, 
Stats has gained notoriety for its aberrant role in human 
BACKGROUND 
STAT proteins were originally discovered as latent cyto-
plasmic transcription factors that mediate cytokine and 
growth factor responses (Darnell, J. E., Jr. (1996) Recent 
Prag. Norm. Res. Sl, 391-403; Darnell. J. E. (200S) Nat. 
Med. 11, S9S-S96). Seven members of the family, STATl, 
STAT2, STAT3, STAT4, STATSa and STATSb, and STAT6, 
mediate several physiological effects including growth and 
differentiation, survival, development and inflammation. 
STATs are SH2 domain-containing proteins. Upon ligand 
binding to cytokine or growth factor receptors. STATs 
become phosphorylated on critical Tyr residue (Tyr70S for 
STAT3) by growth factor receptors, cytoplasmic Janus 
kinases (Jaks) or Src family kinases. Two phosphorylated and 
activated STAT monomers dimerize through reciprocal pTyr-
SH2 domain interactions, translocate to the nucleus, and bind 
to specific DNA-response elements of target genes, thereby 
inducing gene transcription (Darnell, J. E., Jr. (1996) Recent 
Prag. Norm. Res. Sl, 391-403; Darnell. J. E. (200S) Nat. 
Med. 11, S9S-S96). In contrast to normal STAT signaling, 
many human solid and hematological tumors harbor aberrant 
STAT3 activity (Turkson, J. Expert Opin. Ther. Targets 2004, 
8, 409-422; Darnell, J.E., Jr. (1996) Recent Prag. Norm. Res. 
Sl, 391-403; Darnell. J.E. (200S) Nat. Med. 11, S9S-S96). In 
contrast to normal STAT signaling, many human solid and 
hematological tumors harbor aberrant STAT3 activity (3 and 
Darnell. J. E. (200S) Nat. Med. 11, S9S-S96; Bowman, T., et 
25 cancers and tumorigenesis, having been found to be consti-
tutively activated in many cancers including those of the 
breast, liver, prostate, blood, skin, head and neck. (Muller, J., 
et al. ChemBioChem 2008, 9, 723-727). In cancer cells, Stats 
is routinely constitutively phosphorylated which leads to the 
30 aberrant expression of Stats target genes resulting in malig-
nant transformation. Cancer cells harbouring persistently 
activated Stats over express anti-apoptotic proteins, such as 
Bcl-xL, Myc and MCL-1, conferring significant resistance to 
natural apoptotic cues and administered chemotherapeutic 
35 agents. 8 Of particular interest, Stats has been identified as a 
key regulator in the development and progression of acute 
myelogenic (AML) and acute lymphoblastic leukemias 
(ALL; Gouilleux-Gruart, V., et al. Leukemia and Lymphoma 
1997, 28, 83-88; Gouilleux-Gruart, V., et al. Blood 1996, 87, 
40 1692-1697; Weber-Nordt, R. M., et al. Blood 1996, 88, 809-
816). Moreover, inhibitors of upstream Stats activators (such 
as JAK and FLT3) have been shown to exhibit promising 
anti-cancer properties (Pardanani, A., et al. Leukemia 2011, 
2S, 218-22S; Quintas-Cardama, A., et al. Nature Reviews 
45 Drug Discovery 2011, 10, 127-140). 
Despite advances in drug discovery directed to identifying 
inhibitors of STAT protein activity, there is still a scarcity of 
compounds that are both potent, efficacious, and selective 
activators of STAT3 and STATS and also effective in the 
50 treatment of cancer and other diseases associated with dys-
function in STAT3, STATS or both proteins, and diseases in 
which one or both of STAT3 and STATS is involved. These 
needs and other needs are satisfied by the present invention. al. (2000) Oncogene 19, 2474-2488; Buettner, et al. (2002) 
Clin. Cancer Res. 8, 94S-9S4; Yu, H. and Jove. R. (2004) Nat. 
Rev. Cancer 4, 97-lOS; Haura, E. B., et al. (200S) Nat. Clin. 55 
Pract. Oneal. 2, 31S-324).). 
SUMMARY 
Constitutive STAT3 activity mediates dysregulated growth 
and survival, angiogenesis, as well as suppresses the host's 
immune surveillance of the tumor, making constitutively-
active STAT3 a critical molecular mediator of carcinogenesis 60 
and tumor progression. 
Genetic and other molecular evidence reveals persistent 
Tyr phosphorylation of STAT3 is mediated by aberrant 
upstream Tyr kinases and shows cancer cell requirement for 
constitutively-active and dimerized STAT3 for tumor main- 65 
tenance and progression. Thus, in numerous proof-of-con-
cept studies (Turkson, J.; et al. Mo!. Cancer. Ther. 2004, 3, 
In accordance with the purpose(s) of the invention, as 
embodied and broadly described herein, the invention, in one 
aspect, relates to compounds useful useful as inhibitors of 
STAT. In a further aspect, the disclosed compounds and prod-
ucts of disclosed methods of making, or a pharmaceutically 
acceptable salt, hydrate, solvate, or polymorph thereof, are 
modulators of STAT activity, methods of making same, phar-
maceutical compositions comprising same, and methods of 
treating disorders associated with a STAT activity dysfunci-
ton using same. In a still further aspect, the present invention 
relates to compounds that bind to a STAT protein and nega-
US 8,846,707 B2 
3 
tively modulate STAT activity. The disclosed compounds can, 
in one aspect, exhibit subtype selectivity. In a further aspect, 
the disclosed compounds exhibit selectivity for the STAT3 
member of the STAT protein family. In a still further aspect, 
the disclosed compounds exhibit selectivity for the STATS 
member of the STAT protein family. 
Also disclosed are pharmaceutical compositions compris-
ing a therapeutically effective amount of a disclosed com-
pound and a pharmaceutically acceptable carrier. 
Disclosed are methods for the treatment of a disorder asso-
ciated with STAT activity dysfunction in a mammal compris-
ing the step of administering to the mammal a therapeutically 
effective amount of a disclosed compound, or a pharmaceu-
tically acceptable salt, hydrate, solvate, or polymorph 
thereof. 
Also disclosed are method for inhibition of STAT activity 
in a mammal comprising the step of administering to the 
mammal a therapeutically effective amount of least one dis-
closed compound, or a pharmaceutically acceptable salt, 
hydrate, solvate, or polymorph thereof. 
Also disclosed are methods for inhibiting STAT activity in 
at least one cell, comprising the step of contacting the at least 
one cell with an effective amount ofleast one disclosed com-
pound, or a pharmaceutically acceptable salt, hydrate, sol-
vate, or polymorph thereof. 
Also disclosed are uses of a disclosed compound, or a 
pharmaceutically acceptable salt, hydrate, solvate, or poly-
morph thereof. In a further aspect, the invention relates to 
pharmaceutical compositions comprising a pharmaceutically 
acceptable carrier and an effective amount of a disclosed 
compound, or a pharmaceutically acceptable salt, hydrate, 
solvate, or polymorph thereof. 
Also disclosed are kits comprising at least one disclosed 
compound, or a pharmaceutically acceptable salt, hydrate, 
solvate, or polymorph thereof, and one or more of: (a) at least 
one agent known to decrease STAT3 activity; (b) at least one 
agent known to increase STAT3 activity; ( c) at least one agent 
know to treat a disease of uncontrolled cellular proliferation; 
( d) at least one agent known to treat psoriasis; ( e) at least one 
agent known to treat pulmonary arterial hypertension; or (f) 
instructions for treating a disorder associated with STAT3 
dysfunction. 
Also disclosed are kits comprising at least one disclosed 
compound, or a pharmaceutically acceptable salt, hydrate, 
solvate, or polymorph thereof, and one or more of: (a) at least 
one agent known to decrease STATS activity; (b) at least one 
agent known to increase STATS activity; ( c) at least one agent 
know to treat a disease of uncontrolled cellular proliferation; 
or ( d) instructions for treating a disorder associated with a 
STATS dysfunction. 
Also disclosed are methods for manufacturing a medica-
ment comprising combining at least one disclosed compound 
or at least one disclosed product with a pharmaceutically 
acceptable carrier or diluent. In a further aspect, the invention 
relates to the use of a disclosed compound in the manufacture 
of a medicament for the treatment of a a disorder associated 
with STAT activity dysfunction. In a yet further aspect, the 
STAT activity dysfunction is a STAT3 activity dysfunction. In 
an even further aspect, the STAT activity dysfunction is a 
STATS activity dysfunction. In a still further aspect, the 
invention relates to the used of disclosed compound in the 
manufacture of a medicament for the treatment of a a disorder 
of uncontrolled cellular proliferation. 
While aspects of the present invention can be described and 
claimed in a particular statutory class, such as the system 
statutory class, this is for convenience only and one of skill in 
the art will understand that each aspect of the present inven-
4 
tion can be described and claimed in any statutory class. 
Unless otherwise expressly stated, it is in no way intended 
that any method or aspect set forth herein be construed as 
requiring that its steps be performed in a specific order. 
Accordingly, where a method claim does not specifically state 
in the claims or descriptions that the steps are to be limited to 
a specific order, it is no way intended that an order be inferred, 
in any respect. This holds for any possible non-express basis 
for interpretation, including matters of logic with respect to 
10 arrangement of steps or operational flow, plain meaning 
derived from grammatical organization or punctuation, or the 
number or type of aspects described in the specification. 
15 
BRIEF DESCRIPTION OF THE FIGURES 
The accompanying figures, which are incorporated in and 
constitute a part of this specification, illustrate several aspects 
and together with the description serve to explain the prin-
ciples of the invention. 
20 FIG. 1 shows in Panels A and B, various representative 
models for inhibition of Stat3 activation and transcriptional 
activity and the consequent effects on Stat3-dependent 
events, tumor processes, and tumorgrowth. 
FIG. 2 shows the structure of a representative compound 
25 (Panel A) and representative computational modeling of the 
indicated compound binding to the SH2 domain of STAT3 
(Panel B). The left side of Panel B shows a monomer Stat3 
with the solvent-accessible surface of the SH2 domain with 
hydrophilic residues and hydrophobic residues highlighted, 
30 and overlaid with the indicated compound. The right side of 
Panel B shows three solvent-accessible sub-pockets of the 
SH2 domain surface accessed by the indicated compound, 
with the pentafluorobenzene sulfonamide component pro-
jecting into the third sub-pocket composed of LysS91, 
35 GlyS94, Ile634, andArgS9S. 
FIG. 3 shows representative computational modeling of 
representative compounds. The figure shows the compound 
on the left side and the low energy GOLD20 docking confor-
mation of compound in the SH2 domain on the right side. The 
40 hydrophobic and hydrophilic are highlighted. 
FIG. 4 shows representative data for the indicated test 
compound. The data show modulation of Stat3 activation and 
intracellular distribution. (a and b) EMSA analysis of Stat3 
DNA-binding activity in nuclear extracts of equal total pro-
45 tein (a) pre-treated with 0-20 µM test compound, or (b) pre-
pared from the designated tumor cells treated with 0-20 µM 
test compound; and (c and d) immunoblotting analysis of 
cytosolic (Cyto ), nuclear (Nuc) or mitochondrial (Mita) frac-
tions of equal total protein prepared from MDA-MB-231 
50 cells untreated (0) or treated with test compound at (c) 10 µM 
for the indicated times, or ( d) 1 S µM for 24 hand probing for 
pY70SStat3, Stat3, pS727Stat3, histone deacetylase 1 
(HDACl) or ~-actin. Positions of Stat3:DNA complexes or 
proteins in gel are labeled; control lanes (0) represent nuclear 
55 extracts treated with O.OS% DMSO, or nuclear extracts, 
whole-cell lysates, or nuclear, cytosolic or membrane frac-
tions prepared from O.OS% DMSO-treated cells. Data are 
representative of3-4 independent determinations. 
FIG. 5 shows representative data for the effect ofrepresen-
60 tative disclosed compounds, wherein the compound ID cor-
responds to the compound ID given in Table 1, on STAT3: 
STAT3 binding as determined in an EMSA assay. 
FIG. 6 shows representative data for the effect ofrepresen-
tative disclosed compounds, wherein the compound ID cor-
65 responds to the compound ID given in Table 1, on STAT3-
regulated genes. The figure shows SDS-Page and Western 
blotting analysis of whole cell lysates prepared from MDA-
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468 human breast cancer and multiple myeloma JJN3 cells 
untreated (DMSO, control) or treated with 450 (15 µM), 45e 
(125 or 150 µM), 27h (100 or 125 µM), 27kg (150 µM) and 
27nh (150 µM) for 24 hrs and subjected to immunoblotting 
analysis for (A, B) pY705Stat3, Stat3; (C, D) c-Myc, Bcl-xD 5 
Mcl-1 and Survivin. Positions of protein in gel are shown. 
compound to the full-length Stat3; and (b) FP assay of the 
binding to the 5-carboxyfluorescein-Gp YLPQTV-NH2 pro be 
of a fixed amount of purified His-Stat3 (200 nM) in the 
presence ofincreasing concentrations oftest compound. Data 
are representative of 3 independent determinations. 
FIG. 12 shows representative data for the effect of a repre-
sentative disclosed compound on induction of STAT3 activa-
tion and transcriptional activity, other signaling proteins, and 
known STAT3-regulated genes. (Panels A and B) Immunob-
lotting analysis of (Panel A) nuclear (Nuc) or cytosolic (Cyto) 
lysates or (Panel B) whole-cell lysates of equal total protein 
FIG. 7 shows representative representative data for a dis-
closed compound wherein the compound ID corresponds to 
the compound ID given in Table 1, on apoptosis. The figure 
shows results for induction of apoptosis in JJN3 cell lines 10 
treated with vehicle control or indicated concentration of 450 
for 24 hr. % viable cells determined by exclusion of Amlexin 
V and PI staining. 
FIG. 8 shows representative data for the effect of the indi-
cated test compound on STAT3 mediated cellular function in 
the presence and absence of STAT3 siRNA. The effect of the 
test compound was assessed for on FAK, paxillin, E-Cad-
herin, KLF8, EPSTil, and NFIB induction and sICAM, 
G-CSF and MIF/GIF production. (Panels A and B) Immuno-
blotting analysis ofwhole-cell lysates prepared from MDA-
MB-231 cells treated with (a and b(i)) 0-15 µM test com-
pound for 24 h or (b(ii)) transfected with control (-)or Stat3 
siRNA (+)and probing for FAK, phospho-FAK, paxillin, 
phospho-paxillin, E-cadherin, KLF8, EPSTil, or ~-actin, ( c ), 
immunoblotting analysis of (c) whole-cell (WC), nuclear 
(Nuc), or cytosolic (Cyto) lysates of MDA-MB-231 cells 
treated with or without 15 µM test compound. Data are rep-
resentative of 3-4 independent determinations. Values, 
mean±S.D., n=9. *p<0.05 and **p-<0.01. 
FIG. 9 shows data for the effect of the indicated test com-
pound on STAT3 mediated cellular function in the presence 
and absence of STAT3 siRNA. The effect of the test com-
pound was assessed for on FAK, paxillin, E-Cadherin, KLF8, 
EPSTil, and NFI B induction and sICAM, G-CSF and MIF/ 
GIF production. (Panel A) immunecomplexes ofStat3 (upper 
panel) or RelA (lower panel) prepared from MDA-MB-231 
cells, or (Panel B) whole-cell lysates ofMDA-MB-231 cells 
transfected with control (-) or Stat3 siRNA ( +) and probing 
for p Y705Stat3, Stat3, pRelA, RelA, ~-actin or HDACl; and 
(Panel C) a plot of GCSF, sICAM, and MIF/GIF levels 
assayed in conditioned medium from cultures ofMDA-MB-
231 cells treated with or without 10 µM test compound for 48 
h. Positions of proteins in gel are shown. Data are represen-
tative of3-4 independent determinations. Values, mean±S.D., 
n=9. *p<0.05 and **p-<0.01. 
FIG. 10 shows representative data for the effect of a repre-
sentative disclosed compound in an in vivo model of cancer. 
The figure shows data for growth of human breast and non-
small cell lung tumor xenografts and the effects and the in 
vivo pharmacokinetic properties of the indicated test com-
pound. (a, b, and c) Mice bearing human breast (MDA-MB-
231) (a, b) or non-small cell lung (A549) (c) tumors were 
administered test compound via i.v., 1 or 3 mg/kg or vehicle 
(0.05% DMSO in PBS) (a and c) or oral gavage, 3 mg/kg or 
vehicle (0.05% DMSO) (b) every 2 or 3 days. Tumor sizes, 
measured every 2 or 3 days were converted to tumor volumes 
and plotted against days of treatment; and ( d and e) graphical 
representations of the analyses of test compound in ( d) 
plasma samples collected from mice 15-360 min post single 
dosing of3 mg/kg via i.v. (i) or oral gavage (ii), and ( e) tumor 
tissues extracted 15 min or 24 hours after the last dosing with 
3 mg/kg, i.v. or oral gavage. Values, mean±S.D., n=7-10. 
*p-<0.05, **p-<0.01, and ***p-<0.005. 
FIG. 11 shows representative data for a representative dis-
closed compound analyzed in surface plasmon resonance 
(SPR) and fluorescence polarization (FP) assays. (a) SPR 
analysis of the binding of increasing concentration of test 
prepared from the designated tumor cells treated with 0-20 
µM BP-1-102 for 24 hand probing for pY705Stat3, Stat3, 
15 
pS727Stat3, pShc, She, pJaks, Jak, pSrc, Src, pErkl/2, Erkl/ 
2, or ~-actin. Values are the mean and S.D of 3 independent 
determinations each performed in triplicate. *p-<0.05 and 
**p-<0.01. 
FIG. 13 shows representative data for the effect of a repre-
20 sentative disclosed compound on induction of STAT3 activa-
tion and transcriptional activity, other signaling proteins, and 
known STAT3-regulated genes. (Panel C) Cytosolic extracts 
of equal total protein were prepared from 24-h BP-1-102-
treated or untreated MDA-MB-231, Panc-1, or DU145 cells 
25 transiently-transfected with the Stat3-dependent 
(pLucTKS3, TKS3) or the Stat3-independent (pLucSRE, 
SRE) luciferase reporter and analyzed for luciferase activity 
using a luminometer; and (Panel D) immunoblotting analysis 
of whole-cell lysates prepared from tumor cell lines treated 
30 with or without 15 µM BP-1-102 for 24 h and probing for 
c-Myc, Cyclin Dl, Bcl-xL, Survivin, VEGF, and ~-actin. 
Positions of proteins in gel are labelled; control (0) or (-) 
represents cytosolic or whole-cell lysates prepared from 
0.05% DMSO-treated cells. Data are representative of 3-4 
35 independent determinations. Values are the mean and S.D of 
3 independent determinations each performed in triplicate. 
*p-<0.05 and **p-<0.01. 
FIG. 14 shows representative data for the effect of a repre-
sentative disclosed compound on suppression of viability, 
40 survival, migration and invasion in vitro of malignant cells. 
The figure shows results for the assessment of the indicated 
test compound in the indicated assays. (Panels A-C) Tumor 
cells harboring aberrantly-active Stat3 (MDA-MB-231, 
DU145, Panc-1, and NIH3T3/v-Src) or cells that do not 
45 (NIH3T3, NIH3T3/v-Ras, mouse thymus stromal epithelial 
cells, TE-71, Cisplatin-sensitive ovarian cancer cells, 
A2780s, or the Stat3-null mouse embryonic fibroblasts, 
Stat3-/-MEFs) and growing in culture were treated once 
(Panel A) with 0-30 µM BP-1-102 for 24 hand subjected to 
50 CyQuant cell viability assay or (Panel B) with or without 15 
µM BP-1-102 for 24-96 h cell and cell viability was assessed 
each day by trypan blue exclusion/phase contrast microscopy 
and plotted, or (Panel C) seeded as a single-cell culture were 
treated once with 0-15 µM BP-1-102 for 24 h and allowed to 
55 culture until large colonies were visible, which were stained 
with crystal violet and photographed (upper panel) or enu-
merated and plotted (lower panel); 
FIG. 15 shows representative data for the effect of a repre-
sentative disclosed compound on suppression of viability, 
60 survival, migration and invasion in vitro of malignant cells. 
The figure shows results for the effect of the indicated test 
compound in a wound-healing assay of cultures of malignant 
cells harboring aberrant Stat3 activity (MDA-MB-221, 
DU145, Panc-1, NIH3T3/v-Src) or not (NIHT3T/v-Ras) 
65 were wounded and treated once with 0-15 µM BP-1-102 for 
16 h and allowed to migrate into the denuded area, repre-
sented as photomicrographs. 
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FIG. 16 shows representative data for the effect of a repre-
sentative disclosed compound on suppression of viability, 
survival, migration and invasion in vitro of malignant cells. 
(Panel A) shows results for the effect of the indicated test 
compound in a wound-healing assay of cultures of malignant 5 
cells harboring aberrant Stat3 activity (MDA-MB-221, 
DU14S, Panc-1, NIH3T3/v-Src) or not (NIHT3T/v-Ras) 
were wounded and treated once with 0-1 S µM BP-1-102 for 
16 h and allowed to migrate into the denuded area, repre-
sented as plots of migrated cells; and (Panels e-g) Bio-Coat 10 
migration/invasion chamber assay and the effects of 16-h-
treatment with 0-lS µM BP-1-102 on the (b) invasion of 
MDA-MB-231 cells, represented as (i) photomicrographs or 
(ii) plots of number of invaded cells, or 
FIG. 17 shows representative data for the effect of a repre- 15 
sentative disclosed compound on suppression of viability, 
survival, migration and invasion in vitro of malignant cells. 
(Panel F) migration and (Panel G) invasion of doxycycline 
(Dox)-induced (I) or un-induced (U) MDA-MB-231-K8ikd 
cells, represented as (i) rates or (ii) relative inhibition derived 20 
from bars 2 versus 3 or S versus 6 in (i) and normalized to the 
U condition. Visualization was done at !Ox magnification by 
light microscopy. Data are representative of3-4 independent 
determinations. Values are the mean and S.D. of 4 indepen-
dent determinations each performed in triplicates. *p-<O.OS, 25 
**p-<0.01, and ***p-<O.OOS. 
8 
breast tumor xenografts or residual tumor (Tl-T4) tissues 
from mice treated with test compound (1 or 3 mg/kg) via i.v. 
or oral gavage were subjected to (a, upper panel) Stat3 DNA-
binding activity/EMSA analysis or (a, lower panel and b) 
immunoblotting analysis probing for pY70SStat3, Stat3, 
c-Myc, Cyclin Dl, Bcl-xL, Survivin, VEGF, pFAK, FAK, 
pPaxillin, Paxillin, E-cadherin, KLF8, EPSTil, pRelA, 
RelA, or ~-actin as indicated. 
FIG. 21 shows representative data for the effect of a repre-
sentative disclosed compound on STAT3 activity, Stat3-regu-
lated genes, cytokine production, and factors that promote 
tumor motility, migration and invasiveness, and weights of 
mice. Tumor lysates prepared from control (Con) human 
breast tumor xenografts or residual tumor (Tl-T4) tissues 
from mice treated with test compound (1 or 3 mg/kg) via i.v. 
or oral gavage were subjected to) immunoblotting analysis 
probing for pY70SStat3, Stat3, c-Myc, Cyclin Dl, Bcl-xL, 
Survivin, VEGF, pFAK, FAK, pPaxillin, Paxillin, E-cadherin, 
KLF8, EPSTil, pRelA, RelA, or ~-actin, as indicated (Panel 
A), or nalysis for sICAM, MIG/GIF Serpinel, and IL-IRA 
levels (Panel B). Positions of Stat3:DNA complexes or pro-
teins in gel are labeled; control (Con or 0) represents tumor 
tissue lysates prepared from O.OS% DMSO-treated mice. 
Data are representative of 3-4 independent determinations. 
Values are the mean and S.D. from replicates of7-10 tumor-
bearing mice in each group. 
FIG. 22 shows representative computational modeling of a 
representative compound. The figure shows the compound 
docked in the STATS SH2 domain (low energy GOLD45 -
30 docked) with hydrophobic and hydrophilic residues high-
lighted. 
FIG. 18 shows representative data for the effect of a repre-
sentative disclosed compound on the transcriptional induc-
tion of KLF8 and the activation and localization of NFKB/ 
p6SRelA. (Panel A) normalized luciferase reporter activity in 
cytosolic extracts of equal total protein prepared from normal 
NIH3T3 fibroblasts transiently co-transfected with the KLF8 
promoter-driven luciferase reporter, pLucKLF8, v-Src and 
~-galactosidase expression vectors and the effect of 16-h 
treatment with BP-1-102; (Panel B) immunofluorescence 
imaging/confocal microscopy of Stat3 colocalization with 
p6SRelA in MDA-MB-231 cells growing in culture and 
treated with or without S-2S µM BP-1-102 for 2 or 16 h, fixed 
and stained with (i) anti-Stat3 antibody and secondary Alex-
aFluorS46 antibody or (ii) anti-p6SRelA and secondary Alex-
aFluor488 antibody, or DAPI nuclear staining (blue). Images 
were captured using Leica TCS SPS laser-scanning confocal 
microscope; (Panel C) IKB immunecomplex prepared from 
MDA-MB-231 cells treated with or without IS µMBP-1-102 
and probing for RelA or IKB; and (Panel D) immunoblotting 
analysis ofwhole-cell lysates ofMDA-MB-231 cells stimu-
lated with G-CSF in the presence or absence ofBP-1-102 and 
probing for pY70SStat3, Stat3, pRelA, RelA, and ~-actin. 
Data are representative of 3 independent studies. Values are 
the mean and S.D. of 2 independent determinations each 50 
performed in triplicates. *p-<O.OS, and **p-<0.01. 
FIG. 23 shows representative data for inhibition of phos-
phorylation of STATS by representative disclosed com-
pounds. (Panel A) shows Western blot analysis of Stats inhi-
35 bition in KS62 cells treated with BP-1-107 (corresponding to 
compound ID 4Sb in Table I), BP-1-108 (corresponding to 
compound ID 4Sc in Table I), SF-1-087 and SF-1-088; B (the 
latter two compounds have corresponding compound IDs 
used in the experimental methods). (Panel B) shows dose-
40 dependant inhibition of pStatS by BP-1-108 (compound ID 
4Sc) as measured by phospho-flow cytometry. 
FIG. 24 shows representative data for inhibition of expres-
sion of STATS-regulated proteins by representative disclosed 
compounds. The figure shows SDS-PAGE and Western blot-
45 ting analysis of KS62 whole cell lysates treated with BP-1-
108, BP-1-7S (corresponding to compound ID 27na in Table 
I), BP-1-111 (corresponding to compound ID 4Sk in Table I) 
and SF-1-087 and probed with anti-cMyc, cyclin Dl, cyclin 
D2 and MCL-1 antibodies. 
FIG. 19 shows representative data for the effect of a repre-
sentative disclosed compound on STAT3 activity, Stat3-regu-
lated genes, cytokine production, and factors that promote 
tumor motility, migration and invasiveness, and weights of 55 
mice. (Panels A and B) Mice bearing human breast (MDA-
MB-231) and treated with BP-1-102 via (a) i.v., 1or3 mg/kg 
or vehicle (0.1 % DMSO in PBS) or (Panel B) oral gavage 1 or 
3 mg/kg or vehicle (0.1 % DMSO) every 1-3 days. Mice were 
weighed every day or every 2 days and weights plotted 60 
against days of treatment. Values are the mean and S.D. from 
replicates of7-10 tumor-bearing mice in each group. 
FIG. 20 shows representative data for the effect of a repre-
sentative disclosed compound on STAT3 activity, Stat3-regu-
lated genes, cytokine production, and factors that promote 65 
tumor motility, migration and invasiveness, and weights of 
mice. Tumor lysates prepared from control (Con) human 
FIG. 25 shows representative data for the effect of a repre-
sentative disclosed compound on binding of STATS fo c-myc 
and cyclin Dl promoter regions. The figure shows results for 
chromatin immunoprecipitation of C-MYC and Cyclin Dl 
promoters using STATS antibody in KS62 cells treated with 
40 µM BP-1-108 (corresponding to compound ID 4Sc in 
Table I). 
FIG. 26 shows representative data for the effect represen-
tative compounds on apoptosis in JJN3 cells. 
FIG. 27 shows representative data for the effect represen-
tative compounds on apoptosis in OPM2 cells. 
Additional advantages of the invention will be set forth in 
part in the description which follows, and in part will be 
obvious from the description, or can be learned by practice of 
the invention. The advantages of the invention will be realized 
and attained by means of the elements and combinations 
particularly pointed out in the appended claims. It is to be 
understood that both the foregoing general description and 
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the following detailed description are exemplary and 
explanatory only and are not restrictive of the invention, as 
claimed. 
DESCRIPTION 
The present invention can be understood more readily by 
reference to the following detailed description of the inven-
tion and the Examples included therein. 
Before the present compounds, compositions, articles, sys-
tems, devices, and/or methods are disclosed and described, it 
10 
References in the specification and concluding claims to 
parts by weight of a particular element or component in a 
composition denotes the weight relationship between the ele-
ment or component and any other elements or components in 
the composition or article for which a part by weight is 
expressed. Thus, in a compound containing 2 parts by weight 
of component X and S parts by weight component Y, X and Y 
are present at a weight ratio of 2:S, and are present in such 
ratio regardless of whether additional components are con-
10 tained in the compound. 
is to be understood that they are not limited to specific syn-
thetic methods unless otherwise specified, or to particular 
reagents unless otherwise specified, as such may, of course, 
vary. It is also to be understood that the terminology used 15 
herein is for the purpose of describing particular aspects only 
and is not intended to be limiting. Although any methods and 
materials similar or equivalent to those described herein can 
A weight percent (wt. % ) of a component, unless specifi-
cally stated to the contrary, is based on the total weight of the 
formulation or composition in which the component is 
included. 
As used herein, the terms "optional" or "optionally" means 
that the subsequently described event or circumstance can or 
can not occur, and that the description includes instances 
where said event or circumstance occurs and instances where 
it does not. be used in the practice or testing of the present invention, 
example methods and materials are now described. 
All publications mentioned herein are incorporated herein 
20 
by reference to disclose and describe the methods and/or 
materials in connection with which the publications are cited. 
The publications discussed herein are provided solely for 
their disclosure prior to the filing date of the present applica- 25 
tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica-
tion by virtue of prior invention. Further, the dates of publi-
cation provided herein can be different from the actual pub-
lication dates, which can require independent confirmation. 30 
As used herein, the term "STAT" and "signal transducer 
and activator of transcription" can be used interchangeably, 
and refer to a protein family comprising at least the following 
members: STAT!, 2, 3, 4, Sa, Sb, and 6. The STAT family of 
proteins are latent cytoplasmic transcription factors that 
mediate cellular responses to cytokines, growth factors, and 
other polypeptide ligands. 
As used herein, the terms "S TAT3 ," "signal transducer and 
activator of transcription 3 (acute-phase response)," and "sig-
nal transducer and activator of transcription 3" can be used 
interchangeably and refer to a a transcription factor encoded 
by a gene designated in human as the STAT3 gene, which has 
A. DEFINITIONS 
As used herein, nomenclature for compounds, including 
organic compounds, can be given using common names, 
IUPAC, IUBMB, or CAS recommendations for nomencla-
ture. When one or more stereochemical features are present, 
Cahn-Ingold-Prelog rules for stereochemistry can be 
employed to designate stereochemical priority, E/Z specifi-
cation, and the like. One of skill in the art can readily ascertain 
the structure of a compound if given a name, either by sys-
temic reduction of the compound structure using naming 
conventions, or by commercially available software, such as 
CHEMDRAW™ (Cambridgesoft Corporation, U.S.A.). 
As used in the specification and the appended claims, the 
singular forms "a," "an" and "the" include plural referents 
unless the context clearly dictates otherwise. Thus, for 
example, reference to "a functional group," "an alkyl," or "a 
residue" includes mixtures of two or more such functional 
groups, alkyls, or residues, and the like. 
Ranges can be expressed herein as from "about" one par-
ticular value, and/or to "about" another particular value. 
When such a range is expressed, a further aspect includes 
from the one particular value and/or to the other particular 
value. Similarly, when values are expressed as approxima-
tions, by use of the antecedent "about," it will be understood 
that the particular value forms a further aspect. It will be 
further understood that the endpoints of each of the ranges are 
significant both in relation to the other endpoint, and inde-
pendently of the other endpoint. It is also understood that 
there are a number of values disclosed herein, and that each 
value is also herein disclosed as "about" that particular value 
in addition to the value itself. For example, ifthe value "10" 
is disclosed, then "about 10" is also disclosed. It is also 
understood that each unit between two particular units are 
also disclosed. For example, if 10 and lS are disclosed, then 
11, 12, 13, and 14 are also disclosed. 
a human gene map locus of 17q21 and described by Entrez 
Gene cytogenetic band: 17 q21.31; Ensembl cytogenetic 
band: 17q21.2; and, HGNC cytogenetic band: 17q21. The 
35 term STAT3 refers to a human protein that has 770 amino 
acids and has a molecular weight of about 88,068 Da. The 
term is inclusive of splice isoforms or variants, and also 
inclusive of that protein referred to by such alternative des-
ignations as: APRF, MGC16063, Acute-phase response fac-
40 tor, DNA-binding protein APRF, HIES as used by those 
skilled in the art to that protein encoded by human gene 
STAT3. The term is also inclusive of the non-human ortholog 
or homo log thereof. 
As used herein, "STATS," refers to STATSA and/or 
45 STATSB. If specific reference to either STATSA or STATSB 
is required, the specific term will be used herein. 
As used herein, "STATSA" and "signal transducer and 
activator of transcription SA" can be used interchangeably 
and refer to a a transcription factor encoded by a gene desig-
50 nated in human as the STATS A gene, which has a human gene 
map locus described by Entrez Gene cytogenetic band: 
17qll.2; Ensembl cytogenetic band: 17q21.2; and, HGNC 
cytogenetic band: 17q 11.2. The term STATSA refers to a 
human protein that has 794 amino acids and has a molecular 
55 weight of about 90,647 Da. The term is inclusive of splice 
isoforms or variants, and also inclusive of that protein 
referred to by such alternative designations as MGF and 
STATS as used by those skilled in the art to that protein 
encoded by human gene STATSA. The term is also inclusive 
60 of the non-human ortholog or homolog thereof. 
As used herein, "STATSB" and "signal transducer and 
activator of transcription SB" can be used interchangeably 
and refer to a a transcription factor encoded by a gene desig-
nated in human as the STAT SB gene, which has a human gene 
65 map locus described by Entrez Gene cytogenetic band: 
17811.2; Ensembl cytogenetic band: 17q21.2; and, HGNC 
cytogenetic band: 17qll.2. The term STATSA refers to a 
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human protein that has 787 amino acids and has a molecular 
weight of about 89,866 Da. The term is inclusive of splice 
isoforms or variants, and also inclusive of that protein 
referred to by such alternative designations as transcription 
factor STAT5B as used by those skilled in the art to that 
protein encoded by human gene STAT5A. The term is also 
inclusive of the non-human ortholog or homolog thereof. 
As used herein, the term "subject" can be a vertebrate, such 
12 
disorder treatable by STAT3 inhibition" means having been 
subjected to a physical examination by a person of skill, for 
example, a physician, and found to have a condition that can 
be diagnosed or treated by a compound or composition that 
can inhibit or negatively modulate STAT3. As a further 
example, "diagnosed with a need for inhibition of STAT3" 
refers to having been subjected to a physical examination by 
a person of skill, for example, a physician, and found to have 
a condition characterized by a dysfunction in STAT3 activity. as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, 
the subject of the herein disclosed methods can be a human, 
non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, 
cat, guinea pig or rodent. The term does not denote a particu-
lar age or sex. Thus, adult and newborn subjects, as well as 
fetuses, whether male or female, are intended to be covered. 
In one aspect, the subject is a mammal. A patient refers to a 
subject afflicted with a disease or disorder. The term "patient" 
includes human and veterinary subjects. In some aspects of 
the disclosed methods, the subject has been diagnosed with a 
need for treatment of one or more oncological disorders or 
cancers prior to the administering step. In some aspects of the 
disclosed method, the subject has been diagnosed with a need 
for inhibition or negative modulation of STAT3 prior to the 
administering step. In some aspects of the disclosed method, 
the subject has been diagnosed with a need for treatment of 
one or more oncological disorders or cancers associated with 
STAT3 dysfunction prior to the administering step. 
10 Such a diagnosis can be in reference to a disorder, such as an 
oncological disorder or disease, cancer and/or disorder of 
uncontrolled cellular proliferation and the like, as discussed 
herein. For example, the term "diagnosed with a need for 
inhibition ofSTAT3 activity" refers to having been subjected 
15 to a physical examination by a person of skill, for example, a 
physician, and found to have a condition that can be diag-
nosedortreated by inhibition ofSTAT3 activity. For example, 
"diagnosed with a need for modulation of STAT3 activity" 
means having been subjected to a physical examination by a 
20 person of skill, for example, a physician, and found to have a 
condition that can be diagnosed or treated by modulation of 
STAT3 activity, e.g. negative modulation. For example, 
"diagnosed with a need for treatment of one or more disorder 
of uncontrolled cellular proliferation associated with STAT3 
25 dysfunction" means having been subjected to a physical 
examination by a person of skill, for example, a physician, 
and found to have one or disorders of uncontrolled cellular 
proliferation, e.g. a cancer, associated with STAT3 dysfunc-
tion. 
As used herein, the term "treatment" refers to the medical 
management of a patient with the intent to cure, ameliorate, 
stabilize, or prevent a disease, pathological condition, or dis-
order. This term includes active treatment, that is, treatment 30 
directed specifically toward the improvement of a disease, 
pathological condition, or disorder, and also includes causal 
treatment, that is, treatment directed toward removal of the 
cause of the associated disease, pathological condition, or 
disorder. In addition, this term includes palliative treatment, 35 
that is, treatment designed for the relief of symptoms rather 
than the curing of the disease, pathological condition, or 
disorder; preventative treatment, that is, treatment directed to 
minimizing or partially or completely inhibiting the develop-
ment of the associated disease, pathological condition, or 40 
disorder; and supportive treatment, that is, treatment 
employed to supplement another specific therapy directed 
toward the improvement of the associated disease, pathologi-
cal condition, or disorder. In various aspects, the term covers 
any treatment of a subject, including a marmnal (e.g., a 45 
human), and includes: (i) preventing the disease from occur-
ring in a subject that can be predisposed to the disease but has 
not yet been diagnosed as having it; (ii) inhibiting the disease, 
i.e., arresting its development; or (iii) relieving the disease, 
i.e., causing regression of the disease. In one aspect, the 50 
subject is a mammal such as a primate, and, in a further 
aspect, the subject is a human. The term "subject" also 
includes domesticated animals (e.g., cats, dogs, etc.), live-
stock (e.g., cattle, horses, pigs, sheep, goats, etc.), and labo-
ratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, 55 
etc.). 
As used herein, the term "prevent" or "preventing" refers to 
precluding, averting, obviating, forestalling, stopping, or hin-
dering something from happening, especially by advance 
action. It is understood that where reduce, inhibit or prevent 60 
are used herein, unless specifically indicated otherwise, the 
use of the other two words is also expressly disclosed. 
As used herein, the term "diagnosed" means having been 
subjected to a physical examination by a person of skill, for 
example, a physician, and found to have a condition that can 65 
be diagnosed or treated by the compounds, compositions, or 
methods disclosed herein. For example, "diagnosed with a 
As used herein, the phrase "identified to be in need of 
treatment for a disorder," or the like, refers to selection of a 
subject based upon need for treatment of the disorder. For 
example, a subject can be identified as having a need for 
treatment of a disorder (e.g., a disorder related to STAT3 
activity) based upon an earlier diagnosis by a person of skill 
and thereafter subjected to treatment for the disorder. It is 
contemplated that the identification can, in one aspect, be 
performed by a person different from the person making the 
diagnosis. It is also contemplated, in a further aspect, that the 
administration can be performed by one who subsequently 
performed the administration. 
As used herein, the terms "administering" and "adminis-
tration" refer to any method of providing a pharmaceutical 
preparation to a subject. Such methods are well known to 
those skilled in the art and include, but are not limited to, oral 
administration, transdermal administration, administration 
by inhalation, nasal administration, topical administration, 
intravaginal administration, ophthalmic administration, 
intraaural administration, intracerebral administration, rectal 
administration, sublingual administration, buccal administra-
tion, and parenteral administration, including injectable such 
as intravenous administration, intra-arterial administration, 
intramuscular administration, and subcutaneous administra-
tion. Administration can be continuous or intermittent. In 
various aspects, a preparation can be administered therapeu-
tically; that is, administered to treat an existing disease or 
condition. In further various aspects, a preparation can be 
administered prophylactically; that is, administered for pre-
vention of a disease or condition. 
The term "contacting" as used herein refers to bringing a 
disclosed compound and a cell, target STAT3 protein, or other 
biological entity together in such a manner that the compound 
can affect the activity of the target (e.g., spliceosome, cell, 
etc.), either directly; i.e., by interacting with the target itself, 
or indirectly; i.e., by interacting with another molecule, co-
factor, factor, or protein on which the activity of the target is 
dependent. 
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response can be determined using a cell-line derived from a 
human breast cancer, human pancreatic cancer, and human 
prostate cancer. For example, the response can be measured in 
a cell-line selected from MDA-MB-231, Panc-1, and 
DU-14S. Cell-lines transfected with specific genes can also 
be used. For example, the response can be measured in a 
cell-line transfected with v-Src. Alternatively, the cell-line 
transfected with v-Src is a permanent cell-line. In some cases, 
the STAT3 IC50 is the half-maximal concentration required to 
As used herein, the terms "effective amount" and "amount 
effective" refer to an amount that is sufficient to achieve the 
desired result or to have an effect on an undesired condition. 
For example, a "therapeutically effective amount" refers to an 
amount that is sufficient to achieve the desired therapeutic 
result or to have an effect on undesired symptoms, but is 
generally insufficient to cause adverse side affects. The spe-
cific therapeutically effective dose level for any particular 
patient will depend upon a variety of factors including the 
disorder being treated and the severity of the disorder; the 
specific composition employed; the age, body weight, gen-
eral health, sex and diet of the patient; the time of adminis-
tration; the route of administration; the rate of excretion of the 
specific compound employed; the duration of the treatment; 
drugs used in combination or coincidental with the specific 
compound employed and like factors well known in the medi-
cal arts. For example, it is well within the skill of the art to 
start doses of a compound at levels lower than those required 
10 inhibit STAT3 activity in a cell-free assay, e.g. an electro-
phoretic mobility shift assay ("EMSA"). Alternatively, the 
STAT3 IC50 is the half-maximal concentration required to 
inhibit cell-growth, cell viability or cell migration activity. 
As used herein, the term "STAT3 Kn" refers to the binding 
to achieve the desired therapeutic effect and to gradually 
increase the dosage until the desired effect is achieved. If 
desired, the effective daily dose can be divided into multiple 
doses for purposes of administration. Consequently, single 
dose compositions can contain such amounts or submultiples 
thereof to make up the daily dose. The dosage can be adjusted 
15 affinity of a compound or substance for the STAT3 deter-
mined in an in vitro assay. The Kn of a substance for a protein 
can be determined by a variety of methods known to one 
skilled in the art, e.g. equilibrium dialysis, analytical ultra-
centrifugation and surface plasmon resonance ("SPR") 
20 analysis. As typically used herein, STAT3 Kn is defined as the 
ratio of association and dissociation rate constants deter-
mined using SPR analysis using purified STAT3 protein. 
As used herein, the term "STAT3 K,'' refers to the inhibi-
tion constant for the displacement of a STAT3 SH2 probe 
25 from STAT3 protein. For example, the STAT3 SH2 can be 
fluorescence-labelled GpYLPQTV. As described herein, the 
fluorescence label is S-carboxyfluorescein, although other 
suitable fluorescence probes can be used as determined to be 
by the individual physician in the event of any contraindica-
tions. Dosage can vary, and can be administered in one or 
more dose administrations daily, for one or several days. 
Guidance can be found in the literature for appropriate dos-
ages for given classes of pharmaceutical products. In further 
various aspects, a preparation can be administered in a "pro- 30 
phylactically effective amount"; that is, an amount effective 
for prevention of a disease or condition. 
useful and convenient by one skilled in the art. 
As used herein, "STATS IC50" refers to the concentration 
of a substance (e.g., a compound or a drug) that is required for 
SO% inhibition of a STAT3 activity. In some contexts, an IC50 
can refer to the plasma concentration of a substance that is 
required for SO% inhibition of an in vivo activity or process as 
As used herein, "EC50,'' is intended to refer to the concen-
tration of a substance (e.g., a compound or a drug) that is 
required for SO% agonism or activation of a biological pro-
cess, or component of a process, including a protein, subunit, 
organelle, ribonucleoprotein, etc. In one aspect, an EC50 can 
refer to the concentration of a substance that is required for 
SO% agonism or activation in vivo, as further defined else-
where herein. In a further aspect, EC50 refers to the concen-
tration of agonist or activator that provokes a response half-
way between the baseline and maximum response. 
35 further defined elsewhere herein, e.g. tumor growth in an 
animal or human. In other contexts, STATS IC50 refers the 
half maximal (SO%) inhibitory concentration (IC) of a sub-
stance or compound required to inhibit a process or activity an 
in vitro context, e.g. a cell-free or cell-based assay. For 
40 example, the STATS IC50 can be in the context of the half-
maximal concentration required to inhibit cell growth. As 
discussed below, the response is measured in a cell-line with 
aberrant STATS activity. Alternatively, the response is mea-
sured in a cell-line with persistently active STATS. The 
As used herein, "IC50,'' is intended to refer to the concen-
tration of a substance (e.g., a compound or a drug) that is 
required for SO% inhibition of a biological process, or com-
ponent of a process, including a protein, subunit, organelle, 
ribonucleoprotein, etc. In some contexts, an IC50 can refer to 
the plasma concentration of a substance that is required for 
SO% inhibition in vivo, as further defined elsewhere herein. 
More commonly, IC50 refers to the half maximal (SO%) 50 
inhibitory concentration (IC) of a substance required to 
inhibit a process or activity in vitro. 
45 response can be determined using a cell-line derived from a 
human breast cancer, human pancreatic cancer, and human 
prostate cancer. For example, the response can be measured in 
a cell-line selected from KS62 and MV-4-11 cells. Cell-lines 
As used herein, "STAT3 IC50" refers to the concentration 
of a substance (e.g., a compound or a drug) that is required for 
SO% inhibition of a STAT3 activity. In some contexts, an IC50 55 
can refer to the plasma concentration of a substance that is 
required for SO% inhibition of an in vivo activity or process as 
further defined elsewhere herein, e.g. tumor growth in an 
animal or human. In other contexts; STAT3 IC50 refers the 
half maximal (SO%) inhibitory concentration (IC) of a sub- 60 
stance or compound required to inhibit a process or activity an 
in vitro context, e.g. a cell-free or cell-based assay. For 
example, the STAT3 IC50 can be in the context of the half-
maximal concentration required to inhibit cell growth. As 
discussed below, the response is measured in a cell-line with 65 
aberrant STAT3 activity. Alternatively, the response is mea-
sured in a cell-line with persistently active STAT3. The 
transfected with specific genes can also be used. In some 
cases, the STATS IC50 is the half-maximal concentration 
required to inhibit STATS activity in a cell-free assay, e.g. an 
electrophoretic mobility shift assay ("EMSA"). Alterna-
tively, the STATS IC50 is the half-maximal concentration 
required to inhibit cell-growth, cell viability or cell migration 
activity. 
As used herein, the term "STATS Kn" refers to the binding 
affinity of a compound or substance for the STATS deter-
mined in an in vitro assay. The Kn of a substance for a protein 
can be determined by a variety of methods known to one 
skilled in the art, e.g. equilibrium dialysis, analytical ultra-
centrifugation and surface plasmon resonance ("SPR") 
analysis. As typically used herein, STATS Kn is defined as the 
ratio of association and dissociation rate constants deter-
mined using SPR analysis using purified STATS protein. 
As used herein, the term "STATS K,'' refers to the inhibi-
tion constant for the displacement of a STAT3 SH2 probe 
from STATS protein. For example, the STATS SH2 can be 
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fluorescence-labelled GpYLPQTV. As described herein, the 
fluorescence label is 5-carboxyfluorescein, although other 
suitable fluorescence probes can be used as determined to be 
useful and convenient by one skilled in the art. 
The term "pharmaceutically acceptable" describes a mate-
rial that is not biologically or otherwise undesirable, i.e., 
without causing an unacceptable level of undesirable biologi-
cal effects or interacting in a deleterious manner. 
As used herein, the term "derivative" refers to a compound 
having a structure derived from the structure of a parent 
compound (e.g., a compound disclosed herein) and whose 
structure is sufficiently similar to those disclosed herein and 
based upon that similarity, would be expected by one skilled 
in the art to exhibit the same or similar activities and utilities 
16 
in the polyester, regardless of whether the residue is obtained 
by reacting sebacic acid or an ester thereof to obtain the 
polyester. 
As used herein, the term "substituted" is contemplated to 
include all permissible substituents of organic compounds. In 
a broad aspect, the permissible substituents include acyclic 
and cyclic, branched and unbranched, carbocyclic and het-
erocyclic, and aromatic and nonaromatic substituents of 
organic compounds. Illustrative substituents include, for 
10 example, those described below. The permissible substituents 
can be one or more and the same or different for appropriate 
organic compounds. For purposes of this disclosure, the het-
eroatoms, such as nitrogen, can have hydrogen substituents 
as the claimed compounds, or to induce, as a precursor, the 15 
same or similar activities and utilities as the claimed com-
and/or any permissible substituents of organic compounds 
described herein which satisfy the valences of the heteroat-
oms. This disclosure is not intended to be limited in any 
pounds. Exemplary derivatives include salts, esters, amides, 
salts of esters or amides, and N-oxides of a parent compound. 
As used herein, the term "pharmaceutically acceptable car-
rier" refers to sterile aqueous or nonaqueous solutions, dis-
persions, suspensions or emulsions, as well as sterile powders 
for reconstitution into sterile injectable solutions or disper-
sions just prior to use. Examples of suitable aqueous and 
nonaqueous carriers, diluents, solvents or vehicles include 
water, ethanol, polyols (such as glycerol, propylene glycol, 
polyethylene glycol and the like), carboxymethylcellulose 
and suitable mixtures thereof, vegetable oils (such as olive 
oil) and injectable organic esters such as ethyl oleate. Proper 
fluidity can be maintained, for example, by the use of coating 
materials such as lecithin, by the maintenance of the required 
particle size in the case of dispersions and by the use of 
surfactants. These compositions can also contain adjuvants 
such as preservatives, wetting agents, emulsifying agents and 
dispersing agents. Prevention of the action of microorgan-
isms can be ensured by the inclusion of various antibacterial 
and antifungal agents such as paraben, chlorobutanol, phenol, 
sorbic acid and the like. It can also be desirable to include 
isotonic agents such as sugars, sodium chloride and the like. 
Prolonged absorption of the injectable pharmaceutical form 
can be brought about by the inclusion of agents, such as 
aluminum monostearate and gelatin, which delay absorption. 
Injectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as poly-
lactide-polyglycolide, poly(orthoesters) and poly(anhy-
drides ). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro-
emulsions which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorporat-
ing sterilizing agents in the form of sterile solid compositions 
which can be dissolved or dispersed in sterile water or other 
sterile injectable media just prior to use. Suitable inert carriers 
can include sugars such as lactose. Desirably, at least 95% by 
weight of the particles of the active ingredient have an effec-
tive particle size in the range of0.01to10 micrometers. 
A residue of a chemical species, as used in the specification 
and concluding claims, refers to the moiety that is the result-
ing product of the chemical species in a particular reaction 
scheme or subsequent formulation or chemical product, 
regardless of whether the moiety is actually obtained from the 
chemical species. Thus, an ethylene glycol residue in a poly-
ester refers to one or more -OCH2CH20- units in the 
polyester, regardless of whether ethylene glycol was used to 
prepare the polyester. Similarly, a sebacic acid residue in a 
polyester refers to one or more -CO(CH2 ) 8CO- moieties 
manner by the permissible substituents of organic com-
pounds. Also, the terms "substitution" or "substituted with" 
include the implicit proviso that such substitution is in accor-
20 dance with permitted valence of the substituted atom and the 
substituent, and that the substitution results in a stable com-
pound, e.g., a compound that does not spontaneously undergo 
transformation such as by rearrangement, cyclization, elimi-
nation, etc. It is also contemplated that, in certain aspects, 
25 unless expressly indicated to the contrary, individual substitu-
ents can be further optionally substituted (i.e., further substi-
tuted or unsubstituted). 
In defining various terms, "A1 ," "A2 ," "A3 ," and "A4 " are 
used herein as generic symbols to represent various specific 
30 substituents. These symbols can be any substituent, not lim-
ited to those disclosed herein, and when they are defined to be 
certain substituents in one instance, they can, in another 
instance, be defined as some other substituents. 
The term "alkyl" as used herein is a branched or 
35 unbranched saturated hydrocarbon group of 1 to 24 carbon 
atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, 
isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, s-pentyl, neo-
pentyl, hexyl, heptyl, octyl, nonyl, decyl, dode cyl, tetradecyl, 
hexadecyl, eicosyl, tetracosyl, and the like. The alkyl group 
40 can be cyclic or acyclic. The alkyl group can be branched or 
unbranched. The alkyl group can also be substituted or unsub-
stituted. For example, the alkyl group can be substituted with 
one or more groups including, but not limited to, alkyl, 
cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, 
45 sulfo-oxo, orthiol, as described herein. A "lower alkyl" group 
is an alkyl group containing from one to six (e.g., from one to 
four) carbon atoms. 
Throughout the specification "alkyl" is generally used to 
refer to both unsubstituted alkyl groups and substituted alkyl 
50 groups; however, substituted alkyl groups are also specifi-
cally referred to herein by identifying the specific substitu-
ent(s) on the alkyl group. For example, the term "halogenated 
alkyl" or "haloalkyl" specifically refers to an alkyl group that 
is substituted with one or more halide, e.g., fluorine, chlorine, 
55 bromine, or iodine. The term "alkoxyalkyl" specifically refers 
to an alkyl group that is substituted with one or more alkoxy 
groups, as described below. The term "alkylamino" specifi-
cally refers to an alkyl group that is substituted with one or 
more amino groups, as described below, and the like. When 
60 "alkyl" is used in one instance and a specific term such as 
"alkylalcohol" is used in another, it is not meant to imply that 
the term "alkyl" does not also refer to specific terms such as 
"alkylalcohol" and the like. 
This practice is also used for other groups described herein. 
65 That is, while a term such as "cycloalkyl" refers to both 
unsubstituted and substituted cycloalkyl moieties, the substi-
tuted moieties can, in addition, be specifically identified 
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herein; for example, a particular substituted cycloalkyl can be 
referred to as, e.g., an "alkylcycloalkyl." Similarly, a substi-
tuted alkoxy can be specifically referred to as, e.g., a "halo-
genated alkoxy," a particular substituted alkenyl can be, e.g., 
an "alkenylalcohol," and the like. Again, the practice ofusing 
a general term, such as "cycloalkyl," and a specific term, such 
as "alkylcycloalkyl," is not meant to imply that the general 
term does not also include the specific term. 
The term "cycloalkyl" as used herein is a non-aromatic 
carbon-based ring composed of at least three carbon atoms. 10 
Examples of cycloalkyl groups include, but are not limited to, 
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, 
and the like. The term "heterocycloalkyl" is a type of 
cycloalkyl group as defined above, and is included within the 
meaning of the term "cycloalkyl," where at least one of the 15 
carbon atoms of the ring is replaced with a heteroatom such 
as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. 
The cycloalkyl group and heterocycloalkyl group can be sub-
stituted or unsubstituted. The cycloalkyl group and heterocy-
cloalkyl group can be substituted with one or more groups 20 
including, but not limited to, alkyl, cycloalkyl, alkoxy, amino, 
ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol as 
described herein. 
The term "polyalkylene group" as used herein is a group 
having two or more CH2 groups linked to one another. The 25 
polyalkylene group can be represented by the formula 
-(CH2)a-, where "a" is an integer of from 2 to 500: 
The terms "alkoxy" and "alkoxyl" as used herein to refer to 
an alkyl or cycloalkyl group bonded through an ether linkage; 
that is, an "alkoxy" group can be defined as -DA 1 where A 1 30 
is alkyl or cycloalkyl as defined above. "Alkoxy" also 
includes polymers of alkoxy groups as just described; that is, 
18 
The term "alkynyl" as used herein is a hydrocarbon group 
of 2 to 24 carbon atoms with a structural formula containing 
at least one carbon-carbon triple bond. The alkynyl group can 
be unsubstituted or substituted with one or more groups 
including, but not limited to, alkyl, cycloalkyl, alkoxy, alk-
enyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, 
aldehyde, amino, carboxylic acid, ester, ether, halide, 
hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as 
described herein. 
The term "cycloalkynyl" as used herein is a non-aromatic 
carbon-based ring composed of at least seven carbon atoms 
and containing at least one carbon-carbon triple bound. 
Examples of cycloalkynyl groups include, but are not limited 
to, cycloheptynyl, cyclooctynyl, cyclononynyl, and the like. 
The term "heterocycloalkynyl" is a type of cycloalkenyl 
group as defined above, and is included within the meaning of 
the term "cycloalkynyl," where at least one of the carbon 
atoms of the ring is replaced with a heteroatom such as, but 
not limited to, nitrogen, oxygen, sulfur, or phosphorus. The 
cycloalkynyl group andheterocycloalkynyl group can be sub-
stituted or unsubstituted. The cycloalkynyl group and hetero-
cycloalkynyl group can be substituted with one or more 
groups including, but not limited to, alkyl, cycloalkyl, alkoxy, 
alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, 
aldehyde, amino, carboxylic acid, ester, ether, halide, 
hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol as 
described herein. 
The term "aryl" as used herein is a group that contains any 
carbon-based aromatic group including, but not limited to, 
benzene, naphthalene, phenyl, biphenyl, phenoxybenzene, 
and the like. The term "aryl" also includes "heteroaryl," 
which is defined as a group that contains an aromatic group 
that has at least one heteroatom incorporated within the ring 
of the aromatic group. Examples ofheteroatoms include, but 
an alkoxy can be a polyether such as -DA 1-0A 2 or -OA 1 -
(0A 2)a -OA3, where "a" is anintegeroffrom 1to200 andA1 , 
A2 , andA3 are alkyl and/or cycloalkyl groups. 35 are not limited to, nitrogen, oxygen, sulfur, and phosphorus. 
Likewise, the term "non-heteroaryl," which is also included 
in the term "aryl," defines a group that contains an aromatic 
group that does not contain a heteroatom. The aryl group can 
be substituted or unsubstituted. The aryl group can be substi-
The term "alkenyl" as used herein is a hydrocarbon group 
of from 2 to 24 carbon atoms with a structural formula con-
taining at least one carbon-carbon double bond. Asymmetric 
structures such as (A1A2 )C=C(A3A4 ) are intended to 
include both the E and Z isomers. This can be presumed in 
structural formulae herein wherein an asymmetric alkene is 
present, or it can be explicitly indicated by the bond symbol 
C=C. The alkenyl group can be substituted with one or more 
groups including, but not limited to, alkyl, cycloalkyl, alkoxy, 
alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, 
aldehyde, amino, carboxylic acid, ester, ether, halide, 
hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as 
described herein. 
40 tuted with one or more groups including, but not limited to, 
alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, 
cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic 
acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, 
sulfo-oxo, or thiol as described herein. The term "biaryl" is a 
45 specific type of aryl group and is included in the definition of 
"aryl." Biaryl refers to two aryl groups that are bound together 
via a fused ring structure, as in naphthalene, or are attached 
via one or more carbon-carbon bonds, as in biphenyl. 
The term "aldehyde" as used herein is represented by the 
50 formula --C(O)H. Throughout this specification "C(O)" is a 
short hand notation for a carbonyl group, i.e., C=O. 
The term "cycloalkenyl" as used herein is a non-aromatic 
carbon-based ring composed of at least three carbon atoms 
and containing at least one carbon-carbon double bound, i.e., 
C=C. Examples of cycloalkenyl groups include, but are not 
limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, 
cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norborne-
nyl, and the like. The term "heterocycloalkenyl" is a type of 
cycloalkenyl group as defined above, and is included within 
the meaning of the term "cycloalkenyl," where at least one of 
the carbon atoms of the ring is replaced with a heteroatom 
such as, but not limited to, nitrogen, oxygen, sulfur, or phos-
phorus. The cycloalkenyl group and heterocycloalkenyl 60 
group can be substituted or unsubstituted. The cycloalkenyl 
group and heterocycloalkenyl group can be substituted with 
one or more groups including, but not limited to, alkyl, 
cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalky-
nyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, 65 
ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or 
thiol as described herein. 
The terms "amine" or "amino" as used herein are repre-
sented by the formula -NA1A2 , where A1 and A2 can be, 
independently, hydrogen or alkyl, cycloalkyl, alkenyl, 
55 cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group 
as described herein. 
The term "alkylamino" as used herein is represented by the 
formula-NH(-alkyl) where alkyl is a described herein. Rep-
resentative examples include, but are not limited to, methy-
lamino group, ethylamino group, propylamino group, isopro-
pylamino group, butylamino group, isobutylamino group, 
(sec-butyl)amino group, (tert-butyl)amino group, penty-
lamino group, isopentylamino group, (tert-pentyl)amino 
group, hexylamino group, and the like. 
The term "dialkylamino" as used herein is represented by 
the formula -N(-alkyl)2 where alkyl is a described herein. 
Representative examples include, but are not limited to, dim-
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ethylamino group, diethylamino group, dipropylamino 
group, diisopropylamino group, dibutylamino group, 
diisobutylamino group, di(sec-butyl)amino group, di(tert-bu-
tyl)amino group, dipentylamino group, diisopentylamino 
group, di(tert-pentyl)amino group, dihexylamino group, 5 
N-ethyl-N-methylamino group, N-methyl-N-propylamino 
group, N-ethyl-N-propylamino group and the like. 
The term "carboxylic acid" as used herein is represented by 
the formula --C(O)OH. 
The term "ester" as used herein is represented by the for- 10 
mula -OC(O)A1 or --C(O)OA1, where A1 can be alkyl, 
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, 
ary 1, or heteroary 1 group as described herein. The term "poly-
ester" as used herein is represented by the formula -(A 10(0) 
15 
C-A2-C(O)O)a- or -(A10(0)C-A2-0C(O))a-, where A1 
and A2 can be, independently, an alkyl, cycloalkyl, alkenyl, 
cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group 
described herein and "a" is an integer from 1 to 500. "Poly-
ester" is as the term used to describe a group that is produced 20 
by the reaction between a compound having at least two 
carboxylic acid groups with a compound having at least two 
hydroxyl groups. 
The term "ether" as used herein is represented by the for-
mula A10A2, where A1 and A2 can be, independently, an 25 
alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalky-
nyl, aryl, or heteroaryl group described herein. The term 
"polyether" as used herein is represented by the formula 
-(A10-A20)a-, whereA1 andA2 can be, independently, an 
alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalky- 30 
nyl, aryl, or heteroaryl group described herein and "a" is an 
integer of from 1 to 500. Examples of polyether groups 
include polyethylene oxide, polypropylene oxide, and poly-
butylene oxide. 
The term "halide" as used herein refers to the halogens 35 
fluorine, chlorine, bromine, and iodine. 
The term "heterocycle," as used herein refers to single and 
multi-cyclic aromatic or non-aromatic ring systems in which 
20 




OA 1, where A 1 can be hydrogen or an alkyl, cycloalkyl, alk-
enyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl 
group as described herein. Throughout this specification 
"S(O)" is a short hand notation for S=O. The term "sulfonyl" 
is used herein to refer to the sulfo-oxo group represented by 
the formula -S(0)2A
1
, where A1 can be hydrogen or an 
alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalky-
nyl, aryl, or heteroaryl group as described herein. The term 
"sulfone" as used herein is represented by the formula A1S 
(0)2A
2, where A1 and A2 can be, independently, an alkyl, 
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, 
aryl, or heteroaryl group as described herein. The term "sul-
foxide" as used herein is represented by the formula A 1S(O) 
A2, where A1 and A2 can be, independently, an alkyl, 
cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, 
aryl, or heteroaryl group as described herein. 
The term "thiol" as used herein is represented by the for-
mula -SH. 
"R 1," "R 2 ," "R3 ,""Rn," where n is an integer, as used herein 
can, independently, possess one or more of the groups listed 
above. For example, ifR1 is a straight chain alkyl group, one 
of the hydrogen atoms of the alkyl group can optionally be 
substituted with a hydroxyl group, an alkoxy group, an alkyl 
group, a halide, and the like. Depending upon the groups that 
are selected, a first group can be incorporated within second 
group or, alternatively, the first group can be pendant (i.e., 
attached) to the second group. For example, with the phrase 
"an alkyl group comprising an amino group," the amino 
group can be incorporated within the backbone of the alkyl 
group. Alternatively, the amino group can be attached to the 
backbone of the alkyl group. The nature of the group(s) that is 
(are) selected will determine if the first group is embedded or 
attached to the second group. 
As described herein, compounds of the invention may con-
tain "optionally substituted" moieties. In general, the term 
"substituted," whether preceded by the term "optionally" or 
not, means that one or more hydrogens of the designated 
moiety are replaced with a suitable substituent. Unless oth-
erwise indicated, an "optionally substituted" group may have 
a suitable substituent at each substitutable position of the 
group, and when more than one position in any given struc-
ture may be substituted with more than one substituent 
selected from a specified group, the substituent may be either 
the same or different at every position. Combinations of sub-
stituents envisioned by this invention are preferably those that 
result in the formation of stable or chemically feasible com-
pounds. In is also contemplated that, in certain aspects, unless 
at least one of the ring members is other than carbon. Hetero-
cycle includes azetidine, dioxane, furan, imidazole, isothiaz- 40 
ole, isoxazole, morpholine, oxazole, oxazole, including, 1,2, 
3-oxadiazole, 1,2,5-oxadiazole and 1,3,4-oxadiazole, 
piperazine, piperidine, pyrazine, pyrazole, pyridazine, pyri-
dine, pyrimidine, pyrrole, pyrrolidine, tetrahydrofuran, tet-
rahydropyran, tetrazine, including 1,2,4,5-tetrazine, tetra- 45 
zole, including 1,2,3,4-tetrazole and 1,2,4,5-tetrazole, 
thiadiazole, including, 1,2,3-thiadiazole, 1,2,5-thiadiazole, 
and 1,3,4-thiadiazole, thiazole, thiophene, triazine, including 
1,3,5-triazine and 1,2,4-triazine, triazole, including, 1,2,3-
triazole, 1,3,4-triazole, and the like. 50 expressly indicated to the contrary, individual substituents 
can be further optionally substituted (i.e., further substituted 
or unsubstituted). 
The term "hydroxyl" as used herein is represented by the 
formula -OH. 
The term "ketone" as used herein is represented by the 
formulaA1C(O)A2, whereA1 andA2 can be, independently, 
an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, 
cycloalkynyl, aryl, or heteroaryl group as described herein. 
The term "azide" as used herein is represented by the 
formula -N 3. 
The term "nitro" as used herein is represented by the for-
mula -N02. 
The term "nitrile" as used herein is represented by the 
formula --CN. 
The term "silyl" as used herein is represented by the for-
mula -SiA1A2 A3, where A1, A2, and A3 can be, indepen-
dently, hydrogen or an alkyl, cycloalkyl, alkoxy, alkenyl, 
cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group 
as described herein. 
The term "stable," as used herein, refers to compounds that 
are not substantially altered when subjected to conditions to 
55 allow for their production, detection, and, in certain aspects, 
their recovery, purification, and use for one or more of the 
purposes disclosed herein. 
Suitable monovalent substituents on a substitutable carbon 















; -(CH2)0_4Ph, which may be substituted 
with R 0 ; -(CH2)0_40(CH2)0_1 Ph which may be substituted 
with R0 ; -CH=CHPh, which may be substituted with R0 ; 
65 -(CH2)0_40(CH2)0_1 -pyridyl which may be substituted with 
R0 ; -N02; -CN; -N3; -(CH2)0_4N(R0 )2; -(CH2)0_4N 
(R 0 )C(O)R 0 ; -N(R0 )C(S)R 0 ; -(CH2)0_4N(R 0 )C(O)NR 0 2; 
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-N(R 0 C(S)NR 0 2; -(CH2)0_4N(R 0 )C(O)OR 0 ; -N(R 0 )N 
(R 0 )C(O)R 0 ; -N(R 0 )N(R 0 C(O)NR 0 2; -N(R 
0 )N(R 0 )C(O) 
OR0 ; -(CH2)0_4C(O)R0 ; --C(S)R0 ; -(CH2)0_4C(O)OR0 ; 
-( CH2)0_4 C(O )SR 
0
; -( CH2)0_4 C(O )OSiR 
0 
3 ; -( CH2)0_4 
OC(O)R0 ; -OC(O)(CH2)0_4SR-, SC(S)SR
0
; -(CH2)0_4 5 
SC(O)R 0 ; -(CH2)0_4C(O)NR 0 2; --C(S)NR 0 2; --C(S)SR 0 ; 
-SC(S)SR0 , -(CH2)0_40C(O)NR0 2; -C(O)N(OR0 )R0 ; 
-C(O)C(O)R 0 ; --C(O)CH2C(O)R 0 ; -C(NOR 0 )R 0 ; 
-(CH2)0_4SSR 0 ; -(CH2)0_4S(0)2R 0 ; -(CH2)0_4S(0)2 
OR0 ; -(CH2)0_40S(0)2R0 ; -S(0)2NR0 2; -(CH2)0_4S(O) 10 
R 0 ; -N(R 0 )S(0)2NR 0 2; -N(R 0 )S(0)2R 0 ; -N(OR 0 )R 0 ; 
-C(NH)NR 0 2;-P(0)2R 
0 ;-P(O)R 0 2;-0P(O)R 
0 
2;---0P 
(O)(OR0 ) 2; SiR
0
3 ; -(C1 -4 straight or branched)alkylene) 
O-N(R0 ) 2; or -(C1 -4 straight or branched alkylene)C(O) 
O-N(R0 ) 2, wherein each R
0 may be substituted as defined 15 
below and is independently hydrogen, cl-6 aliphatic, 
-CH2Ph, ---O(CH2)0_1Ph, --CH2-(5-6 membered het-
eroaryl ring), or a 5-6-membered saturated, partially unsatur-
ated, or aryl ring having 0-4 heteroatoms independently 
selected from nitrogen, oxygen, or sulfur, or, notwithstanding 20 
the definition above, two independent occurrences of R0 , 
taken together with their intervening atom(s), form a 3-12-
membered saturated, partially unsaturated, or aryl mono- or 
bicyclic ring having 0-4 heteroatoms independently selected 
from nitrogen, oxygen, or sulfur, which may be substituted as 25 
defined below. 
22 
partially unsaturated, or aryl ring having 0-4 heteroatoms 
independently selected from nitrogen, oxygen, or sulfur. 
Suitable substituents on a substitutable nitrogen of an 
"optionally substituted" group include -Rt, -NRt2, 
--C(O)Rt, --C(O)ORt, --C(O)C(O)Rt, -C(O)CH2C(O) 
Rt, -S(0)2Rt, -S(0)2NRt 2, -C(S)NRt 2, -C(NH)NRt 2, 
or -N(Rt)S(0)2Rt; wherein each Rt is independently 
hydrogen, C1 _6 aliphatic which may be substituted as defined 
below, unsubstituted ---OPh, or an unsubstituted 5-6-mem-
bered saturated, partially unsaturated, or aryl ring having 0-4 
heteroatoms independently selected from nitrogen, oxygen, 
or sulfur, or, notwithstanding the definition above, two inde-
pendent occurrences ofR t, taken together with their interven-
ing atom( s) form an unsubstituted 3-12-membered saturated, 
partially unsaturated, or aryl mono- or bicyclic ring having 
0-4 heteroatoms independently selected from nitrogen, oxy-
gen, or sulfur. 
Suitable substituents on the aliphatic group of Rt are inde-
pendently halogen, -R•, -(haloR•), -OH, -OR•, 
---O(haloR•), --CN, -C(O)OH, -C(O)OR•, -NH2, 
-NHR•, or -N02, wherein each R• is unsubstituted or 
where preceded by "halo" is substituted only with one or 
more halogens, and is independently C1 _4 aliphatic, 
--CH2Ph, ---O(CH2)0_1Ph, or a 5-6-membered saturated, 
partially unsaturated, or aryl ring having 0-4 heteroatoms 
independently selected from nitrogen, oxygen, or sulfur. 
The term "leaving group" refers to an atom (or a group of 
atoms) with electron withdrawing ability that can be dis-
Suitable monovalent substituents on R 0 (or the ring formed 
by taking two independent occurrences of R 0 together with 
their intervening atoms), are independently halogen, 
-(CH2)0_2R•, -(haloR•), -(CH2)0_20H, -(CH2)0_20R•, 
-(CH2)0_2CH(OR•)2; ---O(haloR•), -CN, -N3 , 
-(CH2)0-2CCO)R•, -(CH2)0-2CCO)OH, -(CH2)0-2CCO) 
oR•, -(CH2)0_2sR•, -(CH2)0_2SH, -(CH2)0_2NH2, 
-(CH2)0_2NHR•, -(CH2)0_2NR•2, -N02, -SiR•3 , 
30 placed as a stable species, taking with it the bonding elec-
trons. Examples of suitable leaving groups include halides-
including chloro, bromo, and iodo-and pseudohalides 
(sulfonate esters)-including triflate, mesylate, tosylate, and 
-OSiR•3 , --C(O)SR•. -(C1 -4 straight or branched alky-
lene)C(O)OR•, or -SsR• wherein each R• is unsubsti-
tuted or where preceded by "halo" is substituted only with one 
or more halogens, and is independently selected from C1_4 
aliphatic, -CH2Ph, -O(CH2)0_1 Ph, or a 5-6-membered 
saturated, partially unsaturated, or aryl ring having 0-4 het-
eroatoms independently selected from nitrogen, oxygen, or 
sulfur. Suitable divalent substituents on a saturated carbon 
atom of R 0 include =0 and =S. 
Suitable divalent substituents on a saturated carbon atom of 
35 
brosylate. It is also contemplated that a hydroxyl moiety can 
be converted into a leaving group via Mitsunobu reaction. 
The terms "hydrolysable group" and "hydrolysable moi-
ety" refer to a functional group capable of undergoing 
hydrolysis, e.g., under basic or acidic conditions. Examples 
40 of hydrolysable residues include, without limitation, acid 
halides, activated carboxylic acids, and various protecting 
groups known in the art (see, for example, "Protective Groups 
in Organic Synthesis," T. W. Greene, P. G. M. Wuts, Wiley-
Interscience, 1999). 
an "optionally substituted" group include the following: =0, 45 
=S, NNR*2, =NNHC(O)R*, NNHC(O)OR*, 
=NNHS(0)2R*, NR*, =NOR*, ---O(C(R*2))2_30-, or 
-S(C(R * 2) )2_3S-, wherein each independent occurrence of 
The term "organic residue" defines a carbon containing 
residue, i.e., a residue comprising at least one carbon atom, 
and includes but is not limited to the carbon-containing 
groups, residues, or radicals defined hereinabove. Organic 
residues can contain various heteroatoms, or be bonded to R * is selected from hydrogen, C1 _6 aliphatic which may be 
substituted as defined below, or an unsubstituted 5-6-mem-
bered saturated, partially unsaturated, or aryl ring having 0-4 
heteroatoms independently selected from nitrogen, oxygen, 
or sulfur. Suitable divalent substituents that are bound to 
vicinal substitutable carbons of an "optionally substituted" 
group include: -O(CR * 2)2_30-, wherein each independent 
occurrence of R * is selected from hydrogen, C1 aliphatic 
which may be substituted as defined below, or an unsubsti-
tuted 5-6-membered saturated, partially unsaturated, or aryl 
ring having 0-4 heteroatoms independently selected from 
nitrogen, oxygen, or sulfur. 
Suitable substituents on the aliphatic group of R * include 
halogen, -R•, -(haloR•), -OH, -OR•, ---O(haloR•), 
-CN, --C(O)OH, --C(O)OR•, -NH2, -NHR•, 
-NR • 2, or -N02, wherein each R • is unsubstituted or 
where preceded by "halo" is substituted only with one or 
more halogens, and is independently C1 _4 aliphatic, 
-CH2Ph, ---O(CH2)0_1Ph, or a 5-6-membered saturated, 
50 another molecule through a heteroatom, including oxygen, 
nitrogen, sulfur, phosphorus, or the like. Examples of organic 
residues include but are not limited alkyl or substituted alkyls, 
alkoxy or substituted alkoxy, mono or di-substituted amino, 
55 
amide groups, etc. Organic residues can preferably comprise 
1 to 18 carbon atoms, 1 to 15, carbon atoms, 1 to 12 carbon 
atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 
carbon atoms. In a further aspect, an organic residue can 
comprise 2 to 18 carbon atoms, 2 to 15, carbon atoms, 2 to 12 
60 carbon atoms, 2 to 8 carbon atoms, 2 to 4 carbon atoms, or 2 
to 4 carbon atoms. 
A very close synonym of the term "residue" is the term 
"radical," which as used in the specification and concluding 
claims, refers to a fragment, group, or substructure of a mol-
65 ecule described herein, regardless of how the molecule is 
prepared. For example, a 2,4-thiazolidinedione radical in a 
particular compound has the structure 
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isomers, as well as other conformational isomers. Unless 
stated to the contrary, the invention includes all such possible 
isomers, as well as mixtures of such isomers. 
Unless stated to the contrary, a formula with chemical 
bonds shown only as solid lines and not as wedges or dashed 
lines contemplates each possible isomer, e.g., each enanti-
omer and diastereomer, and a mixture of isomers, such as a 
racemic or scalemic mixture. Compounds described herein 
can contain one or more asymmetric centers and, thus, poten-regardless of whether thiazolidinedione is used to prepare the 
compound. In some embodiments the radical (for example an 
alkyl) can be further modified (i.e., substituted alkyl) by hav-
ing bonded thereto one or more "substituent radicals." The 
number of atoms in a given radical is not critical to the present 
invention unless it is indicated to the contrary elsewhere 
herein. 
10 tially give rise to diastereomers and optical isomers. Unless 
stated to the contrary, the present invention includes all such 
possible diastereomers as well as their racemic mixtures, their 
substantially pure resolved enantiomers, all possible geomet-
ric isomers, and pharmaceutically acceptable salts thereof. 
"Organic radicals," as the term is defined and used herein, 
contain one or more carbon atoms. An organic radical can 
have, for example, 1-26 carbon atoms, 1-18 carbon atoms, 
1-12 carbon atoms, 1-8 carbon atoms, 1-6 carbon atoms, or 
1-4 carbon atoms. In a further aspect, an organic radical can 
have 2-26 carbon atoms, 2-18 carbon atoms, 2-12 carbon 
atoms, 2-8 carbon atoms, 2-6 carbon atoms, or 2-4 carbon 
atoms. Organic radicals often have hydrogen bound to at least 
some of the carbon atoms of the organic radical. One 
example, of an organic radical that comprises no inorganic 
atoms is a 5, 6, 7, 8-tetrahydro-2-naphthyl radical. In some 
embodiments, an organic radical can contain 1-10 inorganic 
heteroatoms bound thereto or therein, including halogens, 
oxygen, sulfur, nitrogen, phosphorus, and the like. Examples 
15 Mixtures of stereoisomers, as well as isolated specific stere-
oisomers, are also included. During the course of the syn-
thetic procedures used to prepare such compounds, or in 
using racemization or epimerization procedures known to 
those skilled in the art, the products of such procedures can be 
20 a mixture of stereoisomers. 
Many organic compounds exist in optically active forms 
having the ability to rotate the plane of plane-polarized light. 
In describing an optically active compound, the prefixes D 
and Lor Rand Sare used to denote the absolute configuration 
25 of the molecule about its chiral center(s). The prefixes d and 
1 or ( +) and (-) are employed to designate the sign of rotation 
of plane-polarized light by the compound, with (-)or mean-
ing that the compound is levorotatory. A compound prefixed 
with (+)or dis dextrorotatory. For a given chemical structure, 
30 these compounds, called stereoisomers, are identical except 
that they are non-superimposable mirror images of one 
another. A specific stereoisomer can also be referred to as an 
enantiomer, and a mixture of such isomers is often called an 
enantiomeric mixture. A 50:50 mixture of enantiomers is 
of organic radicals include but are not limited to an alkyl, 
substituted alkyl, cycloalkyl, substituted cycloalkyl, mono-
substituted amino, di-substituted amino, acyloxy, cyano, car-
boxy, carboalkoxy, alkylcarboxamide, substituted alkylcar-
boxamide, dialkylcarboxamide, substituted 
dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, 
thiohaloalkyl, alkoxy, substituted alkoxy, haloalkyl, 
haloalkoxy, aryl, substituted aryl, heteroaryl, heterocyclic, or 
substituted heterocyclic radicals, wherein the terms are 
defined elsewhere herein. A few non-limiting examples of 
organic radicals that include heteroatoms include alkoxy 40 
radicals, trifluoromethoxy radicals, acetoxy radicals, dim-
ethylamino radicals and the like. 
35 referred to as a racemic mixture. Many of the compounds 
described herein can have one or more chiral centers and 
therefore can exist in different enantiomeric forms. If desired, 
a chiral carbon can be designated with an asterisk(*). When 
bonds to the chiral carbon are depicted as straight lines in the 
disclosed formulas, it is understood that both the (R) and (S) 
configurations of the chiral carbon, and hence both enanti-
omers and mixtures thereof, are embraced within the formula. 
As is used in the art, when it is desired to specify the absolute 
configuration about a chiral carbon, one of the bonds to the 
chiral carbon can be depicted as a wedge (bonds to atoms 
above the plane) and the other can be depicted as a series or 
wedge of short parallel lines is (bonds to atoms below the 
plane). The Cahn-Inglod-Prelog system can be used to assign 
the (R) or (S) configuration to a chiral carbon. 
Compounds described herein comprise atoms in both their 
natural isotopic abundance and in non-natural abundance. 
The disclosed compounds can be isotopically-labelled or iso-
topically-substituted compounds identical to those described, 
but for the fact that one or more atoms are replaced by an atom 
having an atomic mass or mass number different from the 
atomic mass or mass number typically found in nature. 
Examples of isotopes that can be incorporated into com-
pounds of the invention include isotopes ofhydrogen, carbon, 
nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 
2H, 3H, 13C, i4c, isN, 180, 170, 3ss, isp and 36Cl, respec-
tively. Compounds further comprise prodrugs thereof, and 
pharmaceutically acceptable salts of said compounds or of 
said prodrugs which contain the aforementioned isotopes 
and/or other isotopes of other atoms are within the scope of 
"Inorganic radicals," as the term is defined and used herein, 
contain no carbon atoms and therefore comprise only atoms 
other than carbon. Inorganic radicals comprise bonded com- 45 
binations of atoms selected from hydrogen, nitrogen, oxygen, 
silicon, phosphorus, sulfur, selenium, and halogens such as 
fluorine, chlorine, bromine, and iodine, which can be present 
individually or bonded together in their chemically stable 
combinations. Inorganic radicals have 10 or fewer, or prefer- 50 
ably one to six or one to four inorganic atoms as listed above 
bonded together. Examples of inorganic radicals include, but 
not limited to, amino, hydroxy, halogens, nitro, thiol, sulfate, 
phosphate, and like commonly known inorganic radicals. The 
inorganic radicals do not have bonded therein the metallic 55 
elements of the periodic table (such as the alkali metals, 
alkaline earth metals, transition metals, lanthanide metals, or 
actinide metals), although such metal ions can sometimes 
serve as a pharmaceutically acceptable cation for anionic 
inorganic radicals such as a sulfate, phosphate, or like anionic 60 
inorganic radical. Inorganic radicals do not comprise metal-
loids elements such as boron, aluminum, gallium, germa-
nium, arsenic, tin, lead, or tellurium, or the noble gas ele-
ments, unless otherwise specifically indicated elsewhere 
herein. 65 this invention. Certain isotopically-labelled compounds of 
the present invention, for example those into which radioac-
tive isotopes such as 3H and 14C are incorporated, are useful 
Compounds described herein can contain one or more 
double bonds and, thus, potentially give rise to cis/trans (E/Z) 
US 8,846,707 B2 
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in drug and/or substrate tissue distribution assays. Tritiated, 
i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly 
preferred for their ease of preparation and detectability. Fur-
ther, substitution with heavier isotopes such as deuterium, 
i.e., 2 H, can afford certain therapeutic advantages resulting 
from greater metabolic stability, for example increased in 
vivo half-life or reduced dosage requirements and, hence, 
may be preferred in some circumstances. Isotopically 
labelled compounds of the present invention and prodrugs 
thereof can generally be prepared by carrying out the proce- 10 
<lures below, by substituting a readily available isotopically 
labelled reagent for a non-isotopically labelled reagent. 
The compounds described in the invention can be present 
26 
for particular modifications to be metastable. Unless stated to 
the contrary, the invention includes all such possible poly-
morphic forms. 
In some aspects, a structure of a compound can be repre-
sented by a formula: 
15 
which is understood to be equivalent to a formula: as a solvate. In some cases, the solvent used to prepare the 
solvate is an aqueous solution, and the solvate is then often 
referred to as a hydrate. The compounds can be present as a 
hydrate, which can be obtained, for example, by crystalliza-
tion from a solvent or from aqueous solution. In this connec-
tion, one, two, three or any arbitrary number of solvate or 20 
water molecules can combine with the compounds according 
to the invention to form solvates and hydrates. Unless stated 
to the contrary, the invention includes all such possible sol-
vates. 
The term "co-crystal" means a physical association of two 25 
or more molecules which owe their stability through non-
covalent interaction. One or more components of this 
molecular complex provide a stable framework in the crys-
talline lattice. In certain instances, the guest molecules are 
incorporated in the crystalline lattice as anhydrates or sol- 30 
vates, see e.g. "Crystal Engineering of the Composition of 
Pharmaceutical Phases. Do Pharmaceutical Co-crystals Rep-
resent a New Path to Improved Medicines?" Almarasson, 0., 
et. al., The Royal Society of Chemistry, 1889-1896, 2004. 
35 
Examples of co-crystals include p-toluenesulfonic acid and 
benzenesulfonic acid. 
wherein n is typically an integer. That is, Rn is understood to 
represent five independent substituents, Rn(a), Rn(b)' Rn(c), 
RnCdJ, Rn(e). By "independent substituents," it is meant that 
each R substituent can be independently defined. For 
example, if in one instance Rn(a) is halogen, then Rn(b) is not 
necessarily halogen in that instance. 
Certain materials, compounds, compositions, and compo-
nents disclosed herein can be obtained commercially or 
readily synthesized using techniques generally known to 
those of skill in the art. For example, the starting materials and 
reagents used in preparing the disclosed compounds and 
compositions are either available from commercial suppliers 
such as Aldrich Chemical Co., (Milwaukee, Wis.), Acros 
It is also appreciated that certain compounds described 
herein can be present as an equilibrium of tautomers. For 
example, ketones with an a-hydrogen can exist in an equilib-
rium of the keto form and the enol form. 
~ 
40 Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh, 
Pa.), or Sigma (St. Louis, Mo.) or are prepared by methods 
known to those skilled in the art following procedures set 
forth in references such as Fieser and Fieser's Reagents for 
Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 
H 
keto form enol form 
amide form imidic acid form 
Likewise, amides with an N-hydrogen can exist in an equi-
librium of the amide form and the imidic acid form. Unless 
45 1991); Rodd's Chemistry of Carbon Compounds, Volumes 
1-5 and Supplementals (Elsevier Science Publishers, 1989); 
Organic Reactions, Volumes 1-40 (John Wiley and Sons, 
1991); March's Advanced Organic Chemistry, (John Wiley 
and Sons, 4th Edition); and Larock' s Comprehensive Organic 
50 Transformations (VCH Publishers Inc., 1989). 
Unless otherwise expressly stated, it is in no way intended 
that any method set forth herein be construed as requiring that 
its steps be performed in a specific order. Accordingly, where 
a method claim does not actually recite an order to be fol-
55 lowed by its steps or it is not otherwise specifically stated in 
the claims or descriptions that the steps are to be limited to a 
specific order, it is no way intended that an order be inferred, 
in any respect. This holds for any possible non-express basis 
stated to the contrary, the invention includes all such possible 60 
tautomers. 
for interpretation, including: matters of logic with respect to 
arrangement of steps or operational flow; plain meaning 
derived from grammatical organization or punctuation; and 
It is known that chemical substances form solids which are 
present in different states of order which are termed polymor-
phic forms or modifications. The different modifications of a 
polymorphic substance can differ greatly in their physical 65 
properties. The compounds according to the invention can be 
present in different polymorphic forms, with it being possible 
the number or type of embodiments described in the specifi-
cation. 
Disclosed are the components to be used to prepare the 
compositions of the invention as well as the compositions 
themselves to be used within the methods disclosed herein. 
These and other materials are disclosed herein, and it is under-
US 8,846,707 B2 
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stood that when combinations, subsets, interactions, groups, 
etc. of these materials are disclosed that while specific refer-
ence of each various individual and collective combinations 
and permutation of these compounds can not be explicitly 
disclosed, each is specifically contemplated and described 5 
herein. For example, if a particular compound is disclosed 
and discussed and a number of modifications that can be made 
1. Structure 
In one aspect, the invention relates to a compound having a 
structure represented by Formula (I): 
(I) 
to a number of molecules including the compounds are dis-
cussed, specifically contemplated is each and every combi-
nation and permutation of the compound and the modifica- 10 
tions that are possible unless specifically indicated to the 
contrary. Thus, if a class of molecules A, B, and C are dis-
closed as well as a class of molecules D, E, and F and an 
example of a combination molecule, A-D is disclosed, then 
15 
even if each is not individually recited each is individually 
and collectively contemplated meaning combinations, A-E, 
A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered 
disclosed. Likewise, any subset or combination of these is 
also disclosed. Thus, for example, the sub-group of A-E, B-F, 20 
and C-E would be considered disclosed. This concept applies 
wherein each of m and n is independently an integer from 0-3; 
whereinR1 is selectedfromA1,A2, -(A1)-(A2), -(A2)-(A3), 
-(A3)-(A2), -(A3)-(A 4), -(As)-(A i )-(A7), -(As)-(A2)-(A s), to all aspects of this application including, but not limited to, 
steps in methods of making and using the compositions of the 
invention. Thus, if there are a variety of additional steps that 
can be performed it is understood that each of these additional 25 
steps can be performed with any specific embodiment or 
combination of embodiments of the methods of the invention. 
-(A5)-(A3)-(A7), and -(A5 )-(A6)-L-(A7); wherein A 1 is 
C3-C6 cycloalkyl, and substituted with 0-3 groups selected 
from halo, hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, 
Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, 
Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkyl-
It is understood that the compositions disclosed herein 
have certain functions. Disclosed herein are certain structural 
requirements for performing the disclosed functions, and it is 
understood that there are a variety of structures that can 
perform the same function that are related to the disclosed 
structures, and that these structures will typically achieve the 
same result. 
B. COMPOUNDS 
In one aspect, the invention relates to compounds useful as 
inhibitors of STAT. In a further aspect, the disclosed com-
pounds and products of disclosed methods of making are 
modulators of STAT activity. In various aspects, the present 
invention relates to compounds that bind to a STAT protein 
and negatively modulate STAT activity. In a further aspect, 
the disclosed compounds exhibit inhibition of STAT activity. 
The compounds can, in one aspect, exhibit subtype selectiv-
ity. In a further aspect, the compounds exhibit selectivity for 
the STAT3 member of the STAT protein family. In a yet 
further aspect, the compounds exhibit selectivity for the 
STATS members of the STAT protein family. 
In one aspect, the compounds of the invention are useful in 
the treatment of a disorder of uncontrolled cellular prolifera-
tion associated with STAT dysfunction and other diseases in 
which a STAT protein is involved, as further described herein. 
In a further aspect, the STAT is STAT3. In a still further 
aspect, the compounds are useful in the treatment of a disor-
der of uncontrolled cellular proliferation or other disorder 
associated with a STAT3 dysfunction. In a yet further aspect, 
the compounds are useful in the treatment of a disorder of 
uncontrolled cellular proliferation or other disorder associ-
ated with a STATS dysfunction. 
It is contemplated that each disclosed derivative can be 
optionally further substituted. It is also contemplated that any 
one or more derivative can be optionally omitted from the 
invention. It is understood that a disclosed compound can be 
provided by the disclosed methods. It is also understood that 
the disclosed compounds can be employed in the disclosed 
methods of using. 
hio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, Cl-C6 
dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-
30 (Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyhaloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-alkylthio, (Cl-C6)-alk-(Cl-C6)-ha-
loalkylhio, (Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, C02H, 
(C=O)R4 , (C=O)OR4 , and (C=O)NHR4 ; wherein A2 is 
C3-C6 heterocycloalkyl, and substituted with 0-3 groups 
35 selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-





, (C=O)OR5 , and (C=O)NHR5 ; wherein 
A3 is aryl, and substituted with 0-3 groups selected from halo, 
45 hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-






OR6 , and (C=O)NHR6 ; whereinA4 is aryl, and substituted 
with 1-3 groups selected from halo, hydroxyl, amino, nitro, 
55 cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
60 (Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl -C6)-alk-( Cl -C6)-haloalky lhio, (Cl -C6)-alk-( Cl -C6)-
polyhaloalky lthio, C02H, (C=O)R
7, (C=O)OR7, and 
(C=O)NHR7; wherein A5 is selected from C3-C6 
cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and substituted 
65 with 0-3 groups selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
US 8,846,707 B2 
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alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
( C 1-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)- 5 
polyhaloalkylthio, C02H, (C=O)R
8
, (C=O)OR8 , and 
(C=O)NHR8 ; wherein A6 is selected from C3-C6 
cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and substituted 
with 0-3 groups selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 10 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 







, (C=O)OR9 , and 
(C=O)NHR9 ; wherein A7 is selected from C3-C6 
cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and substituted 20 
with 0-3 groups selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl- 25 
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
( C 1-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkylthio, C02 H, (C=O)R
10
, (C=O)OR10, and 
(C=O)NHR10; wherein A8 is selected from C3-C6 30 
cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and substituted 
with 0-3 groups selected from halo, hydroxyl, amino, nitro, 
Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, 
35 
Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alky-
lamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 
(Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-alky lthio, (Cl -C6)-
alk-( C 1-C6)-haloalky lhio, (Cl-C6)-alk-(Cl-C6)-polyha- 40 
loalkylthio, C02H, (C=O)R
11
, (C=O)OR11 , and (C=O) 
NHR11 ; wherein L is selected from -(C=O)- and 
-S02-; wherein R
2 is selected from Cl-C6 alkyl, C2-C6 
alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, C2-C6 haloalk-
enyl, C2-C6 haloalkynyl, Cl-C6 polyhaloalkyl, C2-C6 poly- 45 
haloalkenyl, C2-C6 polyhaloalkynyl; or wherein R2 is aryl, 
and substituted with 0-5 groups independently selected from 
halo, hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 
polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 
polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, 50 
Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, Cl-C6 dialky-
lamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-
haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyhaloalkoxy, (Cl -C6)-
alk-( C 1-C6)-alkylthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, 
55 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, C02 H, (C=O) 
OR11 , and(C=O)NHR11 ; whereinR3 is aryl substituted with 
0-5 groups independently selected from halo, hydroxyl, 
amino, nitro, cyano, Cl-C6 alkyl, Cl-C6 haloalkyl, Cl-C6 
polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 60 
polyhaloalkoxy, Cl-C6 alkylamino, Cl-C6 dialkylamino, 
(Cl -C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-ha-
loalkoxy, and (Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy; 
wherein each of R4 , R5 , R6 , R7 , R8 , R9 , R10, and R11 is 
independently selected from hydrogen, Cl-C6 alkyl, Cl-C6 65 
haloalkyl, and Cl-C6 polyhaloalkyl; or a pharmaceutically 
acceptable salt, hydrate, solvate, or polymorph thereof. 
30 
In a further aspect, the compound of Formula I has a 
structure represented by a formula: 
In a further aspect, the compound of Formula I has a 
structure represented by a formula: 
US 8,846,707 B2 
31 
wherein each of mis 0 and n is O; wherein R 1 is selected from 
a structure represented by a formula: 
........ 
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wherein R2 is selected from a structure represented by a 
formula: -- 35 --
CN, 40 
-CH;v·· .. f)· ... 
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In a further aspect, the compound of Formula I has a 
structure represented by a formula: 
wherein each of m and n is O; wherein R 1 is selected from a 

































































wherein R2 is --CH3 ; and wherein R
3 is a structure repre-
sented by a formula: 
In one aspect, the invention relates to a compound having a 
structure represented by Formula (II): 
(II) 
wherein mis an integer from 0-3 when R2 is aryl; wherein 
m=O when R2 is non-aryl; wherein n is an integer from 0-3; 
wherein R 1 is -(A5)-(A 6)-L-(A7); whereinA5 is selected from 
50 C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and 
substituted with 0-3 groups selected from halo, hydroxyl, 
amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, 
Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, 
Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalky-
55 lthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-
(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-
C6)-alk-( Cl -C6)-polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-
alky lthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-
(Cl-C6)-polyhaloalkylthio, C02H, (C=O)OR 
8
, and (C=O) 
60 NHR 8 ; wherein A 6 is selected from C3-C6 cycloalkyl, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
65 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-
C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyha-






, and (C=O)NHR9 ; wherein A7 is 
selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, 
and aryl, and substituted with 0-3 groups selected from halo, 5 
hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 10 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02 H, (C=O)OR
10
, and 
(C=O)NHR10; wherein Lis optionally present, and when 
15 
present is selected from -(C=O)- and-S02-; wherein 
R2 is selected from C3-C8 alkyl, C3-C8 alkenyl, C3-C8 alky-
nyl, C3-C8 haloalkyl, C3-C8 haloalkenyl, C3-C8 haloalky-
nyl, C3-C8 polyhaloalkyl, C3-C8 polyhaloalkenyl, C3-C8 
polyhaloalkynyl; or wherein R2 is aryl, and substituted with 
20 
0-5 groups independently selected from halo, hydroxyl, 
amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, 
Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, 
Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalky-
lthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-
25 
(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-
C6)-alk-( Cl -C6)-polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-
alky lthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-
(Cl-C6)-polyhaloalkylthio, C02 H, (C=O)OR 
11
, and 
(C=O)NHR11 ; wherein R3 is aryl substituted with 0-5 
30 
groups independently selected from halo, hydroxyl, amino, 
nitro, cyano, Cl-C6 alkyl, Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-
alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, and 
35 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy; wherein each of R8 , 
R9 , R10, and R11 is independently selected from hydrogen, 
Cl-C6 alkyl, Cl-C6 haloalkyl, andC1-C6 polyhaloalkyl; or a 
pharmaceutically acceptable salt, hydrate, solvate, or poly-
morph thereof. 
40 
In a further aspect, the compound of Formula II has a 






In a further aspect, the compound of Formula II has a 
structure represented by a formula: 
wherein each of m and n is O; wherein R 1 is selected from a 
55 structure represented by a formula: 
60 
65 
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wherein R2 is selected from a structure represented by a 
30 formula: 
CN, 
-(CH2)2CH3, -CH2CH(CH3)2, -CH2CH=CHi, 
' ' ' 
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wherein R3 is selected from a structure represented by a 
formula: 
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In a further aspect, the compound of Formula II has a 




wherein R2 is selected from a structure represented by a 
formula: 
49 
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In one aspect, the invention relates to a compound having a 
structure represented by Formula (III): 
(III) 
wherein each of m and n is independently an integer from 0-3; 
wherein R 1 is -(A5)-(A 6)-L-(A7 ); whereinA5 is selected from 
C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and 
substituted with 0-3 groups selected from halo, hydroxyl, 
40 amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, 
Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, 
Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalky-
lthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-
(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-
45 C6)-alk-( Cl -C6)-polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-
alky lthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-
(Cl-C6)-polyhaloalkylthio, C02H, (C=O)OR 
8
, and (C=O) 
NHR 8 ; wherein A 6 is selected from C3-C6 cycloalkyl, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 
50 selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-





, and (C=O)NHR9 ; wherein A7 is 
selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, 
and aryl, and substituted with 0-3 groups selected from halo, 
60 hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
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(C=O)NHR10; wherein Lis optionally present, and when 
present is selected from -(C=O)- and-S02-; wherein 
R2 is selected from Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 alky-
nyl, Cl-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalky-
nyl, Cl-C6 polyhaloalkyl, C2-C6 polyhaloalkenyl, C2-C6 5 
polyhaloalkynyl; or wherein R2 is aryl, and substituted with 
0-5 groups independently selected from halo, hydroxyl, 
amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, 
Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, 
Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalky- 10 
lthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-
(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-
C6)-alk-( Cl -C6)-polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-
alky lthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-
(Cl-C6)-polyhaloalkylthio, C02H, (C=O)OR
7
, and (C=O) 15 
NHR7 ; wherein R3 is aryl substituted with 0-5 groups 
independently selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)- 20 
alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, and (Cl-C6)-alk-
(Cl-C6)-polyhaloalkoxy; wherein each of R8 , R9 , R10, and 
R11 is independently selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl; or a pharmaceu-
tically acceptable salt, hydrate, solvate, or polymorph 25 
thereof. 
In a further aspect, the compound of Formula III has a 
structure represented by a formula: 
In a further aspect, the compound of Formula III has a 




wherein each of mis 0 and n is O; wherein R 1 is selected from 
a structure represented by a formula: 
........... 
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In a further aspect, the compound of Formula III has a 
58 
wherein R2 is --CH3 ; and wherein R
3 is selected from a 
10 
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In one aspect, the invention relates to a compound having a 
structure represented by Formula (IV): 
(IV) 
structure represented by a formula: 50 
wherein each of m is 0 and n is O; wherein R 1 is a structure 
represented by a formula: 
55 
60 wherein n is an integer from 0-3; wherein R1 is -(A5)-(A6)-
L-( A 7 ); wherein A 5 is selected from C3-C6 cycloalky 1, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
65 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-







, and (C=O)NHR8 ; wherein A6 is 
selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, 5 
and aryl, and substituted with 0-3 groups selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl- 10 
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02H, (C=O)OR
9
, and 15 
(C=O)NHR9 ; wherein A7 is selected from C3-C6 
cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and substituted 
with 0-3 groups selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 20 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
( C 1-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)- 25 
polyhaloalkylthio, C02H, (C=O)OR
10
, and (C=O)NHR10 ; 
wherein Lis optionally present, and when present is selected 
from -(C=O)- and -S02-; wherein R
3 is aryl substi-
tuted with 0-5 groups independently selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 alkyl, Cl-C6 haloalkyl, 30 
Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, 
Cl-C6 polyhaloalkoxy, Cl-C6 alkylamino, Cl-C6 dialky-
lamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-
haloalkoxy, and (Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy; 
35 
whereineachofR8 , R9 , R10, R12a, R126, andR12c is indepen-
dently selected from hydrogen, Cl-C6 alkyl, Cl-C6 
haloalkyl, and Cl-C6 polyhaloalkyl; or a pharmaceutically 
acceptable salt, hydrate, solvate, or polymorph thereof. 
In a further aspect, the compound of Formula IV has a 40 









In one aspect, A 1 is C3-C6 cycloalkyl, and substituted with 
0-3 groups selected from halo, hydroxyl, amino, nitro, cyano, 
Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, 
Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alky-
lamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 
(Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-
polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-alkylthio, (Cl -C6)-
alk-( C 1-C6)-haloalky lhio, (Cl-C6)-alk-(Cl-C6)-polyha-
loalkylthio, C02 H, (C=O)R
4
, (C=O)OR4 , and (C=O) 
NHR4 . 
In a further aspect, A 1 is C3-C6 cycloalkyl, and substituted 
with 0-3 groups selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 





45 alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
( C 1-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 




R12a--< l ~ 
OH, 
N0 I N 0 :::::::::8 'ccHJ :::::::::-0 2n I I 
R3 0 R1 
50 polyhaloalkylthio, C02 H, (C=O)OR
4
, and (C=O)NHR4 . 
In a further aspect, A1 is substituted with 1-3 groups, 1-2 
groups, 2-3 groups, 0 groups, 1 group, 2 groups, or 3 groups. 
In a further aspect, the groups are selected from halo, 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
55 groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-







(C=O)NHR4 . In a further aspect, the groups are selected 
from C02 H, (C=O)OR
4
, and (C=O)NHR4 . 
b.A2 Groups 
In one aspect, A2 is C3-C6 heterocycloalkyl, and substi-
tuted with 0-3 groups selected from halo, hydroxyl, amino, 
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nitro, cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-C6)-alk- 5 
(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkylthio, C02H, (C=O)Rs, (C=O)ORs, and 
(C=O)NHRs. 
In a further aspect, A2 is C3-C6 heterocycloalkyl, and sub- 10 
stituted with 0-3 groups selected from halo, hydroxyl, amino, 
nitro, cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
15 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
( C 1-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkylthio, C02 H, (C=O)ORs, and (C=O)NHRs. 20 
In a further aspect, A2 is substituted with 1-3 groups, 1-2 
groups, 2-3 groups, 0 groups, 1 group, 2 groups, or 3 groups. 
In a further aspect, the groups are selected from halo, 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha- 25 
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl- 30 
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02H, (C=O)ORs, and 
(C=O)NHRs. In a further aspect, the groups are selected 
from C02 H, (C=O)ORs, and (C=O)NHRs. 
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(C=O)NHR6 . In a further aspect, the groups are selected 
from C02 H, (C=O)OR
6
, and (C=O)NHR6 . 
d.A4 Groups 
In one aspect, A 4 is aryl, and substituted with 1-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-





, (C=O)OR7 , and (C=O)NHR7 . 
In a further aspect, A4 is aryl substituted with 1-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-





, and (C=O)NHR7 . 
In a further aspect, A 4 is substituted with 1-2 groups, 2-3 
groups, 1 group, 2 groups, or 3 groups. 
In a further aspect, the groups are selected from halo, 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alkylthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-
c.A3 Groups 35 alk-(Cl-C6)-polyhaloalkylthio, C02H, (C=O)OR
7
, and 
(C=O)NHR7 . In a further aspect, the groups are selected 
from C02 H, (C=O)OR
7
, and (C=O)NHR7 . 
In one aspect, A3 is aryl, and substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 40 






, (C=O)OR6 , and (C=O)NHR6 . 
e.As Groups 
In one aspect, As is selected from C3-C6 cycloalky 1, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
45 Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-
C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyha-
loalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, (Cl-C6)-alk-(Cl-
C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, 
In a further aspect, A3 is aryl substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 50 






, and (C=O)NHR6 . 
C02H, (C=O)R
8
, (C=O)OR8 , and (C=O)NHR8 . 
In a further aspect, As is selected from C3-C6 cycloalkyl, 
C3-C6 heterocycloalkyl, and aryl, and substituted with 0-3 
groups selected from halo, hydroxyl, amino, nitro, cyano, 
Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, 
In a further aspect, A3 is substituted with 1-3 groups, 1-2 
groups, 2-3 groups, 0 groups, 1 group, 2 groups, or 3 groups. 
55 Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alky-
lamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 
(Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-
polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-alkylthio, (Cl -C6)-In a further aspect, the groups are selected from halo, 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha- 60 
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl- 65 
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02H, (C=O)OR
6
, and 
alk-( C 1-C6)-haloalky lhio, (Cl-C6)-alk-(Cl-C6)-polyha-
loalkylthio, C02 H, (C=O)OR
8
, and (C=O)NHR8 . 
In a further aspect, As is C3-C6 cycloalkyl. In a further 
aspect, As is C3-C6 heterocycloalkyl. In a further aspect, As 
is aryl. 
In a further aspect, As is substituted with 1-3 groups, 1-2 
groups, 2-3 groups, 0 groups, 1 group, 2 groups, or 3 groups. 
In a further aspect, the groups are selected from halo, 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
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groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 5 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02H, (C=O)R
8
, (C=O) 
OR8 , and (C=O)NHR8 . In a further aspect, the groups are 
selected from C02 H, (C=O)R
8
, (C=O)OR8 , and (C=O) 10 
NHR8 . 
f.A6 Groups 
In one aspect, A 6 is selected from C3-C6 cycloalky 1, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 15 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-





, (C=O)OR9 , and (C=O)NHR9 . 
In a further aspect, A 6 is selected from C3-C6 cycloalkyl, 
C3-C6 heterocycloalkyl, and aryl, and substituted with 0-3 25 
groups selected from halo, hydroxyl, amino, nitro, cyano, 
Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, 
Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alky-
lamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 30 
(Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-alky lthio, (Cl -C6)-
alk-( C 1-C6)-haloalky lhio, (Cl-C6)-alk-(Cl-C6)-polyha-
loalkylthio, C02 H, (C=O)OR
9
, and (C=O)NHR9 . 
In a further aspect, A6 is C3-C6 cycloalkyl. In a further 35 
aspect, A 6 is C3-C6 heterocycloalkyl. In a further aspect, A 6 
is aryl. 
In a further aspect, A6 is substituted with 1-3 groups, 1-2 
groups, 2-3 groups, 0 groups, 1 group, 2 groups, or 3 groups. 
In a further aspect, the groups are selected from halo, 40 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl- 45 
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02H, (C=O)R
9
, (C=O) 
OR9 , and (C=O)NHR9 . In a further aspect, the groups are 50 
selected from C02 H, (C=O)R
9
, (C=O)OR9 , and (C=O) 
NHR9 . 
g.A7 Groups 
In one aspect, A 7 is selected from C3-C6 cycloalky 1, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 55 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 






, (C=O)OR16, and (C=O)NHR10. 
In a further aspect, A7 is selected from C3-C6 cycloalkyl, 65 
C3-C6 heterocycloalkyl, and aryl, and substituted with 0-3 
groups selected from halo, hydroxyl, amino, nitro, cyano, 
64 
Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, 
Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alky-
lamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 
(Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-
polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-alkylthio, (Cl -C6)-
alk-( C 1-C6)-haloalky lhio, (Cl-C6)-alk-(Cl-C6)-polyha-
loalkylthio, C02 H, (C=O)OR
16
, and (C=O)NHR10. 
In a further aspect, A7 is C3-C6 cycloalkyl. In a further 
aspect, A7 is C3-C6 heterocycloalkyl. In a further aspect, A7 
is aryl. 
In a further aspect, A7 is substituted with 1-3 groups, 1-2 
groups, 2-3 groups, 0 groups, 1 group, 2 groups, or 3 groups. 
In a further aspect, the groups are selected from halo, 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-






OR10, and (C=O)NHR10 . In a further aspect, the groups are 
selected from C02 H, (C=O)R 
10
, (C=O)OR 10, and (C=O) 
NHR10 . 
h.A8 Groups 
In one aspect, A 8 is selected from C3-C6 cycloalky 1, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, Cl-C6 haloalkyl, 
Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, 
Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkyl-
hio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, Cl-C6 
dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-
( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyhaloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-alkylthio, (Cl-C6)-alk-(Cl-C6)-ha-
loalkylhio, (Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, C02 H, 
(C=O)R11 , (C=O)OR11 , and (C=O)NHR11 . 
In a further aspect, A 8 is selected from C3-C6 cycloalkyl, 
C3-C6 heterocycloalkyl, and aryl, and substituted with 0-3 
groups selected from halo, hydroxyl, amino, nitro, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-





, (C=O)OR11 , and (C=O)NHR11 . 
In a further aspect, A8 is C3-C6 cycloalkyl. In a further 
aspect, A8 is C3-C6 heterocycloalkyl. In a further aspect, A8 
is aryl. 
In a further aspect, A8 is substituted with 1-3 groups, 1-2 
groups, 2-3 groups, 0 groups, 1 group, 2 groups, or 3 groups. 
In a further aspect, the groups are selected from halo, 
hydroxyl, amino, nitro, and cyano. In a further aspect, the 
groups are selected from Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alkylthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-
alk-(Cl-C6)-polyhaloalkylthio, C02H, (C=O)R 
11
, (C=O) 
OR 11 , and (C=O)NHR 11 . In a further aspect, the groups are 
selected from C02 H, (C=O)R
11
, (C=O)OR11 , and (C=O) 
NHR11 . 
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i. L Groups -continued 
In one aspect, L is selected from -(C=O)- and 
~J. -S02-. In a further aspect, L is optionally present, and when present is selected from -(C=O)- and -S02-. In N N 
a further aspect, Lis -(C=O)-. In a further aspect, Lis 
-S02-. In a further aspect, Lis present. In a further aspect, 
Lis absent. 
j. R1 Groups ----
In one aspect, R 1 is selected from A 1,A2, -(A 1 )-(A2), -(A2)- 10 0 
(A3), -(A3)-(A2), -(A3)-(A 4), -(As)-( Ai )-(A7), -(As)-(A2)-
(A8), -(A5 )-(A3)-(A7), and -(A5 )-(A6)-L-(A7). 
In a further aspect, R 1 is A 1 . In a further aspect, R 1 is A 2. In 
a further aspect, R1 is -(A1)-(A2). In a further aspect, R1 is 15 
~ -(A2)-(A3). In a further aspect, R1 is -(A3)-(A2). In a further N, 
aspect, R 1 is -(A3)-(A 4 ). In a further aspect, R 1 is -(A5)-(A 1 )- ----
(A7). In a further aspect, R1 is -(A5)-(A2)-(A8 ). In a further «N aspect, R1 is -(A5 )-(A3)-(A7). In a further aspect, R1 is -(A5)- ~ (A6)-L-(A7). In a further aspect, R1 is -(A5 )-(A6)-L-(A7). 20 
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In a further aspect, R 1 is selected from 
30 In a further aspect, R1 is selected from biphenyl and ter-
phenyl, and substituted with 0-3 groups selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
35 haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-







OR4 , and (C=O)NHR4 . 
In a further aspect, R 1 is biphenyl. In a further aspect, R 1 is 
terphenyl. In further aspects, R1 is substituted with 1-3 
groups, 1-2 groups, 2-3 groups, 0 groups, 1 group, 2 groups, 
45 or 3 groups . 
k. R2Groups 
In one aspect, R2 is selected from Cl-C6 alkyl, C2-C6 
alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, C2-C6 haloalk-
enyl, C2-C6 haloalkynyl, Cl-C6 polyhaloalkyl, C2-C6 poly-
50 haloalkenyl, and C2-C6 polyhaloalkynyl. 
In a further aspect, R2 is selected from Cl-C6 alkyl, C2-C6 
alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, C2-C6 haloalk-
enyl, C2-C6 haloalkynyl, Cl-C6 polyhaloalkyl, C2-C6 poly-
55 haloalkenyl, and C2-C6 polyhaloalkynyl; or wherein R2 is 
aryl substituted with 0-5 groups independently selected from 
halo, hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 
polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 
polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, 




(Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, C02 H, (C=O) 
65 OR 
11
, and (C=O)NHR 11 . 
In a further aspect, R2 is aryl substituted with 0-5 groups 
independently selected from halo, hydroxyl, amino, nitro, 
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cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-C6)-alk- 5 
(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkylthio, C02H, (C=O)OR 
11 , and (C=O)NHR 11 . 
Ina further aspect, R2 is selected from Cl-C6 alkyl, C2-C6 10 
alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, C2-C6 haloalk-
enyl, C2-C6 haloalkynyl, Cl-C6 polyhaloalkyl, C2-C6 poly-
haloalkenyl, and C2-C6 polyhaloalkynyl; or wherein R2 is 
aryl substituted with 0-5 groups independently selected from 
halo, hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 
polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 
polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, 
Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, Cl-C6 dialky-
lamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-
haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyhaloalkoxy, (Cl -C6)-
alk-( Cl -C6)-alkylthio, (Cl -C6)-alk-( Cl -C6)-haloalky lhio, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, C02 H, (C=O) 
OR7 , and (C=O)NHR7 . 
In a further aspect, R2 is aryl substituted with 0-5 groups 
independently selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl- 30 
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
(Cl -C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkylthio, C02 H, (C=O)OR
7
, and (C=O)NHR7 . 
In a further aspect, R2 is selected from hydrogen, Cl-C6 
35 
alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, 
C2-C6 haloalkenyl, C2-C6 haloalkynyl, Cl-C6 polyha-
loalkyl, C2-C6 polyhaloalkenyl, C2-C6 polyhaloalkynyl, 
(C=O)OR13, and (C=O)NR13R14; or wherein R2 is aryl 40 
substituted with 0-5 groups independently selected from 
halo, hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 
polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 
polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, 
Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, Cl-C6 dialky- 45 
!amino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-
haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyhaloalkoxy, (Cl -C6)-
alk-( Cl -C6)-alkylthio, (Cl -C6)-alk-( Cl -C6)-haloalky lhio, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, C02 H, (C=O) 
OR13, and (C=O)NR13R14. 50 
In a further aspect, R2 is aryl substituted with 0-5 groups 
independently selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 55 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
(Cl -C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkylthio, C02 H, (C=O)OR
13, and (C=O) 60 
NR13R14. 
In various aspects, R2 is aryl substituted with 0-4 groups, 
0-3 groups, 0-2 groups, 0-1 groups, 1-5 groups, 1-4 groups, 
1-3 groups, 1-2 groups, 2-3 groups, 0 groups, 1 group, 2 65 
groups, 3 groups, 4 groups, or 5 groups. 
In a further aspect, wherein R2 is -CH3. 
74 
In a further aspect, R 2 is selected from 
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-continued 
Ina further aspect, R2 is selected from phenyl, napthyl, and 
monocylic C3-C6 heteroaryl, and substituted with 0-5 groups 
independently selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
15 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
( C 1-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
20 (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-
polyhaloalkylthio, C02H, (C=O)OR 
11
, and (C=O)NHR 11 . 
In a further aspect, R2 is phenyl. In a further aspect, R2 is 
napthyl. In a further aspect, R2 is monocylic C3-C6 het-
eroaryl. In further aspects, R2 is substituted with 0-4 groups, 
25 0-3 groups, 0-2 groups, 0-1 groups, 1-5 groups, 1-4 groups, 
1-3 groups, 1-2 groups, 2-3 groups, 0 groups, 1 group, 2 
groups, 3 groups, 4 groups, or 5 groups. 
30 
I. R3 Groups 
In one aspect, R3 is aryl substituted with 0-5 groups inde-
pendently selected from halo, hydroxyl, amino, nitro, cyano, 
Cl-C6 alkyl, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-
35 alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, and (Cl-C6)-alk-
(Cl-C6)-polyhaloalkoxy. 
In a further aspect, R3 is 
40 
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In a further aspect, R3 is selected from 
Cl'O 






In a further aspect, R3 is selected from phenyl, biphenyl, 
napthyl, and imidazole, and substituted with 0-5 groups inde-
pendently selected from halo, hydroxyl, amino, nitro, cyano, 
Cl-C6 alkyl, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 
alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-
alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, and (Cl-C6)-alk-
(Cl-C6)-polyhaloalkoxy. 
In a further aspect, R3 is phenyl. In a further aspect, R3 is 
biphenyl. In a further aspect, R3 is napthyl. In a further aspect, 
R3 is imidazole. In a further aspect, R3 is pentafluorophenyl. 
In further aspects, R3 is substituted with 0-4 groups, 0-3 
groups, 0-2 groups, 0-1 groups, 1-5 groups, 1-4 groups, 1-3 
groups, 1-2 groups, 2-3 groups, 0 groups, 1 group, 2 groups, 
3 groups, 4 groups, or 5 groups. 
80 
m. R4 Groups 
In one aspect, R4 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, R 4 is selected from Cl -C6 alky 1, Cl -C6haloalky1, and 
5 Cl-C6 polyhaloalkyl. In a further aspect, R4 is hydrogen. In a 
further aspect, R4 is Cl-C6 alkyl. In a further aspect, R4 is 
Cl-C6 haloalkyl. In a further aspect, R4 is Cl-C6 polyha-
loalkyl. 
n. Rs Groups 
10 In one aspect, Rs is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, Rs is selected from Cl -C6 alky 1, Cl -C6haloalky1, and 
Cl-C6 polyhaloalkyl. In a further aspect, Rs is hydrogen. In a 
further aspect, Rs is Cl-C6 alkyl. In a further aspect, Rs is 
15 Cl-C6 haloalkyl. In a further aspect, Rs is Cl-C6 polyha-
loalkyl. 
o. R6 Groups 
In one aspect, R 6 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
20 aspect, R 6 is selected from Cl -C6 alky 1, Cl -C6haloalky1, and 
Cl-C6 polyhaloalkyl. In a further aspect, R 6 is hydrogen. In a 
further aspect, R6 is Cl-C6 alkyl. In a further aspect, R6 is 
Cl-C6 haloalkyl. In a further aspect, R6 is Cl-C6 polyha-
loalkyl. 
25 p. R7 Groups 
In one aspect, R7 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, R 7 is selected from Cl -C6 alky 1, Cl -C6haloalky1, and 
Cl-C6 polyhaloalkyl. Ina further aspect, R7 is hydrogen. In a 
30 further aspect, R7 is Cl-C6 alkyl. In a further aspect, R7 is 
Cl-C6 haloalkyl. In a further aspect, R7 is Cl-C6 polyha-
loalkyl. 
q. R8 Groups 
In one aspect, R 8 is selected from hydrogen, Cl-C6 alkyl, 
35 Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, R 8 is selected from Cl -C6 alky 1, Cl -C6haloalky1, and 
Cl-C6 polyhaloalkyl. In a further aspect, R 8 is hydrogen. In a 
further aspect, R8 is Cl-C6 alkyl. In a further aspect, R8 is 
Cl-C6 haloalkyl. In a further aspect, R8 is Cl-C6 polyha-
40 loalkyl. 
r. R9 Groups 
In one aspect, R9 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, R9 is selected from Cl -C6 alky 1, Cl -C6haloalky1, and 
45 Cl-C6 polyhaloalkyl. In a further aspect, R9 is hydrogen. In a 
further aspect, R9 is Cl-C6 alkyl. In a further aspect, R9 is 
Cl-C6 haloalkyl. In a further aspect, R9 is Cl-C6 polyha-
loalkyl. 
s. RIO Groups 
50 In one aspect, RIO is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, RIO is selected from Cl-C6 alkyl, Cl-C6 haloalkyl, 
and Cl-C6 polyhaloalkyl. In a further aspect, RIO is hydro-
gen. In a further aspect, RIO is Cl-C6 alkyl. In a further aspect, 
55 RIO is Cl-C6 haloalkyl. In a further aspect, RIO is Cl-C6 
polyhaloalkyl. 
t. R 11 Groups 
In one aspect, R 11 is an optionally substituted group 
selected from hydrogen, Cl-C6 alkyl, Cl-C6 haloalkyl, and 
60 Cl-C6 polyhaloalkyl. In a further aspect, R 11 is selected from 
Cl-C6 alkyl, Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a 
further aspect, R 11 is hydrogen. In a further aspect, R 11 is 
Cl -C6 alky I. In a further aspect, R 11 is Cl -C6 haloalky I. In a 
further aspect, R11 is Cl-C6 polyhaloalkyl. 
65 u. R 12 Groups 
In one aspect, R 12a is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
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aspect, R12a is selected from Cl-C6 alkyl, Cl-C6 haloalkyl, 
and Cl-C6 polyhaloalkyl. In a further aspect, R12a is hydro-
gen. In a further aspect, R12a is Cl-C6 alkyl. In a further 
aspect, R12a is Cl-C6 haloalkyl. In a further aspect, R12a is 
Cl-C6 polyhaloalkyl. 
In a further aspect, R 12 is selected from hydrogen, Cl-C6 
alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, 
C2-C6 haloalkenyl, C2-C6 haloalkynyl, Cl-C6 polyha-
loalkyl, C2-C6 polyhaloalkenyl, C2-C6 polyhaloalkynyl, 
(C=O)OR13, (C=O)NR13R14; andaryl, whereinaryl is sub-
stituted with 0-5 groups independently selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02H, (C=O)OR
13, and 
(C=O)NR13R14. 
In one aspect, R 126 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, R126 is selected from Cl-C6 alkyl, Cl-C6 haloalkyl, 
and Cl-C6 polyhaloalkyl. In a further aspect, R126 is hydro-
gen. In a further aspect, R126 is Cl-C6 alkyl. In a further 
aspect, R126 is Cl-C6 haloalkyl. In a further aspect, R126 is 
Cl-C6 polyhaloalkyl. 
In a further aspect, R 126 is selected from hydrogen, Cl-C6 
alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, 
C2-C6 haloalkenyl, C2-C6 haloalkynyl, Cl-C6 polyha-
loalkyl, C2-C6 polyhaloalkenyl, C2-C6 polyhaloalkynyl, 
(C=O)OR13, (C=O)NR13R14; andaryl, whereinaryl is sub-
stituted with 0-5 groups independently selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-
alk-( C 1-C6)-polyhaloalkylthio, C02H, (C=O)OR
13, and 
(C=O)NR13R14. 
In one aspect, R 12c is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, R12c is selected from Cl-C6 alkyl, Cl-C6 haloalkyl, 
and Cl-C6 polyhaloalkyl. In a further aspect, R12c is hydro-
gen. In a further aspect, R12c is Cl-C6 alkyl. In a further 
aspect, R12c is Cl-C6 haloalkyl. In a further aspect, R12c is 
Cl-C6 polyhaloalkyl. 
In a further aspect, R 12c is selected from hydrogen, Cl-C6 
alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl-C6 haloalkyl, 
C2-C6 haloalkenyl, C2-C6 haloalkynyl, Cl-C6 polyha-
82 
loalkyl, C2-C6 polyhaloalkenyl, C2-C6 polyhaloalkynyl, 
(C=O)OR 13, (C=O)NR 13R 14; and aryl, wherein aryl is sub-
stituted with 0-5 groups independently selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
5 haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
10 C6)-alkylthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-
alk-(Cl-C6)-polyhaloalkylthio, C02H, (C=O)OR
13, and 
(C=O)NR 13R 14. 
v. R13 Groups 
In one aspect, R 13 is selected from hydrogen, Cl-C6 alkyl, 
15 ~s~-~~ :~~0~11~:~c':1 f~~c~1~~z~:~~1~Ld~ :a1;:i:;i: 
and Cl-C6 polyhaloalkyl. In a further aspect, R13 is hydro-
gen. In a further aspect, R 13 is Cl-C6 alkyl. In a further aspect, 
R13 is Cl-C6 haloalkyl. In a further aspect, R13 is Cl-C6 
20 
polyhaloalkyl. 
w. R 14 Groups 
In one aspect, R 14 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl. In a further 
aspect, R14 is selected from Cl-C6 alkyl, Cl-C6 haloalkyl, 
and Cl-C6 polyhaloalkyl. In a further aspect, R14 is hydro-
25 gen. In a further aspect, R 14 is Cl-C6 alkyl. In a further aspect, 
R14 is Cl-C6 haloalkyl. In a further aspect, R14 is Cl-C6 
polyhaloalkyl. 
X. Integer Values (M and N) 
30 
In one aspect, mis an integer from 0-3. In a further aspect, 
mis an integer from 0-2. In a yet further aspect, mis an integer 
that is 0 or 1. In a still further aspect, m is 0. In an even further 
aspect, mis 1. In a yet further aspect, mis 2. In a still further 
aspect, mis 3. In an even further aspect, mis an integer from 
35 
1-3. In a yet further aspect, mis an integer from 2-3. 
In one aspect, n is an integer from 0-3. In a further aspect, 
n is an integer from 0-2. In a yet further aspect, n is an integer 
that is 0 or 1. In a still further aspect, n is 0. In an even further 
aspect, n is 1. In a yet further aspect, n is 2. In a still further 
40 
aspect, n is 3. In an even further aspect, n is an integer from 
1-3. In a yet further aspect, n is an integer from 2-3. 
y. Leaving Groups 
In one aspect, X is halide or pseudohalide. In a further 
aspect, Xis halogen, for example, fluororo, chloro, bromo, or 
45 
iodo. In a further aspect, X is chloro, bromo, or iodo. In a 
further aspect, X is bromo or iodo. In a further aspect, X is 
chloro. In one aspect, Xis pseudohalide, for example, triflate, 
mesylate, tosylate, or brosylate. In a further aspect, X is a 
group capable of undergoing a transition-metal mediated 
50 
coupling reaction. 
2. Example Compounds 
In one aspect, a compound of Formula I can be present as 
one or more of the following structures: 
~ N 
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In one aspect, a compound ofFormul 
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In one aspect, a compound of Formula II can be present as 
one or more of the following structures: 
F F 
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In one aspect, a compound of Formula II can be present as 
20 one or more of the following structures: 
0 
, and 60 
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In one aspect, a compound of Formula III can be present as 
one or more of the following structures: 
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In one aspect, a compound of Formula III can be present as 
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In one aspect, a compound of Formula III can be present as 
30 one or more of the following structures: 
35 
In one aspect, a compound of Formula III can be present as 
one or more of the following structures: 
0 
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In one aspect, a compound of Formula III can be present as 
50 one or more of the following structures: 
55 
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In one aspect, a compound of Formula III can be present as 
one or more of the following structures: 
0 
In one aspect, a compound of Formula IV can be present as 
one or more of the following structures: 
~ OH 
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("EMSA"). In one aspect, the disclosed compounds exhibit 
inhibition ofSTAT3 protein activity with an IC50 in an EMSA 
assay ofless than about 300 µM, less than about 100 µM, less 
than about 50 µM, less than about 10 µM, less than about 1 
5 µM, less than about 500 nM, or of less than about 100 nM. 
In one aspect, the disclosed compounds are selective for 
STAT3. In a further aspect, selective inhibition of STAT3 
activity is determined using an EMSA assay. In various fur-
ther aspects, the compound inhibits STAT3 activity in a 
10 EMSA assay with an IC50 less than the IC50 for one or more 
ofSTAT1,STAT2,STAT4,STAT5a,STAT5b,orSTAT6.That 
is, a disclosed compound can have selectivity for the STAT3 
protein vis-a-vis one or more of STAT!, STAT2, STAT4, 
STAT5a, STAT5b, or STAT6 proteins. For example, in one 
15 aspect, a disclosed compound can inhibit STAT3 with an IC50 
ofabout 5-fold less than that for STAT!, of about 10-fold less 
than that for STAT!, of about 20-fold less than that for 
STAT!, of about 30-fold less than that for STAT!, or of about 
50-fold less than that for STAT!. In a further aspect, a dis-
20 closed compound can inhibit STAT3 with an IC50 of about 
5-foldless than that for STAT2, ofabout 10-fold less than that 
for STAT2, ofabout 20-fold less than that for STAT2, ofabout 
30-fold less than that for STAT2, or of about 50-fold less than 
that for STAT2. In a still further aspect, a disclosed compound 
OqOH 
~I n ~N : 
-0-st-Y 11~0 ° 
0 
and 25 can inhibit STAT3 with an IC50 of about 5-fold less than that 
for STAT4, ofabout 10-foldless than that for STAT4, ofabout 
20-fold less than that for STAT4, of about 30-fold less than 
that for STAT4, or of about 50-fold less than that for STAT4. 




--0-s/~ 11~0 ° 
0 
It is understood that the disclosed compounds can be used 
in connection with the disclosed methods, compositions, kits, 
and uses. In a further aspect, it is understood that the disclosed 
compounds further comprise pharmaceutically acceptable 
salts, hydrates, solvates, or polymorphs thereof. 
The pharmaceutically acceptable derivatives of the com-
pounds can include any suitable derivative, such as pharma-
ceutically acceptable salts as discussed below, isomers, radio-
labeled analogs, tautomers, and the like. 
It is contemplated that one or more compounds can option-
ally be omitted from the disclosed invention. 
3. Modulation ofStat3 Activity 
In one aspect, the disclosed compounds exhibit inhibition 
of STAT3 protein activity. In a yet further aspect, the dis-
closed compounds exhibit selective inhibition of STAT3 pro-
tein activity. In a still further aspect, the disclosed compounds 
prevent STAT3 protein dimerization. In a yet further aspect, 
the disclosed compounds exhibit disruption of preformed or 
existing STAT3 dimers. In a still further aspect, the disclosed 
compounds exhibit binding to the SH2 domain of STAT3. 
Inhibition ofSTAT3 activity can be determined by a variety 
of both in vitro and in vivo methods known to one skilled in 
the art. For example, inhibition ofSTAT3 protein activity can 
be determined using a electrophoretic mobility shift assay 
30 STAT3 with an IC50 of about 5-fold less than that for STAT5a, 
of about 10-fold less than that for STAT5a, of about 20-fold 
less than that for STAT5a, of about 30-fold less than that for 
STAT5a, or of about 50-fold less than that for STAT5a. In an 
even further aspect, a disclosed compound can inhibit STAT3 
35 with an IC50 of about 5-fold less than that for STAT5b, of 
about 10-fold less than that for STAT5b, of about 20-fold less 
than that for STAT5b, of about 30-fold less than that for 
STAT5b, or of about 50-fold less than that for STAT5b. In a 
still further aspect, a disclosed compound can inhibit STAT3 
40 with an IC50 ofabout 5-fold less than that for STAT6, ofabout 
10-fold less than that for STAT6, of about 20-fold less than 
that for STAT6, of about 30-fold less than that for STAT6, or 
of about 50-fold less than that for STAT6. 
In various aspects, the disclosed compounds exhibit bind-
45 ing to a STAT protein. In a further aspect, the disclosed 
compounds exhibit binding to the SH2 domain of a STAT 
protein. In a still further aspect, the disclosed compounds 
exhibit binding to STAT3 protein. In a yet further aspect, the 
disclosed compounds exhibit binding to the SH2 domain of 
50 STAT3. The binding affinity of a disclosed compound for a 
STAT protein, e.g. STAT3 protein, can be determined by 
various methods known to one skilled in the art. For example, 
inhibition of STAT protein activity can be determined using a 
surface plasmon resonance ("SPR") assay. In one aspect, the 
55 disclosed compounds exhibit binding to STAT protein with a 
Kn ofless than about 50 µM, less than about 10 less than about 
1 µM, less than about 500 nM, or of less than about 100 nM. 
In a further aspect, the Kn is determined using an SPR 
method. In a still further aspect, the binding is determined 
60 using STAT3 protein. 
In various further aspects, the binding to STAT3 is selec-
tive. In a further aspect, the disclosed compounds exhibit a Kn 
for STAT3 binding less than the Kn for one or more of STAT!, 
STAT2, STAT4, STAT5a, STAT5b, or STAT6. That is, a dis-
65 closed compound can have selectivity for the STAT3 protein 
vis-a-vis one or more of STAT!, STAT2, STAT4, STAT5a, 
STAT5b, or STAT6 proteins. For example, in one aspect, a 
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disclosed compound can bind STAT3 with a Kn of about 
5-foldless than that for STATl, ofabout 10-fold less than that 
for STATl, ofabout 20-fold less than that for STATl, ofabout 
30-foldless than that for STATl, or of about 50-fold less than 
that for STAT!. In a further aspect, a disclosed compound can 5 
bind STAT3 with a Kn of about 5-fold less than that for 
STAT2, of about 10-fold less than that for STAT2, of about 
20-fold less than that for STAT2, of about 30-fold less than 
that for STAT2, or of about 50-fold less than that for STAT2. 
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tent or constitutive activity. For example, the STAT3 protein 
can have a persistent or constitutive activity due to a dysfunc-
tion in an upstream regulatory protein. In a further aspect, the 
STAT3 protein is overexpressed. 
In one aspect, the disclosed compounds and products of 
disclosed methods of making inhibit cell growth. In a still 
further aspect, the disclosed compounds and products of dis-
closed methods inhibit cell growth in an in vitro assay system. 
In an even further aspect, the in vitro assay system makes use 
of a cell-line derived from a from cancer or tumor selected 
from breast cancer, prostate cancer, and pancreatic cancer. In 
a yet further aspect, the cell-line is derived from a human 
source. In a yet further aspect, the disclosed compounds 
inhibit cell growth in a cell with a persistently active STAT3 
protein. In an even further aspect, the cell-line has an acti-
vated STAT3 protein. In a still further aspect, the cell-line is 
selected from MDA-MB-231, MDA-468, Panc-1, DU145, 
0 PM2, OCL-AML2, and A54 9. In an even further aspect, the 
cell-line is selected from DU-145, Panc-1, and MDA-MB-
In a still further aspect, a disclosed compound can bind 10 
STAT3 with a Kn of about 5-foldless than that for STAT4, of 
about 10-fold less than that for STAT4, of about 20-fold less 
than that for STAT4, of about 30-fold less than that for 
STAT4, or of about 50-fold less than that for STAT4. In a yet 
further aspect, a disclosed compound can bind STAT3 with a 15 
Kn ofabout 5-fold less than that for STAT5a, ofabout 10-fold 
less than that for STAT5a, of about 20-fold less than that for 
STAT5a, of about 30-fold less than that for STAT5a, or of 
about 50-fold less than that for STAT5a. In an even further 
aspect, a disclosed compound can bind STAT3 with a Kn of 
about 5-fold less than that for STAT5b, of about 10-fold less 
than that for STAT5b, of about 20-fold less than that for 
STAT5b, of about 30-fold less than that for STAT5b, or of 
about 50-fold less than that for STAT5b. In a still further 
aspect, a disclosed compound can bind STAT3 with a Kn of 
about 5-fold less than that for STAT6, of about 10-fold less 
than that for STAT6, of about 20-fold less than that for 
STAT6, of about 30-fold less than that for STAT6, or of about 
50-fold less than that for STAT6. 
20 231. In a still further aspect, the inhibition of cell growth by 
the disclosed compounds is determined in a cell-line express-
ing v-Src. In an even further aspect, the cell-line is trans-
formed with v-Src. In a yet further aspect, cell-line which is 
transformed in the NIH3T3 cell-line. In one aspect, the dis-
25 closed compounds exhibit inhibition of cell growth activity in 
an in vitro cell-based assay with an IC50 ofless than about 300 
µM, less than about 100 µM, less than about 50 less than about 
10 µM, less than about 1 less than about 500 nM, or of less 
than about 100 nM. 
In one aspect, the disclosed compounds and products of 
disclosed methods of making inhibit cell migration. In a still 
further aspect, the disclosed compounds and products of dis-
closed methods inhibit cell migration in an in vitro assay 
system. In an even further aspect, the in vitro assay system 
In a further aspect, the disclosed compounds exhibit inhi- 30 
bition of binding a reporter molecule to a STAT protein. In a 
further aspect, the disclosed compounds exhibit inhibition of 
binding of a reporter molecule to the SH2 domain of a STAT 
protein. In a still further aspect, the disclosed compounds 
exhibit inhibition of binding of a reporter molecule to the 
STAT3 protein. In a yet further aspect, the disclosed com-
pounds exhibit inhibition of binding of a reporter molecule to 
the SH2 domain of STAT3. The inhibition of binding of a 
reporter molecule to a STAT protein, e.g. STAT3 protein, can 
35 makes use of a cell-line derived from a from cancer or tumor 
by a disclosed compound can be determined by various meth- 40 
ods known to one skilled in the art. For example, inhibition of 
a reporter molecule to STAT3 can be determined using a 
fluorescence polarization assay. In a further aspect, the com-
pound exhibits inhibition with an K, of less than about 300 
µM. In a still further aspect, the compound exhibits inhibition 45 
with an K, ofless than about 100 µM. In a yet further aspect, 
the compound exhibits inhibition with an K, ofless than about 
50 µM. In an even further aspect, the compound exhibits 
inhibition with an K, ofless than about 10 µM. In a still further 
aspect, the compound exhibits inhibition with an K, of less 50 
than about 1 µM. In an even further aspect, the compound 
exhibits inhibition with an K, ofless than about 0.1 µM. In a 
still further aspect, the report molecule is a fluorescently 
labeled peptide. In a yet further aspect, the fluorescently-
labeled reporter peptide 1s 5-carboxyfluorescein- 55 
Gp YLPQTV-NH2. 
Alternatively, the inhibition of STAT protein activity can be 
determined in a cell-based assay. There are a variety of cell-
based assays that are suitable for determination of inhibition 
of STAT protein activity known to one skilled in the art. For 60 
example, cell growth inhibition or cell arrest can be deter-
mined using a cell, either a permanent cell-line or a primary 
cell culture that has a STAT protein with dysfunction activity. 
In a further aspect, the STAT protein is S TAT3. In a yet further 
aspect, the STAT3 protein dysfunction is one wherein the 65 
STAT3 protein is has acquired a gain of function mutation. 
Alternatively, the STAT3 protein has a phenotype of persis-
selected from breast cancer, prostate cancer, and pancreatic 
cancer. In a yet further aspect, the cell-line is derived from a 
human source. In a yet further aspect, the disclosed com-
pounds inhibit cell growth in a cell with a persistently active 
STAT3 protein. In an even further aspect, the cell-line has an 
activated STAT3 protein. In a still further aspect, the cell-line 
is selectedfromMDA-MB-231, MDA-468, Panc-1, DU145, 
0 PM2, OCL-AML2, and A54 9. In an even further aspect, the 
cell-line is selected from DU-145, Panc-1, and MDA-MB-
231. In a still further aspect, the inhibition of cell migration by 
of the disclosed compound is determined in a cell-line 
expressing v-Src. In an even further aspect, the cell-line is 
transformed with v-Src. In a yet further aspect, cell-line 
which is transformed in the NIH3T3 cell-line. In one aspect, 
the disclosed compounds exhibit inhibition of cell migration 
in an in vitro cell-based assay with an IC50 ofless than about 
300 µM, less than about 100 µM, less than about 50 µM, less 
than about 10 µM, less than about 1 µM, less than about 500 
nM, or ofless than about 100 nM. 
Alternatively, the modulatory effects, e.g. inhibition, of the 
disclosed compounds can be determined using other types of 
cell-based assays, e.g. determination of the level of 
pY705STAT3 levels in cells following treatment with a dis-
closed compound and compared to thep Y705STAT3 levels in 
control cells versus the unphosphorylated form of STAT3 in 
the same cell lysate. Determination ofpY705STAT3 can be 
carried by immunoblots of cell lysates, e.g. whole-cell 
lysates, nuclear extracts, and cytosolic lysates. Other markers 
of STAT3 inhibition can be assessed in similar fashion, and 
include markers selected from the phosphorylated and 
unphosphorylated forms She, Jaks, Src, and Erkl/2. In a 
further aspect, the cellular marker determined by immunblot-
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ting is selected from c-myc, cyclin Dl, Bcl-xL, suvivin, and 
VEGF. In various further aspects, the effect of the disclosed 
compounds on the STAT3 transcriptional activity can be 
determined using a luciferase-based transcriptional reporter 
assay. Briefly, the appropriate cell-type, e.g. DU14S, Panc-1, 5 
or MDA-MB-231, is transiently transfected with a plasmid, 
e.g. pLucTKS3 wherein expression of luciferase is STAT3-
dependent, and compared to the expression ofluciferase in a 
cell-line transiently transfected with a plasmid wherein the 
expression of luciferase is not dependent upon STAT3, e.g. 10 
pLucSRE. 
4. Modulation of Stats Activity 
In one aspect, the disclosed compounds exhibit inhibition 
160 
disclosed compounds exhibit binding to the SH2 domain of 
STATS. The binding affinity of a disclosed compound for a 
STAT protein, e.g. STATS protein, can be determined by 
various methods known to one skilled in the art. For example, 
inhibition of STAT protein activity can be determined using a 
surface plasmon resonance ("SPR") assay. In one aspect, the 
disclosed compounds exhibit binding to STATS protein with 
a Kn of less than about SO µM, less than about 10 µM, less 
than about 1 µM, less than about SOO nM, or ofless than about 
100 nM. In a further aspect, the Kn is determined using an 
SPR method. In a still further aspect, the binding is deter-
mined using STAT3 protein. 
In various further aspects, the binding to STATS is selec-
tive. In a further aspect, the disclosed compounds exhibit a Kn 
for STAT3 binding less than the Kn for one or more of STAT!, 
STAT2, STAT3, STAT4, or STAT6. That is, a disclosed com-
pound can have selectivity for the STAT3 protein vis-a-vis 
one or more of STAT!, STAT2, STAT3, STAT4, or STAT6 
of STATS protein activity. In a yet further aspect, the dis-
closed compounds exhibit selective inhibition of STATS pro- 15 
tein activity. In a still further aspect, the disclosed compounds 
prevent STATS protein dimerization. In a yet further aspect, 
the disclosed compounds exhibit disruption of preformed or 
existing STATS dimers. In a still further aspect, the disclosed 
compounds exhibit binding to the SH2 domain of STATS. 20 proteins. For example, in one aspect, a disclosed compound 
can bind STATS with a Kn of about S-fold less than that for 
STAT!, of about 10-fold less than that for STAT!, of about 
20-fold less than that for STAT!, of about 30-fold less than 
that for STAT!, or of about SO-fold less than that for STAT!. 
Inhibition of STATS activity can be determined by a variety 
of both in vitro and in vivo methods known to one skilled in 
the art. For example, inhibition of STATS protein activity can 
be determined using a electrophoretic mobility shift assay 
("EMSA"). In one aspect, the disclosed compounds exhibit 
inhibition of STATS protein activity with an IC50 in an EMSA 
assay ofless than about 300 µM, less than about 100 µM, less 
than about SO µM, less than about 10 µM, less than about 1 
µM, less than about SOO nM, or ofless than about 100 nM. 
25 In a further aspect, a disclosed compound can bind STATS 
with a Kn of about S-fold less than that for STAT2, of about 
10-fold less than that for STAT2, of about 20-fold less than 
that for STAT2, of about 30-fold less than that for STAT2, or 
of about SO-fold less than that for STAT2. In a still further 
In one aspect, the disclosed compounds are selective for 30 
STATS. In a further aspect, selective inhibition of STATS 
activity is determined using an EMSA assay. In various fur-
ther aspects, the compound inhibits STATS activity in a 
EMSA assay with an IC50 less than the IC50 for one or more 
of STAT!, STAT2, STAT3, STAT4, or STAT6. That is, a 35 
disclosed compound can have selectivity for the STAT3 pro-
tein vis-a-vis one or more ofSTATl, STAT2, STAT3, STAT4, 
or STAT6 proteins. For example, in one aspect, a disclosed 
compound can inhibit STATS with an IC50 of about S-foldless 
than that for STAT!, of about 10-fold less than that for 40 
STAT!, of about 20-fold less than that for STAT!, of about 
30-foldless than that for STAT!, or of about SO-fold less than 
that for STAT!. In a further aspect, a disclosed compound can 
inhibit STATS with an IC50 of about S-fold less than that for 
STAT2, of about 10-fold less than that for STAT2, of about 45 
20-fold less than that for STAT2, of about 30-fold less than 
that for STAT2, or of about SO-fold less than that for STAT2. 
In a still further aspect, a disclosed compound can inhibit 
STATS with an IC50 of about S-fold less than that for STAT3, 
of about 10-fold less than that for STAT3, of about 20-fold 50 
less than that for STAT3, of about 30-fold less than that for 
STAT3, or of about SO-fold less than that for STAT3. In a yet 
further aspect, a disclosed compound can inhibit STATS with 
an IC50 of about S-fold less than that for STAT4, of about 
10-fold less than that for STAT4, of about 20-fold less than 55 
that for STAT4, of about 30-fold less than that for STAT4, or 
of about SO-fold less than that for STAT4. In a still further 
aspect, a disclosed compound can inhibit STATS with an IC50 
aspect, a disclosed compound can bind STATS with a Kn of 
about S-fold less than that for STAT3, of about 10-fold less 
than that for STAT3, of about 20-fold less than that for 
STAT3, of about 30-fold less than that for STAT3, or of about 
SO-fold less than that for STAT3. In a yet further aspect, a 
disclosed compound can bind STATS with a Kn of about 
S-foldless than that for STAT4, ofabout 10-fold less than that 
for STAT 4, ofabout 20-fold less than that for STAT 4, ofabout 
30-fold less than that for STAT 4, or of about SO-fold less than 
that for STAT4. In a still further aspect, a disclosed compound 
can bind STATS with a Kn of about S-fold less than that for 
STAT6, of about 10-fold less than that for STAT6, of about 
20-fold less than that for STAT6, of about 30-fold less than 
that for STAT6, or of about SO-fold less than that for STAT6. 
In a further aspect, the disclosed compounds exhibit inhi-
bition of binding a reporter molecule to a STAT protein. In a 
further aspect, the disclosed compounds exhibit inhibition of 
binding of a reporter molecule to the SH2 domain of a STAT 
protein. In a still further aspect, the disclosed compounds 
exhibit inhibition of binding of a reporter molecule to the 
STATS protein. In a yet further aspect, the disclosed com-
pounds exhibit inhibition of binding of a reporter molecule to 
the SH2 domain of STATS. The inhibition of binding of a 
reporter molecule to a STAT protein, e.g. STATS protein, can 
by a disclosed compound can be determined by various meth-
ods known to one skilled in the art. For example, inhibition of 
a reporter molecule to STAT3 can be determined using a 
fluorescence polarization assay. In a further aspect, the com-
pound exhibits inhibition with an K, of less than about 300 
µM. In a still further aspect, the compound exhibits inhibition of about S-fold less than that for STAT6, of about 10-fold less 
than that for STAT6, of about 20-fold less than that for 
STAT6, of about 30-fold less than that for STAT6, or of about 
SO-fold less than that for STAT6. 
In various aspects, the disclosed compounds exhibit bind-
ing to a STAT protein. In a further aspect, the disclosed 
compounds exhibit binding to the SH2 domain of a STAT 
protein. In a still further aspect, the disclosed compounds 
exhibit binding to STATS protein. In a yet further aspect, the 
60 with an K, of less than about 100 µM. In a yet further aspect, 
the compound exhibits inhibition with an K, ofless than about 
SO µM. In an even further aspect, the compound exhibits 
inhibition with an K1 of less than about 10 µM. In a still 
further aspect, the compound exhibits inhibition with an K, of 
65 less than about 1 µM. In an even further aspect, the compound 
exhibits inhibition with an K, of less than about 0.1 µM. In a 
still further aspect, the report molecule is a fluorescently 
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labeled peptide. In a yet further aspect, the fluorescently-
labeled reporter peptide 1s S-carboxyfluorescein-
Gp YLPQTV-NH2. 
Alternatively, the inhibition of STAT protein activity can be 
determined in a cell-based assay. There are a variety of cell-
based assays that are suitable for determination of inhibition 
of STAT protein activity known to one skilled in the art. For 
example, cell growth inhibition or cell arrest can be deter-
mined using a cell, either a permanent cell-line or a primary 
cell culture that has a STAT protein with dysfunction activity. 10 
Ina further aspect, the STAT protein is STATS. Ina yet further 
aspect, the STATS protein dysfunction is one wherein the 
STATS protein is has acquired a gain of function mutation. 
Alternatively, the STATS protein has a phenotype of persis-
tent or constitutive activity. For example, the STATS protein 15 
can have a persistent or constitutive activity due to a dysfunc-
tion in an upstream regulatory protein. In a further aspect, the 
STATS protein is overexpressed. In a further aspect, the cell 
harbors an active oncogene is associated with STATS dys-
function. For example, cell-lines with the BCR-Abl oncogene 20 
are associated with a STATS dysfunction. In a further aspect, 
the cell-line has a FLT-3 dysfunction, e.g. a constitutively 
active FLT-3 protein. FLT-3 dysfunction is associated with 
STATS dysfunction in cell-lines. 
In one aspect, the disclosed compounds and products of 25 
disclosed methods of making inhibit cell growth. In a still 
further aspect, the disclosed compounds and products of dis-
closed methods inhibit cell growth in an in vitro assay system. 
In an even further aspect, the in vitro assay system makes use 
of a cell-line derived from a from cancer or tumor selected 30 
from breast cancer, prostate cancer, and pancreatic cancer. In 
162 
be assessed in similar fashion other methods known to one 
skilled in the art (e.g. ELISA, real-time PCR, Northern blots 
and the liek), and include markers selected from Bcl-xL, 
cyclin D 1, cyclin D2, c-myc, and MCL-1. In various further 
aspects, the effect of the disclosed compounds on the STATS 
activity can be assessed by assays of apoptosis. In is contem-
plated that the pro-apoptotic activity of the compounds can be 
determined in an apoptosis assay as known to one skilled in 
the art. For example, the effect of the disclosed compounds on 
apoptosis can be determined using KS62 or MV-4-11 cells 
and assessed from an amiexin V/Pl assay. In a still further 
aspect, the effect of the disclosed compounds on STATS 
activity can be determined by a chromatin immunoprecipita-
tion assay wherein the presence of STATS bound to the c-myc 
and/or cyclin Dl promoter is determined. 
C. METHODS OF MAKING THE COMPOUNDS 
In one aspect, the invention relates to methods of making 
compounds useful as inhibitors of STAT. In a further aspect, 
the products of disclosed methods of making are modulators 
of STAT activity. In a yet further aspect, the products of 
disclosed methods of making bind to a STAT protein and 
negatively modulate STAT activity. The compounds can, in 
one aspect, exhibit subtype selectivity. In a still further aspect, 
the products of disclosed methods of making exhibit selec-
tivity for the STAT3 member of the STAT protein family. 
The compounds of this invention can be prepared by 
employing reactions as shown in the following schemes, in 
addition to other standard manipulations that are known in the 
literature, exemplified in the experimental sections or clear to 
a yet further aspect, the cell-line is derived from a human 
source. In a yet further aspect, the disclosed compounds 
inhibit cell growth in a cell with a persistently active STATS 
protein. In an even further aspect, the cell-line has an acti-
vated STAT3 protein. In a still further aspect, the cell-line is 
selected from KS62 and MV-4-11. In one aspect, the dis-
closed compounds exhibit inhibition of cell growth activity in 
35 
one skilled in the art. For clarity, examples having a single 
substituent are shown where multiple substituents are 
allowed under the definitions disclosed herein. 
an in vitro cell-based assay with an IC50 ofless than about 300 
µM, less than about 100 µM, less than about SO µM, less than 40 
about 10 µM, less than about 1 µM, less than about SOO nM, 
or of less than about 100 nM. 
Reactions used to generatethe compounds of this invention 
are prepared by employing reactions as shown in the follow-
ing Reaction Schemes, in addition to other standard manipu-
lations known in the literature or to one skilled in the art. The 
following examples are provided so that the invention might 
be more fully understood, are illustrative only, and should not 
be construed as limiting. 
In one aspect, the disclosed compounds comprise the prod-
ucts of the synthetic methods described herein. In a further 
aspect, the disclosed compounds comprise a compound pro-
duced by a synthetic method described herein. In a still fur-
ther aspect, the invention comprises a pharmaceutical com-
In one aspect, the disclosed compounds and products of 
disclosed methods of making inhibit cell migration. In a still 
further aspect, the disclosed compounds and products of dis- 45 
closed methods inhibit cell migration in an in vitro assay 
system. In an even further aspect, the in vitro assay system 
makes use of a cell-line derived from a from cancer or tumor 
selected from breast cancer, prostate cancer, and pancreatic 
cancer. In a yet further aspect, the cell-line is derived from a 
human source. In a yet further aspect, the disclosed com-
pounds inhibit cell growth in a cell with a persistently active 
STATS protein. In an even further aspect, the cell-line has an 
activated STATS protein. In a still further aspect, the cell-line 
50 position comprising a therapeutically effective amount of the 
product of the disclosed methods and a pharmaceutically 
acceptable carrier. In a still further aspect, the invention com-
prises a method for manufacturing a medicament comprising 
combining at least one compound of any of disclosed com-
is selected from MV-4-11 and KS62. In one aspect, the dis-
closed compounds exhibit inhibition of cell migration in an in 
vitro cell-based assay with an IC50 ofless than about 300 µM, 
less than about 100 µM, less than about SO µM, less than about 
55 pounds or at least one product of the disclosed methods with 
a pharmaceutically acceptable carrier or diluent. 
10 µM, less than about 1 µM, less than about SOO nM, or of 
less than about 100 nM. 
In a further aspect, the compound produced is useful in the 
treatment of a disorder of uncontrolled cellular proliferation 
associated with STAT dysfunction and other diseases in 
60 which a STAT protein is involved, as further described herein. 
Alternatively, the modulatory effects, e.g. inhibition, of the 
disclosed compounds can be determined using other types of 
cell-based assays, e.g. determination of the level of pSTATS 
levels in cells following treatment with a disclosed compound 
and compared to the pSTATS levels in control cells versus the 65 
unphosphorylated form of STATS in the same cell lysate by 
Western blot analysis. Other markers of STATS inhibition can 
In a further aspect, the STAT protein is STAT3. 
1. Route I 
In one aspect, substituted 2-hydroxy-4-(2-(phenylsulfona-
mido )acetamido )benzoic acid analogs of the present inven-
tion can be prepared generically by the synthetic scheme as 
shown below. 





Pg = protecting group 
X =halogen or leaving group 
Compounds are represented in generic form, with substitu- 55 
ents as noted in compound descriptions elsewhere herein. A 
more specific example is set forth below. 
In one aspect, Route I begins with a suitable substituted 
4-aminosalicylic acid (1.1) and benzyl bromide. The reaction 60 
of the 4-aminosalicylic acid derivative and benzyl bromide is 
typically carried out in a suitable solvent such as DMF. A 
suitable base, e.g., potassium tert-butoxide is added and the 
reaction stirred for about 15 minutes. Then the initial pre- 65 
scribed portion ofbenzyl bromide is added, and the reaction 




suitable amount of time sufficient to complete the first phase 
of the reaction, e.g., about 4 hours. Then the reaction is cooled 
to about 0° C. and another prescribed amount of potassium 
tert-butoxide is added followed by the second prescribed 
amount ofbenzyl bromide is added. The reaction is stirred for 
a suitable amount of time sufficient to complete reaction, e.g., 
overnight (about 8 to 18 hours) and then water is added to 
afford compounds of type 1.2. The product, a compound of 
type 1.2, is isolated by methods known to one skilled in the art 
e.g., extraction with a solvent (e.g., ethyl acetate), washing 
(e.g., water), drying, filtering, and concentration under 
vacuum; followed by purification if necessary. 















4A molecular sieves 
45° C., 3 h 















In one aspect, compounds of type 1.3, can be prepared by 
reaction of an amine (1.2) with a suitable aldehyde under 
reductive amination conditions. To a stirred solution of the 
amine, compounds of type 1.2, acetic acid and an anhydrous 
solvent, e.g., methanol with molecular sieves is added an 
aldehyde, e.g., R1(CH2)nCHO. The reaction is heated at a 
appropriate temperature, about 45° C., for a sufficient reac-
tion time of about 3 hours and then allowed to cool to about 
room temperature. Then the reducing agent, e.g., sodium 
cyanoborohydride, is added to the reaction mixture and is 
allowed to stir for sufficient time to complete the reaction, 
overnight (about 8 to 18 hours) at an appropriate temperature 
(about 15-30° C.) Upon completion of the reaction, the reac-
tion is diluted with a solvent, e.g., dichloromethane, filtered, 
and concentrated under vacuum to afford the product 1.3 
upon purification if necessary. 
50 
55 
H2. 10% Pd/C, 
CH30H:THF (1:1) 
rt, 1-16 h 
or 
TFA, toluene, (1:1) 
rt, 10 min 
1.9 
In one aspect compounds of type 1.5 can be prepared by the 
reaction of a sulfonyl chloride, R3 S02Cl, with an amine, e.g., 
1.4. To the amine, e.g., 1.4, dissolved in an appropriate sol-
vent, e.g., dichloromethane, is added a suitable base, e.g., 
DlPEA. Then, the appropriate sulfonyl chloride, e.g., 
R3S02 Cl, is added and the reaction is stirred at room tem-
perature (about 15-30° C.) until the reaction is complete 
(about 1 hour). The product, a compound of type 1.5, is 
60 isolated by methods known to one skilled in the art e.g., 
extraction with a solvent (e.g., dichloromethane), washing 
(e.g., water, brine), drying, filtering and concentration under 
vacuum; followed by purification if necessary. 
In one aspect, compounds of type 1.4, can be prepared by 
65 the reaction of an alkyl halide, R2 (CH2)mX, to afford com-
pounds of type 1.6. To a stirred solution of 1.4 and a base, e.g., 
cesium carbonate, in a suitable solvent, e.g., DMF is added a 
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alkyl halide, e.g., R2 (CH2 )mX. The reaction is allowed to stir 
for a sufficient amount of time to complete the reaction, e.g., 
overnight (about 8 to 18 hours, at room temperature (about 
15-30° C.). The product, a compound of type 1.6, is isolated 
by methods known to one skilled in the art e.g., extraction 5 
with a solvent (e.g., dichloromethane ), washing (e.g., brine), 
drying, filtering and concentration under vacuum; followed 
by purification if necessary. 
In one aspect, compounds of type 1.6 can be converted to 
compounds of type 1.7 under the appropriate hydrolysis con- 10 
ditions. Compound 1.7 is dissolved in an appropriate solvent 
combination in the appropriate ratio, e.g., CH30H:THF:H20 
(3: 1: 1) and then a base, e.g, LiOH.H20 is added at an appro-
priate room temperature, (about 15-30° C.). The mixture is 
stirred for an suitable amount of time, e.g., about 3 hours, to 15 
allow for completion reaction to occur. The solvents are 
evaporated, except for water. The remaining aqueous mixture 
is washed with an appropriate solvent, e.g., ethyl acetate. The 
alkaline, aqueous solution is treated with an aqueous acid, 20 
e.g., HCl (aq) to acidify (about pH 2). The product, a com-
pound of type 1. 7, is isolated by methods known to one skilled 
in the art e.g., extraction with a solvent (e.g., ethyl acetate), 
drying, filtering and concentration under vacuum; followed 
by purification if necessary. 25 
In one aspect compounds of type 1.8 can be synthesized by 
reacting compounds of types 1.3 and 1.7 with each other. To 
a stirred solution of the secondary aniline of type 1.3 and the 
carboxylic acid of type 1.7 in a suitable solvent, e.g., chloro-
30 
form, is added PPh3Cl2 . The reaction is heated overnight 
(about 8-18 hours) at an appropriate temperature, e.g., about 
60° C. Upon cooling, the solvent(s) are removed under 
reduced pressure. The concentrated residue is absorbed 
directly onto a suitable stationary phase, e.g., silica gel, and 35 
subjected to chromatography to give the product 1.8. 
In one aspect compounds of type 1.9 can be prepared by the 
deprotection of compounds of type 1.8 using hydrogenolysis 
conditions. For example, the benzyl protected compounds of 
type 1.8 are dissolved in a suitable solvent such as CH3 0H: 
40 
THF (1: 1, about 0.1 M). The mixture is degassed before 
adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 
gas is then bubbled through the reaction mixture for about 5 
minutes and then the reaction mixture is put under an atmo- 45 
sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction. 
Then, the mixture is filtered and concentrated under reduced 
pressure to afford the product 1.9, upon purification if neces-
50 
sary. 
In one aspect compounds of type 1.9 can be prepared by the 
deprotection of compounds of type 1.8 under acidic condi-
tions. For example, the benzyl protected compounds of type 
1.8 are dissolved in a suitable solvent with trifluoroacetic 55 
acid, e.g., toluene:TFA (1:1, about 0.1 M). The mixture is 
stirred for a suitable amount of time to for completion of the 
reaction, e.g., 5 minutes, at the appropriate temperature, e.g., 
room temperature (about 15-30° C.). Upon completion of the 
reaction, the solvents are removed under reduced pressure to 60 
afford the product of type 1.9 upon purification if necessary. 
2. Route II 
In one aspect, substituted 2-hydroxy-4-(2-(phenylsulfona-
mido )acetamido )benzoic acid analogs of the present inven- 65 
tion can be prepared generically by the synthetic scheme as 
shown below. 
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Pg =protecting group 
Compounds are represented in generic form, with substitu-
ents as noted in compound descriptions elsewhere herein. A 





H1, 10% Pd/C 
CH30H:THF (1:1) 





Boc20, cat. DMAP, 
CH2Cli, rt, 1 h 
or 
R1F or R1Cl, DIPEA, 
DMSO, 120' C., 16 h 





H1, 10% Pd/C 
CH30H:THF (1:1) 





In one aspect, Route 11 begins with a suitable substituted compounds of type 2.3, is isolated by methods known to one 
2-hydroxy-4-(2-(phenylsulfonamido )acetamido )benzoic 45 skilled in the art e.g., extraction with a solvent (e.g., ethyl 
acid analogs (2.1) to afford N-Boc derivatives 2.3. Amines of acetate), washing (e.g., brine), drying, filtering and concen-
type 2.1 are mixed with a base, e.g., DIPEA in a suitable tration under vacuum; followed by purification if necessary. 
solvent, e.g., chloroform (about 0.1 M concentration). To this In one aspect compounds of type 2.2 can be prepared by the 
mixture is added Boc20, and mixture is allowed to stir over- deprotection of compounds of type 2.1 using hydrogenolysis 
night (8-18 hours) at room temperature (15-30° C.) until the 50 conditions. For example, the benzyl protected compounds of 
reaction is completed. The product, the Boe protected com- type 2.1 are dissolved in a suitable solvent such as CH3 0H: 
poundoftype 2.3, is isolated by methods known to one skilled THF (1: 1, about 0.1 M). The mixture is degassed before 
in the art e.g., extraction with a solvent (e.g., dichlo- adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 
romethane ), washing (e.g., water and brine), drying, filtering gas is then bubbled through the reaction mixture for about 5 
and concentration under vacuum; followed by purification if 55 minutes and then the reaction mixture is put under an atmo-
sphere ofhydrogen gas and is allowed to stir for about 3 hours necessary. 
In one aspect, a suitable substituted 2-hydroxy-4-(2-(phe- or a suitable amount of time to allow for complete reaction. 
Then, the mixture is filtered and concentrated under reduced 
nylsulfonamido)-acetamido)benzoic acid analogs (2.1) to 
pressure to afford the product 2.2, upon purification if neces-
afford amine derivatives 2.3. The desired secondary amine of 60 sary. 
the type 2.1 and the appropriate aryl halide, e.g., an aryl Inoneaspectcompoundsoftype2.4canbepreparedbythe 
fluoride (R 
1 
F) or aryl chloride (Rice!), are dissolved in a deprotection of compounds of type 2.3 using hydrogenolysis 
appropriate, anhydrous solvent such as DMSO. An appropri- conditions. For example, the benzyl protected compounds of 
ate base, e.g., DIPEA, is added and then the reaction is heated type 2.3 are dissolved in a suitable solvent such as CH
3
0H: 
a suitable temperature (about 120° C.) and time (overnight, 65 THF (1:1, about 0.1 M). The mixture is degassed before 
about 8-18 hours) to allow for enough time for the reaction to adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 
occur. The reaction is quenched with water. The product, gas is then bubbled through the reaction mixture for about 5 
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3. Route III minutes and then the reaction mixture is put under an atmo-
sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction. 
Then, the mixture is filtered and concentrated under reduced 
pressure to afford the product 2.4, upon purification if neces-
sary. 
In one aspect, substituted 2 substituted 2-hydroxy-4-(2-
(phenylsulfonamido )acetamido )benzoic acid analogs of the 
present invention can be prepared generically by the synthetic 
scheme as shown below. 
0=1- )---0---{)-( 



















Compounds are represented in generic form, with substitu- 20 
ents as noted in compound descriptions elsewhere herein. A 






rt, 10 min 
3.3 
Boc20, DIPEA, 
CH2Cli, rt, overnight 
or 
R 1F or R1Cl, DIPEA, 




A Hi,10% Pd/C N 0----.... 
CH30H:THF 
(1:1) 
rt, 1-16 h 
CH30H:THF 
(1:1) 
rt, 1-16 h 
R3C02H (R3LOH), HBTU, DIPEA, 









rt, 1-16 h 
3.5 
In one aspect, Route III begins with a suitable substituted 
20 
2-hydroxy-4-(2-(phenylsulfonamido )acetamido )benzoic 
acid analogs (3.1) to afford N-trifluoracetyl derivatives 3.3. 
For example, compounds of type 3.1 can be converted to 
compounds of type 3.3 under the appropriate hydrolysis con- 25 
ditions. Compound 3.1 is dissolved in an appropriate solvent 
combination in the appropriate ratio, e.g., CH30H:THF:H20 
(3: 1: 1) and then a base, e.g., LiOH.H20 is added at an appro-
priate room temperature, (about 15-30° C.). The mixture is 
stirred for an suitable amount of time, e.g., about 10 minutes, 30 
to allow for completion reaction to occur. The reaction is 
diluted with water and the product, 3.3, extracted with an 
appropriate solvent, e.g., ethyl acetate. The product, a com-
pound of type 3.3, is isolated by methods known to one skilled 
in the art e.g., extraction with a solvent (e.g., ethyl acetate), 35 
washing (aqueous NaHC03 , water, brine), drying, filtering 
and concentration under vacuum; followed by purification if 
necessary. 
In one aspect compounds of type 3 .2 can be prepared by the 
deprotection of compounds of type 3 .1 using hydrogenolysis 
40 
conditions. For example, the benzyl protected compounds of 
type 3.1 are dissolved in a suitable solvent such as CH3 0H: 
THF (1: 1, about 0.1 M). The mixture is degassed before 
adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 45 
gas is then bubbled through the reaction mixture for about 5 
minutes and then the reaction mixture is put under an atmo-
sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction. 
Then, the mixture is filtered and concentrated under reduced 




In one aspect, a suitable substituted 2-hydroxy-4-(2-(phe-
nylsulfonamido )acetamido )benzoic acid analogs (3.3) to 
afford N-Boc derivatives 3.5. Amines of type 3.3 are mixed 
with a base, e.g., DIPEA in a suitable solvent, e.g., chloro-
form (about 0.1 M concentration). To this mixture is added 
Boc20, and mixture is allowed to stir overnight (8-18 hours) 
at room temperature (15-30° C.) until the reaction is com-
pleted. The product, a the Boe protected compound of type 
3.5, is isolated by methods known to one skilled in the art e.g., 
extraction with a solvent (e.g., dichloromethane), washing 
(e.g., water and brine), drying, filtering and concentration 
under vacuum; followed by purification if necessary. 
In one aspect, a suitable substituted 2-hydroxy-4-(2-(phe-
nylsulfonamido )-acetamido )benzoic acid analogs (3.3) to 
afford amine derivatives 3 .5. The desired secondary amine of 
the type 3.3 and the appropriate aryl halide, e.g., an aryl 
fluoride (R 1 F) or aryl chloride (R 1Cl), are dissolved in a 
appropriate, anhydrous solvent such as DMSO. An appropri-
ate base, e.g., DIPEA, is added and then the reaction is heated 
a suitable temperature (about 120° C.) and sufficient time 
(overnight, about 8-18 hours) to allow for reaction to occur. 
The reaction is quenched with water. The product, com-
pounds of type 3.5, is isolated by methods known to one 
skilled in the art e.g., extraction with a solvent (e.g., ethyl 
acetate), washing (e.g., brine), drying, filtering and concen-
tration under vacuum; followed by purification if necessary. 
In one aspect, a suitable substituted 2-hydroxy-4-(2-(phe-
nylsulfonamido)acetamido)benzoic acid analogs (3.3) and 
the appropriate sulfonyl chloride, R3S02 Cl are reacted to 
form compounds of type 3 .5. To the amine, e.g., 3 .3, dissolved 
in an appropriate solvent, e.g., dichloromethane, is added a In one aspect compounds of type 3 .4 can be prepared by the 
deprotection of compounds of type 3 .3 using hydrogenolysis 
conditions. For example, the benzyl protected compounds of 
type 3.3 are dissolved in a suitable solvent such as CH3 0H: 
THF (1: 1, about 0.1 M). The mixture is degassed before 
adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 
gas is then bubbled through the reaction mixture for about 5 
minutes and then the reaction mixture is put under an atmo-
sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction. 
Then, the mixture is filtered and concentrated under reduced 
pressure to afford the product 3 .4, upon purification if neces-
sary. 
55 suitable base, e.g., DIPEA. Then, the appropriate sulfonyl 
chloride, e.g., R3 S02 Cl, is added and the reaction is stirred at 
room temperature (about 15-30° C.) until the reaction is com-
plete (about 1 hour). The product, a compound of type 1.5, is 
isolated by methods known to one skilled in the art e.g., 
60 extraction with a solvent (e.g., dichloromethane), washing 
(e.g., water, brine), drying, filtering and concentration under 
vacuum; followed by purification if necessary. 
In one aspect, a suitable substituted 2-hydroxy-4-(2-(phe-
65 nylsulfonamido)acetamido)benzoic acid analogs (3.3) and 
the appropriate carboxylic acid, R3 C02H are coupled to form 
compounds of type 3.5. The required carboxylic acid of type 
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conditions. For example, the benzyl protected compounds of 
type 3.5 are dissolved in a suitable solvent such as CH3 0H: 
THF (1:1, about 0.1 M). The mixture is degassed before 
adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 
gas is then bubbled through the reaction mixture for about 5 
minutes and then the reaction mixture is put under an atmo-
sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction. 
R3 C02H is added to a solution of the coupling agent, e.g., 
HBTU and a suitable base, e.g., DIPEA in a suitable solvent, 
e.g., DMF at about a 0.1 M concentration. The resulting 
mixture is allowed to stir for about 10 minutes at room tem-
perature (about 15-30° C.). The appropriate amine of type 3.3 5 
is dissolved in a solution of a suitable base, e.g., DIPEA, and 
solvent, e.g., DMF at about a 0.1 M concentration, and then 
this mixture is added to the carboxylic acid/coupling agent 
solution. The reaction is stirred for a sufficient amount of time 
until completed (about 4 hours). The product, compounds of 
type 3.5, is isolated by methods known to one skilled in the art 
e.g., dissolved/extraction with a solvent (e.g., ethyl acetate), 
washings (e.g., about 2M HCl, saturated NaHC03 , brine), 
drying, filtering and concentration under vacuum; followed 15 
by purification if necessary. 
10 Then, the mixture is filtered and concentrated under reduced 
In one aspect compounds of type 3 .6 can be prepared by the 
deprotection of compounds of type 3 .5 using hydrogenolysis 
OPg 
OPg 
R3 A3.4.SB(OH)2 R3 
I I 
pressure to afford the product 3 .6, upon purification if neces-
sary. 
4. Route IV 
In one aspect, substituted 2-hydroxy-4-(2-(phenylsulfona-
mido )acetamido )benzoic acid analogs of the present inven-




R3 - I s TIN Suzuki cross s TIN s TIN o~f'N coupling o~f'N o~f'N 
R2~t O ~ R2~t O ~ R2~t O ~ 
Pg =protecting 
group 






US 8,846,707 B2 
179 
Compounds are represented in generic form, with substitu-
ents as noted in compound descriptions elsewhere herein. A 












l. LiOH, THF:H20 (3:1), 
rt, 24 h 
2. TFA, toluene (1:1), 




In one aspect, Route IV begins with a suitable substituted 





In one aspect compounds of type 4 .3 can be prepared by the 
deprotection of compounds of type 4.2 using hydrogenolysis 






rt, 1-16 h 
A3.4.s 
4.3 
type 4.2 are dissolved in a suitable solvent such as CH3 0H: 
THF (1:1, about 0.1 M). The mixture is degassed before 
adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 
gas is then bubbled through the reaction mixture for about 5 
minutes and then the reaction mixture is put under an atmo-
sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction. 
Then, the mixture is filtered and concentrated under reduced 
55 pressure to afford the product 4.3, upon purification if neces-
sary. 
acid analogs (4.1) to afford biaryl derivatives 4.2. In one 
aspect compounds of type 4.2 can be prepared by the Pd 
mediated coupling of compounds of type 4.1 with aryl 
boronic acid derivatives of type A3 •4 •8B(OH)2 using Suzuki 
cross-coupling reaction conditions. A mixture of the appro-
priate aryl bromide of type 4.1, boronic acid oftypeA3 •4 •8B 
(OH)2 , a suitable base, e.g., K2C03 , and an appropriate cata-
lyst, e.g., Pd(PPh3 ) 4 is suspended in a suitable solvent, e.g., 
DMF, in a sealed tube reaction vessel. The reaction mixture is 
irradiated using a microwave reactor at appropriate tempera-
ture of about 170° C. and for an appropriate amount of time 
for the coupling reaction to go to completion, e.g., about 17 
60 
minutes, After cooling to about room temperature (about 
15-30° C.), the reaction is diluted with an appropriate solvent 
such as dichloromethane. The product, compounds of type 
4.2, is isolated by methods known to one skilled in the art e.g., 
extraction with a solvent (e.g., dichloromethane ), washing 65 
(e.g., brine), drying, filtering and concentration under 
vacuum; followed by purification if necessary. 
For example, compounds of type 4.1 can be converted to 
compounds of type 4.4 under the appropriate two step 
hydrolysis procedure. Step 1: Compound 4.1 is dissolved in 
an appropriate solvent combination in the appropriate ratio, 
e.g., CH30H:THF:H20 (3:1:1) and then a base, e.g., 
LiOH.H20 is added at an appropriate room temperature, 
(about 15-30° C.). The mixture is stirred for an suitable 
amount of time, e.g., about 10 minutes, to allow for comple-
tion reaction to occur. The reaction is diluted with water and 
the mono-benzyl intermediate product of 4.4, extracted with 
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an appropriate solvent, e.g., ethyl acetate. The product, a 
intermediate benzyl ether of type 4.4, is isolated by methods 
known to one skilled in the art e.g., extraction with a solvent 
(e.g., ethyl acetate), washing (aqueous NaHC03 , water, 
brine), drying, filtering and concentration under vacuum, fol-
lowed by purification if necessary. Step 2: The benzyl ether 
intermediate of type 4.4 is dissolved in a suitable solvent with 
trifluoroacetic acid, e.g., toluene:TFA (1: 1, about 0.1 M). The 
mixture is stirred for a suitable amount of time to for comple- 10 
tion of the reaction, e.g., 5 minutes, at the appropriate tem-
perature, e.g., room temperature (about 15-30° C.). Upon 
completion of the reaction, the solvents are removed under 
reduced pressure to afford the product of type 4.4 upon puri- 15 
fication if necessary. 
5. RouteV 
In one aspect, substituted 2-hydroxy-4-(2-(phenylsulfona-
mido )acetamido )benzoic acid analogs of the present inven- 20 









s TIN o~f'N 



















Compounds are represented in generic form, with substitu-
ents as noted in compound descriptions elsewhere herein. A 




I A3.4.SB(OH)2 s TIN Pd(PPh3)4, o~f'N 
K1C03,DMF, 








extraction with a solvent (e,g,, dichloromethane), washing 
( e,g,, brine), drying, filtering and concentration under 
vacuum; followed by purification if necessary, 
In one aspect compounds of type 5 ,3 can be prepared by the 
deprotection of compounds of type 5 ,2 using hydrogenolysis 
conditions, For example, the benzyl protected compounds of 
type 5,2 are dissolved in a suitable solvent such as CH3 0H: 
THF (1:1, about 0,1 M), The mixture is degassed before 
10 adding the hydrogenation catalyst, e,g,, 10% Pd/C, Hydrogen 
gas is then bubbled through the reaction mixture for about 5 
minutes and then the reaction mixture is put under an atmo-
sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction, 
CH30H:THF 
(1:1) 
15 Then, the mixture is filtered and concentrated under reduced 
pressure to afford the product 5 ,3, upon purification if neces-
sary, 










In one aspect, Route V begins with a suitable substituted 
50 
2-hydroxy-4-(2-(phenylsulfonamido )acetamido )benzoic 
acid analogs (5,l) to afford terphenyl derivatives 5,2, In one 
aspect, compounds of type 5,2 can be prepared by the Pd 
mediated coupling of compounds of type 5,1 with aryl 
boronic acid derivatives of type A3 '4 ' 8B(OH)2 using Suzuki 55 
cross-coupling reaction conditions, A mixture of the appro-
priate aryl bromide of type 5,1, boronic acid oftypeA3 '4 ' 8B 
(OH)2 , a suitable base, e,g,, K2C03 , and an appropriate cata-
lyst, e,g,, Pd(PPh3 ) 4 is suspended in a suitable solvent, e,g,, 
DMF, in a sealed tube reaction vesseL The reaction mixture is 60 
irradiated using a microwave reactor at an appropriate tem-
perature of about 170° C, and for an appropriate amount of 
time forthe coupling reaction to go to completion, e,g,, about 
17 minutes, After cooling to about room temperature (about 
15-30° C), the reaction is diluted with an appropriate solvent 65 
such as dichloromethane, The product, compounds of type 
5,2, is isolated by methods known to one skilled in the art e,g,, 
6, Route VI 
In one aspect, substituted 2-hydroxy-4-(2-(phenylsulfona-
mido )acetamido )benzoic acid analogs of the present inven-
tion can be prepared generically by the synthetic scheme as 
shown below, 
US 8,846,707 B2 
Pg = protecting 
group 









S ~N a-9'g'-N 
R2Jt O ~ 
0 
H 
Compounds are represented in generic form, with substitu-
ents as noted in compound descriptions elsewhere herein. A 




















rt, 10 min 
)-p-h R3S02Cl, DIPEA 
BnO \_ j N (~:H CH2Cli, rt, 1 h 
BnO _ R2 
6.4 
6.5 
H2, 10% Pd/C, CH30H:THF 
(1 :1) rt, 1-16 h 
or 
1. LiOH, THF:H20 (3:1), rt, 
lOmin 
2. TFA:CH2Cl2 (1 :2), rt, 5 min 




In one aspect, Route V begins with a suitable substituted 
2-hydroxy-4-(2-(phenylsulfonamido )acetamido )benzoic 
acid analogs (6.1) to afford derivatives 6.3. To a stirred solu-
tion of the secondary aniline of type 6.1 and the carboxylic 
acid of type 6.2 in a suitable solvent, e.g., chloroform, is 
added PPh3 Cl2 . The reaction is heated overnight (about 8-18 
hours) at an appropriate temperature, e.g., about 60° C. Upon 
cooling, the solvent(s) are removed under reduced pressure. 
The concentrated residue is absorbed directly onto a suitable 
stationary phase, e.g., silica gel, and subjected to chromatog-
raphy to give the product 6.3. 
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THF (1:1, about 0.1 M). The mixture is degassed before 
adding the hydrogenation catalyst, e.g., 10% Pd/C, Hydrogen 
gas is then bubbled through the reaction mixture for about 5 
minutes and then the reaction mixture is put under an atmo-
5 sphere ofhydrogen gas and is allowed to stir for about 3 hours 
or a suitable amount of time to allow for complete reaction. 
Then, the mixture is filtered and concentrated under reduced 
pressure to afford the product 6.6, upon purification if neces-
10 
sary. 
For example, compounds of type 6.5 can be converted to 
compounds of type 6.6 under the appropriate two step 
hydrolysis procedure. Step 1: Compound 6.5 is dissolved in 
an appropriate solvent combination in the appropriate ratio, 
e.g., CH30H:THF:H20 (3:1:1) and then a base, e.g., 
15 LiOH.H20 is added at an appropriate room temperature, 
(about 15-30° C.). The mixture is stirred for an suitable 
amount of time, e.g., about 10 minutes, to allow for comple-
tion reaction to occur. The reaction is diluted with water and 
the mono-benzyl intermediate product of 6.6, extracted with 
20 an appropriate solvent, e.g., ethyl acetate. The product, a 
intermediate benzyl ether of type 6.6, is isolated by methods 
known to one skilled in the art e.g., extraction with a solvent 
(e.g., ethyl acetate), washing (aqueous NaHC03 , water, 
brine), drying, filtering and concentration under vacuum, fol-
25 lowed by purification if necessary. Step 2: The benzyl ether 
intermediate of type 6.6 is dissolved in a suitable solvent with 
trifluoroacetic acid, e.g., toluene:TFA (1: 1, about 0.1 M). The 
mixture is stirred for a suitable amount of time to for comple-
tion of the reaction, e.g., 5 minutes, at the appropriate tem-
30 perature, e.g., room temperature (about 15-30° C.). Upon 
completion of the reaction, the solvents are removed under 
reduced pressure to afford the product of type 6.6 upon puri-
fication if necessary. 
In one aspect, compounds of type 6.3 can be converted to 35 
compounds of type 6.4 under the appropriate hydrolysis con-
ditions. Compound 6.3 is dissolved in an appropriate solvent 
combination in the appropriate ratio, e.g., CH30H:THF:H20 
D. STAT PROTEINS 
The STAT family of proteins mediate responses to cytok-
ines and growth factors (Bromberg J (2000) Breast Cancer 
Res. 2(2):86-90; Darnell J E, Jr. (2002) Nat. Rev. Cancer 
2:740-749). The recruitment via the SH2 domain to the recep-
tor phosphotyrosine (pTyr) peptide motifs facilitates STATs 
(3: 1: 1) and then a base, e.g, LiOH.H20 is added at an appro-
priate room temperature, (about 15-30° C.). The mixture is 40 
stirred for an suitable amount of time, e.g., about 10 minutes, 
to allow for completion reaction to occur. The solvents are 
evaporated, except for water. The remaining aqueous mixture 
is washed with an appropriate solvent, e.g., ethyl acetate. The 
alkaline, aqueous solution is treated with an aqueous acid, 45 
e.g., HCl (aq) to acidify (about pH 2). The product, a com-
pound of type 6.4, is isolated by methods known to one skilled 
phosphorylation on a key tyrosyl residue by tyrosine kinases 
of growth factor receptors and cytoplasmic tyrosine kinases, 
such as Janus kinases (Jaks) and the Src family. While pre-
existing dimers have been detected (Sehgal PB (2008) Semin 
Cell Dev Biol. 19:329-340.), phosphorylation induces STAT: 
STAT dimerization through a reciprocal pTyr-SH2 domain 
interaction. The active dimers predominantly in the nucleus 
induce gene transcription by binding to specific DNA-re-
in the art e.g., extraction with a solvent (e.g., ethyl acetate), 
drying, filtering and concentration under vacuum; followed 
by purification if necessary. 
In one aspect, a suitable substituted 2-hydroxy-4-(2-(phe-
nylsulfonamido )acetamido )benzoic acid analogs (6.4) and 
the appropriate sulfonyl chloride, R3S02 Cl are reacted to 
form compounds of type 6.5. To the amine, e.g., 6.4, dissolved 
50 sponse elements in the promoters of target genes. Recently, a 
transcriptional function has been also ascribed for unphos-
phorylated STAT monomers (Yang J, et al. (2005) Cancer 
Res. 65:939-947). 
in an appropriate solvent, e.g., dichloromethane, is added a 55 
suitable base, e.g., DIPEA. Then, the appropriate sulfonyl 
chloride, e.g., R3 S02Cl, is added and the reaction is stirred at 
room temperature (about 15-30° C.) and for a time until the 
reaction is complete (about 1 hour). The product, a compound 
of type 6.5, is isolated by methods known to one skilled in the 60 
art e.g., extraction with a solvent (e.g., dichloromethane), 
washing (e.g., water, brine), drying, filtering and concentra-
tion under vacuum; followed by purification if necessary. 
In one aspect compounds of type 6 .5 can be prepared by the 
deprotection of compounds of type 6.6 using hydrogenolysis 65 
conditions. For example, the benzyl protected compounds of 
type 6.5 are dissolved in a suitable solvent such as CH3 0H: 
STATs have importance in carcinogenesis and tumorigen-
esis. The aberrant activation of the family member, Stat3, 
occurs in many human cancers (Yu H & Jove R (2004) Nat. 
Rev. Cancer 4:97-105; Yue P & Turkson J (2009) Expert Op in 
Investig Drugs. 18:45-56) and promotes tumor progression. 
The mechanisms of Stat3-mediated tumorigenesis include 
de-regulation of gene expression that lead to uncontrolled 
growth and survival of tumor cells, enhanced tumor angio-
genesis, and metastasis (Yu H & Jove R (2004) Nat. Rev. 
Cancer 4:97-105, 7-10; Bromberg J & Darnell J E, Jr. (2000) 
Oncogene 19:2468-2473; Bowman T, Garcia R, TurksonJ, & 
Jove R (2000) Oncogene 19:2474-2488; Turkson J & Jove R 
(2000) Oncogene 19:6613-6626; Turkson J (2004) Expert 
Opin Ther Targets 8(5):409-422). More recent data has also 
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identify Stat3-dependent regulation of mitochondrial func-
tion that promotes malignant transformation (Gough D J, et 
al. (2009) Science 324: 1713-1716). Also, tumor cell-associ-
ated constitutively-active Stat3 suppresses pro-inflammatory 
cytokine expression, including inteluekin-6 (IL-6), 
RANTES, and IP-10, while promoting the induction of vas-
cular endothelial growth factor (VEGF), interleukin-IO (IL-
10) and other soluble factors that activate Stat3 and in den-
dritic cells and inhibit their maturation, thereby suppressing 
tumor-immune surveillance (Wang T, et al. (2004) Nat Med 
10(1):48-S4). Stat3 further engages in signaling cross-talk 
with NF I B directing its functions in support of the malignant 
phenotype (Yu H, Pardall D, & Jove R (2009)Nat Rev Cancer 
9:798-809; Grivennikov SI & Karin M (2010) Cytokine & 
Growth Factor Reviews 21:11-19). 
Without wishing to be bound by a particular theory, a 
model for activity of the disclosed compounds is shown in 
FIG. la, wherein the disclosed compounds mediate inhibition 
190 
towards a potent and direct inhibitor of STATS function for 
the treatment of human malignancies has been disappoint-
ingly limited. 
STATS activation involves a complex signaling cascade 
5 beginning at the cell surface. Stimulation by growth factors 
such as Kit ligand (SCF) erythropoietin or prolactin results in 
receptor dimerization and activation of Stats by intracellular 
kinases such as Janus Kinases (JAKs; Neculai, D., et al. J. 
Biol. Chem. 200S, 280, 40782-40787) In addition oncogenes 
10 such as BCR-ABL and FLT3-ITD induce activation of 
STATS. Phosphorylation of the receptor's cytoplasmic tail 
provides docking sites for recruitment of monomeric, non-
phosphorylated STATS proteins via their SH2 domain. Acti-
vated tyrosine kinases, such as JAK2 phosphorylate recruited 
15 STATS proteins at a specific tyrosine near the carboxy termi-
nus (Tyr694 in StatSA and Tyr699 in STATSB). Phosphory-
lated STATS (pSTATS) protein is released from the receptor, 
and dimerization occurs through reciprocal phosphotyrosine-
SH2 domain interactions. Phosphorylation of a serine residue of Stat3 activation and transcriptional activity and the conse-
quent effects on Stat3-dependent events, tumor processes, 
and tumor growth. In various aspects, in this model the dis-
closed compounds interact with the Stat3 SH2 domain, dis-
rupt pre-existing Stat3:Stat3 dimers, prevent de nova Stat3 
activation by blocking association with phospho (P)-Tyr pep-
tide motifs of receptor (R), and block Stat3 nuclear translo- 25 
cation and transcriptional function. In various aspects, and 
without wishing to be bound by a particular theory, a further 
model for the action of the disclosed compounds is provided 
20 then allows the Stats dimers to translocate to the nucleus 
where Stats binds to a consensus DNA sequence and pro-
motes gene expression (Muller, J., et al. ChemBioChem 
2008, 9, 723-727, Tan, S. H.; Nevalainen, M. T. Endocr. Relat. 
Cancer 2008, IS, 367-390). 
In cancer cells, STATS is routinely constitutively phospho-
rylated which leads to the aberrant expression of STATS 
target genes resulting in malignant transformation. Cancer 
cells harbouring persistently activated Stats over express 
anti-apoptotic proteins, such as Bcl-xL, Myc and MCL-1, in FIG. 1 b, wherein the disclosed compounds mediate inhi-
bition of Stat3-dependent events, tumor processes and tumor 
growth. In various aspects, in this model, the disclosed com-
pounds attenuate aberrant Stat3 signaling, and consequently 
suppressing nuclear Stat3-NFKB crosstalk and nuclear 
pNFKB levels, and the Stat3-mediated E-cadherin repression, 
paxillin, FAK, KLF8, and EPSTil induction, sICAM, 
G-CSF, MIF/GIF, Serpinel, and IL-IRA production, and 
c-Myc, Cyclin Dl, Survivin, VEGF, Bcl-xL induction. Again, 
without wishing to be bound by a particular theor, the modu-
lation of these events through inhibition ofStat3 activity leads 
to inhibition of tumor cell growth, survival, motility, migra-
tion, invasion, and tumor angiogenesis, growth and metasta-
sis Ill VIVO. 
30 conferring significant resistance to natural apoptotic cues and 
administered chemotherapeutic agents (Ferbeyre, G.; 
Moriggl, R. Biochimica et Biophysica Acta-Reviews on 
Cancer 2011, 181S, 104-114). Of particular interest, STATS 
has been identified as a key regulator in the development and 
35 progression of acute myelogenic (AML) and acute lympho-
blastic leukemias (ALL; Gouilleux-Gruart, V., et al. Leuke-
mia and Lymphoma 1997, 28, 83-88; Gouilleux-Gruart, V., et 
al. Blood 1996, 87, 1692-1697; Weber-Nordt, R. M., et al. 
Blood 1996, 88, 809-816). Moreover, inhibitors of upstream 
40 Stats activators (such as JAK and FLT3) have been shown to 
exhibit promising anti-cancer properties (Pardanani, A., et al. 
Leukemia 2011, 2S, 218-22S; Quintas-Cardama, A., et al. 
Nature Reviews Drug Discovery 2011, 10, 127-140). How-
ever, a shortcoming of tyrosine kinase inhibitors, and other 
STATS protein is one of seven members belonging to the 
STAT family of cytosolic proteins. The STAT family of pro-
teins play important and diverse cell signaling and transcrip-
tional roles in cells. Stats signaling, like Stat3 signaling, is 
transiently activated in normal cells and is deactivated by a 
number of different cytosolic and nuclear regulators, includ-
ing phosphatases, SOCS, PIAS, and proteasomal degradation 
(Lai, S.Y.; Johnson, F. M. Drug Resistance Updates 2010, 13, 
67-78.). Like STAT3, STATS has gained notoriety for its 
aberrant role in human cancers and tumorigenesis, having 
been found to be constitutively activated in many cancers. 
including those of the breast, liver, prostate, blood, skin, head 
and neck (Muller, J., et al. ChemBioChem 2008, 9, 723-727.). 55 
Despite significant evidence implicating STATS 's causal role 
45 upstream effectors of kinase activity, is the disruption of 
multiple downstream signaling pathways, increasing the like-
lihood of undesirable toxicity. In addition it is possible that 
other proteins in the malignant cell may also be activating 
STATS; this signaling would not be affected by an upstream-
50 targeted inhibitor. Therefore, silencing a downstream signal-
ing target such as STATS would ultimately result in fewer side 
effects and would thus represent a more attractive candidate 
for a molecularly targeted drug for the treatment of human 
cancers harbouring aberrant STATS activity. 
E. PHARMACEUTICAL COMPOSITIONS 
in human malignancies, unlike STAT3, there has been very 
little progress in identifying small molecule inhibitors of 
STATS function. The majority of medicinal research on STAT 
function in transformed cells has been aimed at identifying an 60 
inhibitor of STAT3 protein. As a result, several direct inhibi-
tors of STAT3 including peptidomimetics, small molecules 
and oligonucleotide-based inhibitors have entered preclinical 
trials as a STAB-targeting therapeutic (Page, B. D., et al. 
Expert Opinion on Therapeutic patents 2011, 21, 6S-83; 65 
Fletcher, S., et al. Cell Biol. 2009, 87, 82S-833; Haftchenary, 
S., et al. Anticancer Drugs 2011, 22, llS-127). Progress 
In one aspect, the invention relates to pharmaceutical com-
positions comprising the disclosed compounds. That is, a 
pharmaceutical composition can be provided comprising a 
therapeutically effective amount of at least one disclosed 
compound or at least one product of a disclosed method and 
a pharmaceutically acceptable carrier. 
In one aspect, the invention relates to a pharmaceutical 
composition comprising a pharmaceutically acceptable car-
rier and an effective amount of a compound of Formula I, II, 
III or IV, or a pharmaceutically acceptable salt, hydrate, sol-
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vate, or polymorph thereof. In a further aspect, the invention 
relates to a pharmaceutical composition comprising a phar-
maceutically acceptable carrier and an effective amount of a 
compound of Formula V, or a pharmaceutically acceptable 
salt, hydrate, solvate, or polymorph thereof. 
In a further aspect, the compound is any of the disclosed 
compounds or at least one product of the disclosed methods of 
making. In a yet further aspect, the pharmaceutical composi-
tion comprises one or more of any of the disclosed com-
pounds or at least one product of the disclosed methods of 10 
making. 
In a further aspect, the compound inhibits STAT protein 
activity with an IC50 in an EMSA assay ofless than about 100 
µM, less than about 50 µM, less than about 10 µM, less than 
about 1 µM, less than about 500 nM, or ofless than about 100 15 
nM. In a further aspect, the IC50 is inhibition of STAT3 pro-
tein activity. In a further aspect, the IC50 is inhibition of 
STATS protein activity. 
In a further aspect, the a compound that inhibits cell 
growth. In a still further aspect, the compound inhibits cell 20 
growth with an IC50 ofless than about 500 µM. In a yet further 
aspect, the compound inhibits cell growth with an IC50 ofless 
than about 250 µM. In an even further aspect, the compound 
inhibits cell growth with an IC50 ofless than about 100 µM. In 
a still further aspect, the compound inhibits cell growth with 25 
an IC50 of less than about 50 µM. In a yet further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
10 µM. In an even further aspect, the compound inhibits cell 
growth with an IC50 of less than about 1 In a still further 
aspect, the IC50 for inhibition of cell growth is determined in 30 
a cell line with a constitutively active STAT protein. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line with a persistently active STAT protein. In 
an even further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line derived from a cancer selected from 35 
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pineocytoma, pineoblastoma, atypical teratoid rhabdoid 
tumor, chondrosarcoma, chondroma, choroid plexus carci-
noma, choroid plexus papilloma, craniopharyngioma, dys-
embryoplastic neuroepithelial tumor, gangliocytoma, germi-
noma, hemangioblastoma, hemangiopercytoma, and 
metastatic brain tumor. In a yet further aspect, the glioma is 
selected from ependymoma, astrocytoma, oligodendro-
glioma, and oligoastrocytoma. In an even further aspect, the 
glioma is selected from juvenile pilocytic astrocytoma, sub-
ependymal giant cell astrocytoma, ganglioglioma, sub-
ependymoma, pleomorphic xanthoastrocytom, anaplastic 
astrocytoma, glioblastoma multiforme, brain stem glioma, 
oligodendroglioma, ependymoma, oligoastrocytoma, cer-
ebellar astrocytoma, desmoplastic infantile astrocytoma, sub-
ependymal giant cell astrocytoma, diffuse astrocytoma, 
mixed glioma, optic glioma, gliomatosis cerebri, multifocal 
gliomatous tumor, multicentric glioblastoma multiforme 
tumor, paraganglioma, and ganglioglioma. 
In a further aspect, the cancer is selected from a cancer of 
the breast, ovary, prostate, head, neck, and kidney. In a still 
further aspect, the cancer is breast cancer. In a yet further 
aspect, the cancer is pancreatic cancer. 
In certain aspects, the disclosed pharmaceutical composi-
tions comprise the disclosed compounds (including pharma-
ceutically acceptable salt(s) thereof) as an active ingredient, a 
pharmaceutically acceptable carrier, and, optionally, other 
therapeutic ingredients or adjuvants. The instant composi-
tions include those suitable for oral, rectal, topical, and 
parenteral (including subcutaneous, intramuscular, and intra-
venous) administration, although the most suitable route in 
any given case will depend on the particular host, and nature 
and severity of the conditions for which the active ingredient 
is being administered. The pharmaceutical compositions can 
be conveniently presented in unit dosage form and prepared 
by any of the methods well known in the art of pharmacy. 
As used herein, the term "pharmaceutically acceptable 
salts" refers to salts prepared from pharmaceutically accept-
able non-toxic bases or acids. When the compound of the 
present invention is acidic, its corresponding salt can be con-
breast cancer, pancreatic cancer, and prostate cancer. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line derived from a cancer with a STAT protein 
activity dysfunction. In a still further aspect, the IC50 for 
inhibition of cell growth is determined in a cell line selected 
from MDA-MB-231, Panc-1, and DU 145. In a yet further 
aspect, the IC50 for inhibition of cell growth is determined in 
a cell line transformed with v-Src. In an even further aspect, 
the IC50 for inhibition of cell growth is determined in the 
NIH3T3 cell-line transformed with v-Src. 
40 veniently prepared from pharmaceutically acceptable non-
toxic bases, including inorganic bases and organic bases. 
Salts derived from such inorganic bases include aluminum, 
ammonium, calcium, copper (-ic and -ous), ferric, ferrous, 
lithium, magnesium, manganese (-ic and -ous), potassium, 
In a further aspect, the pharmaceutical composition treats a 
disorder of uncontrolled cellular proliferation. In a yet further 
aspect, the disorder of uncontrolled cellular proliferation is 
cancer. In a still further aspect, the cancer is selected from a 
cancer of the head, neck, pancreas, brain, ovary, kidney, pros-
tate, breast, lung, colon, and liver. 
45 sodium, zinc and the like salts. Particularly preferred are the 
ammonium, calcium, magnesium, potassium and sodium 
salts. Salts derived from pharmaceutically acceptable organic 
non-toxic bases include salts of primary, secondary, and ter-
tiary amines, as well as cyclic amines and substituted amines 
In a further aspect, the cancer is a hematological cancer. In 
50 such as naturally occurring and synthesized substituted 
amines. Other pharmaceutically acceptable organic non-
toxic bases from which salts can be formed include ion 
exchange resins such as, for example, arginine, betaine, caf-a still further aspect, the hematological cancer is selected 
from acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic myeloid leukemia (CML), chronic 55 
lymphocytic leukemia (CLL), hairy cell leukemia, chronic 
myelomonocytic leukemia (CMML), juvenile myelomono-
cytic leukemia (JMML), Hodgkin lymphoma, Non-Hodgkin 
lymphoma, multiple myeloma, solitary myeloma, localized 
myeloma, and extramedullary myeloma. 
feine, choline, N,N'-dibenzylethylenediamine, diethylamine, 
2-diethylaminoethanol, 2-dimethylaminoethanol, ethanola-
mine, ethylenediamine, N-ethylmorpholine, N-ethylpiperi-
dine, glucamine, glucosamine, histidine, hydrabamine, iso-
propylamine, lysine, methylglucamine, morpholine, 
piperazine, piperidine, polyamine resins, procaine, purines, 
60 theobromine, triethylamine, trimethylamine, tripropylamine, 
tromethamine and the like. In a further aspect, the cancer is a cancer of the brain. In a 
still further aspect, the cancer of the brain is selected from a 
glioma, medulloblastoma, primitive neuroectodermal tumor 
(PNET), acoustic neuroma, glioma, meningioma, pituitary 
adenoma, schwannoma, CNS lymphoma, primitive neuroec- 65 
todermal tumor, craniopharyngioma, chordoma, medullo-
blastoma, cerebral neuroblastoma, central neurocytoma, 
As used herein, the term "pharmaceutically acceptable 
non-toxic acids", includes inorganic acids, organic acids, and 
salts prepared therefrom, for example, acetic, benzene-
sulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, 
fumaric, gluconic, glutamic, hydrobromic, hydrochloric, 
isethionic, lactic, maleic, malic, mandelic, methanesulfonic, 
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mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sul-
furic, tartaric, p-toluenesulfonic acid and the like. Preferred 
are citric, hydrobromic, hydrochloric, maleic, phosphoric, 
sulfuric, and tartaric acids. 
194 
The pharmaceutical compositions of the present invention 
comprise a compound of the invention (or pharmaceutically 
acceptable salts thereof) as an active ingredient, a pharma-
ceutically acceptable carrier, and optionally one or more 
additional therapeutic agents or adjuvants. The instant com-
positions include compositions suitable for oral, rectal, topi-
cal, and parenteral (including subcutaneous, intramuscular, 
and intravenous) administration, although the most suitable 
route in any given case will depend on the particular host, and 
10 nature and severity of the conditions for which the active 
ingredient is being administered. The pharmaceutical com-
positions can be conveniently presented in unit dosage form 
and prepared by any of the methods well known in the art of 
In practice, the compounds of the invention, or pharmaceu-
tically acceptable salts thereof, of this invention can be com-
bined as the active ingredient in intimate admixture with a 
pharmaceutical carrier according to conventional pharma-
ceutical compounding techniques. The carrier can take a wide 
variety of forms depending on the form of preparation desired 
for administration, e.g., oral or parenteral (including intrave-
nous). Thus, the pharmaceutical compositions of the present 
invention can be presented as discrete units suitable for oral 
administration such as capsules, cachets or tablets each con-
15 
taining a predetermined amount of the active ingredient. Fur-
ther, the compositions can be presented as a powder, as gran-
ules, as a solution, as a suspension in an aqueous liquid, as a 
non-aqueous liquid, as an oil-in-wateremulsion or as a water-
in-oil liquid emulsion. In addition to the common dosage 
forms set out above, the compounds of the invention, and/or 
pharmaceutically acceptable salt(s) thereof, can also be 
administered by controlled release means and/or delivery 
devices. The compositions can be prepared by any of the 
methods of pharmacy. In general, such methods include a step 
of bringing into association the active ingredient with the 
carrier that constitutes one or more necessary ingredients. In 
general, the compositions are prepared by uniformly and 
intimately admixing the active ingredient with liquid carriers 
or finely divided solid carriers or both. The product can then 
be conveniently shaped into the desired presentation. 
Thus, the pharmaceutical compositions of this invention 
can include a pharmaceutically acceptable carrier and a com-
pound or a pharmaceutically acceptable salt of the com-
pounds of the invention. The compounds of the invention, or 
pharmaceutically acceptable salts thereof, can also be 
included in pharmaceutical compositions in combination 
with one or more other therapeutically active compounds. 
The pharmaceutical carrier employed can be, for example, 
a solid, liquid, or gas. Examples of solid carriers include 
lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, 
magnesium stearate, and stearic acid. Examples of liquid 
carriers are sugar syrup, peanut oil, olive oil, and water. 
Examples of gaseous carriers include carbon dioxide and 
nitrogen. 
pharmacy. 
Pharmaceutical compositions of the present invention suit-
able for parenteral administration can be prepared as solu-
tions or suspensions of the active compounds in water. A 
suitable surfactant can be included such as, for example, 
hydroxypropylcellulose. Dispersions can also be prepared in 
20 glycerol, liquid polyethylene glycols, and mixtures thereofin 
oils. Further, a preservative can be included to prevent the 
detrimental growth of microorganisms. 
Pharmaceutical compositions of the present invention suit-
able for injectable use include sterile aqueous solutions or 
25 dispersions. Furthermore, the compositions can be in the 
form of sterile powders for the extemporaneous preparation 
of such sterile injectable solutions or dispersions. In all cases, 
the final injectable form must be sterile and must be effec-
tively fluid for easy syringability. The pharmaceutical com-
30 positions must be stable under the conditions of manufacture 
and storage; thus, preferably should be preserved against the 
contaminating action of microorganisms such as bacteria and 
fungi. The carrier can be a solvent or dispersion medium 
containing, for example, water, ethanol, polyol (e.g., glyc-
35 erol, propylene glycol and liquid polyethylene glycol), veg-
etable oils, and suitable mixtures thereof. 
Pharmaceutical compositions of the present invention can 
be in a form suitable for topical use such as, for example, an 
aerosol, cream, ointment, lotion, dusting powder, mouth 
40 washes, gargles, and the like. Further, the compositions can 
be in a form suitable for use in transdermal devices. These 
formulations can be prepared, utilizing a compound of the 
invention, or pharmaceutically acceptable salts thereof, via 
conventional processing methods. As an example, a cream or 
45 ointment is prepared by mixing hydrophilic material and 
water, together with about 5 wt % to about 10 wt % of the 
compound, to produce a cream or ointment having a desired 
consistency. 
In preparing the compositions for oral dosage form, any 
convenient pharmaceutical media can be employed. For 
example, water, glycols, oils, alcohols, flavoring agents, pre-
servatives, coloring agents and the like can be used to form 
oral liquid preparations such as suspensions, elixirs and solu- 50 
tions; while carriers such as starches, sugars, microcrystalline 
cellulose, diluents, granulating agents, lubricants, binders, 
disintegrating agents, and the like can be used to form oral 
solid preparations such as powders, capsules and tablets. 
Because of their ease of administration, tablets and capsules 55 
are the preferred oral dosage units whereby solid pharmaceu-
tical carriers are employed. Optionally, tablets can be coated 
Pharmaceutical compositions ofthis invention can be in a 
form suitable for rectal administration wherein the carrier is a 
solid. It is preferable that the mixture forms unit dose sup-
positories. Suitable carriers include cocoa butter and other 
materials commonly used in the art. The suppositories can be 
conveniently formed by first admixing the composition with 
the softened or melted carrier(s) followed by chilling and 
shaping in moulds. 
In addition to the aforementioned carrier ingredients, the 
by standard aqueous or nonaqueous techniques 
A tablet containing the composition of this invention can 
be prepared by compression or molding, optionally with one 60 
or more accessory ingredients or adjuvants. Compressed tab-
lets can be prepared by compressing, in a suitable machine, 
the active ingredient in a free-flowing form such as powder or 
granules, optionally mixed with a binder, lubricant, inert dilu-
ent, surface active or dispersing agent. Molded tablets can be 65 
made by molding in a suitable machine, a mixture of the 
powdered compound moistened with an inert liquid diluent. 
pharmaceutical formulations described above can include, as 
appropriate, one or more additional carrier ingredients such 
as diluents, buffers, flavoring agents, binders, surface-active 
agents, thickeners, lubricants, preservatives (including anti-
oxidants) and the like. Furthermore, other adjuvants can be 
included to render the formulation isotonic with the blood of 
the intended recipient. Compositions containing a compound 
of the invention, and/or pharmaceutically acceptable salts 
thereof, can also be prepared in powder or liquid concentrate 
form. 
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In the treatment conditions which require modulation of 
STAT protein activity an appropriate dosage level will gen-
erally be about 0.01 to 500 mg per kg patient body weight per 
day and can be administered in single or multiple doses. 
Preferably, the dosage level will be about 0.1 to about 250 
mg/kg per day; more preferably 0.5 to 100 mg/kg per day. A 
suitable dosage level can be about 0.01 to 250 mg/kg per day, 
about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per 
day. Within this range the dosage can be 0.05 to 0.5, 0.5 to 5.0 
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In one aspect, the subject compounds can be coadminis-
tered with 13-cis-Retinoic Acid, 2-CdA, 2-Chlorodeoxyad-
enosine, 5-Azacitidine, 5-Fluorouracil, 5-FU, 6-Mercaptopu-
rine, 6-MP, 6-TG, 6-Thioguanine, Abraxane, Accutane®, 
Actinomycin-D, Adriamycin®, Adrucil®, Afinitor®, Agry-
lin®, Ala-Cort®, Aldesleukin, Alemtuzumab, ALIMTA, Ali-
tretinoin, Alkaban-AQ®, Alkeran®, All-transretinoic Acid, 
Alpha Interferon, Altretamine, Amethopterin, Amifostine, 
or 5.0 to 50 mg/kg per day. For oral administration, the com- 10 
positions are preferably provided in the from of tablets con-
taining 1.0 to 1000 miligrams of the active ingredient, par-
ticularly 1.0, 5.0, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 
300, 400, 500, 600, 750, 800, 900 and lOOOmilligrams of the 
active ingredient for the symptomatic adjustment of the dos- 15 
age of the patient to be treated. The compound can be admin-
istered on a regimen of 1 to 4 times per day, preferably once 
Aminoglutethimide, Anagrelide, Anandron®, Anastrozole, 
Arabinosylcytosine, Ara-C, Aranesp®, Aredia®, Arimi-
dex®, Aromasin®, Arranon®, Arsenic Trioxide, Arzerra™, 
Asparaginase, ATRA, Avastin®, Azacitidine, BCG, BCNU, 
Bendamustine, Bevacizumab, Bexarotene, BEXXAR®, 
Bicalutamide, BiCNU, Blenoxane®, Bleomycin, Bort-
ezomib, Busulfan, Busulfex®, C225Calcium Leucovorin, 
Campath®, Camptosar®, Camptothecin-11, Capecitabine, 
Carac™, Carboplatin, Carmustine, Carmustine Wafer, Caso-
dex®, CC-5013, CCI-779, CCNU, CDDP, CeeNU, Cerubi-
dine®, Cetuximab, Chlorambucil, Cisplatin, Citrovorum 
Factor, Cladribine, Cortisone, Cosmegen®, CPT-11, Cyclo-
phosphamide, Cytadren®, Cytarabine, Cytarabine Liposo-
or twice per day. This dosing regimen can be adjusted to 
provide the optimal therapeutic response. 
It is understood, however, that the specific dose level for 20 
any particular patient will depend upon a variety of factors. 
Such factors include the age, body weight, general health, 
sex, and diet of the patient. Other factors include the time and 
route of administration, rate of excretion, drug combination, 
and the type and severity of the particular disease undergoing 25 
therapy. 
mal, Cytosar-U®, Cytoxan®, Dacarbazine, Dacogen, Dacti-
nomycin, Darbepoetin Alfa, Dasatinib, Daunomycin, 
Daunorubicin, Daunorubicin Hydrochloride, Daunorubicin 
Liposomal, DaunoXome®, Decadron, Decitabine, Delta-
Cortef®, Deltasone®, Denileukin Diftitox, DepoCyt™, 
The present invention is further directed to a method for the 
manufacture of a medicament for modulating STAT protein 
activity activity (e.g., treatment of one or more disorders of 
uncontrolled cellular proliferation associated with a STAT3 30 
protein activity dysfunction) in manmials (e.g., humans) 
comprising combining one or more disclosed compounds, 
products, or compositions with a pharmaceutically accept-
able carrier or diluent. Thus, in one aspect, the invention 
relates to a method for manufacturing a medicament compris- 35 
ing combining at least one disclosed compound or at least one 
disclosed product with a pharmaceutically acceptable carrier 
Dexamethasone, Dexamethasone AcetateDexamethasone 
Sodium PhosphateDexasone, Dexrazoxane, DHAD, DIC, 
Diodex, Docetaxel, Doxil®, Doxorubicin, Doxorubicin 
Liposomal, Droxia™, DTIC, DTIC-Dome®, Duralone®, 
Efudex®, Eligard™, Ellence™, Eloxatin™, Elspar®, 
Emcyt®, Epirubicin, Epoetin Alfa, Erbitux, Erlotinib, 
Erwinia L-asparaginase, Estramustine, Ethyo!Etopophos®, 
Etoposide, Etoposide Phosphate, Eulexin®, Everolimus, 
Evista®, Exemestane, Fareston®, Faslodex®, Femara®, 
Filgrastim, Floxuridine, Fludara®, Fludarabine, Fluo-
roplex®, Fluorouracil, Fluorouracil (cream), Fluoxymester-
one, Flutamide, Folinic Acid, FUDR®, Fulvestrant, G-CSF, 
Gefitinib, Gemcitabine, Gemtuzumab ozogam1cm, 
or diluent. 
The disclosed pharmaceutical compositions can further 
comprise other therapeutically active compounds, which are 
usually applied in the treatment of the above mentioned 
pathological conditions. 
It is understood that the disclosed compositions can be 
prepared from the disclosed compounds. It is also understood 
that the disclosed compositions can be employed in the dis-
closed methods of using. 
F. METHODS OF USING THE COMPOUNDS 
AND COMPOSITIONS 
The disclosed compounds can be used as single agents or in 
combination with one or more other drugs in the treatment, 
prevention, control, amelioration or reduction of risk of the 
aforementioned diseases, disorders and conditions for which 
compounds of formula I or the other drugs have utility, where 
the combination of drugs together are safer or more effective 
than either drug alone. The other drug( s) can be administered 
by a route and in an amount commonly used therefore, con-
temporaneously or sequentially with a disclosed compound. 
When a disclosed compound is used contemporaneously with 
one or more other drugs, a pharmaceutical composition in 
unit dosage form containing such drugs and the disclosed 
compound is preferred. However, the combination therapy 
can also be administered on overlapping schedules. It is also 
envisioned that the combination of one or more active ingre-
dients and a disclosed compound will be more efficacious 
than either as a single agent. 
40 GemzarGleevec™, Gliadel Wafer, GM-CSF, Goserelin, 
Granulocyte-Colony Stimulating Factor, Granulocyte Mac-
rophage Colony Stimulating Factor, Halotestin®, Hercep-
tin®, Hexadrol, Hexylen®, Hexamethylmelamine, HMM, 
Hycamtin®, Hydrea®, Hydrocort Acetate®, Hydrocorti-
45 sane, Hydrocortisone Sodium Phosphate, Hydrocortisone 
Sodium Succinate, Hydrocortone Phosphate, Hydroxyurea, 
Ibritumomab, Ibritumomab Tiuxetanldamycin®, Idarubicin, 
Ifex®, IFN-alphalfosfamide, IL-11IL-2Imatinib mesylate, 
Imidazole Carboxamideinterferon alfa, Interferon Alfa-2b 
50 (PEG Conjugate), Interleukin-2, Interleukin-11, Intron A® 
(interferon alfa-2b) Iressa Irinotecan, Isotretinoin, Ixabepi-
lone, Ixempra™, K, Kidrolase (t), L, Lanacort®, Lapatinib, 
L-asparaginase, LCR, Lenalidomide, Letrozole, Leucovorin, 
Leukeran, Leukine™, Leuprolide, Leurocristine, Leusta-
55 tin™, Liposomal Ara-C, Liquid Pred®, Lomustine, L-PAM, 
L-Sarcolysin, Lupron®, Lupron Depot®, M, Matulane®, 
Maxidex, Mechlorethamine, Mechlorethamine Hydrochlo-
ride, Medralone®, Medrol®, Megace®, Megestrol, Mege-
strol Acetate, Melphalan, Mercaptopurine, Mesna, 
60 Mesnex™, Methotrexate, Methotrexate Sodium, Methyl-
prednisolone, Meticorten®, Mitomycin, Mitomycin-C, 
Mitoxantrone, M-Prednisol®, MTC, MTX, Mustargen®, 
MustineMutamycin®, Myleran®, Mylocel™, Mylotarg®, 
N, Navelbine®, Nelarabine, Neosar®, Neulasta™, Neu-
65 mega®, Neupogen®, Nexavar®, Nilandron®, Nilotinib, 
Nilutamide, Nipent®, Nitrogen Mustard, Novaldex®, 
Novantrone®, Nplate, 0, Octreotide, Octreotide acetate, 
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Ofatumumab, Oncospar®, Oncovin®, Ontak®, Onxal™, 
Oprelvekin, Orapred®, Orasone®, Oxaliplatin, P, Paclitaxel, 
Paclitaxel Protein-bound, Pamidronate, Panitumumab, Pan-
retin Paraplatin®, Pazopanib, Pediapred®, PEG Interferon, 
Pegaspargase, Pegfilgrastim, PEG-INTRON™, PEG-L-as-
paraginase, PEMETREXED, Pentostatin, Phenylalanine 
Mustard, Platinol®, Platinol-AQ®, Prednisolone, Pred-
nisone, Prelone®, Procarbazine, PROCRIT®, Proleukin®, 
Prolifeprospan 20 with Carmustine Implant, Purinethol®, R, 
Raloxifene, Revlimid®, Rheumatrex®, Rituxan®, Ritux-
imab, Roferon-A (Interferon Alfa-2a) Romiplostim, 
Rubex®, Rubidomycinhydrochloride, S, Sandostatin®, San-
dostatin LAR®, Sargramostim, Solu-Cortef®, Solu-
Medrol®, Sorafenib, SPRYCEL™, STI-571, Streptozocin, 
SUl 1248, Sunitinib, Sutent®, T, Tamoxifen, Tarceva®, Tar-
gretin®, Tasigna®, Taxol®, Taxotere®, Temodar®, Temozo-
lomide, Temsirolimus, Teniposide, TESPA, Thalidomide, 
Thalomid®, TheraCys®, Thioguanine, Thioguanine Tab-
loid®, Thiophosphoamide, Thioplex®, Thiotepa, TICE®, 
Toposar®, Topotecan, Toremifene, Torisel®, Tositumomab, 
Trastuzumab, Treanda®, Tretinoin, Trexall™, Trisenox®, 
TSPA, TYKERB®, V, VCR, Vectibix™, Velban®, Velcade®, 
VePesid®, Vesanoid®, Viadur™, Vidaza®, Vinblastine, Vin-
blastine Sulfate, Vincasar Pfs®, Vincristine, Vinorelbine, 
Vinorelbine tartrate, VLB, VM-26, Vorinostat, Votrient, 
VP-16, Vumon®, X, Xeloda®, Z, Zanosar®, Zevalin™, Zin-
ecard®, Zoladex®, Zoledronic acid, Zolinza, Zometa®. 
In another aspect, the subject compounds can be adminis-
tered in combination with 13-cis-Retinoic Acid, 2-CdA, 
2-Chlorodeoxyadenosine, 5-Azacitidine, 5-Fluorouracil, 
5-FU, 6-Mercaptopurine, 6-MP, 6-TG, 6-Thioguanine, 
Abraxane, Accutane®, Actinomycin-D, Adriamycin®, Adru-
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GM-CSF, Goserelin, Granulocyte--Colony Stimulating Fac-
tor, Granulocyte Macrophage Colony Stimulating Factor, 
Halotestin®, Herceptin®, Hexadrol, Hexylen®, Hexameth-
ylmelamine, HMM, Hycamtin®, Hydrea®, Hydrocort 
Acetate®, Hydrocortisone, Hydrocortisone Sodium Phos-
phate, Hydrocortisone Sodium Succinate, Hydrocortone 
Phosphate, Hydroxyurea, Ibritumomab, Ibritumomab Tiux-
etanldamycin®, Idarubicin, Ifex®, IFN-alphalfosfamide, 
IL-11IL-2Imatinib mesylate, Imidazole Carboxamideinter-
10 feron alfa, InterferonAlfa-2b (PEG Conjugate), Interleukin-
2, Interleukin-11, Intron A® (interferon alfa-2b) Iressa®, 
Irinotecan, Isotretinoin, Ixabepilone, Ixempra™, K, Kidro-
lase (t), L, Lanacort®, Lapatinib, L-asparaginase, LCR, 
Lenalidomide, Letrozole, Leucovorin, Leukeran, Leukine™, 
15 Leuprolide, Leurocristine, Leustatin™, Liposomal Ara-C, 
Liquid Pred®, Lomustine, L-PAM, L-Sarcolysin, Lupron®, 
Lupron Depot®, M, Matulane®, Maxidex, Mechlore-
thamine, Mechlorethamine Hydrochloride, Medralone®, 
Medrol®, Megace®, Megestrol, Megestrol Acetate, Mel-
20 phalan, Mercaptopurine, Mesna, Mesnex™, Methotrexate, 
Methotrexate Sodium, Methylprednisolone, Meticorten®, 
Mitomycin, Mitomycin-C, Mitoxantrone, M-Prednisol®, 
MTC, MTX, Mustargen®, MustineMutamycin®, Myle-
ran®, Mylocel™, Mylotarg®, N, Navelbine®, Nelarabine, 
25 Neosar®, Neulasta™, Neumega®, Neupogen®, Nexavar®, 
Nilandron®, Nilotinib, Nilutamide, Nipent®, Nitrogen Mus-
tard, Novaldex®, Novantrone®, Nplate, 0, Octreotide, Oct-
reotide acetate, Ofatumumab, Oncospar®, Oncovin®, 
Ontak®, Onxal™, Oprelvekin, Orapred®, Orasone®, Oxali-
30 platin, P, Paclitaxel, Paclitaxel Protein-bound, Pamidronate, 
Panitumumab, Panretin®, Paraplatin®, Pazopanib, Pedi-
apred®, PEG Interferon, Pegaspargase, Pegfilgrastim, PEG-
INTROWM, PEG-L-asparaginase, PEMETREXED, Pen-
tostatin, Phenylalanine Mustard, Platinol®, Platinol-AQ®, 
cil ®, Afinitor®, Agrylin®, Ala-Cort®, Aldesleukin, Alemtu-
zumab, ALIMTA, Alitretinoin, Alkaban-AQ®, Alkeran®, 
All-transretinoic Acid, Alpha Interferon, Altretamine, Ame-
thopterin, Amifostine, Aminoglutethimide, Anagrelide, 
Anandron®, Anastrozole, Arabinosylcytosine, Ara-C, 
Aranesp®, Aredia®, Arimidex®, Aromasin®, Arranon®, 
Arsenic Trioxide, Arzerra™, Asparaginase, ATRA, Avas-
tin®, Azacitidine, BCG, BCNU, Bendamustine, Bevaci-
zumab, Bexarotene, BEXXAR®, Bicalutamide, BiCNU, 
Blenoxane®, Bleomycin, Bortezomib, Busulfan, Busulfex®, 
C225Calcium Leucovorin, Campath®, Camptosar®, Camp-
tothecin-11, Capecitabine, Carac™, Carboplatin, Carmus-
tine, Carmustine Wafer, Casodex®, CC-5013, CCI-779, 
CCNU, CDDP, CeeNU, Cerubidine®, Cetuximab, Chloram-
bucil, Cisplatin, Citrovorum Factor, Cladribine, Cortisone, 
Cosmegen®, CPT-11, Cyclophosphamide, Cytadren®, Cyt-
arabine, Cytarabine Liposomal, Cytosar-U®, Cytoxan®, 
Dacarbazine, Dacogen, Dactinomycin, Darbepoetin Alfa, 
Dasatinib, Daunomycin, Daunorubicin, Daunorubicin 
Hydrochloride, Daunorubicin Liposomal, DaunoXome®, 
Decadron, Decitabine, Delta-Cortef®, Deltasone®, Denileu-
kin Diftitox, DepoCyt™, Dexamethasone, Dexamethasone 
AcetateDexamethasone Sodium PhosphateDexasone, 
Dexrazoxane, DHAD, DIC, Diodex, Docetaxel, Doxil®, 
Doxorubicin, Doxorubicin Liposomal, Droxia™, DTIC, 
DTIC-Dome®, Duralone®, Efudex®, Eligard™, Ellence™, 
Eloxatin™, Elspar®, Emcyt®, Epirubicin, Epoetin Alfa, 
Erbitux, Erlotinib, Erwinia L-asparaginase, Estramustine, 60 
Ethyo!Etopophos®, Etoposide, Etoposide Phosphate, 
Eulexin®, Everolimus, Evista®, Exemestane, Fareston®, 
Faslodex®, Femara®, Filgrastim, Floxuridine, Fludara®, 
Fludarabine, Fluoroplex®, Fluorouracil, Fluorouracil 
(cream), Fluoxymesterone, Flutamide, Folinic Acid, 65 
FUDR®, Fulvestrant, G-CSF, Gefitinib, Gemcitabine, Gem-
tuzumab ozogamicin, GemzarGleevec™, Gliadel® Wafer, 
35 Prednisolone, Prednisone, Prelone®, Procarbazine, PRO-
CRIT®, Proleukin®, Prolifeprospan 20 with Carmustine 
Implant, Purinethol®, R, Raloxifene, Revlimid®, Rheu-
matrex®, Rituxan®, Rituximab, Roferon-A (InterferonAlfa-
2a)Romiplostim, Rubex®, Rubidomycin hydrochloride, S, 
40 Sandostatin®, Sandostatin LAR®, Sargramostim, Solu-
Cortef®, Solu-Medrol®, Sorafenib, SPRYCEL™, STI-571, 
Streptozocin, SUl 1248, Sunitinib, Sutent®, T, Tamoxifen, 
Tarceva®, Targretin®, Tasigna®, Taxol®, Taxotere®, Temo-
dar®, Temozolomide, Temsirolimus, Teniposide, TESPA, 
45 Thalidomide, Thalomid®, TheraCys®, Thioguanine, 
Thioguanine Tabloid®, Thiophosphoamide, Thioplex®, 
Thiotepa, TICE®, Toposar®, Topotecan, Toremifene, Torisel 
Tositumomab, Trastuzumab, Treanda®, Tretinoin, Trexall™, 
Trisenox®, TSPA, TYKERB®, V, VCR, Vectibix™, Vel-
50 ban®, Velcade VePesid®, Vesanoid®, Viadur™, Vidaza®, 
Vinblastine, Vinblastine Sulfate, Vincasar Pfs®, Vincristine, 
Vinorelbine, Vinorelbine tartrate, VLB, VM-26, Vorinostat, 
Votrient, VP-16, Vumon®, X, Xeloda®, Z, Zanosar®, Zeva-
lin™, Zinecard®, Zoladex®, Zoledronic acid, Zolinza, 
55 Zometa® 
In another aspect, the subject compound can be used in 
combination with 13-cis-RetinoicAcid, 2-CdA, 2-Chlorode-
oxyadenosine, 5-Azacitidine, 5-Fluorouracil, 5-FU, 6-Mer-
captopurine, 6-MP, 6-TG, 6-Thioguanine, Abraxane, Accu-
tane®, Actinomycin-D, Adriamycin®, Adrucil®, Afinitor®, 
Agrylin®, Ala-Cort®, Aldesleukin, Alemtuzumab, 
ALIMTA, Alitretinoin, Alkaban-AQ®, Alkeran®, All-tran-
sretinoic Acid, Alpha Interferon, Altretamine, Amethopterin, 
Amifostine, Aminoglutethimide, Anagrelide, Anandron®, 
Anastrozole, Arabinosylcytosine, Ara-C, Aranesp®, 
Aredia®, Arimidex®, Aromasin®, Arranon®, Arsenic Tri-
oxide, Arzerra™, Asparaginase, ATRA, Avastin®, Azaciti-
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ride, S, Sandostatin®, Sandostatin LAR®, Sargramostim, 
Solu-Cortef®, Solu-Medrol®, Sorafenib, SPRYCEL™, STI-
571, Streptozocin, SU11248, Sunitinib, Sutent®, T, Tamox-
ifen, Tarceva®, Targretin®, Tasigna®, Taxol®, Taxotere®, 
Temodar®, Temozolomide, Temsirolimus, Teniposide, 
TESPA, Thalidomide, Thalomid®, TheraCys®, Thiogua-
nine, Thioguanine Tabloid®, Thiophosphoamide, Thi-
oplex®, Thiotepa, TICE®, Toposar®, Topotecan, 
Toremifene, Torisel®, Tositumomab, Trastuzumab, Tre-
anda®, Tretinoin, Trexall™, Trisenox®, TSPA, TYKERB®, 
V, VCR, Vectibix™, Velban®, Velcade®, VePesid®, 
Vesanoid®, Viadur™, Vidaza®, Vinblastine, Vinblastine Sul-
fate, Vincasar Pfs®, Vincristine, Vinorelbine, Vinorelbine tar-
15 trate, VLB, VM-26; Vorinostat, Votrient, VP-16, Vumon®, X, 
dine, BCG, BCNU, Bendamustine, Bevacizumab, Bexaro-
tene, BEXXAR®, Bicalutamide, BiCNU, Blenoxane®, 
Bleomycin, Bortezomib, Busulfan, Busulfex®, 
C225Calcium Leucovorin, Campath®, Camptosar®, Camp-
tothecin-11, Capecitabine, Carac™, Carboplatin, Carmus-
tine, Carmustine Wafer, Casodex®, CC-5013, CCI-779, 
CCNU, CDDP, CeeNU, Cerubidine®, Cetuximab, Chloram-
bucil, Cisplatin, Citrovorum Factor, Cladribine, Cortisone, 
Cosmegen®, CPT-11, Cyclophosphamide, Cytadren®, Cyt-
arabine, Cytarabine Liposomal, Cytosar-U®, Cytoxan®, 10 
Dacarbazine, Dacogen, Dactinomycin, Darbepoetin Alfa, 
Dasatinib, Daunomycin, Daunorubicin, Daunorubicin 
Hydrochloride, Daunorubicin Liposomal, DaunoXome®, 
Decadron, Decitabine, Delta-Cortef®, Deltasone®, Denileu-
kin Diftitox, DepoCyt™, Dexamethasone, Dexamethasone 
AcetateDexamethasone Sodium PhosphateDexasone, 
Dexrazoxane, DHAD, DIC, Diodex, Docetaxel, Doxil®, 
Doxorubicin, Doxorubicin Liposomal, Droxia™, DTIC, 
DTIC-Dome®, Duralone®, Efudex®, Eligard™, Ellence™, 
Eloxatin™, Elspar®, Emcyt®, Epirubicin, Epoetin Alfa, 20 
Erbitux, Erlotinib, Erwinia L-asparaginase, Estramustine, 
Ethyo!Etopophos®, Etoposide, Etoposide Phosphate, 
Eulexin®, Everolimus, Evista®, Exemestane, Fareston®, 
Faslodex®, Femara®, Filgrastim, Floxuridine, Fludara®, 
Fludarabine, Fluoroplex®, Fluorouracil, Fluorouracil 25 
(cream), Fluoxymesterone, Flutamide, Folinic Acid, 
FUDR®, Fulvestrant, G-CSF, Gefitinib, Gemcitabine, Gem-
tuzumab ozogamicin, GemzarGleevec™, Gliadel® Wafer, 
GM-CSF, Goserelin, Granulocyte--Colony Stimulating Fac-
tor, Granulocyte Macrophage Colony Stimulating Factor, 30 
Halotestin®, Herceptin®, Hexadrol, Hexylen®, Hexameth-
ylmelamine, HMM, Hycamtin®, Hydrea®, Hydrocort 
Acetate®, Hydrocortisone, Hydrocortisone Sodium Phos-
phate, Hydrocortisone Sodium Succinate, Hydrocortone 
Phosphate, Hydroxyurea, Ibritumomab, Ibritumomab Tiux- 35 
etanldamycin®, Idarubicin, Ifex®, IFN-alphaifosfamide, 
IL-11IL-2Imatinib mesylate, Imidazole Carboxamideinter-
feron alfa, InterferonAlfa-2b (PEG Conjugate), Interleukin-
2, Interleukin-11, Intron A® (interferon alfa-2b) Iressa®, 
Irinotecan, Isotretinoin, Ixabepilone, Ixempra™, K, Kidro- 40 
lase (t), L, Lanacort®, Lapatinib, L-asparaginase, LCR, 
Lenalidomide, Letrozole, Leucovorin, Leukeran, Leukine™, 
Leuprolide, Leurocristine, Leustatin™, Liposomal Ara-C, 
Liquid Pred®, Lomustine, L-PAM, L-Sarcolysin, Lupron®, 
Lupron Depot®, M, Matulane®, Maxidex, Mechlore- 45 
thamine, Mechlorethamine Hydrochloride, Medralone®, 
Medrol®, Megace®, Megestrol, Megestrol Acetate, Mel-
phalan, Mercaptopurine, Mesna, MesnexTM, Methotrexate, 
Methotrexate Sodium, Methylprednisolone, Meticorten®, 
Mitomycin, Mitomycin-C, Mitoxantrone, M-Prednisol®, 50 
MTC, MTX, Mustargen®, MustineMutamycin®, Myle-
ran®, Mylocel™, Mylotarg®, N, Navelbine®, Nelarabine, 
Neosar®, Neulasta™, Neumega®, Neupogen®, Nexavar 
Nilandron®, Nilotinib, Nilutamide, Nipent®, Nitrogen Mus-
tard, Novaldex®, Novantrone Nplate, 0, Octreotide, Oct- 55 
reotide acetate, Ofatumumab, Oncospar®, Oncovin®, 
Ontak®, Onxal™, Oprelvekin, Orapred®, Orasone®, Oxali-
platin, P, Paclitaxel, Paclitaxel Protein-bound, Pamidronate, 
Panitumumab, Panretin®, Paraplatin®, Pazopanib, Pedi-
apred®, PEG Interferon, Pegaspargase, Pegfilgrastim, PEG- 60 
INTRON™, PEG-L-asparaginase, PEMETREXED, Pen-
tostatin, Phenylalanine Mustard, Platinol®, Platinol-AQ®, 
Prednisolone, Prednisone, Prelone®, Procarbazine, PRO-
CRIT®, Proleukin®, Prolifeprospan 20 with Carmustine 
Implant, Purinethol®, R, Raloxifene, Revlimid®, Rheu- 65 
matrex®, Rituxan®, Rituximab, Roferon-A® (Interferon 
Alfa-2a) Romiplostim, Rubex®, Rubidomycin hydrochlo-
Xeloda®, Z, Zanosar®, Zevalin™, Zinecard®, Zoladex®, 
Zoledronic acid, Zolinza, Zometa® 
The pharmaceutical compositions and methods of the 
present invention can further comprise other therapeutically 
active compounds as noted herein which are usually applied 
in the treatment of the above mentioned pathological condi-
tions. 
1. Treatment Methods 
The compounds disclosed herein are useful for treating, 
preventing, ameliorating, controlling or reducing the risk of a 
variety of disorders of uncontrolled cellular proliferation 
associated with a STAT protein activity dysfunction. In a yet 
further aspect, the disorder of uncontrolled cellular prolifera-
tion is a cancer. In a still further aspect, the STAT protein 
activity dysfunction is that the STAT protein is persistently 
active. In a yet further aspect, the STAT protein is constitu-
tively active. In an even further aspect, the STAT protein is 
overexpressed. In a still further aspect, the STAT protein is 
STAT3. 
In one aspect, the invention relates to a method for the 
treatment of a disorder associated with a STAT protein activ-
ity dysfunction in a mammal comprising the step of admin-
istering to the mammal at least one disclosed compound or at 
least one disclosed product in a dosage and amount effective 
to treat the disorder in the mammal. In a further aspect, the 
mammal is a human. In a further aspect, the mammal has been 
diagnosed with a need for treatment of the disorder prior to 
the administering step. In a further aspect, the method further 
comprises the step of identifying a mammal in need of treat-
ment of the disorder. 
It is understood that cancer refer to or describe the physi-
ological condition in mammals that is typically characterized 
by unregulated cell growth. The cancer may be multi-drug 
resistant (MDR) or drug-sensitive. Examples of cancer 
include but are not limited to, carcinoma, lymphoma, blas-
toma, sarcoma, and leukemia. More particular examples of 
such cancers include breast cancer, prostate cancer, colon 
cancer, squamous cell cancer, small-cell lung cancer, non-
small cell lung cancer, gastrointestinal cancer, pancreatic 
cancer, cervical cancer, ovarian cancer, peritoneal cancer, 
liver cancer, e.g., hepatic carcinoma, bladder cancer, colorec-
tal cancer, endometrial carcinoma, kidney cancer, and thyroid 
cancer. 
In various aspects, further examples of cancers are basal 
cell carcinoma, biliary tract cancer; bone cancer; brain and 
CNS cancer; choriocarcinoma; connective tissue cancer; 
esophageal cancer; eye cancer; cancer of the head and neck; 
gastric cancer; intra-epithelial neoplasm; larynx cancer; lym-
phoma including Hodgkin's and Non-Hodgkin's lymphoma; 
melanoma; myeloma; neuroblastoma; oral cavity cancer 
(e.g., lip, tongue, mouth, and pharynx); retinoblastoma; rhab-
domyosarcoma; rectal cancer; cancer of the respiratory sys-
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tern; sarcoma; skin cancer; stomach cancer; testicular cancer; 
uterine cancer; cancer of the urinary system, as well as other 
carcinomas and sarcomas 
202 
mia, Childhood Acute Ewing's Family of Tumors Myeloma, 
Multiple Extracranial Germ Cell Tumor, Myeloproliferative 
Disorders, Chronic Childhood Nasal Cavity and Paranasal 
Sinus Cancer Extragonadal Germ Cell Tumor Nasopharyn-
geal Cancer Extrahepatic Bile Duct Cancer Nasopharyngeal 
Cancer, Childhood Eye Cancer, Intraocular Melanoma Neu-
roblastoma Eye Cancer, Retinoblastoma Non-Hodgkin's 
Lymphoma, Adult Gallbladder Cancer Non-Hodgkin's Lym-
phoma, Childhood Gastric (Stomach) Cancer Non-
Hodgkin's Lymphoma During Pregnancy Gastric (Stomach) 
Cancer, Childhood Non-Small Cell Lung Cancer Gas-
trointestinal Carcinoid Tumor Oral Cancer, Childhood Germ 
Cell Tumor, Extracranial, Oral Cavity Cancer, Lip and Child-
hood Oropharyngeal Cancer Germ Cell Tumor, Extra gonadal 
Osteosarcoma/Malignant Fibrous Germ Cell Tumor, Ovarian 
Histiocytoma of Bone Gestational Trophoblastic Tumor Ova-
rian Cancer, Childhood Glioma, Adult Ovarian Epithelial 
Cancer Glioma, Childhood Brain Stem Ovarian Germ Cell 
20 Tumor Glioma, Childhood Cerebral Ovarian Low Malignant 
Potential Tumor Astrocytoma Pancreatic Cancer Glioma, 
Childhood Visual Pathway and Pancreatic Cancer, Childhood 
Hypothalamic Pancreatic Cancer, Islet Cell Skin Cancer 
(Melanoma) Paranasal Sinus and Nasal Cavity Cancer Skin 
Examples of disorders such as a cancer associated with 
STAT protein activity dysfunction, e.g. a STAT3 activity dys- 5 
function, include: Acute Lymphoblastic Leukemia, Adult 
Hairy Cell Leukemia, Acute Lymphoblastic Leukemia, Head 
and Neck Cancer, Childhood Hepatocellular (Liver) Cancer, 
Adult, Acute Myeloid Leukemia, Adult (Primary), Acute 
Myeloid Leukemia, Childhood Hepatocellular (Liver) Can- 10 
cer, Childhood, Adrenocortical Carcinoma (Primary), 
Adrenocortical Carcinoma, Childhood Hodgkin's Lym-
phoma, Adult AIDS-Related Cancers Hodgkin's Lymphoma, 
Childhood AIDS-Related Lymphoma Hodgkin's Lymphoma 
During Pregnancy Anal Cancer Hypopharyngeal Cancer 15 
Astrocytoma, Childhood Cerebellar Hypothalamic and 
Visual Pathway Glioma, Astrocytoma, Childhood Cerebral 
Childhood Basal Cell Carcinoma Intraocular Melanoma Bile 
Duct Cancer, Extrahepatic Islet Cell Carcinoma (Endocrine 
Pancreas )Bladder Cancer Kaposi's Sarcoma Bladder Cancer, 
Childhood Kidney (Renal Cell) Cancer Bone Cancer, 
Osteosarcoma/Malignant Kidney Cancer, Childhood Fibrous 
Histiocytoma Laryngeal Cancer Brain Stem Glioma, Child-
hood Laryngeal Cancer, Childhood Brain Tumor, Adult Leu-
kemia, Acute Lymphoblastic, Adult Brain Tumor, Brain Stem 
Glioma, Leukemia, Acute Lymphoblastic, Childhood Leuke-
mia, Acute Myeloid, Adult Brain Tumor, Cerebellar Astrocy-
toma, Leukemia, Acute Myeloid, Childhood Leukemia, 
Chronic Lymphocytic Brain Tumor, Cerebral Leukemia, 
Chronic Myelogenous Astrocytoma/Malignant Glioma, Leu-
kemia, Hairy Cell Childhood Lip and Oral Cavity Cancer 
Brain Tumor, Ependymoma, Childhood Liver Cancer, Adult 
(Primary) Brain Tumor, Medulloblastoma, Liver Cancer, 
Childhood (Primary) Childhood Lung Cancer, Non-Small 
Cell Brain Tumor, Supratentorial Primitive Lung Cancer, 
Small Cell Neuroectodermal Tumors, Childhood Lym-
phoma, AIDS-Related Brain Tumor, Visual Pathway and 
Lymphoma, Burkitt's Hypothalamic Glioma, Childhood 
Lymphoma, Cutaneous T-Cell, see Mycosis Brain Tumor, 
Childhood Fungoides and Sezary Syndrome Breast Cancer 
Lymphoma, Hodgkin's, Adult Breast Cancer, Childhood 
Lymphoma, Hodgkin's, Childhood Breast Cancer, Male 
Lymphoma, Hodgkin's During Pregnancy Bronchial 
Adenomas/Carcinoids, Lymphoma, Non-Hodgkin's, Adult 
Childhood Lymphoma, Non-Hodgkin's, Childhood Burkitt' s 
Lymphoma Lymphoma, Non-Hodgkin's During Carcinoid 
Tumor, Childhood Pregnancy Carcinoid Tumor, Gastrointes-
tinal Lymphoma, Primary Central Nervous System Carci-
noma of Unknown Primary Macroglobulinemia, Walden-
striim's Central Nervous System Lymphoma, Malignant 
Fibrous Histiocytoma of Primary Bone/Osteosarcoma Cer-
ebellar Astrocytoma, Childhood Medulloblastoma, Child-
hood Cerebral Astrocytoma/Malignant Melanoma Glioma, 
Childhood Melanoma, Intraocular (Eye )Cervical Cancer 
Merkel Cell Carcinoma Childhood Cancers Mesothelioma, 
Adult Malignant Chronic Lymphocytic Leukemia Mesothe-
lioma, Childhood Chronic Myelogenous Leukemia Meta-
static Squamous Neck Cancer with Chronic Myeloprolifera-
tive Disorders Occult Primary Colon Cancer Multiple 
Endocrine Neoplasia Syndrome, Colorectal Cancer, Child-
hood Childhood Cutaneous T-Cell Lymphoma, see Multiple 
Myeloma/Plasma Cell Neoplasm Mycosis Fungoides and 
Sezary Mycosis Fungoides Syndrome Myelodysplastic Syn-
dromes Endometrial Cancer Myelodysplastic/Myeloprolif-
erative Diseases Ependymoma, Childhood Myelogenous 65 
Leukemia, Chronic Esophageal Cancer Myeloid Leukemia, 
Adult Acute Esophageal Cancer, Childhood Myeloid Leuke-
25 Carcinoma, Merkel Cell Parathyroid Cancer Small Cell Lung 
Cancer Penile Cancer Small Intestine Cancer Pheochromocy-
toma Soft Tissue Sarcoma, Adult Pineoblastoma and Suprat-
entorial Primitive Soft Tissue Sarcoma, Childhood Neuroec-
todermal Tumors, Childhood Squamous Cell Carcinoma, see 
30 Skin Pituitary Tumor Cancer (non-Melanoma) Plasma Cell 
Neoplasm/Multiple Myeloma Squamous Neck Cancer with 
Occult Pleuropulmonary Blastoma Primary, Metastatic Preg-
nancy and Breast Cancer Stomach (Gastric) Cancer Preg-
35 nancy and Hodgkin's Lymphoma Stomach (Gastric) Cancer, 
Childhood Pregnancy and Non-Hodgkin's Lymphoma 
Supratentorial Primitive Primary Central Nervous System 
Lymphoma Neuroectodermal Tumors, Childhood Prostate 
Cancer T-Cell Lymphoma, Cutaneous, see Rectal Cancer 
40 Mycosis Fungoides and Sezary Renal Cell (Kidney) Cancer 
Syndrome Renal Cell (Kidney) Cancer, Childhood Testicular 
Cancer Renal Pelvis and Ureter, Transitional Cell Thymoma, 
Childhood Cancer Thymoma and Thymic Carcinoma Retino-
blastoma Thyroid Cancer Rhabdomyosarcoma, Childhood 
45 Thyroid Cancer, Childhood Salivary Gland Cancer Transi-
tional Cell Cancerofthe Renal Salivary Gland Cancer, Child-
hood Pelvis and Ureter Sarcoma, Ewing's Family of Tumors 
Trophoblastic Tumor, Gestational Sarcoma, Kaposi's 
Unknown Primary Site, Carcinoma of, Sarcoma, Soft Tissue, 
50 Adult Adult Sarcoma, Soft Tissue, Childhood Unknown Pri-
mary Site, Cancer of, Sarcoma, Uterine Childhood Sezary 
Syndrome Unusual Cancers of Childhood Skin Cancer (non-
Melanoma)Ureter and Renal Pelvis, Transitional Skin Can-
55 cer, Childhood Cell Cancer Urethral Cancer Uterine Cancer, 
Endometrial Uterine Sarcoma Vaginal Cancer Visual Path-
way and Hypothalamic Glioma, Childhood Vulvar Cancer 
Waldenstrom's Macroglobulinemia Wilms' Tumor. 
The disorders of uncontrolled cellular proliferation, e.g. a 
60 cancer, that can be treated or prevented by the compositions 
disclosed herein include. 
Thus, provided is a method for treating or preventing a 
disorder of uncontrolled cellular proliferation, comprising: 
administering to a subject at least one disclosed compound; at 
least one disclosed pharmaceutical composition; and/or at 
least one disclosed product in a dosage and amount effective 
to treat the disorder in the subject. 
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a. Treatment of a Disorder Associated with Stat3 Activity 
Dysfunction 
In various aspects, the invention relates to a method for the 
treatment of a disorder associated with STAT3 activity dys-
function in a mammal comprising the step of administering to 
the marmnal a therapeutically effective amount of at least one 
compound having a structure represented by Formula I, II, DI 
or IV, or a pharmaceutically acceptable salt, hydrate, solvate, 
or polymorph thereof. 
In a further aspect, the compound administered is any of 10 
the disclosed compounds related to Formula I, II, III or IV, or 
at least one product of the disclosed methods of making a 
compound of Formula I, II, III or IV. 
In a further aspect, the marmnal is a human. In a yet further 
aspect, the mammal has been diagnosed with a need for 15 
treatment of the disorder prior to the administering step. In a 
still further aspect, the method further comprises the step of 
identifying a marmnal in need of treatment of the disorder. 
In a further aspect, the compound administered inhibits 
STAT3 protein activity. In a still further aspect, the compound 20 
administered prevents STAT3 protein dimerization. In a yet 
further aspect, the compound administered disrupts pre-
formed or existing STAT3 dimers. In a still further aspect, the 
compound administered binds to the SH2 domain ofSTAT3. 
In a further aspect, the compound administered inhibits 25 
STAT3 protein activity in an EMSA assay with an IC50 ofless 
than about 100 µM, less than about 50 µM, less than about 10 
µM, less than about 1 µM, less than about 500 nM, or ofless 
than about 100 nM. 
204 
In a further aspect, the cancer is a hematological cancer. In 
a still further aspect, the hematological cancer is selected 
from acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic myeloid leukemia (CML), chronic 
lymphocytic leukemia (CLL), hairy cell leukemia, chronic 
myelomonocytic leukemia (CMML), juvenile myelomono-
cytic leukemia (JMML), Hodgkin lymphoma, Non-Hodgkin 
lymphoma, multiple myeloma, solitary myeloma, localized 
myeloma, and extramedullary myeloma. 
In a further aspect, the cancer is a cancer of the brain. In a 
still further aspect, the cancer of the brain is selected from a 
glioma, medulloblastoma, primitive neuroectodermal tumor 
(PNET), acoustic neuroma, glioma, meningioma, pituitary 
adenoma, schwannoma, CNS lymphoma, primitive neuroec-
todermal tumor, craniopharyngioma, chordoma, medullo-
blastoma, cerebral neuroblastoma, central neurocytoma, 
pineocytoma, pineoblastoma, atypical teratoid rhabdoid 
tumor, chondrosarcoma, chondroma, choroid plexus carci-
noma, choroid plexus papilloma, craniopharyngioma, dys-
embryoplastic neuroepithelial tumor, gangliocytoma, germi-
noma, hemangioblastoma, hemangiopercytoma, and 
metastatic brain tumor. In a yet further aspect, the glioma is 
selected from ependymoma, astrocytoma, oligodendro-
glioma, and oligoastrocytoma. In an even further aspect, the 
glioma is selected from juvenile pilocytic astrocytoma, sub-
ependymal giant cell astrocytoma, ganglioglioma, sub-
ependymoma, pleomorphic xanthoastrocytom, anaplastic 
astrocytoma, glioblastoma multiforme, brain stem glioma, 
In a further aspect, the compound administered inhibits cell 
growth. In a still further aspect, the compound inhibits cell 
growth with an IC50 ofless than about 500 µM. In a yet further 
aspect, the compound inhibits cell growth with an IC50 ofless 
than about 250 µM. In an even further aspect, the compound 
inhibits cell growth with an IC50 ofless than about 100 µM. In 
a still further aspect, the compound inhibits cell growth with 
an IC50 of less than about 50 µM. In a yet further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
30 oligodendroglioma, ependymoma, oligoastrocytoma, cer-
ebellar astrocytoma, desmoplastic infantile astrocytoma, sub-
ependymal giant cell astrocytoma, diffuse astrocytoma, 
mixed glioma, optic glioma, gliomatosis cerebri, multifocal 
gliomatous tumor, multicentric glioblastoma multiforme 
35 tumor, paraganglioma, and ganglioglioma. 
10 µM. In an even further aspect, the compound inhibits cell 
growth with an IC50 of less than about 1 µM. In a still further 40 
aspect, the IC50 for inhibition of cell growth is determined in 
In a further aspect, the cancer is selected from a cancer of 
the breast, ovary, prostate, head, neck, and kidney. In a still 
further aspect, the cancer is breast cancer. In a yet further 
aspect, the cancer is pancreatic cancer. 
b. Inhibition of STAT3 Activity in a Mammal 
In one aspect, the invention relates to a method for inhibi-
tion of STAT3 activity in a marmnal comprising the step of 
administering to the mammal a therapeutically effective 
amount ofleast one compound having a structure represented 
a cell line with a constitutively active STAT3 protein. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line with a persistently active STAT3 protein. 
In an even further aspect, the IC50 for inhibition of cell growth 
is determined in a cell line derived from a cancer selected 
from breast cancer, pancreatic cancer, and prostate cancer. In 
a yet further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line derived from a cancer with a STAT3 
protein activity dysfunction. In a still further aspect, the IC50 
for inhibition of cell growth is determined in a cell line 
selected from MDA-MB-231, Panc-1, and DU 145. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line transformed with v-Src. In an even further 
45 by Formula I, II, III or IV, or a pharmaceutically acceptable 
salt, hydrate, solvate, or polymorph thereof. 
In a further aspect, the compound administered is any of 
the disclosed compounds related to Formula I, II, III, or IV, or 
at least one product of the disclosed methods of making a 
50 compound of Formula I, II, III or IV. 
aspect, the IC50 for inhibition of cell growth is determined in 55 
the NIH3T3 cell-line transformed with v-Src. 
In a further aspect, the mammal is a human. In a yet further 
aspect, the marmnal has been diagnosed with a need for 
treatment of the disorder prior to the administering step. In a 
still further aspect, the method further comprises the step of 
identifying a marmnal in need of treatment of the disorder. 
In a further aspect, the compound administered inhibits 
S TAT3 protein activity. In a still further aspect, the compound 
administered prevents STAT3 protein dimerization. In a yet 
further aspect, the compound administered disrupts pre-
In a further aspect, the compound administered treats a 
disorder is associated with constitutively active STAT3. 
In a further aspect, the compound administered treats a 
disorder selected from psoriasis and pulmonary arterial 
hypertension. 
In a further aspect, the compound administered treats a 
disorder of uncontrolled cellular proliferation. In a yet further 
aspect, the disorder of uncontrolled cellular proliferation is 
cancer. In a still further aspect, the cancer is selected from a 
cancer of the head, neck, pancreas, brain, ovary, kidney, pros-
tate, breast, lung, colon, and liver. 
60 formed or existing STAT3 dimers. In a still further aspect, the 
compound administered binds to the SH2 domain ofSTAT3. 
In a further aspect, the compound administered inhibits 
STAT3 protein activity with an IC50 in an EMSA assay ofless 
than about 100 µM, less than about 50 less than about 10 µM, 
65 less than about 1 µM, less than about 500 nM, or ofless than 
about 100 nM. In a further aspect, the IC50 for inhibition of 
STAT3 activity. 
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In a further aspect, the compound administered inhibits cell 
growth. In a still further aspect, the compound inhibits cell 
growth with an IC50 of less than about 500 In a yet further 
aspect, the compound inhibits cell growth with an IC50 ofless 
than about 250 µM. In an even further aspect, the compound 
inhibits cell growth with an IC50 ofless than about 100 µM. In 
a still further aspect, the compound inhibits cell growth with 
an IC50 of less than about 50 µM. In a yet further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
10 µM. In an even further aspect, the compound inhibits cell 10 
growth with an IC50 of less than about 1 µM. In a still further 
aspect, the IC50 for inhibition of cell growth is determined in 
206 
ebellar astrocytoma, desmoplastic infantile astrocytoma, sub-
ependymal giant cell astrocytoma, diffuse astrocytoma, 
mixed glioma, optic glioma, gliomatosis cerebri, multifocal 
gliomatous tumor, multicentric glioblastoma multiforme 
tumor, paraganglioma, and ganglioglioma. 
In a further aspect, the cancer is selected from a cancer of 
the breast, ovary, prostate, head, neck, and kidney. In a still 
further aspect, the cancer is breast cancer. In a yet further. 
c. Inhibiting STAT3 Activity in Cells 
In one aspect, the invention relates to a method for inhib-
iting STAT3 activity in at least one cell, comprising the step of 
contacting the at least one cell with an effective amount of 
least one compound having a structure represented by For-
mula I, II, III or IV, or a pharmaceutically acceptable salt, 
a cell line with a constitutively active STAT3 protein. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line with a persistently active STAT3 protein. 
In an even further aspect, the IC50 for inhibition of cell growth 
is determined in a cell line derived from a cancer selected 
from breast cancer, pancreatic cancer, and prostate cancer. In 
15 hydrate, solvate, or polymorph thereof. 
a yet further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line derived from a cancer with a STAT3 20 
In a further aspect, the compound administered is any of 
the disclosed compounds represented by Formula I, II, III, or 
rv, or at least one product of the disclosed methods of making. 
In a further aspect, the at least one cell is in a mammal. In 
a still further aspect, the method further comprises adminis-
tering to the mammal the compound in an amount sufficient to 
contact at least one cell in the manimal. In yet further aspect, 
the cell is mammalian. In an even further aspect, the cell is 
human. In a further aspect, the cell has been isolated from a 
protein activity dysfunction. In a still further aspect, the IC50 
for inhibition of cell growth is determined in a cell line 
selected from MDA-MB-231, Panc-1, and DU 145. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line transformed with v-Src. In an even further 
aspect, the IC50 for inhibition of cell growth is determined in 
the NIH3T3 cell-line transformed with v-Src. 
25 mammal prior to the contacting step. 
In a further aspect, the compound administered treats a 
disorder is associated with constitutively active STAT3. 
In a further aspect, contacting is via administration to a 
mammal. In a further aspect, the mammal has been diagnosed 
with a need for modulating S TAT3 protein activity prior to the 
administering step. In a further aspect, the manimal has been 
In a further aspect, the compound administered treats a 
disorder selected from psoriasis and pulmonary arterial 
hypertension. 
30 diagnosed with a need for treatment of a disorder related to a 
STAT3 protein activity dysfunction prior to the administering 
step. 
In a further aspect, the compound administered treats a 
disorder of uncontrolled cellular proliferation. In a yet further 
aspect, the disorder of uncontrolled cellular proliferation is 
cancer. In a still further aspect, the cancer is selected from a 
cancer of the head, neck, pancreas, brain, ovary, kidney, pros-
tate, breast, lung, colon, and liver. 
In a further aspect, the at least one cell is in a human. In a 
yet further aspect, the manimal has been diagnosed with a 
35 need for treatment of the disorder prior to the contacting step. 
In a further aspect, the cancer is a hematological cancer. In 
In a still further aspect, the method further comprises the step 
of identifying a mammal in need of treatment of the disorder. 
In a further aspect, the compound contacting the cell inhib-
its STAT3 protein activity. In a still further aspect, the com-
40 pound contacting the cell prevents STAT3 protein dimeriza-
tion. In a yet further aspect the compound contacting the cell 
disrupts preformed or existing S TAT3 dimers. In a still further 
aspect, the compound contacting the cell binds to the SH2 
domain ofSTAT3. 
a still further aspect, the hematological cancer is selected 
from acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic myeloid leukemia (CML), chronic 
lymphocytic leukemia (CLL), hairy cell leukemia, chronic 
myelomonocytic leukemia (CMML), juvenile myelomono-
cytic leukemia (JMML), Hodgkin lymphoma, Non-Hodgkin 45 
lymphoma, multiple myeloma, solitary myeloma, localized 
myeloma, and extramedullary myeloma. 
In a further aspect, the cancer is a cancer of the brain. In a 
still further aspect, the cancer of the brain is selected from a 
glioma, medulloblastoma, primitive neuroectodermal tumor 50 
(PNET), acoustic neuroma, glioma, meningioma, pituitary 
adenoma, schwannoma, CNS lymphoma, primitive neuroec-
todermal tumor, craniopharyngioma, chordoma, medullo-
blastoma, cerebral neuroblastoma, central neurocytoma, 
pineocytoma, pineoblastoma, atypical teratoid rhabdoid 55 
tumor, chondrosarcoma, chondroma, choroid plexus carci-
noma, choroid plexus papilloma, craniopharyngioma, dys-
embryoplastic neuroepithelial tumor, gangliocytoma, germi-
noma, hemangioblastoma, hemangiopercytoma, and 
metastatic brain tumor. In a yet further aspect, the glioma is 60 
selected from ependymoma, astrocytoma, oligodendro-
glioma, and oligoastrocytoma. In an even further aspect, the 
glioma is selected from juvenile pilocytic astrocytoma, sub-
ependymal giant cell astrocytoma, ganglioglioma, sub-
ependymoma, pleomorphic xanthoastrocytom, anaplastic 65 
astrocytoma, glioblastoma multiforme, brain stem glioma, 
oligodendroglioma, ependymoma, oligoastrocytoma, cer-
In a further aspect, the compound contacting the cell inhib-
its STAT3 protein activity with an IC50 in an EMSA assay of 
less than about 100 µM, less than about 50 less than about 10 
µM, less than about 1 µM, less than about 500 nM, or ofless 
than about 100 nM. In a further aspect, the IC50 for inhibition 
ofSTAT3 activity. 
In a further aspect, the compound contacting the cell inhib-
its cell growth. In a still further aspect, the compound inhibits 
cell growth with an IC50 ofless than about 500 µM. In a yet 
further aspect, the compound inhibits cell growth with an 
IC50 ofless than about 250 µM. In an even further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
100 µM. In a still further aspect, the compound inhibits cell 
growth with an IC50 ofless than about 50 µM. In a yet further 
aspect, the compound inhibits cell growth with an IC50 ofless 
than about 10 µM. In an even further aspect, the compound 
inhibits cell growth with an IC50 ofless than about 1 µM. In a 
still further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line with a constitutively active STAT3 
protein. In a yet further aspect, the IC50 for inhibition of cell 
growth is determined in a cell line with a persistently active 
STAT3 protein. In an even further aspect, the IC50 for inhibi-
tion of cell growth is determined in a cell line derived from a 
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cancer selected from breast cancer, pancreatic cancer, and 
prostate cancer. In a yet further aspect, the IC50 for inhibition 
of cell growth is determined in a cell line derived from a 
cancer with a STAT3 protein activity dysfunction. In a still 
further aspect, the IC50 for inhibition of cell growth is deter- 5 
mined in a cell line selected from MDA-MB-231, Panc-1, and 
DU 14S. In a yet further aspect, the IC50 for inhibition of cell 
growth is determined in a cell line transformed with v-Src. In 
an even further aspect, the IC50 for inhibition of cell growth is 
determined in the NIH3T3 cell-line transformed with v-Src. 10 
In a further aspect, the compound contacting the cell treats 
a disorder is associated with constitutively active STAT3. 
In a further aspect, the compound contacting the cell treats 
a disorder selected from psoriasis and pulmonary arterial 
hypertension. 
In a further aspect, the compound contacting the cell treats 
a disorder of uncontrolled cellular proliferation. In a yet fur-
ther aspect, the disorder of uncontrolled cellular proliferation 
is cancer. In a still further aspect, the cancer is selected from 
15 
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In various aspects, the invention relates to a method for the 
treatment of a disorder associated with STATS activity dys-
function in a mammal comprising the step of administering to 
the manimal a therapeutically effective amount of least one 




a cancer of the head, neck, pancreas, brain, ovary, kidney, 20 
prostate, breast, lung, colon, and liver. 
In a further aspect, the cancer is a hematological cancer. In wherein each of m and n is independently an integer from 0-3; 
a still further aspect, the hematological cancer is selected wherein R 1 is -(A5)-(A 6)-L-(A7 ); whereinA5 is selected from 
from acute myeloid leukemia (AML), acute lymphoblastic C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and 
leukemia (ALL), chronic myeloid leukemia (CML), chronic 25 substituted with 0-3 groups selected from halo, hydroxyl, 
lymphocytic leukemia (CLL), hairy cell leukemia, chronic amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, 
myelomonocytic leukemia (CMML), juvenile myelomono- Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, 
cytic leukemia (JMML), Hodgkin lymphoma, Non-Hodgkin Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalky-
lymphoma, multiple myeloma, solitary myeloma, localized lthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-
myeloma, and extramedullary myeloma. 30 (Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-
In a further aspect, the cancer is a cancer of the brain. In a C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-
still further aspect, the cancer of the brain is selected from a alkylthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-
glioma, medulloblastoma, primitive neuroectodermal tumor (Cl-C6)-polyhaloalkylthio, C02H, (C=O)OR 
8
, and (C=O) 
(PNET), acoustic neuroma, glioma, meningioma, pituitary NHR 8 ; wherein A 6 is selected from C3-C6 cycloalkyl, C3-C6 
adenoma, schwannoma, CNS lymphoma, primitive neuroec- 35 heterocycloalkyl, and aryl, and substituted with 0-3 groups 
todermal tumor, craniopharyngioma, chordoma, medulla- selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
blastoma, cerebral neuroblastoma, central neurocytoma, haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
pineocytoma, pineoblastoma, atypical teratoid rhabdoid haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
tumor, chondrosarcoma, chondroma, choroid plexus carci- haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 
noma, choroid plexus papilloma, craniopharyngioma, dys- 40 Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-
embryoplastic neuroepithelial tumor, gangliocytoma, germi- C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-polyha-
noma, hemangioblastoma, hemangiopercytoma, and loalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, (Cl-C6)-alk-(Cl-
metastatic brain tumor. In a yet further aspect, the glioma is C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)-polyhaloalkylthio, 
selected from ependymoma, astrocytoma, oligodendro- C02H, (C=O)OR
9
, and (C=O)NHR9 ; wherein A7 is 
glioma, and oligoastrocytoma. In an even further aspect, the 45 selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, 
glioma is selected from juvenile pilocytic astrocytoma, sub- and aryl, and substituted with 0-3 groups selected from halo, 
ependymal giant cell astrocytoma, ganglioglioma, sub- hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
ependymoma, pleomorphic xanthoastrocytom, anaplastic haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
astrocytoma, glioblastoma multiforme, brain stem glioma, loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
oligodendroglioma, ependymoma, oligoastrocytoma, cer- 50 haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-
ebellar astrocytoma, desmoplastic infantile astrocytoma, sub- C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-haloalkoxy, 
ependymal giant cell astrocytoma, diffuse astrocytoma, (Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
mixed glioma, optic glioma, gliomatosis cerebri, multifocal C6)-alkylthio, (Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-
gliomatous tumor, multicentric glioblastoma multiforme alk-(Cl-C6)-polyhaloalkylthio, C02H, (C=O)OR
16
, and 
tumor, paraganglioma, and ganglioglioma. 55 (C=O)NHR10; wherein Lis optionally present, and when 
In a further aspect, the cancer is selected from a cancer of present is selected from -(C=O)- and-S02-; wherein 
the breast, ovary, prostate, head, neck, and kidney. In a still R2 is selected from hydrogen, Cl-C6 alkyl, C2-C6 alkenyl, 
further aspect, the cancer is breast cancer. In a yet further. C2-C6 alkynyl, Cl-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 
d. Treatment of a Disorder Associated with STATS Activity haloalkynyl, Cl-C6 polyhaloalkyl, C2-C6 polyhaloalkenyl, 
Dysfunction 60 C2-C6 polyhaloalkynyl, (C=O)OR13 , and (C=O)NR13R14; 
In various aspects, the invention relates to a method for the or wherein R 2 is aryl, and substituted with 0-S groups inde-
treatment of a disorder associated with STATS activity dys- pendently selected from halo, hydroxyl, amino, nitro, cyano, 
function in a mammal comprising the step ofadministering to Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
the manimal a therapeutically effective amount of at least one Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, 
compound having a structure represented by Formula I, II, DI 65 Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alky-
or IV, or a pharmaceutically acceptable salt, hydrate, solvate, !amino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 
or polymorph thereof. (Cl-C6)-alk-(Cl-C6)-haloalkoxy, (Cl-C6)-alk-(Cl-C6)-
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polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-alky lthio, (Cl -C6)-
alk-( C 1-C6)-haloalky lhio, (Cl-C6)-alk-(Cl-C6)-polyha-
loalkylthio, C02 H, (C=O)OR
13
, and (C=O)NR13R14; 
wherein R3 is aryl substituted with 0-5 groups independently 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 5 
alkyl, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alky-
lamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 
(Cl-C6)-alk-(Cl-C6)-haloalkoxy, and (Cl-C6)-alk-(Cl-
C6)-polyhaloalkoxy; wherein each of R 8 , R9 , R 10, R 13 , and 10 
R14 is independently selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl; or a pharmaceu-
tically acceptable salt, hydrate, solvate, or polymorph 
thereof. 
In a further aspect, the compound of Formula Vis selected 
from: 
HqOH 
~ UP ~I o......._ 
0 i'N~N ~ 
o I o 
qOH 0 NH2, 
~ UP ~I 
i'N~N ~ 
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In a further aspect, the compound of Formula Vis selected 
from: 
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wherein each of R12a, R126, and R12c is independently 
selected from hydrogen, Cl-C6 alkyl, C2-C6 alkenyl, C2-C6 
alkynyl, Cl-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 
haloalkynyl, Cl-C6 polyhaloalkyl, C2-C6 polyhaloalkenyl, 
In various aspects, the invention relates to a method for the 
treatment of a disorder associated with STATS activity dys-
function in a mammal comprising the step of administering to 
the mammal a therapeutically effective amount of least one 
compound having a structure represented by a formula (VI): 
(VI) 
HO 
5 C2-C6 polyhaloalkynyl, (C=O)OR13 , (C=O)NR13R14; and 
aryl, wherein aryl is substituted with 0-S groups indepen-
dently selected from halo, hydroxyl, amino, nitro, cyano, 
Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, 
Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, 
OH, 
R12b R12c 
R'm '!-! ~----(CH,). 
10 Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alky-
lamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, 
(Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-( Cl -C6)-
polyhaloalkoxy, (Cl -C6)-alk-( Cl -C6)-alkylthio, (Cl -C6)-
alk-( C 1-C6)-haloalky lhio, (Cl-C6)-alk-(Cl-C6)-polyha-
Al~ I 
15 loalkylthio, C02H, (C=O)OR
13
, and (C=O)NR13R14; or a 
pharmaceutically acceptable salt, hydrate, solvate, or poly-
morph thereof. 
O=S=O 0 RI 
I 
R3 
In a further aspect, the mammal is a human. In a yet further 
aspect, the mammal has been diagnosed with a need for 
20 treatment of the disorder prior to the administering step. In a 
still further aspect, the method further comprises the step of 
identifying a mammal in need of treatment of the disorder. 
wherein n is an integer from 0-3; wherein R1 is -(A5)-(A6)-
L-(A7); whereinA5 is selected from C3-C6 cycloalkyl, C3-C6 
heterocycloalkyl, and aryl, and substituted with 0-3 groups 
selected from halo, hydroxyl, amino, nitro, cyano, Cl-C6 
haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 
haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 alkylthio, Cl-C6 
haloalkylhio, Cl-C6 polyhaloalkylthio, Cl-C6 alkylamino, 






, and (C=O)NHR8 ; wherein A6 is 
selected from C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, 35 
and aryl, and substituted with 0-3 groups selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 haloalkyl, Cl-C6 poly-
haloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyha-
loalkoxy, Cl-C6 alkylthio, Cl-C6 haloalkylhio, Cl-C6 poly-
haloalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl- 40 
C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, 
(Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-
C6)-alky lthio, (Cl -C6)-alk-( Cl -C6)-haloalkylhio, (Cl -C6)-




(C=O)NHR9 ; wherein A7 is selected from C3-C6 
cycloalkyl, C3-C6 heterocycloalkyl, and aryl, and substituted 
with 0-3 groups selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, Cl-C6 50 
alkylthio, Cl-C6 haloalkylhio, Cl-C6 polyhaloalkylthio, 
Cl-C6 alkylamino, Cl-C6 dialkylamino, (Cl-C6)-alk-(Cl-
C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-haloalkoxy, (Cl -C6)-alk-
In a further aspect, the compound administered prevents 
STATS protein dimerization. In a yet further aspect, the com-
25 pound administered disrupts preformed or existing STATS 
dimers. In a still further aspect, the compound administered 
binds to the SH2 domain of STATS. 
( C 1-C6)-polyhaloalkoxy, (Cl-C6)-alk-(Cl-C6)-alkylthio, 
(Cl-C6)-alk-(Cl-C6)-haloalkylhio, (Cl-C6)-alk-(Cl-C6)- 55 
polyhaloalkylthio, C02H, (C=O)OR
10
, and (C=O)NHR10 ; 
wherein Lis optionally present, and when present is selected 
from -(C=O)- and -S02-; wherein R
3 is aryl substi-
tuted with 0-S groups independently selected from halo, 
hydroxyl, amino, nitro, cyano, Cl-C6 alkyl, Cl-C6 haloalkyl, 60 
Cl-C6 polyhaloalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, 
Cl-C6 polyhaloalkoxy, Cl-C6 alkylamino, Cl-C6 dialky-
lamino, (Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)-
haloalkoxy, and (Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy; 
wherein each ofR8 , R9 , R10, R13 , and R14 is independently 65 
selected from hydrogen, Cl-C6 alkyl, Cl-C6 haloalkyl, and 
Cl-C6 polyhaloalkyl; 
In a further aspect, the compound administered inhibits 
STATS protein activity. In a still further aspect, inhibition of 
STATS protein activity is determined in an EMSA assay. In a 
yet further aspect, the compound inhibits STATS activity in an 
EMSA assay with an IC50 ofless than about 100 µM, less than 
about SO µM, less than about 10 µM, less than about 1 µM, less 
than about SOO nM, or ofless than about 100 nM. 
In a further aspect, the compound administered inhibits 
phosphorylation of STATS with an IC50 ofless than about 100 
µM, less than about SOl lM, less than about 10 less than about 
1 µM, less than about SOO nM, or of less than about 100 nM. 
In a further aspect, the compound administered inhibits 
binding to the SH2 domain of STATS. In a still further aspect, 
the inhibition of binding to the SH2 domain of STATS is 
determined in an in vitro fluorescence polarization assay 
using STATS protein and a reporter molecule. In a yet further 
aspect, the compound administered inhibits binding of a 
reporter molecule to STATS with a K, ofless than about 100 
µM, less than about SO µM, less than about 10 µM, less than 
about 1 µM, less than about SOO nM, or ofless than about 100 
nM. In a still further aspect, the reporter molecule is S-car-
boxyfluorescein-Gp YLVLDKW. 
In a further aspect, the compound administered inhibits cell 
growth. In a still further aspect, the compound inhibits cell 
growth with an IC50 ofless than about SOO µM. In a yet further 
aspect, the compound inhibits cell growth with an IC50 ofless 
than about 2SO µM. In an even further aspect, the compound 
inhibits cell growth with an IC50 ofless than about 100 µM. In 
a still further aspect, the compound inhibits cell growth with 
an IC50 of less than about SO µM. Ina yet further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
10 W. In an even further aspect, the compound inhibits cell 
growth with an IC50 ofless than about 11 µM. In a still further 
aspect, the IC50 for inhibition of cell growth is determined in 
a cell line with a constitutively active STATS protein. In a still 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line with an activated STATS protein. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line with a persistently active STATS protein. 
In an even further aspect, the IC50 for inhibition of cell growth 
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is determined in a cell line derived from a cancer selected 
from breast cancer, pancreatic cancer, and prostate cancer. In 
216 
sion of a STATS-regulated gene is determined in a cell line 
derived from a cancer selected from a leukemia, lymphoma, 
breast cancer, pancreatic cancer, and prostate cancer. In a yet 
further aspect, the IC50 inhibition of expression of a STATS-
regulated gene is determined in a cell line derived from a 
cancer with a STATS protein activity dysfunction. In a still 
further aspect, the IC50 for inhibition of expression of a 
STATS-regulated gene is determined in a cell line selected 
from MV-4-11 and KS62. In a still further aspect, the IC50 for 
a yet further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line derived from a cancer with a STATS 
protein activity dysfunction. In a still further aspect, the IC50 
for inhibition of cell growth is determined in a cell line 
selected from MV-4-11 and KS62. In a still further aspect, the 
IC50 for inhibition of cell growth is determined in a cell line 
wherein STATS is activated due to the presence of constitu-
tively active FLT-3. In a still further aspect, the IC50 for 
inhibition of cell growth is determined in a cell line wherein 
STATS is activated due ofBCR-Abl. 
10 inhibition of expression of a STATS-regulated gene is deter-
mined in a cell line wherein STATS is activated due to the 
presence of constitutively active FLT-3 in the cell. In a still 
further aspect, the IC50 for inhibition of expression of a 
STATS-regulated gene is determined in a cell line wherein 
15 STATS is activated due to the presence ofBCR-Abl in the cell. 
In a further aspect, the compound administered inhibits cell 
migration. In a still further aspect, the compound inhibits cell 
migration with an IC50 of less than about SOO In a yet further 
aspect, the compound inhibits cell migration with an IC50 of 
less than about 2SO µM. In an even further aspect, the com-
pound inhibits cell migration with an IC50 of less than about 
100 In a still further aspect, the compound inhibits cell migra-
tion with an IC50 of less than about SO µM. In a yet further 20 
aspect, the compound inhibits cell migration with an IC50 of 
less than about 10 µM. In an even further aspect, the com-
pound inhibits cell migration with an IC50 of less than about 
1 µM. In a still further aspect, the IC50 for inhibition of cell 
migration is determined in a cell line with a constitutively 25 
active STATS protein. In a still further aspect, the IC50 for 
inhibition of cell migration is determined in a cell line with an 
activated STATS protein. In a yet further aspect, the IC50 for 
inhibition of cell migration is determined in a cell line with a 
persistently active STATS protein. In an even further aspect, 30 
the IC50 for inhibition of cell migration is determined in a cell 
line derived from a cancer selected from breast cancer, pan-
creatic cancer, and prostate cancer. In a yet further aspect, the 
IC50 for inhibition of cell migration is determined in a cell line 
derived from a cancer with a STATS protein activity dysfunc- 35 
tion. In a still further aspect, the IC50 for inhibition of cell 
migration is determined in a cell line selected from MV-4-11 
and KS62. In a still further aspect, the IC50 for inhibition of 
cell migration is determined in a cell line wherein STATS is 
activated due to the presence of constitutively active FLT-3 in 40 
the cell. In a still further aspect, the IC50 for inhibition of cell 
migration is determined in a cell line wherein STATS is acti-
vated due to the presence of BCR-Abl in the cell. 
In a further aspect, the compound administered inhibits 
expression of STATS-regulated genes. In a still further aspect, 45 
the STATS-regulated gene is selected from Bcl-xL, cyclin D 1, 
cyclin D2, c-myc, and MCL-1. In a still further aspect, the 
compound inhibits expression of a STATS-regulated gene 
with an IC50 ofless than about SOO µM. In a yet further aspect, 
the compound inhibits cell migration with an IC50 ofless than 50 
about 2SO µM. In an even further aspect, the compound inhib-
its expression of a STATS-regulated gene with an IC50 ofless 
than about 100 µM. In a still further aspect, the compound 
inhibits expression of a STATS-regulated gene with an IC50 of 
less than about SO In a yet further aspect, the compound 55 
inhibits cell migration with an IC50 ofless than about 101 µM. 
In an even further aspect, the compound inhibits expression of 
a STATS-regulated gene with an IC50 ofless than about 1 µM. 
In a still further aspect, the IC50 for inhibition of expression of 
a STATS-regulated gene is determined in a cell line with a 60 
constitutively active STATS protein. In a still further aspect, 
the IC50 for inhibition of expression of a STATS-regulated 
gene is determined in a cell line with an activated STATS 
protein. In a yet further aspect, the IC50 for inhibition of 
expression of a STATS-regulated gene is determined in a cell 65 
line with a persistently active STATS protein. In an even 
further aspect, the IC50 for inhibition of inhibition of expres-
In a further aspect, the compound administered treats a 
disorder is associated with constitutively active STATS. In a 
further aspect, the compound administered treats a disorder is 
associated with an activated STATS. 
In a further aspect, the compound administered treats a 
disorder of uncontrolled cellular proliferation. In a yet further 
aspect, the disorder of uncontrolled cellular proliferation is 
cancer. 
In a still further aspect, the cancer is selected from a cancer 
of the head, neck, pancreas, brain, ovary, kidney, prostate, 
breast, lung, colon, rectum, uterine, and liver. 
In a further aspect, the cancer is a hematological cancer. In 
a still further aspect, the hematological cancer is selected 
from acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic myeloid leukemia (CML), chronic 
lymphocytic leukemia (CLL), hairy cell leukemia, chronic 
myelomonocytic leukemia (CMML), juvenile myelomono-
cytic leukemia (JMML), Hodgkin lymphoma, Non-Hodgkin 
lymphoma, multiple myeloma, solitary myeloma, localized 
myeloma, and extramedullary myeloma. 
In a further aspect, the cancer is a cancer of the brain. In a 
still further aspect, the cancer of the brain is selected from a 
glioma, medulloblastoma, primitive neuroectodermal tumor 
(PNET), acoustic neuroma, glioma, meningioma, pituitary 
adenoma, schwannoma, CNS lymphoma, primitive neuroec-
todermal tumor, craniopharyngioma, chordoma, medullo-
blastoma, cerebral neuroblastoma, central neurocytoma, 
pineocytoma, pineoblastoma, atypical teratoid rhabdoid 
tumor, chondrosarcoma, chondroma, choroid plexus carci-
noma, choroid plexus papilloma, craniopharyngioma, dys-
embryoplastic neuroepithelial tumor, gangliocytoma, germi-
noma, hemangioblastoma, hemangiopercytoma, cerebral 
menangioma, and metastatic brain tumor. In a yet further 
aspect, the glioma is selected from ependymoma, astrocy-
toma, oligodendroglioma, and oligoastrocytoma. In an even 
further aspect, the glioma is selected from juvenile pilocytic 
astrocytoma, subependymal giant cell astrocytoma, gan-
glioglioma, subependymoma, pleomorphic xanthoastrocy-
tom, anaplastic astrocytoma, glioblastoma multiforme, brain 
stem glioma, oligodendroglioma, ependymoma, oligoastro-
cytoma, cerebellar astrocytoma, desmoplastic infantile astro-
cytoma, subependymal giant cell astrocytoma, diffuse astro-
cytoma, mixed glioma, optic glioma, gliomatosis cerebri, 
multifocal gliomatous tumor, multicentric glioblastoma mul-
tiforme tumor, paraganglioma, and ganglioglioma. 
In a further aspect, the cancer is selected from a cancer of 
the breast, ovary, prostate, head, neck, and kidney. In a still 
further aspect, the cancer is breast cancer. In a yet further 
aspect, the cancer is pancreatic cancer. In an even further 
aspect, the cancer is uterine cancer. In a yet further aspect, the 
cancer is colorectal cancer. In a still further aspect, the cancer 
is a melanoma. In an even further aspect, the cancer is non-
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small cell lung cancer. In a yet further aspect, the cancer is 
squamous cell carcinoma of the head and neck. 
e. Inhibition of STATS Activity in a Mammal 
218 
about 100 µM, less than about SO µM, less than about 10 µM, 
less than about 11 µM, less than about SOO nM, or ofless than 
about 100 nM. 
In one aspect, the invention relates to a method for inhibi-
tion of STATS activity in a mammal comprising the step of 5 
administering to the mammal a therapeutically effective 
amount ofleast one compound having a structure represented 
by Formula I, II, III or IV, or a pharmaceutically acceptable 
salt, hydrate, solvate, or polymorph thereof. 
In a further aspect, the compound contacting the at least 
one cell inhibits phosphorylation of STATS with an IC50 of 
less than about 100 µM, less than about SO µM, less than about 
10 µM, less than about 1 µM, less than about SOO nM, or of 
less than about 100 nM. 
In a further aspect, the compound contacting the at least 
one cell inhibits binding to the SH2 domain of STATS. In a 
still further aspect, the inhibition of binding to the SH2 
domain of STATS is determined in an in vitro fluorescence 
polarization assay using STATS protein and a reporter mol-
ecule. In a yet further aspect, the compound contacting the at 
In various aspects, the invention relates to a method for 10 
inhibition of STATS activity in a mammal comprising the step 
of administering to the mammal a therapeutically effective 
amount ofleast one compound having a structure represented 
by a Formula V or VI, or a pharmaceutically acceptable salt, 
hydrate, solvate, or polymorph thereof. 
In a further aspect, the mammal is a human. In a yet further 
aspect, the mammal has been diagnosed with a need for 
inhibition of STATS activity prior to the administering step. In 
15 least one cell inhibits binding of a reporter molecule to STATS 
with a Ki ofless than about 100 µM, less than about SO µM, 
less than about 10 less than about 1 µM, less than about SOO 
nM, or ofless than about 100 nM. In a still further aspect, the 
a still further aspect, the method further comprises the step of 
identifying a mammal in need of treatment of the disorder. 20 
compound contacting the at least one cell inhibits phospho-
rylation of STATS with an IC50 for inhibition of phosphory-
lation of STATS of less than about 100 µM, In a still further In a further aspect, inhibition of STATS activity treats a 
disorder of uncontrolled cellular proliferation. In a yet further 
aspect, the disorder of uncontrolled cellular proliferation is a 
cancer or tumor. 
f. Inhibiting STATS Activity in Cells 
In one aspect, the invention relates to a method for inhib-
iting STATS activity in at least one cell, comprising the step of 
contacting the at least one cell with an effective amount of 
least one compound having a structure represented by For-
mula I, II, III or IV, or a pharmaceutically acceptable salt, 
hydrate, solvate, or polymorph thereof. 
In various aspects, the invention relates to a method for 
inhibiting STATS activity in at least one cell, comprising the 
step of contacting the at least one cell with an effective 
amount ofleast one compound having a structure represented 
by a Formula V or VI, or a pharmaceutically acceptable salt, 
hydrate, solvate, or polymorph thereof. 
a further aspect, the at least one cell is in a mammal. In a 
still further aspect, the method further comprises administer-
ing to the mammal the compound in an amount sufficient to 
contact at least one cell in the mammal. In yet further aspect, 
the cell is mammalian. In an even further aspect, the cell is 
human. In a further aspect, the cell has been isolated from a 
mammal prior to the contacting step. 
aspect, the reporter molecule is S-carboxyfluorescein-
GpYLVLDKW. 
In a further aspect, the compound contacting the at least 
25 one cell inhibits cell growth. In a still further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
SOO µM. In a yet further aspect, the compound inhibits cell 
growth with an IC50 of less than about 2SO µM. In an even 
further aspect, the compound inhibits cell growth with an 
30 IC50 of less than about 100 µM. In a still further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
SO µM. In a yet further aspect, the compound inhibits cell 
growth with an IC50 of less than about 10 µM. In an even 
further aspect, the compound inhibits cell growth with an 
35 IC50 ofless than about 1 µM. In a still further aspect, the IC50 
for inhibition of cell growth is determined in a cell line with a 
constitutively active STATS protein. In a still further aspect, 
the IC50 for inhibition of cell growth is determined in a cell 
line with an activated STATS protein. In a yet further aspect, 
40 the IC50 for inhibition of cell growth is determined in a cell 
line with a persistently active STATS protein. In an even 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line derived from a cancer selected from breast 
In a further aspect, contacting is via administration to a 45 
mammal. In a further aspect, the mammal has been diagnosed 
with aneed for modulating STATS protein activity prior to the 
administering step. In a further aspect, the mammal has been 
diagnosed with a need for treatment of a disorder related to a 
STATS protein activity dysfunction prior to the administering 50 
step. 
cancer, pancreatic cancer, and prostate cancer. In a yet further 
aspect, the IC50 for inhibition of cell growth is determined in 
a cell line derived from a cancer with a STATS protein activity 
dysfunction. In a still further aspect, the IC50 for inhibition of 
cell growth is determined in a cell line selected from MV-4-11 
and KS62. In a still further aspect, the IC50 for inhibition of 
cell growth is determined in a cell line wherein STATS is 
activated due to the presence of constitutively active FLT-3. In 
In a further aspect, the at least one cell is in a human. In a 
yet further aspect, the mammal has been diagnosed with a 
need fortreatment of the disorder prior to the contacting step. 
In a still further aspect, the method further comprises the step 55 
of identifying a mammal in need of treatment of the disorder. 
In a further aspect, the compound contacting the at least 
one cell prevents STATS protein dimerization. In a yet further 
aspect, the compound contacting the at least one cell disrupts 
preformed or existing STATS dimers. In a still further aspect, 60 
the compound contacting the at least one cell binds to the SH2 
domain of STATS. 
a still further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line wherein STATS is activated due of 
BCR-Abl. 
In a further aspect, the compound contacting the at least 
one cell inhibits cell migration. In a still further aspect, the 
compound inhibits cell migration with an IC50 of less than 
about SOO µM. In a yet further aspect, the compound inhibits 
cell migration with an IC50 ofless than about 2SO µM. In an 
even further aspect, the compound inhibits cell migration 
with an IC50 of less than about 100 µM. In a still further 
aspect, the compound inhibits cell migration with an IC50 of 
less than about SO µM. In a yet further aspect, the compound 
inhibits cell migration with an IC50 ofless than about 10 µM. 
In a further aspect, the compound contacting the at least 
one cell inhibits STATS protein activity. In a still further 
aspect, inhibition of STATS protein activity is determined in 
an EMSA assay. In a yet further aspect, the compound inhibits 
STATS activity in an EMSA assay with an IC50 ofless than 
65 In an even further aspect, the compound inhibits cell migra-
tion with an IC50 of less than about 1 µM. In a still further 
aspect, the IC50 for inhibition of cell migration is determined 
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in a cell line with a constitutively active STATS protein. In a 
still further aspect, the IC50 for inhibition of cell migration is 
determined in a cell line with an activated STATS protein. In 
a yet further aspect, the IC50 for inhibition of cell migration is 
determined in a cell line with a persistently active STATS 
protein. In an even further aspect, the IC50 for inhibition of 
cell migration is determined in a cell line derived from a 
cancer selected from breast cancer, pancreatic cancer, and 
prostate cancer. In a yet further aspect, the IC50 for inhibition 
of cell migration is determined in a cell line derived from a 
cancer with a STATS protein activity dysfunction. In a still 
further aspect, the IC50 for inhibition of cell migration is 
determined in a cell line selected from MV-4-11 and KS62. In 
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tion. In a yet further aspect, the disorder of uncontrolled 
cellular proliferation is cancer. 
In a still further aspect, the cancer is selected from a cancer 
of the head, neck, pancreas, brain, ovary, kidney, prostate, 
breast, lung, colon, rectum, uterine, and liver. 
In a further aspect, the cancer is a hematological cancer. In 
a still further aspect, the hematological cancer is selected 
from acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic myeloid leukemia (CML), chronic 
10 lymphocytic leukemia (CLL), hairy cell leukemia, chronic 
myelomonocytic leukemia (CMML), juvenile myelomono-
cytic leukemia (JMML), Hodgkin lymphoma, Non-Hodgkin 
lymphoma, multiple myeloma, solitary myeloma, localized 
myeloma, and extramedullary myeloma. 
In a further aspect, the cancer is a cancer of the brain. In a 
still further aspect, the cancer of the brain is selected from a 
glioma, medulloblastoma, primitive neuroectodermal tumor 
(PNET), acoustic neuroma, glioma, meningioma, pituitary 
adenoma, schwannoma, CNS lymphoma, primitive neuroec-
a still further aspect, the IC50 for inhibition of cell migration 15 
is determined in a cell line wherein STATS is activated due to 
the presence of constitutively active FLT-3 in the cell. Ina still 
further aspect, the IC50 for inhibition of cell migration is 
determined in a cell line wherein STATS is activated due to the 
presence ofBCR-Abl in the cell. 20 todermal tumor, craniopharyngioma, chordoma, medullo-
blastoma, cerebral neuroblastoma, central neurocytoma, 
pineocytoma, pineoblastoma, atypical teratoid rhabdoid 
tumor, chondrosarcoma, chondroma, choroid plexus carci-
noma, choroid plexus papilloma, craniopharyngioma, dys-
In a further aspect, the compound contacting the at least 
one cell inhibits expression of STATS-regulated genes. In a 
still further aspect, the STATS-regulated gene is selected from 
Bcl-xL, cyclin Dl, cyclin D2, c-myc, and MCL-1. In a still 
further aspect, the compound inhibits expression of a STATS-
regulated genewithanIC50 ofless than about SOO µM. Ina yet 
further aspect, the compound inhibits cell migration with an 
IC50 ofless than about 2SO µM. In an even further aspect, the 
compound inhibits expression of a STATS-regulated gene 
with an IC50 of less than about 100 µM. In a still further 
aspect, the compound inhibits expression of a STATS-regu-
lated gene with an IC50 of less than about SO µM. In a yet 
further aspect, the compound inhibits cell migration with an 
IC50 ofless than about 10 µM. In an even further aspect, the 
compound inhibits expression of a STATS-regulated gene 
with an IC50 ofless than about 1 µM. In a still further aspect, 
the IC50 for inhibition of expression of a STATS-regulated 
gene is determined in a cell line with a constitutively active 
STATS protein. In a still further aspect, the IC50 for inhibition 
25 embryoplastic neuroepithelial tumor, gangliocytoma, germi-
noma, hemangioblastoma, hemangiopercytoma, cerebral 
menangioma, and metastatic brain tumor. In a yet further 
aspect, the glioma is selected from ependymoma, astrocy-
toma, oligodendroglioma, and oligoastrocytoma. In an even 
30 further aspect, the glioma is selected from juvenile pilocytic 
astrocytoma, subependymal giant cell astrocytoma, gan-
glioglioma, subependymoma, pleomorphic xanthoastrocy-
tom, anaplastic astrocytoma, glioblastoma multiforme, brain 
stem glioma, oligodendroglioma, ependymoma, oligoastro-
35 cytoma, cerebellar astrocytoma, desmoplastic infantile astro-
cytoma, subependymal giant cell astrocytoma, diffuse astro-
cytoma, mixed glioma, optic glioma, gliomatosis cerebri, 
multifocal gliomatous tumor, multicentric glioblastoma mul-
tiforme tumor, paraganglioma, and ganglioglioma. 
In a further aspect, the cancer is selected from a cancer of 
the breast, ovary, prostate, head, neck, and kidney. In a still 
further aspect, the cancer is breast cancer. In a yet further 
aspect, the cancer is pancreatic cancer. In an even further 
aspect, the cancer is uterine cancer. In a yet further aspect, the 
of expression of a STATS-regulated gene is determined in a 40 
cell line with an activated STATS protein. In a yet further 
aspect, the IC50 for inhibition of expression of a STATS-
regulated gene is determined in a cell line with a persistently 
active STATS protein. In an even further aspect, the IC50 for 
inhibition of inhibition of expression of a STATS-regulated 
gene is determined in a cell line derived from a cancer 
selected from a leukemia, lymphoma, breast cancer, pancre-
atic cancer, and prostate cancer. In a yet further aspect, the 
IC50 inhibition of expression of a STATS-regulated gene is 
determined in a cell line derived from a cancer with a STATS 50 
45 cancer is colorectal cancer. In a still further aspect, the cancer 
is a melanoma. In an even further aspect, the cancer is non-
small cell lung cancer. In a yet further aspect, the cancer is 
squamous cell carcinoma of the head and neck. 
2. Manufacture of a Medicament 
In one aspect, the invention relates to a method for the 
protein activity dysfunction. In a still further aspect, the IC50 
for inhibition of expression of a STATS-regulated gene is 
determined in a cell line selected from MV-4-11 and KS62. In 
a still further aspect, the IC50 for inhibition of expression of a 
STATS-regulated gene is determined in a cell line wherein 
STATS is activated due to the presence of constitutively active 
FLT-3 in the cell. In a still further aspect, the IC50 for inhibi-
tion of expression of a STATS-regulated gene is determined in 
a cell line wherein STATS is activated due to the presence of 
BCR-Abl in the cell. 
In a further aspect, the compound contacting the at least 
one cell treats a disorder is associated with constitutively 
active STATS. In a further aspect, the compound contacting 
the at least one cell treats a disorder is associated with an 
activated STATS. 
In a further aspect, the compound contacting the at least 
one cell treats a disorder of uncontrolled cellular prolifera-
manufacture of a medicament for uncontrolled cellular pro-
liferation activity in a mammal comprising combining a 
therapeutically effective amount of a disclosed compound or 
product of a disclosed method with a pharmaceutically 
55 acceptable carrier or diluent. 
3. Use of Compounds 
In one aspect, the invention relates to the use of a com-
pound having a structure represented by Formula I, II, III, IV, 
V or VI, or a pharmaceutically acceptable salt, hydrate, sol-
60 vate, or polymorph thereof. 
In a further aspect, the compound is a disclosed compound 
described by Formula I, II, III, IV, V or VI, or a product of a 
disclosed method. 
In a further aspect, the use relates to inhibition of STAT 
65 protein activity. In a further aspect, the use relates to inhibi-
tion ofSTAT3 protein activity. In a still further aspect, the use 
relates to prevention of STAT3 protein dimerization. In a yet 
US 8,846,707 B2 
221 
further aspect, the use relates to disruption of preformed or 
existing S TAT3 dimers. In a still further aspect, the use relates 
to binding to the SH2 domain of STAT3. 
In a further aspect, the use relates to inhibition of STATS 
protein activity. In a still further aspect, the use relates to 
prevention of STATS protein dimerization. In a yet further 
aspect, the use relates to disruption of preformed or existing 
STATS dimers. In a still further aspect, the use relates to 
binding to the SH2 domain of STATS. 
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In a further aspect, the use relates to the manufacture of a 
medicament for the treatment of a disorder associated with 
STAT3 protein activity dysfunction in a mammal. In a further 
aspect, the disorder associated with a STAT3 dysfunction is a 
disorder uncontrolled cellular proliferation. In a further 
aspect, the disorder is a disease of uncontrolled cellular pro-
liferation. In a further aspect, a use relates to treatment of a 
disorder of controlled cellular proliferation associated with a 
STAT3 protein activity dysfunction in a marmnal. 
In a further aspect, the use relates to the manufacture of a 
medicament for the treatment of a disorder associated with 
STATS protein activity dysfunction in a mammal. In a further 
aspect, the disorder associated with a STATS dysfunction is a 
disorder uncontrolled cellular proliferation. In a further 
In a further aspect, the use relates to inhibition of STAT 10 
protein activity with an IC50 in an EMSA assay of less than 
about 100 µM, less than about SO µM, less than about 10 µM, 
less than about 1 µM, less than about SOO nM, or ofless than 
about 100 nM. In a further aspect, the IC50 is for inhibition of 
STAT3 activity. In a further aspect, the IC50 is for inhibition of 
STATS activity. 
15 aspect, the disorder is a disease of uncontrolled cellular pro-
liferation. In a further aspect, a use relates to treatment of a 
disorder of controlled cellular proliferation associated with a 
STATS protein activity dysfunction in a marmnal. 
In a further aspect, the use relates to inhibition of cell 
growth. In a still further aspect, the use relates to inhibition of 
cell growth with an IC50 ofless than about SOO µM. In a yet 
further aspect, the use relates to inhibition of cell growth with 
In one aspect, a use is associated with the treatment of a 
20 disorder associated with uncontrolled cellular proliferation. 
an IC50 ofless than about 2SO µM. In an even further aspect, 
the use relates to inhibition of cell growth with an IC50 ofless 
than about 100 µM. In a still further aspect, the use relates to 
inhibition of cell growth with an IC50 of less than about SO 
µM. In a yet further aspect, the use relates to inhibition of 25 
inhibits cell growth with an IC50 ofless than about 10 µM. In 
In a further aspect, the disorder is cancer. In a still further 
aspect, the cancer is selected from a cancer of the head, neck, 
pancreas, brain, ovary, kidney, prostate, breast, lung, colon, 
and liver. 
In a further aspect, the cancer is a hematological cancer. In 
a still further aspect, the hematological cancer is selected 
from acute myeloid leukemia (AML), acute lymphoblastic 
leukemia (ALL), chronic myeloid leukemia (CML), chronic 
lymphocytic leukemia (CLL), hairy cell leukemia, chronic 
myelomonocytic leukemia (CMML), juvenile myelomono-
cytic leukemia (JMML), Hodgkin lymphoma, Non-Hodgkin 
an even further aspect, the use relates to inhibition of cell 
growth with an IC50 of less than about 1 µM. In a still further 
aspect, the IC50 for inhibition of cell growth is determined in 
a cell line with a constitutively active STAT protein. In a yet 30 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line with a persistently active STAT protein. In lymphoma, multiple myeloma, solitary myeloma, localized 
myeloma, and extramedullary myeloma. an even further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line derived from a cancer selected from 
breast cancer, pancreatic cancer, and prostate cancer. In a yet 
further aspect, the IC50 for inhibition of cell growth is deter-
mined in a cell line derived from a cancer with a STAT protein 
activity dysfunction. In a still further aspect, the IC50 for 
inhibition of cell growth is determined in a cell line selected 
from MDA-MB-231, Panc-1, and DU 14S. In a yet further 
aspect, the IC50 for inhibition of cell growth is determined in 
a cell line transformed with v-Src. In an even further aspect, 
the IC50 for inhibition of cell growth is determined in the 
NIH3T3 cell-line transformed with v-Src. In a yet further 
aspect, the IC50 for inhibition of cell growth is determined in 
a cell line selected from KS 62 and MV-4-11. 
In a further aspect, the use treats a disorder is associated 
with constitutively active STAT3. In a still further aspect, the 
use treats a disorder is associated with constitutively active 
STATS. 
In a further aspect, the use treats a disorder selected from 
psoriasis and pulmonary arterial hypertension. 
In a further aspect, the use treats a disorder of uncontrolled 
cellular proliferation. In a yet further aspect, the disorder of 
uncontrolled cellular proliferation is cancer. In a still further 
aspect, the cancer is selected from a cancer of the head, neck, 
pancreas, brain, ovary, kidney, prostate, breast, lung, colon, 
and liver. 
In a further aspect, the use relates to the manufacture of a 
medicament for the treatment of a disorder associated with 
STAT protein activity dysfunction in a mammal. In a further 
aspect, the disorder is a disorder uncontrolled cellular prolif-
eration. In a further aspect, the disorder is a disease of uncon-
trolled cellular proliferation. In a further aspect, a use relates 
In a further aspect, the cancer is a cancer of the brain. In a 
35 still further aspect, the cancer of the brain is selected from a 
glioma, medulloblastoma, primitive neuroectodermal tumor 
(PNET), acoustic neuroma, glioma, meningioma, pituitary 
adenoma, schwannoma, CNS lymphoma, primitive neuroec-
todermal tumor, craniopharyngioma, chordoma, medullo-
40 blastoma, cerebral neuroblastoma, central neurocytoma, 
pineocytoma, pineoblastoma, atypical teratoid rhabdoid 
tumor, chondrosarcoma, chondroma, choroid plexus carci-
noma, choroid plexus papilloma, craniopharyngioma, dys-
embryoplastic neuroepithelial tumor, gangliocytoma, germi-
45 noma, hemangioblastoma, hemangiopercytoma, and 
metastatic brain tumor. In a yet further aspect, the glioma is 
selected from ependymoma, astrocytoma, oligodendro-
glioma, and oligoastrocytoma. In an even further aspect, the 
glioma is selected from juvenile pilocytic astrocytoma, sub-
50 ependymal giant cell astrocytom, ganglioglioma, subependy-
moma, pleomorphic xanthoastrocytom, anaplastic astrocy-
toma, glioblastoma multiforme, brain stem glioma, 
oligodendroglioma, ependymoma, oligoastrocytoma, cer-
ebellar astrocytoma, desmoplastic infantile astrocytoma, sub-
55 ependymal giant cell astrocytoma, diffuse astrocytoma, 
mixed glioma, optic glioma, gliomatosis cerebri, multifocal 
gliomatous tumor, multicentric glioblastoma multiforme 
tumor, paraganglioma, and ganglioglioma. 
In a further aspect, the cancer is selected from a cancer of 
60 the breast, ovary, prostate, head, neck, and kidney. In a still 
further aspect, the cancer is breast cancer. In a yet further 
In a further aspect, the disorder is selected from psoriasis 
and pulmonary arterial hypertension. 
4. Kits 
to treatment of a disorder of controlled cellular proliferation 65 
associated with a STAT protein activity dysfunction in a 
In one aspect, the invention relates to a kit comprising at 
least one compound having a structure represented by For-
mula I, II, III or IV, or a pharmaceutically acceptable salt, mammal. 
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hydrate, solvate, or polymorph thereof, and one or more of: 
(a) at least one agent known to decrease STAT3 activity; (b) at 
least one agent known to increase STAT3 activity; ( c) at least 
one agent know to treat a disease of uncontrolled cellular 
proliferation; (d) at least one agent known to treat psoriasis; 
( e) at least one agent known to treat pulmonary arterial hyper-
tension; or (f) instructions for treating a disorder associated 
with STAT dysfunction. 
In one aspect, the invention relates to a kit comprising at 
least one compound having a structure represented by For- 10 
mula V or VI, or a pharmaceutically acceptable salt, hydrate, 
solvate, or polymorph thereof, and one or more of: (a) at least 
one agent known to decrease STATS activity; (b) at least one 
agent known to increase STATS activity; ( c) at least one agent 
know to treat a disease of uncontrolled cellular proliferation; 15 
or ( d) instructions for treating a disorder associated with 
STATS dysfunction. 
In a further aspect, the kit comprises a disclosed compound 
described by Formula I, II, III, or IV, or a product of a dis-
closed method. In a still further aspect, the kit comprises a 20 
disclosed compound described by Formula IV or V, or a 
product of a disclosed method. 
In a further aspect, the at least one compound and the at 
least one agent are co-formulated. In a still further aspect, the 
at least one compound and the at least one agent are co- 25 
packaged. 
In a further aspect, the at least one compound in the kit 
exhibits inhibition of a STAT protein. In a yet further aspect, 
the compound in the kit inhibits the STAT protein is STAT3. 
In a still further aspect, the compound in the kit inhibits the 30 
STAT protein is STATS. 
In a further aspect, the at least one compound in the kit 
inhibits STAT protein activity with an IC50 in an EMSA assay 
of less than about 100 µM, less than about SO µM, less than 
about 10 µM, less than about 1 µM, less than about SOO nM, 35 
orofless than about 100 nM. In a further aspect, the IC50 is for 
inhibition ofSTAT3 activity. In a further aspect, the IC50 is for 
inhibition of STATS activity. 
In a further aspect, the at least one compound in the kit 
inhibits cell growth. In a still further aspect, the compound 40 
inhibits cell growth with an IC50 ofless than about SOO µM. In 
a yet further aspect, the compound inhibits cell growth with 
an IC50 ofless than about 2SO µM. In an even further aspect, 
the compound inhibits cell growth with an IC50 ofless than 
about 100 µM. In a still further aspect, the compound inhibits 45 
cell growth with an IC50 of less than about SO µM. In a yet 
further aspect, the compound inhibits cell growth with an 
IC50 ofless than about 10 µM. In an even further aspect, the 
compound inhibits cell growth with an IC50 ofless than about 
1 µM. In a still further aspect, the IC50 for inhibition of cell 50 
growth is determined in a cell line with a constitutively active 
STAT protein. In a yet further aspect, the IC50 for inhibition of 
cell growth is determined in a cell line with a persistently 
active STAT protein. In an even further aspect, the IC50 for 
inhibition of cell growth is determined in a cell line derived 55 
from a cancer selected from breast cancer, pancreatic cancer, 
and prostate cancer. In a yet further aspect, the IC50 for inhi-
bition of cell growth is determined in a cell line derived from 
a cancer with a STAT protein activity dysfunction. In a still 
further aspect, the IC50 for inhibition of cell growth is deter- 60 
mined in a cell line selected from MDA-MB-231, Panc-1, and 
DU 14S. In a yet further aspect, the IC50 for inhibition of cell 
growth is determined in a cell line transformed with v-Src. In 
an even further aspect, the IC50 for inhibition of cell growth is 
determined in the NIH3T3 cell-line transformed with v-Src. 65 
In a yet further aspect, the IC50 for inhibition of cell growth is 
determined in a cell line selected from KS62 and MV-4-11. 
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In a further aspect, the at least one compound in the kit 
treats a disorder is associated with constitutively active 
STAT3. In a still further aspect, the at least one compound in 
the kit treats a disorder is associated with constitutively active 
STATS. 
In a further aspect, the at least one agent is a hormone 
therapy agent. In a still further aspect, the hormone therapy 
agent is selected from one or more of the group consisting of 
leuprolide, tamoxifen, raloxifene, megestrol, fulvestrant, 
triptorelin, medroxyprogesterone, letrozole, anastrozole, 
exemestane, bicalutamide, goserelin, histrelin, fluoxymester-
one, estramustine, flutamide, toremifene, degarelix, niluta-
mide, abarelix, and testolactone, or a pharmaceutically 
acceptable salt, hydrate, solvate, or polymorph thereof. 
In a further aspect, the at least one agent is a chemothera-
peutic agent. In a yet further aspect, the chemotherapeutic 
agent is selected from one or more of the group consisting of 
an alkylating agent, an antimetabolite agent, an antineoplastic 
antibiotic agent, a mitotic inhibitor agent, a mTor inhibitor 
agent or other chemotherapeutic agent. In a still further 
aspect, the antineoplastic antibiotic agent is selected from one 
or more of the group consisting of doxorubicin, mitox-
antrone, bleomycin, daunorubicin, dactinomycin, epirubicin, 
idarubicin, plicamycin, mitomycin, pentostatin, and valrubi-
cin, or a pharmaceutically acceptable salt, hydrate, solvate, or 
polymorph thereof. In an even further aspect, the antimetabo-
lite agent is selected from one or more of the group consisting 
of gemcitabine, S-fluorouracil, capecitabine, hydroxyurea, 
mercaptopurine, pemetrexed, fludarabine, nelarabine, 
cladribine, clofarabine, cytarabine, decitabine, pralatrexate, 
floxuridine, methotrexate, and thioguanine, or a pharmaceu-
tically acceptable salt, hydrate, solvate, or polymorph 
thereof. In a still further aspect, the alkylating agent is 
selected from one or more of the group consisting of carbo-
platin, cisplatin, cyclophosphamide, chlorambucil, mel-
phalan, carmustine, busulfan, lomustine, dacarbazine, oxali-
platin, ifosfamide, mechlorethamine, temozolomide, 
thiotepa, bendamustine, and streptozocin, or a pharmaceuti-
cally acceptable salt, hydrate, solvate, or polymorph thereof. 
In a yet further aspect, the mitotic inhibitor agent is selected 
from one or more of the group consisting of irinotecan, topo-
tecan, rubitecan, cabazitaxel, docetaxel, paclitaxel, etopside, 
vincristine, ixabepilone, vinorelbine, vinblastine, and tenipo-
side, or a pharmaceutically acceptable salt, hydrate, solvate, 
or polymorph thereof. In an even further aspect, the mTor 
inhibitor agent is selected from one or more of the group 
consisting of everolimus, siroliumus, and temsirolimus, or a 
pharmaceutically acceptable salt, hydrate, solvate, or poly-
morph thereof. 
In a further aspect, the at least one compound and the at 
least one agent are co-packaged. In a still further aspect, the at 
least one agent that is co-packaged with the at least one 
compound is one of the agents described herein. 
In a further aspect, the at least one compound and the at 
least one agent are co-formulated. In a still further aspect, the 
at least one agent that is co-formulated with the at least one 
compound is one of the agents described herein. 
In a further aspect, the instructions further comprise pro-
viding the compound in connection surgery. In a still further 
aspect, the instructions provide that surgery is performed 
prior to the administering of at least one compound. In a yet 
further aspect, the instructions provide that surgery is per-
formed after the administering of at least one compound. In 
an even further aspect, the instructions provide that the 
administering of at least one compound is to effect presurgi-
cal debulking of a tumor. In a yet further aspect, the instruc-
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tions provide that surgery is performed at about the same time 
as the administering of at least one compound. 
In a further aspect, the instructions further comprise pro-
viding the compound in connection with radiotherapy. In a 
yet further aspect, the instructions provide that radiotherapy 
is performed prior to the administering of at least one com-
pound. In a still further aspect, the instructions provide that 
radiotherapy is performed after the step of the administering 
of at least one compound. In an even further aspect, the 
instructions provide that radiotherapy is performed at about 10 
the same time as the step of the administering of at least one 
compound. In a still further aspect, the instructions further 
comprise providing the compound in connection with at least 
one agent that is a chemotherapeutic agent. 
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invention in any way. The Examples are typically depicted in 
free base form, according to the IUPAC naming convention. 
However, some of the Examples were obtained or isolated in 
salt form. 
As indicated, some of the Examples were obtained as race-
mic mixtures of one or more enantiomers or diastereomers. 
The compounds may be separated by one skilled in the art to 
isolate individual enantiomers. Separation can be carried out 
by the coupling of a racemic mixture of compounds to an 
enantiomerically pure compound to form a diastereomeric 
mixture, followed by separation of the individual diastere-
omers by standard methods, such as fractional crystallization 
or chromatography. A racemic or diastereomeric mixture of 
the compounds can also be separated directly by chromato-
graphic methods using chiral stationary phases. 
1. General Methods 
Anhydrous solvents methanol, DMSO, CH2 Cl2 , THF and 
The kits can also comprise compounds and/or products 15 
co-packaged, co-formulated, and/or co-delivered with other 
components. For example, a drug manufacturer, a drug 
reseller, a physician, a compounding shop, or a pharmacist 
can provide a kit comprising a disclosed compound and/or 
product and another component for delivery to a patient. 20 DMF were purchased from Sigma Aldrich and used directly 
from Sure-Seal bottles. Molecular sieves were activated by 
heating to 300° C. under vacuum overnight. All reactions 
were performed under an atmosphere of dry nitrogen in oven-
It is contemplated that the disclosed kits can be used in 
connection with the disclosed methods of making, the dis-
closed methods of using, and/or the disclosed compositions. 
S. Non-Medical Uses 
Also provided are the uses of the disclosed compounds and 25 
products as pharmacological tools in the development and 
standardization of in vitro and in vivo test systems for the 
evaluation of the effects of inhibitors of STAT protein related 
activity in laboratory animals such as cats, dogs, rabbits, 
monkeys, rats and mice, as part of the search for new thera- 30 
peutic agents targeting STAT protein. Also provided are the 
uses of the disclosed compounds and products as pharmaco-
logical tools in the development and standardization of in 
vitro and in vivo test systems for the evaluation of the effects 
of inhibitors of STAT protein related activity in laboratory 35 
animals such as cats, dogs, rabbits, monkeys, rats and mice, as 
part of the search for new therapeutic agents targeting STATS 
protein. In various further aspects, als provided are the uses of 
the disclosed compounds and products as pharmacological 
tools in the development and standardization of in vitro and in 40 
vivo test systems for the evaluation of the effects ofinhibitors 
of STAT protein related activity in laboratory animals such as 
cats, dogs, rabbits, monkeys, rats and mice, as part of the 
search for new therapeutic agents targeting STATS protein. 
dried glassware and were monitored for completeness by 
thin-layer chromatography (TLC) using silica gel (visualized 
by UV light, or developed by treatment with KMnO 4 stain or 
phosphomolybdic acid stain). 1 Hand 13C NMR spectra were 
recorded on Bruker 400 MHz and a Varian SOO MHz spec-
trometers in either CDC13 , CD30D or d6-DMSO. Chemical 
shifts (o) are reported in parts per million after calibration to 
residual isotopic solvent. Coupling constants (J) are reported 
in Hz. Before biological testing, inhibitor purity was evalu-
ated by reversed-phase HPLC (rpHPLC). Analysis by 
rpHPLC was performed using a Microsorb-MV 300 A C18 
2SO mmx4.6 mm colunm run at 1 mL/min, and using gradient 
mixtures of (A) water with O.lM CH3COONH4 and (B) 
methanol. Ligand purity was confirmed using linear gradients 
from 7S% A and 2S% B to 100% B after an initial 2 minute 
period of 100%A. The linear gradient consisted of a changing 
solvent composition of either (I) 4.7% per minute and UV 
detection at 2S4 nm or (II) 1.4% per minute and detection at 
214 nm, each ending with S minutes of 100% B. For reporting 
HPLC data, percentage purity is given in parentheses afterthe 
retention time for each condition. All biologically evaluated 
45 compounds are >9S% chemical purity as measured by HPLC. 
G. EXPERIMENTAL 
The following examples are put forth so as to provide those 
of ordinary skill in the art with a complete disclosure and 
description of how the compounds, compositions, articles, 50 
devices and/or methods claimed herein are made and evalu-
ated, and are intended to be purely exemplary of the invention 
and are not intended to limit the scope of what the inventors 
regard as their invention. Efforts have been made to ensure 
accuracy with respect to numbers (e.g., amounts, tempera- 55 
ture, etc.), but some errors and deviations should be 
accounted for. Unless indicated otherwise, parts are parts by 
weight, temperature is in ° C. or is at ambient temperature, 
and pressure is at or near atmospheric. 
Several methods for preparing the compounds of this 60 
invention are illustrated in the following Examples. Starting 
materials and the requisite intermediates are in some cases 
commercially available, or can be prepared according to lit-
erature procedures or as illustrated herein. 
The following exemplary compounds of the invention were 65 
synthesized. The Examples are provided herein to illustrate 
the invention, and should not be construed as limiting the 
2. General Procedure a (Reductive Amination of 
Amino Salicyclic Acid)-Reaction of R 1 Aldehydes 
with Benzyl Protected 4-Aminosalicyclic Acid 
To a solution of amine (1.0 equiv) and acetic acid (1.S 
equiv) stirred in anhydrous MeOH (0.1 M) with 4 A molecu-
lar sieves was added 1.0 equiv of aldehyde. The solution was 
then heated to 4S° C. for 3 h and then allowed to cool to rt. 
Next, NaCNBH3 (1.3 equiv) was added portion-wise and the 
reaction allowed to stir at rt overnight. When TLC indicated 
the reaction was complete, the reaction was diluted with 
CH2Cl2 , filtered and concentrated in vacuo. 
3. General Procedure B (PPh3 Cl2 Mediated Amide 
Coupling)-Reaction of Secondary Anilines with 
Carboxylic Acids 
To a stirred solution of the secondary aniline (1.0 equiv) 
and carboxylic acid (1.0 equiv) in CHC13 (0.1 M) was added 
PPh3 Cl2 (2.S equiv). The reaction was then heated to 60° C. 
and stirred overnight. The reaction was allowed to cool and 
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the solvents removed under reduced pressure. The concen-
trate was absorbed directly onto silica for colunm chroma-
tography purification. 
228 
diated in a Biotage Initiator microwave reactor (17 min, 170° 
C.). After cooling to rt, the reaction was diluted with water 
and repeatedly extracted with CH2 Cl2 . The combined organic 
extracts were washed with brine, dried over anhydrous 
4. General Procedure C (Boe Protection) 5 Na2S04 , filtered and concentrated under reduced pressure. 
To a stirred solution of the appropriate secondary amine 
(1.0 equiv) and DIPEA (2.0 equiv) in CHC13 (0.1 M), was 
added Boc2 0 (1.1 equiv) and left to stir overnight at rt. The 
reaction was then diluted with CH2Cl2 , washed with H20, 
10 
brine and dried over Na2 S04 , filtered and concentrated under 
reduced pressure. 
10. General Procedure I (Hydrogenolysis ofbenzyl 
ether and benzyl ester)--Global deprotection of 
benzylated salicyclic acid 
The benzyl protected salicyclic acid (1 equiv) was dis-
solved in a stirred solutionofMeOH/THF (1:1) (0.1 M). The 
solution was degassed thoroughly before careful addition of 5. General Procedure D (Nucleophilic Aromatic 
Substitution) 
The desired secondary amine (1.0 equiv) and arylfluoride 
substrate (1.5 equiv) were dissolved in anhydrous DMSO (0.1 
M) followed by the addition ofDIPEA (3.0 equiv). The reac-
tion was heated to 120° C. and allowed to stir overnight. The 
reaction was quenched with H2 0 and the aqueous layer 
extracted repeatedly into EtOAc. The combined organic lay-
ers were then washed with brine, dried over anhydrous 
Na2S04 and the solvent removed under reduced pressure. 
15 10% Pd/C (10 mg/mmol). H2 gas was bubbled through the 
solvent for 5 min before the solution was put under an atmo-
sphere of H2 gas and stirred continuously for 3 h. The H2 gas 
was evacuated and the reaction filtered (to remove the Pd 
20 
catalyst) and concentrated under reduced pressure. 
6. General Procedure E (TFA Deprotection with 
K2C03 and MeOH) 
25 
LiOH.H2 0 (3.0 equiv) was added to a stirred solution of 
the TFA (trifluoroacetyl)-protected compound (1 equiv.) in 30 
THF and water (3: 1, 0.1 M). The reaction was allowed to stir 
at room temperature for 10 min and then was then diluted with 
H2 0 and the product was extracted into EtOAc. The organic 
layers were then combined, washed with saturated NaHC03 , 
water, brine and dried over anhydrous Na2S04 , filtered and 
35 
the solvent removed under reduced. 
7. General Procedure F (HBTU Mediated 
Condensation Reactions) 
40 
The required carboxylic acid (1 equiv) was added in one 
portion to a solution ofHBTU (1.1 equiv) and DIPEA (3.0 
equiv) in DMF (0.1 M), and the resulting solution stirred at 
room temperature for 10 minutes. The required amine was 
then dissolved in a solutionofDIPEA(2.0equiv) inDMF (0.1 45 
M) and added to the activated acid in one portion. The result-
ing solution was stirred for 4 h, then diluted with EtOAc (0.1 
11. General Procedure J (TFA deprotection of benzyl 
ether) 
The benzyl protected compound (1 equiv) was dissolved in 
a 1:1 mixture ofTFA:toluene (0.1 M) at rt for 5 min, then all 
solvents were evaporated under reduced pressure. 






To a stirred solution of 4-aminosalicyclic acid (3 .00 g, 19 .6 
mmol) in DMF (0.1 M) at 0° C., was added KOtBu (2.42 g, 
21.6 mmol). After 15 min, benzyl bromide (2.57 mL, 21.6 
M) and washed successively with equal volumes of: 2M HCl, 
saturated bicarbonate and brine. The organic layer was dried 
over anhydrous Na2S04 , filtered and concentrated. 
8. General Procedure G (Sulfonylation of Secondary 
Amines) 
50 mmol) was added drop-wise. The suspension was allowed to 
stir at rt for a further 4 h before the reaction vessel was again 
cooled to 0° C. A further 1.1 equiv of KtOBu (2.42 g, 21.6 
mmol) were added prior to the drop-wise addition ofbenzyl 
bromide (2.57 mL, 21.6 mmol). The reaction was then stirred 
To a stirred solution of amine (1.0 equiv) dissolved in 
CH2 Cl2 (0.1 M) was added DIPEA (1.1 equiv) and the appro-
priate sulfony 1 chloride ( 1.1 equiv). After 1 h, the reaction was 
diluted with CH2 Cl2 , washed with water, followed by a brine 
wash and dried over Na2 S04 . The organic layer was then 
concentrated under reduced pressure and purified by silica gel 
colunm chromatography to yield product. 
9. General Procedure H (Suzuki Cross Coupling) 
55 overnight before quenching with H20. The solution was then 
repeatedly extracted with ethyl acetate and the organics com-
bined. The organics were then washed with H20 and brine 
then concentrated, dried over Na2S04 and concentrated in 
vacuo to afford the title compound (3.40 g, 74%): OH (400 
60 MHz, dcDMSO) 5.07 (s, 2H, CH2Ph), 5.21 (s, 2H, CH2 Ph), 
5.99 (br s, 2H, NH2), 6.18 (dd, J=S.6 and 1.8 Hz, lH, CH 
(Ph)), 6.32 (d, J=l.7 Hz, lH, CH (Ph)), 7.28-7.38 (SH, m, CH 
(Ph)), 7.47 (d, J=7.2 Hz, 2H, CH (Ph)), 7.60 (d, J=S.6 Hz, lH, 
A mixture of arylbromide (1.0 equiv), boronic acid (1.1 65 
equiv), K2C03 (2.5 equiv) and Pd(PPh3 ) 4 (0.03 equiv) was 
suspended in DMF (0.1 M) in a sealed tube vessel and irra-
CH (Ph)); Oc (100 MHz, CDC13 ) 65.8, 70.2, 99.1, 106.7, 
109.0, 126.3, 126.8, 127.5, 127.7, 127.9, 128.1, 128.3, 128.4, 
134.3, 136.6, 136.7, 152.2, 160.7, 165.7; LRMS (ES+) calcd 
for [C21H19N03 +H] 334.14 found 334.17. 
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13. Benzyl 




Primary aniline 1 was coupled to 4-bromobenzaldehyde on 
a 0. 7 mmol scale via General Procedure A to furnish 2 (27 4 
mg, 78%): OH (400 MHz, CDCl3) 4.12 (s, 2H, CH2, 
NHCH2Ph), 4.SO (br s, lH, NH), 4.92 (s, 2H, CH2, CH2Ph), 25 
S.18 (s, 2H, CH2, CH2Ph), S.98 (d, J=l.8 Hz, lH, CH (Ph)), 
6.04 (dd, J=S.6 and 1.8 Hz, lH, CH (Ph)), 7.02 (d, J=S.2 Hz, 
2H, 2 CH (Ph)), 7.11-7.34 (m, 12H, 12 CH (Ph)), 7.70 (d, 
J=S.6 Hz, lH, CH (Ph)); oc (100 MHz, CDCl3) 46.S, 6S.4, 
30 69.9, 97.0, 104.S, 108.2, 120.7, 126.4, 127.2, 127.4, 127.6, 
128.0, 128.1, 128.4, 131.4, 133.9, 136.3, 137.0, 1S2.3, 160.4, 
l6S.3; LRMS (ES+) calcd for [C28H24BrN03+H] S02.l0. 
found S02.06. 
230 
lS. Preparation ofBenzyl 
2-(benzyloxy)-4-( 4-cyclohexylbenzylamino )benzoate 
(4) 
Primary aniline 17 was coupled to 4-cyclohexylbenzalde-
hyde on a 0.6 mmol scale via General Procedure A to furnish 
4 (2SO mg, 83%): OH (400 MHz, CDCl3) 1.2S-1.48 (m, 6H, 
CH2CH2), 1.74-1.9S (m, 4H, CH2CH2), 2.48-2.S2 (m, lH, 
CH), 4.28 (s, 2H, NH2CH2), 4.49 (br s, lH, NH), S.08 (s, 2H, 
CH2Ph), S.32 (s, 2H, CH2Ph), 6.17 (d, J=2.0 Hz, lH, CH 
(Ph)), 6.21 (dd, J=S.6 and2.0 Hz, lH, CH (Ph)), 7.19-7.27 (m, 
4H, 4 CH (Ph)), 7.28-7.37 (m, 6H, 6 CH (Ph)), 7.40-7.49 (m, 
4H, 4 CH (Ph)), 7.SS (d, J=S.6 Hz, lH, 1 CH (Ar)); Oc (100 
MHz, CDCl3) 26.0, 26.7, 34.3, 44.1, 47.3, 6S.7, 70.3, 97.1, 
104.8, 108.2, 126.8, 127.0, 127.4, 127.S, 127.6, 127.9, 128.2, 
14. Preparation ofbenzyl 2-(benzyloxy)-4-((cyclo-
hexylmethy !)amino) benzoate ( 19e) 
35 128.3, 134.2, l3S.4, 136.7, 136.8, 147.4, 1S2.9, 160.8, 16S.8; 






Primary aniline 1 was coupled to cyclohexanecarboxalde-
hyde on a 0.6 mmol scale via General Procedure A to furnish 
3 (184 mg, 72%): OH (400 MHz, CDCl3) 1.lS-1.30 (m, SH, 




(d, J=6.4 Hz, 2H, CH2), S.14 (s, 2H, CH2), S.32 (s, 2H, CH2), 60 
6.11 (d, J=2.0Hz, lH, CH), 6.16 (dofd, J=S.8 and2.0Hz, lH, 
CH), 7.29-7.36 (m, lOH, CH), 7.41 (d, J=S.O Hz, 2H, CH), 
7.48 (d, J=S.O Hz, 2H, CH), 7.SS (d, J=S.8 Hz, lH, CH); Oc 
(100 MHz, CDCl3) 2S.7, 26.3, 31.0, 37.S, 49.8, 6S.6, 70.3, 
96.8, 104.6, 107.S, 126.8, 127.S, 127.6, 127.9, 128.3, 128.4, 65 
134.2, 136.8, 136.9, 1S3.4, 161.0, 16S.7, 171.0; LRMS (ES+) 
calcd for [C28H31 N03+H] 430.24 found 430.20. 
16. Preparation ofbenzyl 2-(benzyloxy)-4-(((4'-
bromo-[1, 1 '-biphenyl]-4-yl)methyl)amino )benzoate 
(S) 
Primary aniline 1 was coupled to 4'-bromo-[1,1'-biphe-
nyl]-4-carbaldehyde on a 3.7 mmol scale via General Proce-
dureA to furnish S (l.S2 g, 70%): oH(400MHz, CDCl3) 4.39 
(s, 2H, CH2), 4.S9 (br s, lH, NH), S.10 (s, 2H, CH2), S.31 (s, 
2H, CH2), 6.20 ( d, J=2.0 Hz, lH, CH), 6.24 ( d of d, J=S.6 and 
2.0 Hz, lH, CH), 7.2S-7.36 (m, 6H, CH), 7.37-7.49 (m, SH, 
CH), 7.S3 (d, J=S.4 Hz, 2H, CH), 7.S7 (d, J=S.4 Hz, 2H, CH) 
7.SS (d, J=S.6 Hz, lH, CH); oc(lOOMHz, CDCl3) 47.3, 6S.7, 
70.3, 97.4, 104.9, 108.7, 121.S, 126.8, 127.1, 127.S, 127.6, 
127.8, 127.9, 128.3, 128.3, 128.S, 131.8, 134.3, 136.6, 136.7, 
137.6, 139.1, 139.4, lS2.6, 160.8, 16S.6. 
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17. Preparation of methyl 
2(N,4-dimethylphenylsulfonamido )acetate (6) 
232 
7.43 (d, J=7.2 Hz, 2H, CH), 7.64 (s, lH, CH), 7.67 (d, J=S.O 
Hz, 2H, CH), 7.89 (d, J=S.O Hz, lH, CH); oc (100 MHz, 
CDC13 ) 21.4, 37.1, 54.7, 66.4, 70.4, 104.6, 111.2, 115.6, 
127.1, 127.5, 127.7, 127.9, 128.0, 128.3, 128.4, 130.0, 132.6, 
5 133.0, 136.1, 136.2, 142.3, 144.5, 159.4, 165.5, 166.4;LRMS 
(ES+) calcd for [C31H30N2 0 6S+H] 559.19. found 559.19. 
10 
To a stirred solution of methyl 2-(4-methylphenylsulfona-
mido )acetate (3.10 g, 12.8 mmol) and Cs2 C03 (8.31 g, 25.5 
mmol) inDMF (0.1 M)was added Mel (877 µL, 14.1 mmol). 
The reaction was allowed to stir overnight at rt. The reaction 
15 
was then diluted with water and repeatedly extracted with 
CH2 Cl2 . The combined organic extracts were washed with 
brine, dried over anhydrous Na2 S04 , filtered and concen-
trated under reduced pressure to furnish 6 (2.80 g, 85%): OH 
( 400 MHz, CDC13 ) 2.42 (s, 3H, CH3 ), 2.87 (s, 3H, CH3 ), 3.66 20 
(s, 3H, CH3 ), 3.97 (s, 2H, CH2 ), 7.31 (d, J=S.4 Hz, 2H, CH), 
7.69 (d, J=S.4 Hz, 2H, CH); LRMS (ES+) calcd for 
[C11 H15N04 S+H] 258.08. found 258.06 [M+H]. 
18. Preparation of 
2-(N,4-dimethylphenylsulfonamido )acetic acid (7) 25 
Benzyl 2-(benzyloxy)-4-(N-( 4-bromobenzyl)-2-(N, 




Secondary aniline 2 was coupled to carboxylic acid 6 on a 
30 0.2 mmol scale via General Procedure B to furnish 9 (167 mg, 
90%): OH (400 MHz, CDC13 ) 2.33 (s, 3H, CH3 Ar), 2.73 (s, 
3H, CH3Ar), 3.54 (s, 2H, CH2CO), 4.64 (s, 2H, CH2Ar), 4.99 
(s, 2H, CH2Ar), 5.28 (s, 2H, CH2Ar), 6.50 (brs, lH, CH (Ar)), 
Methyl ester 6 (2.60 g, 10.1 mmol) was dissolved in a 3:1: 1 
35 
mixture of MeOH-THF-H20. LiOH.H2 0 (0.53 g, 12.6 
mmol) was added at room temperature and the reaction 
allowed to stir for 3 h. All solvents were evaporated, apart 
from water. The remaining aqueous solvent was diluted fur-
ther and thoroughly washed with ethyl acetate. The aqueous 
basic aqueous layer was then acidified to pH 2 with 1 M HCl 40 
and the product extracted with ethyl acetate. The organic 
layers were then combined and dried over Na2S04 , filtered 
and concentrated to afford the title compound. (2.33 g, 95% ): 
OH (400 MHz, CDC13 ) 2.43 (s, 3H, CH3 ), 2.87 (s, 3H, CH3 ), 
3.99 (s, 2H, CH2), 7.32 (d, J=S.O Hz, 2H, CH), 7.69 (d, J=S.O 45 
Hz, 2H, CH); Oc (100 MHz, CDC13 ) 21.4, 35.7, 50.6, 127.3, 
129.6, 134.8, 143.7, 173.5; LRMS (ES+) calcd for 
[C10H13N04 S+H] 244.06. found 244.07 [M+H]. 
19. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(N,4-
dimethylphenylsulfonamido )-acetamido )benzoate (8) 




I o ~0~60 
0 
6.55 (dd, J=S.3 and 1.8 Hz, lH, CH (Ar)), 6.88 (d, J=S.3 Hz, 
2H, 2 CH (Ar)), 7.16-7.34 (m, 14H, 14 CH (Ar)), 7.51 (d, 
J=S.3 Hz, 2H, 2 CH (Ar)), 7.75 (d, J=S.3 Hz, lH, CH (Ar)); Oc 
(100 MHz, CDC13 ) 21.4, 29.6, 36.0, 51.2, 52.4, 53.3, 66.9, 
70.7, 113.9, 119.8, 120.9, 121.7, 126.9, 127.3, 127.9, 128.2, 
128.5, 129.4, 130.5, 131.6, 133.1, 135.2, 135.5, 135.6, 135.7, 
143.3, 144.7, 158.7, 165.2, 167.0; LRMS (ES+) Calcd for 
[C38H35BrN2 0 6S+H] 727.15 found 726.83. 
20. Preparation ofbenzyl 2-(benzyloxy)-4-(N(( 4'-
bromo-[1, 1 '-biphenyl]-4-yl)methyl)-2-(N,4-dimeth-
ylphenylsulfonamido )acetamido )benzoate (5) 
Br. 
Secondary aniline 26ja was coupled to 7 on a 1.7 mmol 
scale via General Procedure B to furnish 5 (1.15 g, 84%) OH 
(400MHz, CDC13 ) 2.39 (s, 3H, CH3 ), 2.82 (s, 3H, CH3 ), 3.67 
(s, 2H, CH2 ), 4.82 (s, 2H, CH2), 5.02 (s, 2H, CH2), 5.34 (s, 
2H,CH2 ), 6.61 (s, lH, CH), 6.68 (d, J=8.0Hz, lH,CH), 7.17 
( d, J=S.O Hz, 2H, CH), 7 .22-7.46 (m, 16H, CH), 7 .54 ( d, J=S.4 
Hz, 2H, CH), 7.60 (d, J=S.4 Hz, 2H, CH), 7.83 (d, J=S.O Hz, 
Primary aniline 17 was coupled to 7 on a 1.3 mmol scale via 
General Procedure B to furnish 8 (650 mg, 92%): OH (400 
MHz, CDC13 ) 2.38 (s, 3H, CH3 ), 2.83 (s, 3H, CH3 ), 3.75 (s, 
2H, CH2 ), 5.08 (s, 2H, CH2), 5.33 (s, 2H, CH2 ), 7.10 (d, J=S.4 
Hz, lH, CH), 7 .25-7 .34 (m, SH, CH), 7 .36-7.40 (m, 2H, CH), 
65 lH, CH); Oc (100 MHz, CDC13 ) 21.4, 35.9, 51.3, 52.7, 66.9, 
70.7, 114.0, 119.9, 120.8, 121.6, 126.9, 127.4, 127.9, 128.1, 
128.2, 128.4, 128.5, 129.3, 129.4, 131.8, 133.1, 135.2, 135.6, 
US 8,846,707 B2 
233 
l3S.6, l3S.9, 139.3, 144.9, 1S8.7, 16S.2, 166.9; LRMS (ES+) 
calcd for [C44H39BrN2 0 6 S+H] 803.18 found 803.69. 
21. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(cy-
clohexylmethyl)-2-(N,4-dimethylphenyl-sulfona-




Secondary aniline 3 was coupled to carboxylic acid 7 on a 
0.2 mmol scale via General Procedure B to furnish 11 (92 mg, 25 
68% ): OH ( 400 MHz, CDCl3 ) 1.04-1.17 (m, 3H, CH2 ), 1.2S-
1.41 (m, 3H, CH2 and CH), 1.S0-1.71 (m, SH, CH2 ), 2.39 (s, 
3H, CH3 ), 2.86 (s, 3H, CH3 ), 3.47 (d, J=8.4 Hz, 2H, CH2 ), 
3.67 (s, 2H, CH2 ), S.22 (s, 2H, CH2), S.38 (s, 2H, CH2), 
6.79-6.84 (m, 2H, CH), 7.2S (d, J=8.4 Hz, 2H, CH), 7.28-7.39 30 
(m, 6H, CH), 7.40-7.47 (m, 4H, CH), 7.61 (d, J=8.4 Hz, 2H, 
CH), 7.91 (d, J=8.4 Hz, lH, CH); oc(lOOMHz, CDCl3 ) 21.S, 
2S.6, 26.2, 30.6, 3S.9, Sl.3, SS.4, 67.0, 70.8, 113.8, 119.8, 
120.6, 127.0, 127.4, 128.0, 128.1, 128.2, 128.S, 128.6, 129.4, 
133.1, 13S.7, 13S.9, 143.2, 14S.9, 1S8.9, l6S.4, 167.0;LRMS 
35 (ES+) calcd for [C38H42N20 6 S+Na] 677.27 found 677.36. 
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66.8, 70.S, 114.1, 119.9, 120.S, 126.8, 126.9, 127.3, 127.8, 
128.0, 128.1, 128.4, 128.S, 128.7, 129.3, 133.0, 133.8, 13S.2, 
l3S.6, 13S.7, 143.1, 144.9, 147.6, 1S8.6, l6S.2, 166.6;LRMS 
(ES+) calcd for [C44H46N2 0 6S+H] 731.32 found 731.28. 
23. Preparation ofBenzyl 2-(benzyloxy)-4-(2-(N,4-
dimethy lpheny lsulfonamido )-N-(piperidin-4-y lm-
ethyl )acetamido )benzoate (13) 
Secondary aniline tert-butyl 4-((3-(benzyloxy)-4-((benzy-
loxy )carbony I) pheny !)amino )methy l)piperidine-1-carboxy-
late was coupled to carboxylic acid 7 on a 2.8 mmol scale via 
General Procedure B to furnish 13 (1.SO g, 67%): OH (400 
MHz, CDCl3 ) 1.40-1.86 (m, 4H, CH2 ), 2.38 (s, 3H, CH3 Ar), 
2.64-2.93 (m, SH, CH and CH2 ), 2.72 (s, 3H, NCH3 ), 3.28-
3.70 (m, 4H, CH2 ), S.24 (s, 2H, CH2 Bn), S.38 (s, 2H, 
CH2Bn), 6.8S (dd, J=8.2 and 1.7 Hz, lH, CH (Ar)), 6.89 (d, 
J=l.7 Hz, lH, CH (Ar)), 7.20-7.43 (m, llH, 13 CH (Ar)), 
7.S8 (d, J=8.2 Hz, lH, 1 CH (Ar)), 7.90 (d, J=8.2 Hz, lH, CH 
(Ar)); oc(lOO MHz, CDCl3 ) 21.4, 27.4, 29.7, 33.2, 36.1, 44.1, 
Sl.S, S4.3, 67.0, 70.7, 113.7, 119.S, 120.9, 127.0, 127.3, 
127.4, 128.0, 128.2, 128.S, 128.6, 129.4, 129.S, 133.3, 13S.O, 
13S.7, 13S.9, 143.S, l4S.S, 1S8.9, 16S.3, 167.1, 167.6;LRMS 
22. Preparation of Benzyl 2-(benzyloxy)-4-(N-( 4-
cyclohexylbenzyl)-2-(N,4-dimethylphenyl-sulfona-
mido) acetamido) benzoate (12) 
40 
(ES+) calcd for [C37H41N3 0 6S+H] 6S6.28 found 6S6.44. 
°' 45 0 0 
50 
Secondary aniline 4 was coupled to carboxylic acid 7 on a 
0.2 mmol scale via General Procedure B to furnish 12 (14S 
mg, 86%): OH (400 MHz, CDCl3 ) l.lS-l.3S (m, 6H, CH2 ), 
1.61-1.80 (m, 4H, CH2 ), 2.31 (s, 3H, CH3Ar), 2.37-2.38 (m, 
60 
lH, CH), 2.73 (s, 3H, CH3 N), 3.S7 (s, 2H, CH2 CO), 4.67 (s, 
2H, CH2Ar), 4.86 (s, 2H, CH2Ar), S.26 (s, 2H, CH2Ar), 6.43 
(s, lH, CH (Ar)), 6.S9 (dd, J=8.2 and 1.S Hz, lH, CH (Ar)), 
6.93 (d, J=8.0 Hz, 2H, 2 CH (Ar)), 7.02 (d, J=8.0 Hz, 2H, 2 
CH (Ar)), 7.14-7.3S (m, 12H, 12 CH (Ar)), 7.S2 (d, J=8.2 Hz, 65 
2H, 2 CH (Ar)), 7.7S (d, J=8.2 Hz, 2H, 2 CH (Ar)); oc (400 
MHz, CDCl3 ) 21.4, 2S.9, 26.6, 34.3, 3S.8, 44.0, Sl.2, S2.7, 






Compound 13 was Boe protected with (Boe )2 via General 
Procedure Con a 0.1 S mmol scale to furnish 14 (99 mg, 86% ): 
OH ( 400 MHz, CDCl3 ) 0.80-1.02 (m, 3H, CH2 ), 1.10-1.2S (m, 
2H, CH2 ), 1.36 (s, 9H, 3 CH3 ), 2.31(s,3H, CH3 Ar), 2.4S-2.SS 
(m, 2H, CH2 ), 2.72 (s, 3H, NCH3 ), 3.42 (s (br), 2H, CH2 ), 
3.S8 (s, 2H, CH2), 3.93 (br s, 2H, CH2), S.16 (s, 2H, CH2 Bn), 
US 8,846,707 B2 
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5.30 (s, 2H, CH2Bn), 6.71-6.75 (m, 2H, 2 CH (Ar)), 7.15-7.38 
(m, 12H, 12CH (Ar)), 7.52 (d, J=8.2Hz, 2H, 2CH (Ar)), 7.83 
(d, J=S.2 Hz, lH, CH (Ar)); oc(lOO MHz, CDC13 ) 21.4, 28.3, 
29.6, 34.5, 36.0, 36.5, 51.3, 54.7, 66.9, 70.7, 79.3, 113.7, 
119.5, 120.7, 126.9, 127.3, 128.0, 128.1, 128.5, 128.6, 129.4, 5 
133.2, 135.6, 135.8, 143.3, 145.6. 154.5, 158.9, 165.2, 167.2. 
7.38-7.45 (m, 4H, CH), 7.60 (d, J=S.O Hz, 2H, CH), 7.91 (d, 
J=S.8 Hz, lH, CH), 8.27 ( d, J=4.8 Hz, 2H, CH); oc (100 MHz, 
CDC13 ) 21.4, 29.4, 34.8, 35.9, 36.5, 43.4, 51.3, 54.8, 66.9, 
70.7, 109.3, 113.7, 119.5, 120.7, 126.9, 127.3, 128.0, 128.1, 
128.4, 128.6, 129.4, 133.2, 135.2, 135.6, 135.8, 143.3, 145.7, 
157.5, 158.9, 161.2, 165.2, 167.1. 
25. Preparation ofbenzyl 2-(benzyloxy)-4-(N-((l-(4-
cyanophenyl)piperidin-4-yl)methyl)-2-(N,4-dimeth-
ylphenylsulfon amido )acetamido )benzoate (15) 
Nucleophilic aromatic substitution of13 with 4-fluoroben-
zonitrile on a 0.2 mmol scale via General Procedure D fur-
nished 15 (87 mg, 76%): oH(400MHz, CDC13 ) 1.20-1.31 (m, 
3H, CH2 ), 1.60-1.68 (m, 2H, CH2 ), 2.38 (s, 3H, CH3 Ar), 2.72 
(t, J=12.0 Hz, 2H, CH2 ), 2.78 (s, 3H, NCH3 ), 3.55 (d, J=6.8 
Hz, 2H, CH2 CH), 3.66 (s, 2H, CH2 ), 3.74 (d, J=13.0 Hz, 2H, 
CH2 ), 5.24 (s, 2H, CH2Bn), 5.38 (s, 2H, CH2Bn), 6.77-6.84 
(m, 4H, 4 CH (Ar)), 7.21-7.47 (m, 14H, 14 CH (Ar)), 7.59 (d, 
J=8.2Hz, 2H, 2 CH (Ar)), 7.91 (d, J=8.2Hz, lH, CH (Ar)); Oc 
(100 MHz, CDC13 ) 21.4, 28.9, 34.3, 36.1, 47.1, 51.3, 54.5, 
67.0, 70.7, 99.2, 113.7, 114.1, 119.5, 120.1, 120.8, 126.9, 
127.3, 128.0, 128.2, 128.5, 128.6, 129.4, 133.2, 133.4, 135.6, 
135.8, 143.3, 145.6, 152.9, 158.8, 165.2, 167.3. 
26. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(N,4-
dimethylphenylsulfonamido )-N-((1-(pyrimidin-2-yl) 
piperidin-4-yl)methyl)acetamido )benzoate (16) 
°' 0 0 
Nucleophilic aromatic substitution of 13 with 2-chloropy-
rimidine on a 0.2 mmol scale via General Procedure D fur-
nished 16 (108 mg, 96%): OH (400 MHz, CDC13 ) 1.15-1.40 
(m, 2H, CH2), 1.54-1.75 (m, 3H, CH2 and CH), 2.38 (s, 3H, 




27. Preparation of 4-(1-(2,2,2-trifluoroacetyl)piperi-
din-4-yl)benzaldehyde (2 step procedure) (19) 
o~ 
To a flask containing Al Cl3 (534 mg, 4.0 mmol) under an 
N 2 atmosphere was added anhydrous CH2 Cl2 (0.1 M), and the 
drop wise addition of oxalyl chloride (523 µL, 6.0 mmol) over 
a 20 min period at 15° C. Next, a solution of 2,2,2-trifluoro-
l-( 4-phenylpiperidin-1-yl)ethanone (17) (2.0 mmol) in anhy-
25 drous CH2 Cl2 (0.1 M) was added drop-wise to the initial 
solution over a 45 min period at 15° C. When the reaction was 
complete as judged by TLC, ice was added to the solution in 
addition to CaC12 (1.70 g). The product was extract into 
CH2Cl2 , washed with brine and dried over anhydrous 
30 Na2 SO 4 before concentrating under reduced pressure to yield 
crude 4-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)benzoyl 
chloride (18). (b) To a stirred solution of 18 (2.0 mmol) and 
DIPEA(697 µL, 4.0mmol)inEtOAc (0.1M)wasadded10% 
Pd/C. The flask was then evacuated and filled with H2 gas and 
35 allowed to stir for 30 min. After which time the reaction 
contents were filtered and concentrated under reduced pres-
sure to give crude product which was purified by silica gel 
column chromatography (hexanes:EtOAc, 2:1) to furnish 19 
(320 mg, 59% (yield over 2 steps)) OH (400 MHz, CDC13 ) 
1.69-1.81 (m, 2H, CH2 ), 1.98-2.06 (m, 2H, CH2 ), 2.83-2.97 40 (m, 2H, CH2), 3.27 (td, J=12.8 and 2.4 Hz, lH, CH), 4.13-
4.21 (m, lH, CH), 4.70-4.76 (m, lH, CH2 ), 7.37 (d, J=S.4 Hz, 
2H, CH), 7.85 (d, J=S.4 Hz, 2H, CH), 9.99 (s, lH, CHO); 




28. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(N,4-
dimethylphenylsulfonamido )-N-( 4-(piperidin-4-yl) 
benzyl)acetamido )benzoate (21) 
°' 0 0 
(d, J=7.2 Hz, 2H, CH2), 3.68 (s, 2H, CH2 ), 4.64 (d, J=13.2 Hz, 65 
2H, CH2 ), 5.23 (s, 2H, CH2 ), 5.37 (s, 2H, CH2), 6.42 (t, J=4.8 
Hz, lH, CH), 6.80-6.85 (m, 2H, CH), 7.23-7.37 (m, SH, CH), 
Benzyl 2-(benzyloxy)-4-(2-(N,4-dimethylphenylsulfona-
mido )-N-( 4-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)benzyl) 
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acetamido )benzoate (20) was TFA-deprotected on a 0.04 
mmol scale via General Procedure E to furnish 21 (0.89 g, 
81 %): OH (400 MHz, CDC13 ) 1.68-1.82 (m, 2H, CH2 ), 1.95-
2.05 (m, 2H, CH2 ) 2.41 (s, 3H, CH3 ), 2.55-2.64 (m, lH, CH), 
2.69-2.78 (m, 2H, CH2 ), 2.80 (s, 3H, CH3 ), 3.17-3.21 (m, 2H, 5 
CH2 ), 4.70 (s, 2H, CH2 ), 4.75 (s, 2H, CH2), 4.99 (s, 2H, CH2), 
5.30 (s, 2H, CH2 ), 6.53 (s, lH, CH), 6.66 (d, J=8.4 Hz, lH, 
CH), 7.03 (d, J=8.0Hz, 2H, CH), 7.11 (d, J=8.0Hz, 2H, CH), 
7.22-7.40 (m, 12H, CH), 7.60 (d, J=8.4 Hz, 2H, CH), 7.80 (d, 
J=8.4 Hz, lH, CH); LRMS (ES+) calcd for [C43H45N30 6 S+ 10 
H] 732.31 found 732.40. 
29. Preparation oftert-butyl 4-(4-((N-(3-(benzy-
loxy)-4-((benzyloxy)carbonyl)phenyl)-2-(N,4-dim-
ethyl-phenylsulfonamido )acetamido )methyl)phenyl) 
piperidine-1-carboxylate (22) 15 
238 
135.6, 135.7, 143.2, 144.9, 145.3, 154.7, 158.6, 165.2, 166.7; 
LRMS (ES+) calcd for [C48H53N30 8 S+Na] 854.35. found 
854.62 [M+Na]. 
30. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(N,4-
dimethylphenylsulfonamido )-n-( 4-(1-(pyrimidin-2-
yl)piperidin-4-yl)benzyl)acetamido )benzoate (23) 
°' ~o ~~ 
N N 
~'90 0 
I~ 20U1 0 # 
~ // 
S ~N 
Compound 21 was Boe protected with (Boe )2 via General 
Procedure Con a 0.10 mmol scale to furnish 22 (83 mg, 99% ): 
OH ( 400 MHz, CDC13 ) 1.47 (s, 9H, CH3 ), 1.53-1.64 (m, 2H, 
CH2 ), 1.72-1.80 (m, 2H, CH2 ), 2.39 (s, 3H, CH3 ), 2.54-2:64 
(m, 2H, CH2 ), 2.70-2.82 (m, 4H, CH3 and CH), 3.64 (s, 2H, 
CH2 ), 4.75 (s, 2H, CH2 ), 4.97 (s, 2H, CH2), 5.34 (s, 2H, CH2), 
6.56 (s, lH, CH), 6.65 (dd, J=8.0 and 1.6 Hz, lH, CH), 7.03 
// 'N 
o I o 
Nucleophilic aromatic substitution of21with2-chloropy-
rimidine on a 0.1 mmol scale via General Procedure D fur-
nished23 (70mg, 80%): oH(400MHz, CDC13 ) 1.59-1.72 (m, 
2H, CH2 ), 1.83-1.94 (m, 2H, CH2 ), 2.39 (s, 3H, CH3 ), 2.71-
2.83 (m, 4H, CH3 and CH), 2.88-2.99 (m, 2H, CH2 ), 3.65 (s, 
2H, CH2 ), 4.75 (s, 2H, CH2 ), 4.86-4.94 (m, 2H, CH2 ), 4.97 (s, 
2H, CH2), 5.34 (s, 2H, CH2 ), 6.46 (t, J=8.4 Hz, lH, CH), 6.56 
(s, lH, CH), 6.65 (dd, J=8.0 and 2.0 Hz, lH, CH), 7.03 (d, 
35 J=8.0Hz,2H,CH), 7.11(d,J=8.0Hz,2H,CH),7.24(d,J=8.4 
Hz, 2H, CH), 7.27-7.41 (m, !OH, CH), 7.59 (d, J=8.4 Hz, 2H, 
CH), 7.82 (d, J=8.4 Hz, lH, CH), 8.30 (d, J=8.8 Hz, 2H, CH); 
oc(lOO MHz, CDC13 ) 21.4, 32.9, 35.8, 41.9, 48.1, 51.3, 52.7, 
66.9, 70.6, 109.4, 113.9, 119.9, 120.6, 126.9, 127.0, 127.4, 
40 127.9, 128.1, 128.2, 128.4, 128.5, 128.9, 129.4, 133.0, 134.4, 
135.2, 135.6, 135.7, 143.2, 144.9, 145.5, 157.6, 158.6, 161.4, 
165.2, 166.7; LRMS (ES+) calcd for [C47H47N5 0 6S+H] 
810.33 found 810.44. 
(d, J=8.0 Hz, 2H, CH), 7.09 (d, J=8.0 Hz, 2H, CH), 7.24 (d, 
J=8.0 Hz, 2H, CH), 7.28-7.40 (m, !OH, CH), 7.59 (d, J=8.0 
Hz, 2H, CH), 7.81 (d, J=8.4 Hz, lH, CH); Oc (100 MHz, 
CDC13 ) 21.4, 28.3, 33.0, 35.9, 40.8, 42.2, 51.3, 52.7, 66.9, 45 
70.6, 79.3, 114.0, 119.9, 120.6, 126.8, 127.0, 127.3, 127.9, 
128.1, 128.2, 128.4, 128.5, 128.9, 129.4, 133.0, 134.5, 135.2, 
31. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-(l-
( 4-cyano benzoyl )piperidin-4-y l)benzy 1)-2-(N,4-dim -
ethylphenylsulfonamido )acetamido )benzoate (24) 
°' ~o ~o 0 0 
~ N 
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Condensation of 21 with 4-cyanobenzoic acid on a 0.10 
mmol scale via General Procedure F furnished 24 (63 mg, 
89% ): OH ( 400 MHz, CDC13 ) 1.59-1.72 (m, 4H, CH2 ), 1.83-
1.94 (m, 2H, CH2 ), 2.39 (s, 3H, CH3 ), 2.79-3.21 (m, SH, CH3 , 
CH and CH2), 3.65 (s, 2H, CH2 ), 4.77 (s, 2H, CH2 ), 4.95 (s, 5 
2H, CH2 ), 4.97 (s, 2H, CH2 ), 5.34 (s, 2H, CH2), 6.60 (t, J=S.4 
Hz, lH, CH), 6.69 (dd, J=S.Oand 1.6Hz, lH,CH), 7.03-7.12 
(m,4H,4CH(Ar)), 7.21-7.82(m, 12H, 12CH(Ar)); oc(lOO 
MHz, CDC13 ) 21.4, 29.5, 35.9, 42.0, 48.1, 51.3, 52.7, 66.9, 
70.6, 113.3, 113.9, 119.9, 120.7, 126.7, 126.9, 127.3, 127.4, 10 
127.9, 128.1 (2), 128.4, 128.5, 129.0, 129.4, 132.3, 132.9, 
134.8, 135.0, 135.5, 135.6, 140.0, 143.3, 144.0, 144.8, 158.6, 
165.2, 167.0, 168.3; LRMS (ES+) calcd for [C51 H48N4 0 7 S+ 
H] 861.33 found 861.38. 
32. Preparation ofbenzyl 2-(benzyloxy)-4-(N-( 4-(1-
( ( 4-cyanophenyl )sulfony l)piperidin-4-y 1 )benzyl )-2-
(N,4-dimethylpheny lsulfonamido )acetamido )ben-
zoate (25) 
°' ~o ~o 0 
15 
Sulfonylation of secondary amine 21 with 4-cyano-ben- 45 
zene-1-sulfonyl chloride on a 0.08 mmol scale via General 
240 
Procedure F furnished 25 (77 mgs, 99%): OH (400 MHz, 
CDC13 ) 1.72-1.91 (m, 4H, CH2 ), 2.31-2.45 (m, 7H, CH3 and 
2 CH2 ), 2.80 (s, 3H, CH3 ), 3.62 (s, 2H, CH2 ), 3.89-3.99 (m, 
2H, CH2), 4.74 (s, 2H, CH2), 5.01 (s, 2H, CH2), 5.34 (s, 2H, 
CH2), 6.60 (t, J=S.4 Hz, lH, CH), 6.69 ( dd, J=S.O and 1.6 Hz, 
lH, CH), 6.99-7.09 (m, 4H, 4 CH (Ar)), 7.21-7.91(m,12H, 
12 CH (Ar)); Oc (100 MHz, CDC13 ) 21.3, 29.5, 32.3, 35.9, 
40.8, 41.1, 46.5, 51.3, 52.6, 66.9, 70.6, 113.9, 116.3, 117.1 
119.9, 120.6, 126.6, 126.9, 127.3, 127.9, 128.0, 128.1 (2), 
128.4, 128.5, 129.0, 129.3, 132.7, 132.9, 134.9, 135.1, 135.5, 
135.6, 140.7, 143.2, 143.8, 144.9, 158.6, 165.2, 166.S;LRMS 
(ES+) calcd for [C50H48N4 0 8S2 +Na] 919.28 found 919.40. 
33. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-(l-
( 4-( tert-butoxycarbony 1 )pheny l)piperidin-4-yl )ben-
zy l)-2(N,4-dimethylpheny lsulfonamido )acetamido) 
benzoate (26) 
°' 0 0 
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Nucleophilic aromatic substitution of 21 with tert-butyl 
4-fluoro benzoate on a 0 .11 mmol scale via General Procedure 
Dfurnished26 (113 mg, 98%): oH(400MHz, CDC13 ) 1.57 (s, 
9H, 3CH3 ), 1.72-1.84 (m, 2H, CH2 ), 1.86-1.96 (m, 2H, CH2 ), 
2.39 (s, 3H, CH3 ), 2.64-2.75 (m, lH, CH), 2.81 (s, 3H, CH3 ), 5 
2.91 (t, J=l0.4 Hz, 2H, CH2), 3.66 (s, 2H, CH2 ), 3.93 (d, 
J=12.8 Hz, 2H, CH2 ), 4.77 (s, 2H, CH2), 4.98 (s, 2H, CH2), 
5.35 (s, 2H, CH2 ), 6.57 (s, lH, CH), 6.67 (d, J=8.0 Hz, lH, 
CH), 6.88 (d, J=8.8 Hz, 2H, CH), 7.06 (d, J=8.0Hz, 2H, CH), 
7.12 (d, J=8.0 Hz, 2H, CH), 7.24 (d, J=7.6 Hz, 2H, CH), 
10 
7.29-7.39 (m, lOH, CH), 7.60 (d, J=8.0 Hz, 2H, CH), 7.83 (d, 
J=8.4Hz, lH, CH), 7.88 (d, J=8.8Hz, 2H, CH); oc(lOOMHz, 
CDC13 ) 21.4, 28.2, 32.6, 35.9, 42.1, 48.7, 51.3, 52.7; 66.9, 
70.6, 79.9, 113.8, 114.0, 119.8, 120.3, 121.2, 126.8, 127.0, 
127.4, 128.0, 128.1, 128.2, 128.4, 128.5, 129.0, 129.4, 130.9, 
133.0, 134.5, 135.3, 135.6, 135.7, 143.2, 144.8, 145.2, 153.8, 15 
158.6, 165.3, 165.9, 166.8. 
34. Preparation of 4-(4-(4-((N-(4-((benzyloxy)carbo-
nyl)-3-hydroxyphenyl)-2-(N,4-dimethylphenylsul-
fon-amido )acetamidomethyl)phenyl)piperidin-1-yl) 
benzoic acid (27) 
242 
through a short pad of silica gel (CH2 Cl2 ) to furnish 27 (130 
mg, 95%): OH (400 MHz, CDC13 ) 1.73-1.85 (m, 2H, CH2 ), 
1.90-1.98 (m, 2H, CH2 ), 2.40 (s, 3H, CH3 ), 2.68-2.78 (m, lH, 
CH), 2.86 (s, 3H, CH3 ), 2.98 (t, J=12.0 Hz, 2H, CH2 ), 3.82 (s, 
2H, CH2), 4.02 (d, J=12.8 Hz, 2H, CH2), 4.80 (s, 2H, CH2), 
5.28 (s, 2H, CH2), 5.39 (s, 2H, CH2 ), 6.56 (dd, J=8.4 and 1.6 
Hz, lH, CH), 6.67 (d, J=l.6 Hz, lH, CH), 6.91 (d, J=8.8 Hz, 
2H, CH), 7.08 (d, J=8.0 Hz, 2H, CH), 7.12 (d, J=8.0 Hz, 2H, 
CH), 7.26 (d, J=7.6 Hz, 2H, CH), 7.34-7.48 (m, SH, CH), 7.64 
(d, J=8.0 Hz, 2H, CH), 7.87 (d, J=8.4 Hz, lH, CH), 7.98 (d, 
J=8.8 Hz, 2H, CH); Oc (100 MHz, CDC13 ) 21.4, 32.5, 35.7, 
42.0, 48.3, 51.4, 52.7, 53.3, 67.3, 112.2, 113.5, 116.8, 117.9, 
119.0, 126.8, 127.4, 128.3, 128.6 (br), 129.4, 131.4, 131.9, 
134.4, 134.8, 135.2, 143.3, 144.9, 147.2, 154.4, 162.4, 166.7, 
169.1, 171.9. 
35. Preparation of 4-(N-(4-(1-(4-carbamoylphenyl) 
piperidin-4-yl)benzyl)-2-(N,4-dimethylphenyl-sul-






t-Butyl ester26 (0.14 mmol) was dissolved in a 1:1 mixture 
45 
ofTFA:toluene (2.8 ml) and stirred at rt for 4 h. All solvents 
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Condensation of26 with NH4Cl on a 0.10 nnnol scale via 
General Procedure F furnished 61 (58 mg, 98%): OH (400 
MHz, d-CDCl3 ) 1.70-1.96 (m, 4H, CH2 ), 2.39 (s, 3H, CH3 ), 
2.63-2.73 (m, lH, CH), 2.85 (s, 3H, CH3 ), 2.86-2.9 (m, 2H, 
CH2 ), 3.80 (s, 2H, CH2), 3.92-3.97 (m, 2H, CH2), 4.79 (s, 2H, 5 
CH2 ), 5.38 (s, 2H, CH2 ), 6.56(dd,1=8.4 and2.0Hz, lH, CH), 
6.67 (d, 1=2.0 Hz, lH, CH), 6.91 (d, 1=8.4 Hz, 2H, CH), 
7.03-7.14 (m, 4H, CH), 7.35-7.43 (m, SH, CH), 7.63(d,1=8.4 
Hz, 2H, CH), 7.73 (d, 1=7.6 Hz, 2H, CH), 7.86 (d, 1=8.4 Hz, 
lH, CH); oc(lOOMHz, d-CDCl3 )21.4, 32.6, 35.7, 41.9, 48.7, 10 
51.4, 52.7, 67.3, 112.2, 114.2, 116.8, 117.9, 118.9, 122.2, 
126.8, 127.4, 128.3, 128.5, 128.6, 128.9, 129.4, 131.4, 134.4, 
134.8, 135.2, 143.2, 145.0, 147.2, 153.6, 162.4, 166.6, 169.0; 
LRMS (ES+) Calcd for [C43H44N4 0 7 S+Na] 783.28 found 
783.34. 15 













Ary! halide 9 was coupled to 3-(methoxycarbonyl)phenyl-
35 
boronic acid to give 28 on a 0.1 nnnol scale via General 
Procedure H (65 mg, 62%): OH (400 MHz, CDCl3 ) 2.40 (s, 
3H, CH3 ), 2.83 (s, 3H, CH3 ), 3.68 (s, 2H, CH2 ), 3.94 (s, 3H, 
CH3 ), 4.84 (s, 2H, CH2 ), 5.03 (s, 2H, CH2), 5.35 (s, 2H, CH2), 
6.62 (s, lH, CH), 6.68 (dd, 1=8.0 and 1.6 Hz, lH, CH), 7.19 
40 
(d, 1=8.0Hz, 2H, CH), 7.30-7.42 (m, !OH, CH), 7.52(d,1=8.4 
Hz, 2H, CH), 7.60-7.64 (m, 4H, CH), 7.78 (d, 1=7.6 Hz, 2H, 
CH), 7.84 (d, lH, 1=8.0 Hz, CH), 8.02 (dt, 1=8.0 and 1.2 Hz, 
lH, CH), 8.25 (t, 1=2.0 Hz, lH, CH); Oc (100 MHz, CDCl3 ) 
21.5, 36.0, 52.2, 52.8, 56.0, 67.5, 70.7, 117.2, 117.5, 120.1, 
125.2, 127.0, 127.2, 127.4, 127.5, 128.0, 128.1, 128.1, 128.2, 45 
128.2, 128.5, 128.6, 128.9, 129.5, 130.7, 131.3, 133.2, 135.7, 
135.7, 136.1, 139.5, 141.2, 142.4, 158.8, 161.7, 166.9, 167.0, 
168.4; LRMS (ES+) calcd for [C46H42N20 8 S+H] 783.27. 
244 
Ary! halide 9 was coupled to 3-cyanophenylboronic acid to 
give 29 on a 0.1 mmol scale via General Procedure H (58 mg, 
60%): oH(400 MHz, CDCl3 ) 2.33 (s, 3H, CH3 ), 2.76 (s, 3H, 
CH3), 3.62 (s, 2H, CH2), 4.78 (s, 2H, CH2), 4.97 (s, 2H, CH2), 
5.28 (s, 2H, CH2 ), 6.60-6.62 (m, 2H, CH), 7.14-7.28 (m, 12H, 
CH), 7.25-7.28 (m, 2H, CH), 7.38 (d, 1=8.0 Hz, 2H, CH), 
7.44-7.49 (m, lH, CH), 7.54-7.57 (m, 3H, CH), 7.71 (dt, 
1=7.6 and 1.2 Hz, lH, CH), 7.76 (s, lH, CH), 7.78 (s, lH, 
CH); oc(lOOMHz, CDCl3 ) 21.4, 36.0, 51.4, 52.7, 67.0, 70.7, 
112.9, 114.0, 118.6, 120.0, 120.9, 127.0, 127.1, 127.4, 128.0, 
128.2, 128.2, 128.5, 128.6, 128.7, 129.5, 129.5, 129.6, 130.5, 
130.8, 131.2, 133.1, 135.6, 135.7, 136.8, 138.2, 141.7, 143.3, 
158.8, 165.2, 167.1, 167.7; LRMS (ES+) calcd for 
[C45H39N30 6 S+H] 750.26. found 750.26. 
38. Preparation ofbenzyl 2-(benzyloxy)-4-(N-((3'-
carbamoylbiphenyl-4-yl)methyl)-2-(N,4-dimethyl 
phenylsulfonamido )acetamido )benzoate (30) 
0 
Ary! halide 9 was coupled to 3-carbamoylphenylboronic 
acid to give 30 on a 0.1 nnnol scale via General Procedure H 
(57 mg, 52% ): OH ( 400 MHz, CDCl3 ) 2.38 (s, 3H, CH3 ), 2.81 
(s, 3H, CH3 ), 3.68 (s, 2H, CH2 ), 4.83 (s, 2H, CH2 ), 5.02 (s, 
2H, CH2), 5.34 (s, 2H, CH2 ), 5.93 (s, lH, NH2 ), 6.33 (s, 2H, 
NH2 ), 6.64 (s, lH, CH), 6.67(dd,1=6.0and1.2 Hz, lH, CH), 
7.18(d,1=6.0Hz,2H,CH), 7.31-7.39(m, 13H,CH), 7.50(d, 
1=6.0Hz, 2H, CH), 7.60(d,1=6.3 Hz, 2H, CH), 7.70(d,1=5.7 
Hz, lH, CH), 7.77 (d, 1=5.7 Hz, lH, CH), 7.83 (d, 1=6.0 Hz, 
lH, CH), 8.03 (s, lH, CH); oc (100 MHz, CDCl3 ) 21.3, 35.9, 
51.3, 52.7, 66.9, 70.6, 113.9, 119.2, 119.9, 126.0, 126.9, 
127.0, 127.2, 127.3, 127.9, 128.1, 128.1, 128.4, 128.4, 128.7, 
found 783.26. 
37. Preparation ofbenzyl 2-(benzyloxy)-4-(N((3'-
cyanobiphenyl-4-yl)methyl)-2-(N,4-dimethylphenyl-
sulfon-amido )acetamido )benzoate (29) 





US 8,846,707 B2 
245 
135.6, 136.0, 139.4, 140.8, 143.3, 144.8, 158.7, 165.2, 167.0, 
169.1; LRMS (ES+) calcd for [C45H41N3 0 7 S+H]768.27 
found 768.27. 





Ary! halide 9 was coupled to 4-(methoxycarbonyl)phenyl-
boronic acid to give 31, on a 0.1 mmol scale via General 
Procedure H (53 mg, 52%): OH (400 MHz, CDCl3 ) 2.39 (s, 
3H, CH3 ), 2.82 (s, 3H, CH3 ), 3.68 (s, 2H, CH2 ), 3.93 (s, 3H, 
CH3 ), 4.84 (s, 2H, CH2 ), 5.03 (s, 2H, CH2), 5.34 (s, 2H, CH2), 
6.64 (s, lH, CH), 6.68 (dd, J=S.4 and 1.2 Hz, lH, CH), 7.19 
(d, J=S.O Hz, 2H, CH), 7.23-7.34 (m, SH, CH), 7.37-7.40 (m, 
2H, CH), 7.50-7.54 (m, 3H, CH), 7.60 (d, J=S.O Hz, 2H, CH), 
7.22 (d, J=S.4 Hz, 2H, CH), 7.70 (dd, J=5.6 and 3.2 Hz, lH, 




41. Preparation ofBenzyl 2-(benzyloxy)-4-(N-((4'-
cyanobiphenyl-4-yl)methyl)-2-(N,4-dimethylphenyl-
sulfon-amido )acetamido )benzoate (33) 
Ary! halide 9 was coupled to 4-cyanophenylboronic acid to 
give 33 on a 0.1 mmol scale via General Procedure H (73 mg, 
71%): oH(400 MHz, CDCl3 ) 2.39 (s, 3H, CH3 ), 2.82 (s, 3H, 
25 CH3), 3.68 (s, 2H, CH2), 4.85 (s, 2H, CH2), 5.05 (s, 2H, CH2), 
5.35 (s, 2H, CH2 ), 6.67 (s, lH, CH), 6.69 (d, J=l.2 Hz, lH, 
CH), 7.22-7.34 (m, 13H, CH), 7.38-7.40 (m, 2H, CH), 7.61 
(d, J=S.O Hz, 2H, CH), 7.64 (d, J=S.4 Hz, 2H, CH), 7.70-7.72 
(m, 3H, CH), 7.84 (d, J=S.4 Hz, lH, CH); Oc (100 MHz, 
30 CDCl3 ) 21.4, 36.0, 51.4, 52.7, 67.0, 70.7, 111.0, 114.0, 118.7, 
119.9, 120.8, 126.9, 127.3, 127.4, 127.5, 128.0, 128.2, 128.2, 
128.5, 128.5, 128.7, 129.5, 130.8, 132.4, 132.5, 133.1, 135.6, 
135.7, 137.1, 138.4, 143.3, 144.8, 158.8, 165.2, 167.1, 167.6; 
LRMS (ES+) calcd for [C45H39N3 0 6S+H] 750.26 found 
750.26. 
Oc (100 MHz, CDCl3 ) 21.4, 36.0, 51.4, 52.1, 52.8, 67.0, 70.7, 
35 
114.1, 120.0, 120.9, 126.8, 126.9, 127.3, 127.4, 128.0, 128.2, 
128.2, 128.5, 128.6, 128.7, 129.0, 129.4, 129.5, 130.1, 132.4, 
133.1, 135.3, 135.7, 135.7, 136.5, 139.3, 143.3, 144.8, 144.9, 
158.8, 166.8, 167.0, 167.7; LRMS (ES+) calcd for 
42. Preparation ofBenzyl 2-(benzyloxy)-4-(N-((4'-
carbamoylbiphenyl-4-yl)methyl)-2-(N,4-dimethyl 
phenylsulfonamido )acetamido )benzoate (34) 
[C46H42N20 8 S+H] 783.27 found 783.26. 40 
40. Preparation of 4'-((N-(3-(benzyloxy)-4-((benzy-
loxy)carbonyl)phenyl)-2-(N,4-dimethylphenylsul-
fonamido )acetamido )methyl)-[1,1 '-biphenyl]-4-car-
boxylic acid (32) 
0 
OH 
Ary! halide 9 was coupled to 4-carboxyphenylboronic acid 
to give 32 on a 0.1 mmol scale via General Procedure H. 32 




Ary! halide 9 was coupled to 4-carbamoylphenylboronic 
acid to give 34 on a 0.1 mmol scale via General Procedure H 
(62 mg, 49%): oH(400 MHz, CDCl3 ) 2.38 (s, 3H, CH3 ), 2.82 
(s, 3H, CH3 ), 3.68 (s, 2H, CH2 ), 4.39 (s, 2H, CH2 ), 5.03 (s, 
60 2H, CH2), 5.34 (s, 2H, CH2 ), 5.91 (s, lH, NH2 ), 6.44 (s, lH, 
NH), 6.65 (s, lH, CH2 ), 6.68 (d, lH, CH), 7.19 (d, J=6.0 Hz, 
2H, CH), 7.24-7.35 (m, 4H, CH), 7.38-7.41 (m, 2H, CH), 
7.44-7.50 (m, 6H, CH), 7.53 (d, J=4.8 Hz, lH, CH), 7.59 (s, 
2H, CH), 7.61 (s, 2H, CH), 7.64 (d, J=5.4 Hz, 2H, CH), 7.68 
65 (d, J=5.4 Hz, 2H, CH), 7.83 (d, J=6.3 Hz, lH, CH), 7.89 (d, 
1=6.0 Hz, 2H, CH); oc (100 MHz, CDCl3 ) 21.3, 35.9, 51.3, 
52.7, 66.9, 70.6, 113.9, 119.9, 120.8, 126.8, 126.9, 127.1, 
US 8,846,707 B2 
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Ary! halide 5 was coupled to 3-carboxyphenylboronic acid 
on a 0.1 mmol scale via General Procedure H to yield 36 (76 
mg, 64%): OH (400 MHz, CDCl3 ) 2.33 (s, 3H, CH3 ), 2.78 (s, 
3H, CH3 ), 3.65 (s, 2H, CH2 ), 4.80 (s, 2H, CH2 ), 4.80 (s, 2H, 
127.3, 127.9, 128.1, 128.1, 128.3, 128.4, 128.4, 129.4, 131.8, 
131.8, 131.8, 131.9, 132.0, 132.8, 133.0, 135.1, 135.5, 135.6, 
136.3, 139.1, 143.2, 143.8, 144.8, 158.7, 165.2, 167.0, 168.8; 
LRMS (ES+) calcd for [C45H41N3 0 7 S+H] 768.27 found 
768.27. 
43. Preparation of methyl 4'-((N-(3-(benzyloxy)-4-
(benzy loxycarbony I )pheny 1)-2-(N,4-dimethy lpheny I 
sulfonamido )acetamido )methyl )terpheny 1-3-car-
boxy late (35) 
5 CH2), 5.30 (s, 2H, CH2), 6.60 (s, lH, CH), 6.66 (d, J=8.4 Hz, 
2H, CH), 7.15 (d, J=8.0 Hz, 2H, CH), 7.13-7.28 (m, 12H, 
CH), 7.30-7.38 (m, 3H, CH), 7.50 (d, J=7.2 Hz, 2H, CH), 
7.47-7.63 (m, 6H, CH), 7.90 (d, J=8.0 Hz, 2H, CH); LRMS 




Ary! halide 5 was coupled to 3-(methoxycarbonyl)phenyl-
boronic acid on a 0.1 mmol scale via General Procedure H to 
yield 35 (39 mg, 38%): OH (400 MHz, CDCl3 ) 2.40 (s, 3H, 
30 
CH3 ), 2.83 (s, 3H, CH3 ), 3.68 (s, 2H, CH2 ), 3.96 (s, 3H, CH3 ), 
4.84 (s, 2H, CH2 ), 5.02 (s, 2H, CH2), 5.35 (s, 2H, CH2 ), 6.62 
(s, lH, CH), 6.70 (d, J=8.0Hz, lH, CH)7.19 (d, J=8.0Hz, 2H, 
CH), 7.26-7.34 (m, lOH, CH), 7.38-7.41 (m, 3H, CH), 7.54 35 
(d, J=8.0 Hz, 2H, CH), 7.62 (d, J=8.4 Hz, 2H, CH), 7.68 (q, 
J=8.0 Hz, 4H, CH), 7 .84 (t, J=8.0 Hz, 2H, CH), 8.03 ( d, J=8.0 
Hz, lH, CH), 8.32 (s, lH, CH); LRMS (ES+) Calcd for 
[C52H46N20 8 S+H] 859.31. found 859.25. 
44. Preparation of 4'-((N-(3-(benzyloxy)-4-(benzy-
loxycarbonyl)phenyl)-2-(N,4-dimethylphenylsulfon-
amido )acetamido )methyl )terpheny 1-3-carboxylic 
acid (36) 
40 
45. Preparation ofbenzyl 2-(benzyloxy)-4-(N-((3'-
cyanoterpheny 1-4-y l)methy 1)-2-(N,4-dimethy lpheny I 
sulfonamido )acetamido )benzoate (37) 
CN 
Ary! halide 5 was coupled to 3-cyanophenylboronic acid 
on a 0.1 mmol scale via General Procedure H to yield 37 (59 
mg, 56%): OH (400 MHz, CDCl3 ) 2.38 (s, 3H, CH3 ), 2.83 (s, 
3H, CH3 ), 3.69 (s, 2H, CH2 ), 4.85 (s, 2H, CH2 ), 5.03 (s, 2H, 
CH2), 5.34 (s, 2H, CH2), 6.65 (s, lH, CH), 6.70 (d, J=8.0 Hz, 
lH, CH), 7.20 (d, J=8.0 Hz, 2H, CH), 7.23 (t, J=8.4 Hz, 4H, 
CH), 7 .30-7 .34 (m, 6H, CH), 7 .38-7.40 (m, 3H, CH), 7 .50 ( d, 
J=8.4 Hz, 2H, CH), 7.60-7.63 (m, SH, CH), 7.67 (d, J=8.4 Hz, 
2H, CH), 7.81 (d, J=8.0 Hz, 2H, CH), 7.86 (s, lH, CH). 
LRMS (ES+) calcd for [C51 H43N3 0 6S+H] 848.28 found 
848.45. 
OH 




dimethylphenylsulfonamido )acetamido )benzoate 
(38) 
Ary! halide 5 was coupled to 3-carbamoylphenylboronic 
acid on a 0.1 mmol scale via General Procedure H to give 38 
(38 mg, 32%): oH(400 MHz, CDCl3 ) 2.39 (s, 3H, CH3 ), 2.83 
(s, 3H, CH3 ), 3.69 (s, 2H, CH2 ), 4.84 (s, 2H, CH2 ), 5.03 (s, 
2H, CH2), 5.35 (s, 2H, CH2), 6.63 (s, lH, CH), 6.70 (d, J=8.8 
Hz, lH, CH), 7.19 (d, J=8.0 Hz, 2H, CH), 7.30-7.36 (m, !OH, 
CH), 7.38-7.41(m,3H,CH),7.54(d,J=8.0Hz,2H,CH), 7.62 
(d, J=8.0 Hz, 2H, CH), 7.67 (q, J=7.2 Hz, 4H, CH), 7.79 (t, 
10 2H, J=7.6 Hz, CH), 7.85 (d, J=8.0 Hz, lH, CH), 8.12 (s, lH, 
CH). LRMS (ES+) Calcd for [C51H45N30 7 S+Na] 866.29 
found 866.51. 









Ary! halide 5 was coupled to 4-(methoxycarbonyl)phenyl-
boronic acid to give 39 on a 0.1 mmol scale via General 
Procedure H (59 mg, 47%): OH (400 MHz, CDCl3 ) 2.38 (s, 
3H, CH3 ), 2.83 (s, 3H, CH3 ), 3.69 (s, 2H, CH2 ), 3.93 (s, 3H, 
CH3 ), 4.84 (s, 2H, CH2 ), 5.02 (s, 2H, CH2 ), 5.35 (s, 2H, CH2 ), 40 6.64 (s, lH, CH), 6.70 (dd, J=8.4 and 1.6 Hz, lH, CH), 7.20 
(d, J=8.0Hz, 2H, CH), 7.24-7.28 (m, 6H, CH), 7.30-7.33 (m, 
SH, CH), 7.36-7.41(m,3H, CH), 7.54 (d, J=8.4 Hz, 2H, CH), 
7.61 (d, J=8.4 Hz, 2H, CH), 7.64-7.73 (m, 6H, CH), 7.85 (d, 
J=8.4 Hz, lH, CH). LRMS (ES+) calcd for [C52H46N20 8 S+ 
45 HJ 881.29. found 881.39. 
47. Preparation of 4'-((N-(3-(benzyloxy)-4-(benzy-
loxycarbonyl)phenyl)-2-(N,4-dimethylphenyl-sul-
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Ary! halide S was coupled to 4-carboxyphenylboronic acid 
to give 40 on a 0.1 mmol scale via General Procedure H ( 47 
mg, 47%): OH (400 MHz, CDCl3 ) 2.40 (s, 3H, CH3 ), 2.S4 (s, 
2H, CH2 ), 3.70 (s, 2H, CH2 ), 4.S6 (s, 2H, CH2 ), S.04 (s, 2H, 
CH2 ), S.36 (s, 2H, CH2 ), 6.6S (s, lH, CH), 6.71 (d, J=S.4 Hz, 5 
lH, CH), 7.21 (d, J=S.O Hz, 2H, CH), 7.27-7.43 (m, 12H, 
CH), 7.39-7.41(m,3H, CH), 7.SS (d, J=S.4 Hz, 2H, CH), 7.63 
(d, J=S.O Hz, 2H, CH), 7.67-7.7S (m, 4H, CH), 7.S6 (d, J=S.O 
Hz, lH, CH), S.20 (d, J=7.6 Hz, lH, CH); LRMS (ES+) calcd 
for [C51 H44N20 8 S+H] S4S.29 found S4S.3S. 
4S. Preparation ofBenzyl 2-(benzyloxy)-4-(N((4'-
cyanoterphenyl-4-yl)methyl)-2-(N,4-dimethylphenyl 




(s, 3H, CH3 ), 3.69 (s, 2H, CH2 ), 4.SS (s, 2H, CH2 ), S.04 (s, 
2H, CH2), S.36 (s, 2H, CH2), 6.64 (s, lH, CH), 6.70 (d, J=7.6 
Hz, lH, CH), 7.21 (d, J=S.O Hz, CH), 7.24-7.29 (m, SH, CH), 
7 .31-7 .36 (m, SH, CH), 7 .3S-7.42 (m, 2H, CH), 7 .S4 ( d, J=S.4 
Hz, 2H, CH), 7.62 (d, J=S.4 Hz, 2H, CH), 7.6S-7.76 (m, SH, 
CH), 7.SS (d, J=S.O Hz, lH, CH). LRMS (ES+) calcd for 
[C51H45N30 7 S+Na] S66.29 found S66.32. 
SO. Preparation oftert-butyl 
2-(2,2,2-trifluoro-N-methylacetamido )acetate ( 43) 
To a stirred solution of tert-butyl 2-(methylamino )acetate 
(2.00 g, 11 mmol) and DIPEA (3.6S g ( 4.SO ml), 27 .S mmol) 
CN 20 in CHCl3 (0.1 M) was added triflic anhydride (2.S4 g, 12.1 
mmol). The solution was allowed to stir at rt for 3 hr before 
quenching with water and extraction into CH2 Cl2 . The com-
bined organic layers were washed with water and brine, dried 
over Na2S04 and the solution concentrated under reduced 
25 pressure to give 43 (1.44 g, SS%): o H ( 400 MHz, d-CDCl3 ) 
1.46 (s, 9H, 3 CH3 ), 3.0S (s, lH, CH3 ), 3.lS (s, 2H, CH3 ), 4.04 
(s, 2H, CH2 ). 
Ary! halide S was coupled to 4-cyanophenylboronic acid to 30 
give 41 on a 0.1 mmol scale via General Procedure H (32 mg, 
30%): oH(400 MHz, CDCl3 ) 2.36 (s, 3H, CH3 ), 2.79 (s, 3H, 
CH3 ), 3.6S (s, 2H, CH2 ), 4.Sl (s, 2H, CH2), 6.00 (s, 2H, CH2), 
S.31 (s, 2H, CH2 ), 6.61 (s, lH, CH), 6.66 (d, J=S.4 Hz, lH, 
CH), 7.17 (d, J=S.4 Hz, 2H, CH), 7.23 (t, J=S.O Hz, 4H, CH), 35 
7.30-7.33 (m, SH, CH), 7.36-7.40 (m, 3H, CH), 7.70 (d, J=S.O 
Hz, 2H, CH), 7.SS (d, J=S.O Hz, 2H, CH), 7.66-7.73 (m, SH, 
CH), 7.Sl (d, J=S.4 Hz, lH, CH). LRMS (ES+) calcd for 
[C51 H44N30 6 S+H] S4S.2S found S4S.3S. 
49. Preparation ofbenzyl 2-(benzyloxy)-4-(N,4( 4'-
carbamoylterphenyl-4-yl)methyl)-2-(N,4-dimethyl 






S l. Preparation of 
2-(2,2,2-trifluoro-N-methylacetamido )acetic acid 
(44) 
tert-Butyl ester 46 (2.00 g, 11.0 mmol) was dissolved in a 
TFA: CH2Cl2 (1:1) solution (0.1 M) and allowed to stir for S 
0 
Ary! halide S was coupled to 4-carbamoylphenylboronic 65 hrs at rt. The product was then concentrated under reduced 
acid to give 42 on a 0.1 mmol scale via General Procedure H pressure to yield pure compound 44 (2.SO g, 9S%): OH (400 
(31mg,2S%): oH(400 MHz, CDCl3 ) 2.40 (s, 3H, CH3 ), 2.S3 MHz, CDCl3 ) 3.22 (s, 3H, CH3 ), 4.19 (s, 2H, CH2 ). 
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S2. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzyl)-2-(2,2,2-trifluoro-N-methylaceta-




Secondary aniline 4 was coupled to carboxylic acid 44 on 
a3.17 mmol scale via General ProcedureB to fumish4S (2.07 
10 
15 
g, 97%): oH(400MHz, CDCl3 ) 1.3S-l.44 (m, SH, [Cy] CH2 ), 
1.71-1.90 (m, 6H, [Cy] CH2 ), 3.17 (s, 3H, CH3 ), 3.79 (s, 2H, 
CH2 ), 4.84 (s, 2H, CH2 ), 4.97 (s, 2H, CH2), S.3S (s, 2H, CH2), 25 
6.6S (s, lH, CH), 6.78 (dd, J=8.4 and 1.6 Hz, lH, CH), 
7.10-7.19 (m, 4H, CH), 7.29-7.43 (m, !OH, CH), 7.86 (d, 
J=8.4 Hz, lH, CH); Oc (100 MHz, CDCl3 ) 2S.8, 26.6, 34.2, 
44.0, Sl.2, S2.6, 66.7, 70.4, 77.2, 113.9, llS.O, 117.6, 119.8, 
126.8, 126.9, 127.7, 128.0, 128.3, 128.3, 128.4, 128.6, 132.9, 30 
133.6, l3S.S, l3S.6, 144.6, 147.S, 1S7.0, 1S8.4, 16S.1, l6S.4; 
LRMS (ES+) calcd for [C39H39F3 N20 5 +Na] 69S.27. found 
69S.36. 
254 
128.0, 128.1, 128.3, 132.S, 133.9, 13S.3, 13S.43, l4S.O, 
147.0, 1S8.1, 164.8, 169.6; LRMS (ES+) calcd for 
[C37H40N20 4 +H] S77.31 found S77.4S. 
S4. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexy lbenzy 1)-2-(N,3-dimethy lpheny lsulfona-
mido) acetamido )benzoate ( 4 7) 
°' 0 0 
Secondary amine 46 was coupled to 3-methylbenzene-1-
sulfonyl chloride on a 0.2 mmol scale via General Procedure 
G to furnish 47 (116 mg, 94%): OH (400 MHz, CDCl3 ) 1.31-
1.44 (m, SH, CH), 1.70-1.89 (m, SH, CH), 2.36 (s, 3H, CH3 ), 
2.42-2.S2 (m, lH, CH), 2.83 (s, 3H, CH3 ), 3.6S (s, 2H, CH2 ), 
4.77 (s, 2H, CH2 ), 4.96 (s, 2H, CH2), S.3S (s, 2H, CH2 ), 6.S2 
(s, lH, CH), 6.69 (dd, J=8.0 and 1.2 Hz, lH, CH), 7.03 (d, 
J=8.0Hz, 2H, CH), 7.11 (d, J=8.0Hz, 2H, CH), 7.27-7.42 (m, 
12H, CH), 7.S0-7.SS (m, 2H, CH), 7.84 (d, J=8.0 Hz, lH, 
CH); oc (100 MHz, CDCl3 ) 21.2, 2S.9, 26.7, 29.6, 34.2, 34.3, S3. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexy lbenzy 1)-2-( methy !amino )-acetamido ben-
zoate ( 46) 
f) 
35 3S.9, 44.1, Sl.3, S2.7, 66.9, 70.6, 114.2, 120.0, 120.6, 124.4, 
126.9, 127.0, 127.6, 127.9, 128.1, 128.2, 128.4, 128.S, 128.8, 
128.9, 133.0, 133.3, 133.8, 13S.6, l3S.7, 138.0, 138.9, 14S.O, 
147.6, 1S8.6, 16S.3, 166.6; LRMS (ES+) calcd for 





Compound 4S (2.68 mmol) was dissolved in a THF:H20 55 
(3:1) solution and treated with LiOH.H2 0 (337 mg, 8.04 
mmol). After 10 min the reaction was completed and diluted 
with H20. The product was extracted into EtOAc and the 
combined extracts washed with SO% sat. NaHC03 , water, 
brine and dried over Na2S04 and concentrated under reduced 
pressure to yield46 (1.S7 g, 99% ): OH( 400 MHz, CDCl3 ) l.3S 
60 
(m, SH, [Cy] CH2 ), 1.66-1.84 (m, SH, [Cy] CH2 ), 2.28 (s, 2H, 
CH3 ), 2.44 (m, lH, [Cy] CH), 3.02 (s, 2H, CH2 ), 4.81(s,2H, 
CH2 ), 4.89 (s, 2H, CH2), S.30 (s, 2H, CH2), 6.S2 (s, lH, CH), 
6.S4 (d, lH, J=8.0Hz, CH), 7.0S-7.13 (m, 4H, CH), 7.24-7.37 
(m, 12H, CH), 7.80 (d, J=8.0 Hz, lH, CH); Oc (100 MHz, 65 
CDCl3 ) 2S.6, 26.3, 34.0, 3S.4, 43.7, S2.0, S2.2, 66.4, 70.0, 
77.2, 113.6, 119.6, 119.9, 126.4, 126.6, 127.S, 127.6, 127.7, 
SS. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzyl)-2-(N,2,4,6-tetramethylphenyl 
sulfonamido )acetamido )benzoate ( 48) 
°' ~o ~o 0 
Secondary amine 46 was coupled with 2,4,6-trimethylben-
zenesulfonyl chloride on a 0.1 mmol scale via General Pro-
cedure Gto furnish 48 (48 mg, 74%): oH(400 MHz, CDCl3 ) 
1.34-1.43 (m, SH, CH), 1.70-1.87 (m, SH, CH), 2.29 (s, 3H, 
CH3 ), 2.42-2.S2 (m, lH, CH), 2.S6 (s, 6H, CH3 ), 2.79 (s, 3H, 
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(m, SH, CH2 ), 1.71-1.S9 (m, SH, CH2 ), 2.42-2.S2 (m, lH, 
CH), 2.SS (s, 3H, CH3 ), 3.70 (s, 2H, CH2 ), 4.74 (s, 2H, CH2 ), 
4.96 (s, 2H, CH2 ), S.36 (s, 2H, CH2 ), 6.SO (s, lH, CH), 6.6S 
(dd, J=S.4 and 1.6 Hz, lH, CH), 7.01 (d, J=S.4 Hz, 2H, CH), 
7.13 (d, J=S.OHz, 2H, CH), 7.29-7.36 (m, SH, CH), 7.39-7.4S 
(m, 4H, CH), 7.70 (d, J=S.4 Hz, 2H, CH), 7.S4 (d, J=S.4 Hz, 
lH, CH); Oc(lOO MHz, CDC13 ) 2S.9, 26.7, 34.3, 3S.S, 44.1, 
Sl.2, S2.7, 66.9, 70.6, 114.0, 119.9, 120.7, 126.S, 126.9, 
127.9, 12S.1, 12S.2, 12S.4, 12S.S, 12S.7, 12S.S, 129.0, 133.1, 
CH3 ), 3.67 (s, 2H, CH2 ), 4.7S (s, 2H, CH2 ), 4.90 (s, 2H, CH2 ), 
S.3S (s, 2H, CH2 ), 6.43 (s, lH, CH), 6.SS (dd, J=S.O and 1.6 
Hz, lH, CH), 6.93 (s, 2H, CH), 7.00 (d, J=S.O Hz, 2H, CH), 
7.10(d,J=S.0Hz,2H,CH), 7.29-7.42(m, lOH,CH), 7.Sl (d, 
J=S.O Hz, lH, CH); Oc (100 MHz, CDC13 ) 20.9, 22.7, 26.0, 5 
26.7, 34.4, 34.7, 44.1, 49.6, S2.6, 69.9, 70.6, 113.9, 120.0, 
120.S, 126.9, 127.0, 12S.O, 12S.1, 12S.2, 12S.S, 12S.S, 12S.S, 
131.S, 133.1, 134.0, l3S.6, 13S.7, 140.S, 142.4, 147.6, lSS.7, 
l6S.3, 166.7; LRMS (ES+) calcd for [C46H50N20 6 S+Na] 
7Sl.33 found 7Sl.39. 10 133.7, l3S.6, l3S.6, 137.1, 13S.9, 144.S, 147.7, lSS.6, l6S.2, 
166.4; LRMS (ES+) calcd for [C47H46N20 6 S+Na] 7S9.30 
found 7S9.32. S6. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexy lbenzy 1)-2-(N-methylbipheny 1-4-y lsul-




Secondary amine 46 was combined with biphenyl-4-sul-
fonyl chloride on a 0.1 mmol scale via General Procedure G 30 
to fumish49 (SO mg, 70%): oH(400 MHz, CDC13 ) 1.32-1.41 
(m, SH, CH2 ), 1.70-1.S6 (m, SH, CH2 ), 2.3S-2.S2 (m, lH, 
CH), 2.90 (s, 3H, CH3 ), 3.72 (s, 2H, CH2 ), 4.77 (s, 2H, CH2 ), 
4.97 (s, 2H, CH2 ), 4.36 (s, 2H, CH2 ), 6.S3 (s, lH, CH), 6.70 
(dd, J=S.O and 1.6 Hz, lH, CH), 7.02 (d, J=S.O Hz, 2H, CH), 35 
7.09 (d, J=S.OHz, 2H, CH), 7.30-7.36 (m, SH, CH), 7.3S-7.42 
(m, 2H, CH), 7.43-7.SO (m, 3H, CH), 7.60 (dt, J=7.2and1.6 
Hz, 2H, CH), 7.6S (d, J=S.S Hz, 2H, CH), 7.Sl (d, J=S.4 Hz, 
2H, CH), 7 .S6 ( d, J=S.O Hz, lH, CH); Oc (100 MHz, CDC13 ) 
26.0, 26.7, 34.3, 36.0, 44.1, Sl.3, S2.S, 66.9, 70.6, 114.1, 
120.0, 120.6, 126.9, 127.0, 127.2, 127.4, 127.9, 12S.1, 12S.2, 40 
12S.3, 12S.S, 12S.S, 12S.S, 12S.9, 132.0, 133.1, 13S.S, 13S.7, 
13S.7, 137.0, 139.3, 14S.O, 14S.3, 147.6, lSS.7, 16S.3, 166.7; 
LRMS (ES+) calcd for [C49H48N2 0 6S+Na] SlS.31 found 
SlS.44. 
SS. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzyl)-2-(N-methylnaphthalene-l-sul-
fonamido )acetamido )benzoate (62) 
Secondary amine 46 was combined with 1-naphthylsulfo-
nyl chloride on a 0.2 mmol scale via General Procedure G to 
furnish 62 (127 mg, 9S%): OH (400 MHz, CDC13 ) 1.33-1.42 
(m, SH, CH2 ), 1.71-1.S9 (m, SH, CH2 ), 2.42-2.S2 (m, lH, 
CH), 2.96 (s, 3H, CH3 ), 3.7S (s, 2H, CH2 ), 4.76 (s, 2H, CH2 ), 
4.92 (s, 2H, CH2 ), S.37 (s, 2H, CH2 ), 6.49 (s, lH, CH), 6.67 
(d, J=S.4 Hz, lH, CH), 7.01 (d, J=S.O Hz, 2H, CH), 7.11 (d, 
J=S.O Hz, 2H, CH), 7.29-7.36 (m, 13H, CH), 7.S3 (d, J=S.4 
Hz, lH, CH), 7.S9 (d, J=S.4 Hz, lH, CH), S.01 (d, J=S.4 Hz, 
lH, CH), S.19 (d, J=S.O Hz, lH, CH), S.S7 (d, J=S.4 Hz, lH, 
CH); oc(lOOMHz, CDC13 ) 2S.9, 26.7, 34.4, 36.6, 44.1, S2.7, 
S3.4, 66.9, 70.6, 114.2, 120.0, 120.7, 123.9, 124.9, 126.7, 
127.0, 127.9, 12S.1, 12S.2, 12S.S (2), 12S.6, 12S.7, 12S.S, 
S7. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(4-
chloro-N-methylphenylsulfonamido )-N-( 4-cyclo-
hexylbenzyl)acetamido )benzoate (SO) 
45 129.3, 133.0, 133.9, 134.0, 134.2, 134.3, 13S.6, 13S.7, 144.9, 
147.6, lSS.6, 16S.3, 166.7; LRMS (ES+) calcd for 







S9. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzyl)-2-(N-methylquinoline-S-sulfona-
mido )acetamido )benzoate (S 1) 
°' ~o ~o 0 
60
~ I# II° 
r/'-Nl~N 
Secondary amine 46 was combined with 2-naphthylsulfo- 65 II 
nyl chloride on a 0.1 mmol scale via General Procedure G to o 
0 
furnish SO (S3 mg, 79%): OH (400 MHz, CDC13 ) 1.3S-l.42 
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Secondary amine 46 was combined with quinoline-8-sul-
fonyl chloride on a 0.2 mmol scale via General Procedure G 
to furnish SI (128mg, 98%): oH(400MHz, CDC13 ) 1.33-1.4S 
(m, SH, CH2 ), 1.70-1.88 (m, SH, CH2), 2.42-2.S2 (m, lH, 
CH), 2.9S (s, 3H, CH3 ), 4.22 (s, 2H, CH2 ), 4.81 (s, 2H, CH2 ), 5 
4.96 (s, 2H, CH2), S.37 (s, 2H, CH2 ), 6.72 (s, lH, CH), 6.81 
(d, J=8.4 Hz, lH, CH), 7.06 (d, J=8.0 Hz, 2H, CH), 7.11 (d, 
J=8.0Hz, 2H, CH), 7.20-7.30(m, 6H, CH), 7.32-7.36 (m, 3H, 
CH), 7.39-7.44 (m, 2H, CH), 7.SS (t, J=8.0 Hz, lH, CH), 7.87 
(d, J=8.0 Hz, lH, CH), 7.96 (d, J=8.0 Hz, lH, CH), 8.14 (d, 10 
J=8.0 Hz, lH, CH), 8.4S (d, J=7.6 Hz, lH, CH), 8.49 (s (br), 
lH, CH); Oc (100 MHz, CDC13 ) 26.0, 26.7, 34.3, 36.2, 44.1, 
S2.6, S2.7, 66.9, 70.6, 114.4, 120.1, 120.3, 121.7, 12S.2, 
126.8, 127.0, 127.8, 128.1, 128.2, 128.4, 128.S, 128.8, 128.9, 
132.6, 132.7, 133.2, 134.1, 13S.7, 13S.8, 136.3, 137.0, 143.7, 15 
l4S.S, 147.4, lSO.S, lS8.S, l6S.S, 168.0; LRMS (ES+) calcd 
for [C46H45N30 6 S+Na] 790.29 found 790.36. 
60. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzyl)-2-( S-( dimethylamino )-N-methyl 
naphthalene-1-sulfonamido )acetamido )benzoate ( S2) 
20 
258 
61. Preparation of benzyl 2-(benzyloxy )-4-(N-( 4-
cyclohexylbenzyl)-2-(N, l-dimethyl- lh-imidazole-4-
sulfonamido )acetamido )benzoate (S3) 
°' ~o ~o 0 
0 
Secondary amine 46 was combined with l-methyl-lH-
imidazole-4-sulfonyl chloride on a 0.2 mmol scale via Gen-
eral Procedure Gto furnish S3 (116 mg, 9S%): oH(400 MHz, 
25 CDC13 ) 1.32-1.44 (m, SH, CH2 ), 1.68-1.86 (m, SH, CH2 ), 
2.41-2.Sl (m, lH, CH), 2.92 (s, 3H, CH3 ), 3.63 (s, 3H, CH2 ), 
3.80 (s, 2H, CH2 ), 4.77 (s, 2H, CH2), 4.96 (s, 2H, CH2 ), S.32 
(s, 2H, CH2), 6.69 (d, J=8.4 Hz, lH, CH), 6.72 (s, lH, CH), 
7.0S (d, J=8.0 Hz, 2H, CH), 7.09 (d, J=8.0 Hz, 2H, CH), 
30 7.27-7.40 (m, 12H, CH), 7.81 (d, J=8.0 Hz, lH, CH); oc(lOO 
MHz, CDC13 ) 2S.9, 26.7, 33.7, 34.3, 36.2, 44.1, Sl.6, S3.3, 
66.8, 70.6, 114.3, 119.9, 120.2, 123.8, 126.8, 127.1, 127.8, 
128.0, 128.1, 128.4, 128.S, 128.7, 132.9, 133.9, 13S.7, 13S.9, 
138.7, 138.8, 14S.3, 147.4, 1S8.7, 16S.4, 167.1; LRMS (ES+) 
35 





Secondary amine 46 was combined with S-(dimethy-
lamino )naphthalene-1-sulfonyl chloride on a 0.2 mmol scale 
via General Procedure G to furnish S2 (132 mg, 96%): OH 
40 
45 
( 400 MHz, CDC13 ) 1.33-1.44 (m, SH, CH2 ), 1.69-1.88 (m, 
55 
SH, CH2 ), 2.42-2.S2 (m, lH, CH), 2.86 (s, 6H, CH3 ), 2.9S (s, 
3H, CH3 ), 3.76 (s, 2H, CH2 ), 4.77 (s, 2H, CH2 ), 4.92 (s, 2H, 
CH2 ), S.37 (s, 2H, CH2 ), 6.SO (s, lH, CH), 6.67 (d, J=8.4 Hz, 
lH, CH), 7.03 (d, J=8.0 Hz, 2H, CH), 7.12 (d, J=8.0 Hz, 2H, 
CH), 7.23-7.38 (m, 9H, CH), 7.39-7.SO (m, 4H, CH), 7.83 (d, 60 
J=8.0Hz, lH, CH), 8.18 (d, J=7.2 Hz, lH, CH), 8.23 (d, J=8.4 
Hz, lH, CH), 8.S2 (d, J=8.0 Hz, lH, CH); oc (100 MHz, 
CDC13 ) 26.0, 26.7, 34.3, 36.1, 44.1, 4S.3, S0.7, S2.6, 66.9, 
70.6, 114.2, 1 lS.1, 119.6, 119.9, 120.3, 123.0, 126.9, 127.0, 
127.9, 128.1, 128.2, 128.4 (br), 128.8, 129.2, 129.8, 130.0, 65 
130.1, 133.0, 133.9, 134.4, 13S.6, 144.9, 147.6, 1S8.6, 16S.3, 
166.8. 
62. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(4-
cyano-N-methylphenylsulfonamido )-N-( 4-cyclo-
hexyl benzyl)acetamido)benzoate (S4) 
°" 0 0 
Secondary amine 46 was combined with 4-cyanobenzene-
1-sulfonyl chloride on a 0.2 mmol scale via General Proce-
dure G to furnish S4 (122 mg, 97%): OH (400 MHz, CDC13 ) 
1.21-1.39 (m, SH, CH2 ), 1.60-1.80 (m, SH, CH2 ), 2.38-2.S8 
(m, lH, CH), 2.78 (s, 3H, CH3 ), 3.6S (s, 2H, CH2 ), 4.61 (s, 
2H, CH2), 4.87 (s, 2H, CH2), S.26 (s, 2H, CH2), 6.39 (s, lH, 
CH), 6.S8 ( d, J=8.0 Hz, lH, CH), 6.89 ( d, J=8.0 Hz, 2H, CH), 
7.03 (d, J=8.0 Hz, 2H, CH), 7.18-7.3S (m, !OH, CH), 7.6S (d, 
J=8.4 Hz, 2H, CH) 7.7S (d, J=8.0 Hz, lH, CH), 7.79 (d, J=8.4 
Hz, 2H, CH); Oc (100 MHz, CDC13 ) 26.1, 26.8, 34.S, 3S.9, 
44.2, S2.9, S3.S, 67 .1, 70.7, 114.1, 116.2, 117 .S, 120.0, 121.1, 
127.1, 128.2 (br), 128.3, 128.4, 128.6, 128.7, 128.9, 132.6, 
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133.3, 133.S, 13S.7, 13S.S, 143.2, 144.7, 147.9, lSS.S, 16S.3, 
166.3; LRMS (ES+) calcd for [C44H43N30 6 S+Na] 764.2S 
found 764.30. 
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J=S.4 Hz, lH, CH); Oc (100 MHz, CDC13 ) 2S.9, 26.7, 34.3, 
3S.S, 44.1, Sl.2, S2.7, 66.9, 70.6, 114.0, 119.9, 120.7, 126.S, 
126.9, 127.S, 12S.1, 12S.2, 12S.4, 12S.S, 12S.7, 12S.S, 129.0, 
133.1, 133.7, 13S.6, l3S.6, 137.1, 13S.9, 144.S, 147.7, lSS.6, 
63. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(4-
bromo-N-methylphenylsulfonamido )-N-( 4-cyclo-
hexyl benzyl)acetamido )benzoate (SS) 
5 16S.2, 166.4; LRMS (ES+) calcd for [C43H43ClN20 6 S+Na] 





Secondary amine 46 was combined with 4-bromobenzene- 25 
1-sulfonyl chloride on a 0.2 mmol scale via General Proce-
dure G to furnish SS (123 mg, 9S%): OH (400 MHz, CDC13 ) 
1.24-1.3S (m, SH, CH2 ), 1.61-1.SO (m, SH, CH2), 2.34-2.46 
(m, lH, CH), 2.7S (s, 3H, CH3 ), 3.60 (s, 2H, CH2 ), 4.64 (s, 
2H, CH2 ), 4.S6 (s, 2H, CH2 ), S.27 (s, 2H, CH2 ), 6.40 (s, lH, 30 
CH), 6.SS (d, J=S.OHz, lH, CH), 6.91 (d, J=S.OHz, 2H, CH), 
7.03 (d, J=S.O Hz, 2H, CH), 7.1S-7.3S (m, lOH, CH), 7.49-
7.S4 (m, 4H, CH) 7.7S (d, J=S.O Hz, lH, CH); Oc (100 MHz, 
CDC13 ) 2S.9, 26.7, 34.3, 3S.S, 44.1, Sl.2, S2.S, 66.9, 70.6, 
114.1, 119.9, 120.S, 126.9, 130.0, 127.4, 127.9, 12S.1, 12S.2, 35 
12S.4, 12S.S, 12S.S, 12S.9, 132.0, 133.1, 133.7, 13S.6, l3S.7, 
137.7, 144.S, 147.7, lSS.6, l6S.2, 166.4; LRMS (ES+) calcd 
for [C43H43BrN2 0 6S+Na] S17.19 found S17.2S. 
6S. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzy 1)-2-( 4-fluoro-N-methy lpheny lsul-
fon-amido )acetamido )benzoate ( S7) 
C\ 
0 0 
Fu ~ I II° # 
s TIN // '-N 
0 
I a 
Secondary amine 46 was combined with 4-fluorobenzene-
1-sulfonyl chloride on a 0.1 mmol scale via General Proce-
dure G to furnish S7 (4S mg, 71%): 0~400 MHz, CDC13 ) 
1.33-1.42 (m, SH, CH2 ), 1.70-1.S6 (m, SH, CH2 ), 2.42-2.S2 
(m, lH, CH), 2.S4 (s, 3H, CH3 ), 3.70 (s, 2H, CH2 ), 4.74 (s, 
2H, CH2), 4.9S (s, 2H, CH2), S.3S (s, 2H, CH2), 6.49 (s, lH, 
CH), 6.67 ( dd, J=S.4 and 1.6 Hz, lH, CH), 7 .00 ( d, J=S.O Hz, 
2H, CH), 7.10-7.lS (m, 4H, CH), 7.29-7.3S (m, SH, CH), 
7.39-7.41(m,2H, CH), 7.7S-7.79 (m, 2H, CH), 7.S4 (d, J=S.O 
64. Preparation ofbenzyl 2-(benzyloxy)-4-(2-(4-
chloro-N-methylphenylsulfonamido )-N-( 4-cyclo-
hexyl benzyl)acetamido )benzoate (S6) 
Hz, lH, CH); Oc (100 MHz, CDC13 ) 26.0, 26.7, 34.4, 3S.S, 
44.1, Sl.3, S2.S, 67.0, 70.6, 114.1, l lS.S, 116.1, 120.0, 120.S, 
126.9, 127.0, 12S.O, 12S.2, 12S.2, 12S.S, 12S.S, 12S.S, 130.1, 
130.2, 133.1, 133.S, 134.7, 13S.7, l3S.7, 144.9, 147.7, lSS.7, 
40 




~ I II° # 
s TIN // '-N 
a I a 
55 
Secondary amine 46 was combined with 4-chlorobenzene-
sulfonyl chloride and on a 0.2 mmol scale via General Pro-
cedure G to furnish S6 (9S mg, 72%): oH(400 MHz, CDC13 ) 
1.3S-l.42 (m, SH, CH2 ), 1.71-1.S9 (m, SH, CH2), 2.42-2.S2 
(m, lH, CH), 2.SS (s, 3H, CH3 ), 3.70 (s, 2H, CH2 ), 4.74 (s, 
2H, CH2 ), 4.96 (s, 2H, CH2 ), S.36 (s, 2H, CH2 ), 6.SO (s, lH, 
CH), 6.6S (dd, J=S.4 and 1.6 Hz, lH, CH), 7.01 (d, J=S.4 Hz, 65 
2H, CH), 7.13 (d, J=S.O Hz, 2H, CH), 7.29-7.36 (m, SH, CH), 
7.39-7.4S (m, 4H, CH), 7.70 (d, J=S.4 Hz, 2H, CH), 7.S4 (d, 
[C43H43FN2 0 6 S+Na] 7S7.27 found 7S7.3S. 
66. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzyl )-2-( 4-methoxy-N-methy lpheny 1 
sulfonamido )acetamido )benzoate (SS) 
°' 0 0 
Secondary amine 46 was combined with 4-methoxybenze-
nesulfonyl chloride on a 0.1 mmol scale via General Proce-
dure G to furnish SS (S6 mg, 79%): OH (400 MHz, CDC13 ) 
US 8,846,707 B2 
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1.33-1.42 (m, SH, CH2 ), 1.S0-1.S6 (m, SH, CH2), 2.42-2.S l 
(m, lH, CH2 ), 2.Sl (s, 3H, CH3 ), 3.66 (s, 2H, CH2 ), 3.S4 (s, 
3H, CH3 ), 4.76 (s, 2H, CH2 ), 4.9S (s, 2H, CH2 ), S.3S (s, 2H, 
CH2 ), 6.S2 (s, lH, CH), 6.6S ( dd, J=S.O and 1.6 Hz, lH, CH), 5 
6.92 (d, J=S.S Hz, 2H, CH), 7.02 (d, J=S.O Hz, 2H, CH), 7.11 
(d, J=S.OHz, 2H, CH), 7.29-7.36 (m, SH, CH), 7.37-741. (m, 
2H, CH), 7.6S (d, J=S.S Hz, 2H, CH), 7.S4 (d, J=S.4 Hz, lH, 
CH); Oc(lOO MHz, CDC13 ) 26.0, 26.7, 34.4, 3S.4, 44.1, Sl.3, 10 
S2.7, SS.4, 66.9, 70.6, 113.9, 114.1, 120.0, 120.6, 126.9, 
127.0, 127.9, 12S.1, 12S.2, 12S.S, 12S.S, 12S.S, 129.6, 129.9, 
133.0, 133.9, 13S.7, l3S.7, l4S.O, 147.6, lSS.6, 162.7, 16S.3, 
166.S; LRMS (ES+) calcd for [C43H40F5 N20 6 S+H] S07.2S 15 
found S07.20. 





6S. Preparation ofbenzyl 2-(benzyloxy)-4-(N-(4-
cyclohexylbenzyl)-2-(2,3,4,S,6-pentafluoro-N-meth-
ylphenylsulfonamido )acetamido )benzoate (60) 
C? 9 
0 0 
I a ~ a 
I \ ~ 
F ~ F 
F 
Secondary amine 46 was combined with pentafluoroben-
zenesulfonyl chloride on a 0.1 mmol scale via General Pro-
cedure Gto furnish 60 (49 mg, 63%): oH(400 MHz, CDC13 ) 
1.34-1.42 (m, SH, CH2 ), 1.70-1.S6 (m, SH, CH2 ), 2.43-2.S2 
°' 0 0 
30 (m, lH, CH), 3.0S (s, 3H, CH3 ), 3.S6 (s, 2H, CH2 ), 4.67 (s, 
2H, CH2), 4.94 (s, 2H, CH2), S.3S (s, 2H, CH2), 6.44 (s, lH, 
CH), 6.66 ( d, J=S.O Hz, lH, CH), 6.96 ( d, J=7 .2 Hz, 2H, CH), 
7.12 (d, J=7.2 Hz, 2H, CH), 7.30-7.41 (m, lOH, CH), 7.S4 
( dd, J=S.O and 1.2 Hz, lH, CH); Oc (100 MHz, CDC13 ) 26.0, 
35 26.7, 34.4, 3S.4, 44.1, Sl.9, S2.7, 67.0, 70.70, 111.S, 114.0, 
llS.S, 119.9, 127.0, 127.1, 12S.1, 12S.2, 12S.S, 12S.6, 12S.7, 
133.3, 133.4, 13S.6, l3S.6, 137.S, 141.6, 142.9, 144.2, 147.9, 
lSS.7, l6S.2, 16S.S; LRMS (ES+) calcdfor [C44H46N20 7 S+ 
Na] 747.31 found 747.39. 
40 69. Preparation of 4-(N-(cyclohexylmethyl)-2(N,4-
dimethylphenylsulfonamido )acetamido )-2-hydroxy 
benzoic acid (27e) 
Benzyl protected 11 was globally deprotected on a O.OS 
45 mmol scale via General Procedure I to furnish 27e (34 mg, 
SS%): OH (400 MHz, dcDMSO) 1.02-1.11 (m, 3H, CH2), 
1.19-2.26 (m, 2H, CH2 ), 1.S3-1.64 (m, 6H, CH2 and CH), 
2.3S (s, 3H, CH3 ), 2.71 (s, 3H, CH3 ), 2.4S (d, J=7.2 Hz, 2H, 
Secondary amine 46 was combined with 4-nitrobenzene-
50 
sulfonyl chloride on a 0.2 mmol scale via General Procedure 
G to furnish S9 (SS mg, 69%): OH (400 MHz, CDC13 ) 1.33-
1.42 (m, SH, CH2), 1.70-1.S9 (m, SH, CH2), 2.43-2.S 1 (m, 
lH, CH), 2.90 (s, 3H, CH3 ), 3.7S (s, 2H, CH2 ), 4.70 (s, 2H, 55 
CH2 ), 4.70 (s, 2H, CH2), S.36 (s, 2H, CH2), 6.49 (s, lH, CH), 
6.6S (dd, J=S.O and 1.6 Hz, lH, CH), 6.97 (d, J=S.4 Hz, 2H, 
CH), 7.13 (d, J=S.O Hz, 2H, CH), 7.2S-7.37 (m, SH, CH), 
7.39-7.42 (m, 2H, CH), 7.SS (d, J=S.O Hz, lH, CH), 7.9S (d, 
60 
J=S.S Hz, 2H, CH), S.30 ( d, J=S.S Hz, 2H, CH); Oc (100 MHz, 
CDC13 ) 2S.9, 26.7, 34.3, 3S.S, 44.1, Sl.4, S2.S, 67.0, 70.6, 
114.0, 119.9, 121.0, 123.9, 12S.O, 12S.2, 12S.2, 12S.S, 12S.S, 
12S.6, 12S.S, 133.2, 133.6, 13S.6, 13S.6, 144.S, 144.7, 147.9, 65 
149.S, lSS.6, l6S.2, 166.1; LRMS (ES+) calcd for 
CH2), 3.74 (s, 2H, CH2 ), S.73 (s, 2H, CH20, 6.S3 (d, J=S.4 
Hz, lH, CH), 6.91 (s, lH, CH), 7.33 (d, J=S.O Hz, 2H, CH), 
7.S2 (d, J=S.4 Hz, 2H, CH), 7.S2 (d, J=S.4 Hz, lH, CH); oc 
(lOOMHz, dcDMSO) 20.9, 2S.2, 2S.9, 30.0, 3S.6, 3S.S, S0.9, 
S4.l, 112.6, 116.2, llS.7, 126.9, 129.6, 131.S, 13S.1, 143.0, 
147.4, 161.S, 166.3, 171.2; HRMS (ES+) calcd for 
[C24H30N20 6 S+H] 47S.1S97. found 47S.190S; HPLC (III) 
tR=lS.62 min (90.SS%), (IV) tR=40.70 min (90.17%). 
70. Preparation of 4-(2-(N,4-dimethylphenylsulfona-
mido )-N-(piperidin-4-ylmethyl)acetamido )-2-hy-
droxybenzoic acid (27ja) 
Benzyl protected 13 was globally deprotected on a 0.10 
mmol scale via General Procedure I to furnish 27ja (SS mg, 
9S%): OH (400 MHz, dcDMSO) 1.20-1.37 (m, 2H, CH2), 
1.61-1.SO (m, 2H, CH2 ), 2.32 (s, 3H, CH3 ), 2.71-2.73 (m, 4H, 
CH3 and CH), 2.77 (t, J=12.0 Hz, 2H, CH2 ), 3.24 (d, J=l0.4 
Hz, 2H, CH2), 3.4S (d, J=6.S Hz, 2H, CH2), 3.71(s,2H, CH2), 
6.SS (dd, J=S.4 and 2.0 Hz, lH, CH), 6.63 (d, J=2.0 Hz, lH, 
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CH), 7.32 (d, J=8.0Hz, 2H, CH), 7.Sl (d, J=8.0Hz, 2H, CH), 
7.73 (d, J=8.0Hz, lH, CH); oc(lOOMHz, CDC13 ) 21.3, 26.4, 
32.2, 39.2, 43.0, 48.9, Sl.O, S3.l, llS.6, llS.8, 120.2, 127.2, 
129.9, 131.4, 131.4, 13S.6, 143.4, 143.9, 164.3, 167.0, 171.3; 
HRMS (ES+) calcd for [C23H29N3 0 6 S+HJ 476.1849. found 5 
476.18SO; HPLC (I) tR=l4.74 min (98.61%), (H) tR=26.80 
min (100%). 
264 
93%): OH (400 MHz, dcDMSO) 1.61-1.7S (m, 2H, CH2 ), 
1.96-2.00 (m, 2H, CH2 ) 2.40 (s, 3H, CH3 ), 2.82-2.87 (m, SH, 
CH3 and CH2 ), 3.2S (t, J=12.4 Hz, lH, CH2 ), 3.84 (s, 2H, 
CH2 ), 4.13 (d, J=12.4 Hz, lH, CH2 ), 4.69 (d, J=13.2 Hz, lH, 
CH2 ), 4.84 (s, 2H, CH2 ), 6.61 (d, J=8.4 Hz, lH, CH), 6.69 (s, 
lH, CH), 7.09-7.lS (m, 4H, CH), 7.27 (d, J=7.2 Hz, 2H, CH), 
7.64 (d, J=8.4 Hz, 2H, CH), 7.89 (d, J=8.4 Hz, lH, CH); Oc 
(100 MHz, CDC13 ) 21.4, 32.4, 33.4, 3S.8, 41.8, 44.1, 46.2, 
Sl.S, S2.8, S3.3, llS.O, 116.8, 118.9, 126.8, 127.4, 128.8, 
71. Preparation of 4-(N-((1-(tert-butoxycarbonyl) 
piperidin-4-yl)methyl)-2-(N,4-dimethylphenylsulfon 
amido) acetamido )-2-hydroxybenzoic acid (27jb) 
lO 129.4, 132.2, 134.6, 134.8, 143.4, 143.7, 147.3, lSS.2, lSS.6, 
162.8, 167.1, 172.0; HRMS (ES+) calcdfor [C31H32N30 7 S+ 
HJ 648.198S. found 648.1974; HPLC (I) tR=2l.S2 min 
(9S.8S%), (II) tR=4S.49 min (97.12%). 
Benzyl protected 14 was globally deprotected on a 0.10 
mmol scale via General Procedure I to furnish 27jb (S2 mg, 
93%): oH(400 MHz, CDC13 ) 1.44 (s, 9H, 3 CH3 ), 1.S8-1.78 
(m, 2H, CH2 ), 2.39 (s, 3H, CH3 Ar), 2.63-2.70 (m, 2H, CH2 ), 15 2.82 (s, 4H, CH3 and CH), 3.S9 (s (br), 2H, CH2 ), 3.81 (s, 2H, 
CH2 ), 4.06 (s br, 2H, CH2 ), 6.7S (d, J=8.2 Hz, lH, CH (Ar)), 
6.81 (br s, lH, CH (Ar)), 7.26 (d, J=8.2 Hz, 2H, 2 CH (Ar)), 
7.63 (d, J=8.2 Hz, 2H, 2 CH (Ar)), 7.98 (d, J=8.3 Hz, lH, CH 
(Ar)); oc(lOO MHz, CDC13 ) 21.4, 28.4, 29.6, 34.6, 3S.9, Sl .S, 
S4.8, 80.0, 112.2, 116.S, 118.S, 127.4, 129.S, 132.S, 13S.1, 20 
143.4, 147.8, lSS.O, 163.0, 167.4, 171.9; HRMS (ES+) calcd 
for [C28H37N3 0 8S+NaJ S98.2193. found S98.2177; HPLC 
(I) tR=19.33 min (98.24%), (H) tR=39.6S min (97.61 %). 
72. Preparation of 4-(N-(1-(4-cyanophenyl)piperi-
din-4-yl)methyl)-2-(N,4-dimethylphenylsulfona-
mido )acetamido )-2-hydroxybenzoic acid (27jc) 
7S. Preparation of 4-(2-(N,4-dimethylphenylsulfona-
mido )-N-( 4-(piperidin-4-yl)benzyl)acetamido )-2-
hydroxybenzoic acid (27kb) 
Benzyl protected 21 was globally deprotected on a 0.07 
mmol scale via General Procedure I to furnish 27kb ( 43 mg, 
86%): OH (400 MHz, dcDMSO) 1.63-1.78 (m, 2H, CH2 ), 
1.86-2.40 (m, 2H, CH2 ), 2.29-2.33 (m, lH, CH), 2.34 (s, 3H, 
CH3 ), 2.73-2.80 (m, SH, CH3 and CH2 ), 2.90-3.02 (m, 2H, 
25 CH2 ), 3.81(s,2H, CH2 ), 4.77 (s, 2H, CH2 ), 6.63 (d, J=7.2 Hz, 
lH, CH), 6.69 (s, lH, CH), 7.12 (s (br), 4H, CH), 7.33 (d, 
J=8.0Hz, 2H, CH), 7.Sl (d, J=8.0Hz, 2H, CH), 7.70 (d, J=8.0 
Hz, lH, CH); HRMS (ES+) calcd for [C29H33N3 0 6S+HJ 
SS2.2l62. found SS2.2149; HPLC (IR) tR=l 7.99 min 
Benzyl protected lS was globally deprotected on a 0.09 
mmol scale via General Procedure I to furnish 27jc (SO mg, 
9S%): oH(400 MHz, CDC13 ) 1.2S-l.41(m,2H, CH2 ), 1.70-
1.89 (m, 2H, CH2 ), 2.39 (s, 3H, CH3Ar), 2.80-2.90 (m, 6H, 
CH, CH2 and CH3 ), 3.6S (d, J=6.7 Hz, 2H, CH2CH), 3.S9-
3.91 (m, 4H, CH2 ), 6.77-6.90 (m, 4H, 4 CH (Ar)), 7.27 (d, 
J=8.6 Hz, 2H, 2 CH (Ar)), 7.4S (d, J=8.6 Hz, 2H, 2 CH (Ar)), 
7.63 (d, J=8.6 Hz, 2H, 2 CH (Ar)), 8.00 (d, J=8.2 Hz, lH, CH 
35 
(Ar)); oc(lOO MHz, CDC13 ) 21.S, 28.9, 34.S, 36.0, 47.3, Sl .7, 
S4.7, 99.3, 111.9, 114.3, 116.7, 118.7, 120.0, 127.4, 129.S, 
132.6, 133.S, 134.9, 143.S, 148.0, 1S3.0, 163.1, 167.6, 172.2; 
HRMS (ES+) calcd for [C30H32N4 0 6 S+HJ S77.211S. found 
477.2093; HPLC (I) tR=20.91 min (98.2S%), (II) tR=43.S2 
min (98.91%). 
30 (71.92%), (IV) tR=3S.S8 min (71.04%). 
76. Preparation of 4-(N-(4-(1-(tert-butoxycarbonyl) 
piperidin-4-yl)benzyl)-2-(N,4-dimethylphenylsulfon-
amido )acetamido )-2-hydroxybenzoic acid (27kc) 
Benzyl protected 22 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27kc (S8 mg, 
89%): OH (400 MHz, d6-DMSO) 1.38-1.39 (m, 2H, CH2 ), 
1.39 (s, 9H, CH3 ), 1.69 (s, 2H, CH2 ), 1.72 (s, lH, CH2 ), 2.36 
40 (s (br), 2H, CH2 ), 2.7S-2.79 (m, SH, CH3 and CH2 ), 4.0S (s, 
2H, CH2 ), 4.80 (s, 2H, CH2 ), 6.79 (dd, J=8.4 and 2.0 Hz, lH, 
CH), 6.87 ( d, J=2.0 Hz, lH, CH), 7 .08 ( d, J=8.0 Hz, 2H, CH), 
7.lS (d, J=8.4 Hz, 2H, CH), 7.3S (d, J=8.0 Hz, 2H, CH), 7.S4 
(d, J=8.4 Hz, 2H, CH), 7.77 (d, J=8.4 Hz, lH, CH); Oc (100 
73. Preparation of 4-(2(N,4-dimethylphenylsulfona-
mido )-N-( (1-(pyrimidin-2-yl)piperidin-4-yl)methyl) 
acetamido )-2-hydroxybenzoic acid (27jd) 
Benzyl protected 16 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27jd ( 41 mg, 
92%): OH (400 MHz, dcDMSO) 1.60-1.73 (m, 3H, CH2 ), 
2.34 (s, 3H, CH3Ar), 2.46-2.48 (m, 2H, CH2 ), 2.74 (s, 3H, 
CH3 N), 2.80 (t, J=12.0 Hz, lH, CH2 ), 3.S2 (d, J=7.0 Hz, 2H, 
CH2 CH), 3.79 (s, 2H, CH2 ), 4.S7 (d, J=13.0 Hz, 2H, CH2 ), 
6.S7 (t, J=4.7 Hz, lH, CH (Ar)), 6.93 (dd, J=8.4 and 2.0 Hz, 
lH, CH (Ar)), 7.02 (d, J=2.0 Hz, lH, CH (Ar)), 7.3S (d, J=8.4 
Hz, 2H, 2 CH (Ar)), 7.SS (d, J=8.2 Hz, 2H, 2 CH (Ar)), 7.86 
45 MHz, CDC13 ), 21.4, 28.3, 29.S, 29.8, 30.2, 32.9, 3S.8, 42.1, 
44.3, Sl.4, S2.8, 79.9, 114.2, 116.6, 118.7, 126.8, 127.4, 
128.6, 129.4, 132.1, 134.2, 13S.1, 143.3, 14S.O, 146.8, lSS.O, 
162.7, 166.9, 171.9; HRMS (ES+) calcd for [C34H41 N30 8 S+ 
HJ 6S2.2687. found 6S2.26S8; HPLC (1) tR=23.6S min 
50 (66.Sl %), (II) tR=S0.00 min (74.40%). 
77. Preparation of 4-(2-(N,4-dimethylphenylsulfona-
mido )-N-( 4-(1-(pyrimidin-2-yl)piperidin-4-yl)ben-
zyl)-acetamido )-2-hydroxybenzoic acid (27ke) (d, J=8.4 Hz, lH, CH (Ar)), 8.32 (d, J=4.7Hz, 2H, 2CH (Ar)); 
Benzyl protected 23 was globally deprotected on a 0.07 
mmol scale via General Procedure I to furnish 27ke (Sl mg, 
90%): oH(400 MHz, CDC13 ) l.6S-l.67 (m, 2H, CH2 ), 1.91-
2.03 (m, 2H, CH2 ), 2.30-2.32 (m, lH, CH), 2.39 (s, 3H, CH3 ), 
Oc (100 MHz, d6-DMSO) 21.4, 29.6, 3S.9, 44.1, Sl.S, S3.3, 
55 
S4.9, 109.3, 113.4, 116.3, 118.4, 127.4, 129.S, 132.S, l3S.2, 
143.4, 147.4, 1S7.6, lS9.9, 163.0, 167.4, 172.3; HRMS (ES+) 
calcd for [C27H31N50 6 S+HJ SS4.2067. found SS4.20S8; 
HPLC (I) tR=23.04 min (100.00%), (II) tR=31.37 min 
(98.S4%). 60 2.76-2.79 (m, 2H, CH2 ), 2.8S (s, 3H, CH3 ), 2.97-3.0S (m, 2H, 
CH2 ), 3.83 (s, 2H, CH2 ), 4.80 (s, 2H, CH2 ), 6.48-6.S9 (m, 2H, 
CH), 6.68 (s, lH, CH), 7.04-7.14 (m, 4H, CH), 7.28 (d, J=7.2 
Hz, 2H, CH), 7.6S (d, J=7.2 Hz, 2H, CH), 7.8S (s, lH, CH), 
8.39-8.SO (m, 3H, CH); Oc (100 MHz, CDC13 ) 21.S, 32.7, 
74. Preparation of 4-(2-(N,4-dimethylphenylsulfona-
mido )-N-( 4-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl) 
benzyl)acetamido)-2-hydroxybenzoic acid (27ka) 
Benzyl protected 20 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27ka (SO mg, 
65 3S.9, 41.9, 4S.8, Sl.8, S3.l, 109.0, 112.4, 116.8, 119.0, 122.8, 
126.9, 127.6, 129.0, 129.S, 132.1, 134.8, 13S.3, 137.6, 143.S, 
144.0, 1S2.2, lS7.0, lS9.2, 161.S, 167.0, 171.S; HRMS (ES+) 
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calcd for [C33H35N50 6 S+H] 630.2380. found 630.2379; 
HPLC (I) tR=l8.68 min (100%), (II) tR=37.21 min (9S.91 %). 
78. Preparation of 4-(N-(4-(1-(4-cyanobenzoyl)pip-
eridin-4-yl)benzyl)-2-(N,4-dimethylphenylsulfon-
amido )acetamido )-2-hydroxybenzoic acid (27kf) 
Benzyl protected 24 was globally deprotected on a 0.07 
mmol scale via General Procedure I to furnish 27kf ( 41 mg, 
87%): oH(400MHz, CDC13 ) 1.60-2.03 (m, 4H, CH2 ), 2.39 (s, 
3H, CH3 ), 2.73-2.96 (m, SH, CH2 and CH3 ), 3.11-3.2S (m, 
lH, CH), 3.72(d,1=8.0Hz, 2H, CH2 ), 3.82 (s, 2H, CH2 ), 4.82 
(s, 2H, CH2 ), 6.S8(d,1=8.0 Hz, lH, CH), 7.11 (s br, 4H, CH), 
7.26(d,1=8.0 Hz, 2H, CH), 7.SS (d, 1=7.6 Hz, 2H, CH), 7.64 
266 
90%): OH (400 MHz, dcDMSO) 1.66-1.80 (m, 2H, CH2 ), 
1.82-1.91 (m, 2H, CH2 ), 2.33 (s, 3H, CH3 ), 2.S8-2.68 (m, lH, 
CH), 2.77 (s, 3H, CH3 ), 2.86(t,1=12.0 Hz, 2H, CH2 ), 3.72 (s, 
2H, CH2 ), 3.89 (d, 1=12.0 Hz, 2H, CH2 ), 4.7S (s, 2H, CH2 ), 
5 6.49 (d, 1=7.2 Hz, lH, CH), 6.S8 (s, lH, CH), 6.87 (d, 1=8.8 
Hz, 2H, CH), 7.00-7.09 (m, 4H, CH), 7.20 (d, 1=8.0 Hz, lH, 
CH), 7.S4(d,1=8.0 Hz, lH, CH), 7.67(d,1=8.4 Hz, 2H, CH), 
7.80 (d, 1=8.0 Hz, lH, CH); oc (100 MHz, d6 -DMSO) 21.2, 
29.4, 32.S, 3S.7, 41.9, Sl.3, S2.7, 114.1, 116.4, 118.6, 121.6, 
lO 126.7, 127.2, 128.S, 128.9, 129.4, 132.0, 134.2, 134.9, 143.4, 
144.9, 146.S, lS0.2, lS3.6, 162.4, 166.8, 169.2, 171.3; 
HRMS (ES+) calcd for [C36H38N4 0 7 S+H] 671.2S33. found 
67l .2S4S; HPLC (III) tR=l 7.72 min (84.23%), (IV) tR=24.81 
min (74.07%). (d, 1=8.0 Hz, 2H, CH), 7.73 (d, 1=8.4 Hz, 2H, CH), 7.8S (d, 
1=7.6 Hz, lH, CH); Oc (100 MHz, CDC13 ) 21.4, 29.S, 32.S, 15 
33.7, 3S.8, 42.0, 43.0, 48.3, Sl.S, S2.8, 113.S, 116.8, 117.9, 
118.8, 126.7, 127.4, 127.S, 128.7, 129.4, 132.1, 132.4, 134.7, 
l3S.O, 139.9, 143.4, 147.2, 162.7, 167.0, 168.6, 170.2; 
HRMS (ES+) calcd for [C37H36N4 0 7 S+H] 681.2377. found 
681.236S; HPLC (I) tR=20.49 min (99.7S%), (II) tR=42.0S 20 
min (100%). 
82. Preparation of 4-(2(N,4-dimethylphenylsulfona-
mido )-N-( (3 '-( methoxycarbony l)biphenyl-4-y 1 )me-
thyl) acetamido )-2-hydroxybenzoic acid (27la) 
Benzyl protected 28 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27la (39 mg, 
81%): oH(400 MHz, CDC13 ) 2.36 (s, 3H, CH3 ), 2.78 (s, 3H, 
CH3 ), 3.87 (s, 3H, CH3 ), 3.88 (s, 2H, CH2 ), 4.90 (s, 2H, CH2 ), 
6.82 (dd, 1=8.4 and 2.0 Hz, lH, CH), 6.92 (d, 1=2.0 Hz, lH, 
79. Preparation of 4-(N-( 4-(1-(( 4-cyanophenyl)sulfo-
nyl)piperidin-4-yl)benzyl)-2-(N,4-dimethylphenyl-
sulfonamido )acetamido )-2-hydroxybenzoic acid 
(27kg) 
Benzyl protected 2S was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27kg (S2 mg, 
93%): OH (400 MHz, dcDMSO) 2.00-2.24 (m, 4H, CH2 ), 
2.66-2.78 (m, 6H, CH3 , CHandCH2 ), 3.lS (s, 3H, CH3 ), 4.13 
(s, 2H, CH2 ), 4.24-4.27 (m, 2H, CH2 ), S.12 (s, 2H, CH2 ), 6.88 
25 CH), 7.29(d,1=8.0 Hz, 2H, CH), 7.36(d,1=8.0Hz, 2H, CH), 
7.S6 (d, 1=8.0 Hz, 2H, CH), 7.69 (t, 1=8.0 Hz, lH, CH), 7.64 
(d, 1=8.0 Hz, 2H, CH), 7.78(d,1=8.4 Hz, lH, CH), 7.93 (dd, 
1=7.6 and 1.6 Hz, 2H, CH), 8.16 (t, l=l.6 Hz, lH, CH); Oc 
(100 MHz, CDC13 ) 21.4, 3S.9, Sl.S, S2.l, S2.8, 116.6, 117.8, 
30 118.7, 127.2, 127.S, 128.1, 128.3, 128.8, 129.1, 129.4, 130.S, 
131.4, 132.2, l3S.4, 136.0, 139.4, 140.8, 143.3, 146.7, 162.9, 
163.0, 167.0, 171.8; HRMS (ES+) calcdfor [C32H31N20 8 S+ 
HJ 603.1800. found 603.179S; HPLC (I) tR=23.6S mm 
(100.0%), (II) tR=48.73 min (100.0%). 
(d, 1=8.0 Hz, lH, CH), 6.97 (s, lH, CH), 7.44 (d, 1=8.0 Hz, 
2H, CH), 7.40 (d, 1=8.0 Hz, 2H, CH), 7.S7 (d, 1=8.0 Hz, 2H, 
CH), 7.94 (d, 1=8.0 Hz, 2H, CH), 8.lS-8.24 (m, SH, CH); Oc 
(100 MHz, dcDMSO) 21.4, 32.3, 3S.8, 37.0, 41.2, 46.6, Sl.S, 35 
S2.8, 116.3, 116.7, 116.8, 117.1, 118.7, 126.7, 127.4, 128.1, 
128.7, 129.4, 132.2, 132.8, 134.7, 13S.O, 140.7, 143.4, 143.8, 
147.0, 162.7, 167.0, 170.6; HRMS (ES+) calcd for 
[C36H36N4 0 8 S+H] 717.2047. found 717.2036; HPLC (I) 
tR=22.0l min (94.07%), (II) tR=46.38 min (100%). 40 
83. Preparation of 4-(N-((3'-cyanobiphenyl-4-yl) 
methyl)-2-(N,4-dimethylphenylsulfonamido) aceta-
mido )-2-hydroxybenzoic acid (27lb) 
Benzyl protected 29 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27lb ( 40 mg, 
90%): oH(400 MHz, CDC13 ) 2.37 (s, 3H, CH3 ), 2.80 (s, 3H, 
CH3 ), 3.90 (s, 2H, CH2 ), 4.91 (s, 2H, CH2 ), 6.84 (dd, 1=8.4 
and 1.6 Hz, lH, CH), 6.93 (s, lH, CH), 7 .30 ( d, 1=8.0 Hz, 2H, 
80. Preparation of 4-(N-( 4-(1-( 4-carboxyphenyl) 
piperidin-4-yl)benzyl)-2-(N,4-dimethylphenylsul-
fonamido) acetamido )-2-hydroxybenzoic acid (27kh) 
Benzyl protected 26 was globally deprotected on a O.OS 
mmol scale via General Procedure I to furnish 27kh (2S mg, 
81%): OH (400 MHz, dcDMSO) 1.S8-1.73 (m, 2H, CH2 ), 
1.82 (d, 1=12.8 Hz, 2H, CH2 ), 2.3S (s, 3H, CH3 ), 2.69-2.79 
(m, 4H, CH3 and CH), 2.90 (t, 1=11.2 Hz, 2H, CH2 ), 3.84 (s, 
2H, CH2 ), 4.80(s, 2H, CH2 ), 6.79(d,1=8.4Hz, lH, CH), 6.87 
45 CH), 7.37(d,1=8.0 Hz, 2H, CH), 7.S7(d,1=8.0Hz, 2H, CH), 
7.6S (t, 1=8.0 Hz, lH, CH), 7.70 (d, 1=8.0 Hz, 2H, CH), 7.80 
(t, 1=8.0Hz, 2H, CH), 8.02(d,1=8.0Hz, lH, CH), 8.lS (s, lH, 
CH); Oc (100 MHz, CDC13 ) 20.8, 3S.8, S0.8, Sl.4, 112.0, 
116.0, 118.4, 118.7, 120.0, 126.8, 126.9, 128.3, 128.S, 129.S, 
50 130.0, 130.9, 131.2, 131.3, 13S.O, 136.7, 137.1, 140.6, 143.0, 
146.6, 161.6, 166.7, 171.0; HRMS (ES+) calcd for 
[C31H28N30 6 S+H] S70.1696. found S70.1693; HPLC (I) 
tR=22.84 min (98.3%), (II) tR=47.61 min (98.43%). 
(s, lH, CH), 6.99 (d, 1=8.8 Hz, 2H, CH), 7.09 (d, 1=8.0 Hz, 
2H, CH), 7.18 (d, 1=8.0 Hz, 2H, CH), 7.3S (d, 1=8.0 Hz, 2H, 
CH), 7.S4(d,1=8.0Hz, 2H, CH), 7.76(d,1=8.8 Hz, 2H, CH), 
7.78(d,1=8.4 Hz, lH, CH); oc(lOOMHz, CDC13 ) 21.3; 32.S, 
36.2, 41.4, 48.1, 48.9, Sl.3, S2.0, 113.9, 116.S, 119.0, 119.3, 55 
121.8, 127.0, 127.3, 128.0, 129.9, 131.3, 131.7, 13S.O, l3S.4, 
143.S, 14S.1, 147.S, 1S3.9, 161.9, 167.0, 167.6, 171.S; 
HRMS (ES+) calcd for [C36H37N3 0 8 S+H] 672.2374. found 
672.2372; HPLC (III) tR=l9.l 7 min (82.84%), (IV) tR=39.60 
min (90.47%). 
84. Preparation of 4-(N-((3'-carbamoylbiphenyl-4-yl) 
methyl)-2-(N,4-dimethylphenylsulfonamido) aceta-
mido )-2-hydroxybenzoic acid (27lc) 
Benzyl protected 30 was globally deprotected on a 0.07 
60 mmol scale via General Procedure I to furnish 27lc ( 40 mg, 
92%): OH (400 MHz, d6 -DMSO) 2.37 (s, 3H, CH3 ), 2.80 (s, 
3H, CH3 ), 3.90 (s, 2H, CH2 ), 4.91 (s, 2H, CH2 ), 6.84 (dd, 
1=8.4Hz,1=2.0 Hz, lH, CH), 6.93(d,1=2 Hz, lH, CH), 7.29 
(d, 1=8.0 Hz, 2H, CH), 7.37 (d, 1=8.4 Hz, 2H, CH), 7.42 (s, 
81. Preparation of 4-(N-( 4-(1-( 4-carbamoylphenyl) 
piperidin-4-yl)benzyl)-2-(N,4-dimethylphenylsulfon 
amido) acetamido )-2-hydroxybenzoic acid (27ki) 
Benzyl protected 61 was globally deprotected on a 0.07 
mmol scale via General Procedure I to furnish 27ki (22 mg, 
65 lH, CH), 7.Sl-7.S8 (m, 3H, CH), 7.77(d,1=8.0Hz, 2H, CH), 
7.78-7.8S (m, 3H, CH), 8.09 (s, lH, CH), 8.14 (s, lH, CH); Oc 
(100 MHz, CDC13 ) 20.6, 3S.6, SO.SS, Sl.3, 114.1, l lS.S, 
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83%): OH (400 MHz, dcDMSO) 2.37 (s, 3H, CH3 ), 2.79 (s, 
3H, CH3 ), 3.89 (s, 2H, CH2 ), 4.90 (s, 2H, CH2 ), 6.83 (dd, 
J=8.4 Hzand2.0Hz, lH, CH), 6.92 (d, J=2 Hz, lH, CH), 7.28 
(d, J=7.6 Hz, 2H, CH), 7.37, d, J=8.0 Hz, CH), 7.56 (d, J=8.0 
117.1, 125.2, 126.3, 126.32, 126.6, 128.1, 128.8, 128.9, 
129.3, 130.9, 134.6, 134.8, 136.3, 138.1, 139.3, 142.8, 156.9, 
162.1, 166.5, 167.4, 170.7; HRMS (ES+) calcd for 
[C31 H30N30 7 S+H] 588.1794. found 588.1794; HPLC (I) 
tR=l 7.05 min (100%), (II) tR=39.80 min (98.94%). 
85. Preparation of 4-(2-(N,4-dimethylphenylsulfona-
mido )-N-( ( 4'-(methoxycarbonyl)biphenyl-4-yl)me-
thyl) acetamido )-2-hydroxybenzoic acid (27ld) 
5 Hz, 2H, CH), 7.67 (d, J=8.0 Hz, 2H, CH), 7.74 (d, J=8.4 Hz, 
2H, CH), 7.79 (d, J=8.4 Hz, lH, CH), 7.94 (d, J=8.4 Hz, 2H, 
CH), 8.01 (s, lH, OH); Oc (100 MHz, dcDMSO) 21.2, 36.2, 
51.1, 52.0, 116.0, 117.2, 120.4, 126.6, 127.1, 127.2, 128.4, 
128.7, 129.9, 131.4, 133.3, 135.5, 137.3, 138.3, 142.5, 143.4, 
10 163.0, 167.1, 167.8, 171.2, 172.3; HRMS (ES+) calcd for 
[C31H30N30 7 S+H] 588.1789. found 588.1798; HPLC (I) 
tR=l9.49 min (91.83%), (II) tR=40.09 min (98.42%). 
Benzyl protected 31 was globally deprotected on a 0.06 
mmol scale via General Procedure I to furnish 27ld (34 mg, 
93%): oH(400 MHz, CDC13 ) 2.40 (s, 3H, CH3 ), 2.87 (s, 3H, 
CH3 ), 3.87 (s, 2H, CH2 ), 3.94 (s, 3H, CH3 ), 4.91(s,2H, CH2 ), 
6.64 (d, J=7.6, lH, CH), 6.74 (d, J=l.2 Hz, lH, CH), 7.25-
7.28 (m, 3H, CH), 7.53 (d, J=8.4 Hz, 2H, CH), 7.63 (d, J=8.4 15 
Hz, 2H, CH), 7.66 (d, J=8.4 Hz, 2H, CH), 7.90 (d, J=8.4 Hz, 
lH, CH), 8.09 ( d, J=8.4 Hz, 2H, CH); Oc (100 MHz, CDC13 ) 
21.5, 35.9, 51.6, 52.1, 52.9, 116.9, 117.0, 119.0 126.9, 127.4, 
127.5, 128.9, 129.1, 129.5, 130.1, 132.4, 135.1, 136.3, 139.4, 
143.5, 144.9, 147.5, 162.9, 167.0, 167.2, 171.2; HRMS (ES+) 20 
calcd for [C32H31N20 8 S+H] 603.1816. found 603.1795; 
HPLC (I) tR=23.76 min (99.37%), (II) tR=48.78 min 
(100.0%). 
89. Preparation of 4-(2-(N,4-dimethylphenylsulfona-
mido )-N-( (3 '-(methoxycarbonyl )terpheny 1-4-yl )me-
thyl )-acetamido )-2-hydroxybenzoic acid (27na) 
Benzyl protected 35 was globally deprotected on a 0.06 
mmol scale via General Procedure I to furnish 27na (42 mg, 
100%): oH(400 MHz, dcDMSO) 2.36 (s, 3H, CH3 ), 2.81 (s, 
3H, CH3 ), 4.90 (s, 2H, CH2 ), 6.80 (d, lH, J=8.4Hz, CH), 6.89 
(s, lH, CH), 7.29 (d, J=8.4 Hz, 2H, CH), 7.36 (d, J=8.0 Hz, 
2H, CH), 7.61-7.67 (m, SH, CH), 7.76-7.79 (m, 4H, CH), 7.96 
(d, J=7.6 Hz, lH, CH), 8.00 (d, J=8.0 Hz, lH, CH), 8.24 (s, 86. Preparation of 4'-((N-( 4-carboxy-3-hydroxyphe-
nyl)-2-(N,4-dimethylphenylsulfonamido) acetamido) 
methyl)-[1,1 '-biphenyl]-4-carboxylic acid (27le) 
25 lH, CH), 8.32 (s, lH, CH); Oc (100 MHz, dcDMSO) 20.8, 
35.8, 50.8, 51.5, 52.1, 115.9, 117.4, 118.1, 126.4, 126.8, 
127.1, 127.2, 127.3, 127.8, 128.0, 128.3, 129.4, 129.5, 130.3, 
131.2, 135.0, 136.3, 137.8, 138.1, 139.1, 139.9, 143.0, 146.3, Benzyl protected 32 was globally deprotected on a 0.1 
mmol scale via General Procedure I to furnish 27le (51 mg, 
87%): OH (400 MHz, dcDMSO) 2.37 (s, 3H, CH3 ), 2.80 (s, 
30 
3H, CH3 ), 3.88 (s, 2H, CH2 ), 4.89 (s, 2H, CH2 ), 6.72 (dd, 
J=8.4 Hz and 1.6 Hz, lH, CH), 6.81 (d, J=l.6 Hz, lH, CH), 
7.30 (d, J=8.4 Hz, 2H, CH), 7.37 (d, J=8.0 Hz, 2H, CH), 7.56 
(d, J=8.4 Hz, 2H, CH), 7.68 (d, J=8.4 Hz, 2H, CH), 7.75 (d, 
J=8.4 Hz, lH, CH), 7.79 (d, J=8.4 Hz, 2H, CH), 8.00 (d, J=8.4 35 
Hz, 2H, CH); oc(lOOMHz, d6-DMS0)20.8, 35.8, 50.8, 51.5, 
115.8, 117.6, 118.1, 126.5, 126.8, 126.8, 128.3, 129.4, 129.5, 
129.8, 131.1, 135.0, 137.1, 137.7, 143.0, 143.7, 145.8, 162.2, 
166.6, 167.0; HRMS (ES+) calcd for [C31H29N2 0 8S+H] 
589.1628. found 589.1639; HPLC (I) tR=20.29 min 40 
(98.59%), (H) tR=4l.50 min (98.69%). 
161.8, 166.0, 166.7, 171.0; HRMS (ES+) calcd for 
[C37H32N20 8 S+H] 679.2108. Found 679.2080; HPLC (I) 
tR=23.34 min (96.76%), (H) tR=S0.50 min (98.76%). 
90. Preparation of 4'-((N-( 4-carboxy-3-hydroxyphe-
nyl)-2-(N,4-dimethylphenylsulfonamido )acetamido) 
methyl)terphenyl-3-carboxylic acid (27nb) 
Benzyl protected 36 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27nb ( 46 mg, 
87%): OH (400 MHz, dcDMSO) 2.37 (s, 3H, CH3 ), 2.80 (s, 
3H, CH3 ), 3.87 (s, 2H, CH2 ), 4.87 (s, 2H, CH2 ), 6.68 (dd, 
J=8.4 and 1.2 Hz, lH, CH), 6.76 (d, J=l.2 Hz, lH, CH), 7.29 
(d, J=8.0 Hz, 2H, CH), 7.37 (d, J=8.0 Hz, 2H, CH), 7.56 (d, 
J=8.0 Hz, 2H, CH), 7 .62 (t, J=8.0 Hz, 2H, CH), 7.68 ( d, J=8.0 
Hz, lH, CH), 7.73 (d, J=8.0 Hz, lH, CH), 7.79 (s, 4H, CH), 
87. Preparation of 4-(N-((4'-cyanobiphenyl-4-yl) 
methyl)-2-(N,4-dimethylphenylsulfonamido )aceta-
mido )-2-hydroxybenzoic acid (27lf) 45 7.94 (d, J=8.0 Hz, lH, CH) 7.98 (d, J=8.0 Hz, lH, CH), 8.23 
(s, lH, CH); Oc (100 MHz, dcDMSO) 20.6, 35.8, 50.8, 51.5, 
113.0, 116.0, 118.3, 126.4, 126.9, 127.0, 127.1, 127.2, 128.2, 
128.3, 129.2, 129.5, 130.8, 131.3, 131.4, 135.0, 136.3, 138.0, 
138.2, 138.9, 139.8, 143.0, 146.6, 161.7, 166.7, 167.1, 171.0; 
Benzyl protected 33 was globally deprotected on a 0.09 
mmol scale via General Procedure I to furnish 27lf ( 42 mg, 
82%): oH(400 MHz, CDC13 ) 2.36 (s, 3H, CH3 ), 2.80 (s, 3H, 
CH3 ), 3.69 (s, 2H, CH2 ), 4.91 (s, 2H, CH2 ), 6.78 (dd, J=8.4 
and 1.6 Hz, lH, CH), 6.89 (d, J=2.0 Hz, lH, CH), 7.30 (d, 
J=8.0Hz, 2H, CH), 7.37 (d, J=8.0Hz, 2H, CH), 7.57 (d, J=8.0 
Hz, 2H, CH), 7.70 (d, J=8.0 Hz, 2H, CH), 7.78 (d, J=8.0 Hz, 
lH, CH), 7.86-7.92 (m, 4H, CH); oc(lOOMHz, CDC13 )21.2, 
36.2, 51.2, 51.8, 110.2, 118.6, 118.7, 119.1, 127.2, 127.3, 55 
127.7, 128.8, 129.9, 131.6, 131.8, 132.0, 133.1, 135.4, 137.3, 
138.0, 143.4, 144.4, 146.8, 162.1, 167.1, 167.2, 171.4; 
HRMS (ES+) calcd for [C31H28N3 0 6 S+H] 570.1696. found 
570.1693; HPLC (I) tR=23.18 min (100.0%), (II) tR=47.81 
min (98.78%). 
88. Preparation of 4-(N-(( 4'-carbamoylbiphenyl-4-yl) 
methyl)-2-(N,4-dimethylphenylsulfonamido) aceta-
mido )-2-hydroxybenzoic acid (27lg) 
Benzyl protected 34 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 27lg (39 mg, 
50 HRMS (ES+) calcd for [C37H32N2 0 8S+H] 665.1952. Found 
665.1957; HPLC (I) tR=21.07 min (96.72%), (II) tR=44.44 
min (97.21%). 
91. Preparation of 4-N-((3'-cyanoterphenyl-4-yl) 
methyl)-2-(N,4-dimethylphenylsulfonamido )acet-
amido )-2-hydroxybenzoic acid (27nc) 
Benzyl protected 37 was globally deprotected on a 0.12 
mmol scale via General Procedure I to furnish 27nc (64 mg, 
60 83%): OH (400 MHz, dcDMSO) 2.36 (s, 3H, CH3 ), 2.82 (s, 
3H, CH3 ), 3.92 (s, 2H, CH2 ), 4.92 (s, 2H, CH2 ), 6.85 (dd, 
J=8.4 and 1.6 Hz, lH, CH), 6.95 (d, J=l.6 Hz, lH, CH), 7.30 
(d, J=8.0 Hz, 2H, CH), 7.36 (d, J=8.4 Hz, 2H, CH), 7.58 (d, 
J=8.4Hz, 2H, CH), 7.66-7.71(m,3H, CH), 7.78-7.86 (m, 6H, 
65 CH), 8.05 (d, J=8.0 Hz, lH, CH), 8.20 (s, lH, CH); Oc (100 
MHz, dcDMSO) 20.8, 35.8, 50.9, 51.5, 112.0, 112.5, 116.0, 
118.5, 118.7, 126.5, 126.9, 127.0, 127.3, 128.3, 129.5, 129.9, 
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130.0, 130.9, 131.2, 131.3, 13S.O, 136.4, 136.8, 138.0, 139.4, 
140.S, 143.0, 146.8, 161.6, 166.8, 171.l;HRMS(ES+)calcd 
for [C37H32N30 6 S+H] 646.2006. Found 646.1986; HPLC 
(1) tR=22.62 min (88.6S%), (II) tR=48.72 min (90.98%). 
92. Preparation of 4-(N-((3'-carbamoylterphenyl-4-
yl)methyl)-2-(N,4-dimethylphenylsulfonamido )acet-
amido )-2-hydroxybenzoic acid (27nd) 
270 
82%): OH (400 MHz, dcDMSO) 2.36 (s, 3H, CH3 ), 2.81 (s, 
3H, CH3 ), 3.91(s,2H, CH2 ), 4.92 (s, 2H, CH2 ), 6.8S (d, J=8.4 
Hz, lH, CH), 6.9S (s, lH, CH), 7.30 (d, J=8.0 Hz, 2H, CH), 
7.36 (d, J=8.0 Hz, 2H, CH), 7.S8 (d, J=8.0 Hz, 2H, CH), 7.68 
5 (d, J=8.0Hz, 2H, CH), 7.78-7.82 (m, SH, CH), 7.93-7.9S (m, 
4H, CH); Oc (100 MHz, dcDMSO) 20.8, 3S.8, S0.9, Sl.S, 
109.9, 112.S, 116.0, 118.S, 118.7, 126.S, 126.9, 127.1, 127.2, 
127.S, 128.3, 129.S, 131.3, 132.7, l3S.O, 136.S, 137.0, 138.0, 
139.8, 143.0, 146.8, 161.S, 166.7, 171.1. HRMS (ES+) calcd 
10 for [C37H32N30 6 S+H] 646.2006. Found 646.1987; HPLC (I) 
tR=22.71 min (94.1S%), (II) tR=49.13 min (96.29%). 
Benzyl protected 38 was globally deprotected on a O.OS 
mmol scale via General Procedure I to furnish 27nd (31 mg, 
97%): OH (400 MHz, d6 -DMSO) 2.36 (s, 3H, CH3 ), 2.81 (s, 
3H, CH3 ), 3.91 (s, 2H, CH2 ), 4.91 (s, 2H, CH2 ), 6.91 (dd, 
1=7.6 and 1.2 Hz, lH, CH), 6.90 (s, lH, CH), 7.30 (d, J=8.0 
Hz, 2H, CH), 7.37 (d, J=8.0 Hz, 2H, CH), 7.S3-7.S7 (m, 3H, 
CH), 7.68 (d, J=8.4 Hz, 2H, CH), 7.73 (d, J=7.6 Hz, lH, CH), 15 
7.7S-7.88 (m, 6H, CH), 8.23 (s, lH, CH); Oc (100 MHz, 
d6-DMSO) 20.8, 3S.8, S0.8, Sl.S, 113.3, 1lS.9,118.2, 12S.4, 
126.4, 126.7, 126.9, 127.0, 127.2, 128.3, 128.8, 129.1, 129.3, 
129.S, 131.2, 134.9, l3S.O, 136.3, 138.2, 138.4, 139.4, 143.0, 
146.4, 161.8, 166.7, 167.7, 171.0; HRMS (ES+) calcd for 20 
[C37H33N30 7 S+H] 663.2111. Found 66S.2109; HPLC (I) 
tR=19.89 min (100%), (II) tR=41.08 min (100%). 
96. Preparation of 4-(N-((4"-carbamoyl-[1,1 ':4',1 "-
terphenyl]-4-yl)methyl)-2-(N,4-dimethylphenyl sul-
fonamido )acetamido )-2-hydroxybenzoic acid (27nh) 
Benzyl protected 4S was globally deprotected on a O.OS 
mmol scale via General Procedure I to furnish 27nh (26 mg, 
87%): OH (400 MHz, d6 -DMSO) 2.3S (s, 3H, CH3 ), 2.79 (s, 
3H, CH3 ), 3.87 (s, 2H, CH2 ), 4.88 (s, 2H, CH2 ), 6.78 (d, J=6.4 
Hz, lH, CH), 6.86 (s, lH, CH), 7.29 (d, J=8.4 Hz, 2H, CH), 
7.37 (d, J=8.0Hz, 2H, CH), 7.SS-7.69 (m, 6H, CH), 7.76-7.84 
(m, 4H, CH), 7.9S-8.04 (m, 3H, CH); Oc (100 MHz, 93. Preparation of 4-(2-(N,4-dimethylphenylsulfona-
mido )-N-( ( 4 '-( methoxycarbony l)terpheny 1-4-y 1) 
methyl)-acetamido )-2-hydroxybenzoic acid (27ne) 
Benzyl protected 39 was globally deprotected on a 0.07 
mmol scale via General Procedure I to furnish 27ne ( 46 mg, 
97%): OH (400 MHz, dcDMSO) 2.38 (s, 3H, CH3 ), 2.81 (s, 
3H, CH3 ), 3.88 (s, SH, CH2 and CH3 ), 4.91(s,2H, CH2 ), 6.80 
(d, J=8.4 Hz, lH, CH), 6.89 (s, lH, CH), 7.30 (d, J=8.4 Hz, 
2H, CH), 7.38 (d, J=8.0 Hz, 2H, CH), 7.S7 (d, J=8.4 Hz, 2H, 
CH), 7.69 (d, J=8.0Hz, 2H, CH), 7.7S-7.84 (m, SH, CH), 7.90 
25 dcDMSO) 21.3, 30.7, Sl.3, S2.0, 103.0, 116.2, 118.4, 126.2, 
126.S, 127.0, 127.1, 127.3, 128.2, 128.4, 128.7, 128.8, 129.6, 
131.4, 131.S, 132.0, 132.1, 132.2, 133.1, 133.2, 13S.1, 136.4, 
138.1, 138.3, 139.1, 142.1, 143.1, 146.8, 161.7, 166.8, 167.S, 
171.1, 172.0; HRMS (ES+) calcd for [C37H33N3 0 7 S+H] 
30 664.2111. Found 664.2141; HPLC (III) tR=19.22 min 
(76.63%), (IV) tR=43.81 min (79.9S%). 
(d, J=8.8 Hz, 2H, CH), 8.03 (d, J=8.8 Hz, 2H, CH) Oc (100 35 
MHz, d6-DMSO) 20.8, 3S.8, S0.8, Sl.S, S2.0, 113.S, llS.9, 
118.0, 126.4, 126.6, 126.8, 127.0, 127.2, 127.3, 128.3, 129.S, 
129.7, 131.2, 13S.O, 136.4, 137.S, 138.0, 139.4, 143.0, 143.9, 
146.3, 161.8, 16S.9, 166.7, 171.0; HRMS (ES+) calcd for 
[C37H32N20 8 S+H] 679.2108. Found 679.2081; HPLC (I) 40 
tR=23.S4 min (100%), (II) tR=Sl.01 min (100%). 
97. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N, 
3-dimethylpheny lsulfonamido )acetamido )-2-hy-
droxy-benzoic acid ( 4Sa) 
Benzyl protected 47 was globally deprotected on a 0.13 
mmol scale via General Procedure I to furnish 4Sa (68 mg, 
91 %): OH ( 400 MHz, CDC13 ) 1.31-1.41 (m, SH, CH2 ), 1.73-
1.87 (m, SH, CH2 ), 2.40 (s, 3H, CH3 ), 2.43-2.48 (m, lH, CH), 
2.89 (s, 3H, CH3 ), 3.86 (s, 2H, CH2 ), 4.84 (s, 2H, CH2 ), 6.63 
(dd, J=8.4 and 1.6 Hz, lH, CH), 6.73 (d, J=2.0 Hz, lH, CH), 
7.08 (d, J=8.0 Hz, 2H, CH), 7.12 (d, J=8.0 Hz, 2H, CH), 
94. Preparation of 4'-((N-( 4-carboxy-3-hydroxyphe-
nyl)-2-(N,4-dimethylphenylsulfonamido )acetamido) 
methyl)terphenyl-4-carboxylic acid (27nf) 
Benzyl protected 46 was globally deprotected on a O.OS 
mmol scale via General Procedure I to furnish 27nf (28 mg, 
89%): OH (400 MHz, dcDMSO) 2.37 (s, 2H, CH3 ), 2.80 (s, 
3H, CH3 ), 3.88 (s, 2H, CH2 ), 4.88 (s, 2H, CH2 ), 6.72 (d, J=6.8 
Hz, lH, CH), 6.81 (s, lH, CH), 7.29 (d, J=6.8 Hz, 2H, CH), 
7.37 (d, J=7.6 Hz, 2H, CH), 7.S6 (d, J=6.8 Hz, 2H, CH), 7.68 
45 7.3S-7.40 (m, 2H, CH), 7.S7 (s, 2H, CH), 7.89 (d, J=8.8 Hz, 
lH, CH); oc (100 MHz, CDC13 ) 21.4, 26.1, 26.9, 34.4, 36.0, 
44.2, Sl.7, S3.l, 111.2, 111.7, 119.2, 124.7, 127.1, 127.9, 
128.4, 128.8, 132.2, 133.S, 133.6, 137.8, 139.1, 147.8, 148.1, 
163.0, 167.0, 171.9; HRMS (ES+) calcdfor [C30H34N20 6 S+ 
50 HJ SSl.2210. Found SSl.2199; HPLC (III) tR=22.33 min 
(76.40%), (IV) tR=S0.92 min (100.00%). 
(d, J=7.2 Hz, 2H, CH), 7.78-7.8S (m, 7H, CH), 8.03 (d, J=7.2 
Hz, 2H, CH); Oc (100 MHz, d6 -DMSO) 20.8, 3S.7, Sl .S, SS.7, 
107.4, 107.7, 117.4, 126.4, 126.S, 126.8, 127.1, 127.0, 127.3, 55 
128.3, 129.S, 129.8, 131.1, 136.4, 137.0, 137.7, 138.0, 139.3, 
143.0, 143.S, 1S8.0, 162.3, 166.7, 166.9, 171.4; HRMS (ES+) 
calcd for [C37H32N2 0 8S+H] 66S.l9S2, 
98. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N, 
2,4,6-tetramethylphenylsulfonamido )acetamido )-2-
hydroxy-benzoic acid (4Sb) 
Benzyl protected 48 was globally deprotected on a 0.06 
mmol scale via General Procedure I to furnish 4Sb (31 mg, 
89%): OH (400 MHz, dcDMSO) 1.26-1.40 (m, SH, CH2 ), Found 66S.1962; HPLC (I) tR=l7.2S min (92.99%), (II) 
tR=37.13 min (91.78%). 
9S. Preparation of 4-(N-((4'-cyanoterphenyl-4-yl) 
methyl)-2-(N,4-dimethylphenylsulfonamido )acet-
amido )-2-hydroxybenzoic acid (27ng) 
Benzyl protected 44 was globally deprotected on a 0.1 
mmol scale via General Procedure I to furnish 27 ng (S3 mg, 
60 1.64-1.81 (m, SH, CH2 ), 2.26 (s, 3H, CH3 ), 2.44 (s, 7H, CH3 
and CH), 2.84 (s, 3H, CH3 ), 3.84 (s, 2H, CH2 ), 4.7S (s, 2H, 
CH2 ), 6.62 ( dd, J=8.4 and 2.0 Hz, lH, CH), 6.70 ( d, J=2.0 Hz, 
lH, CH), 6.99 (d, J=8.0 Hz, 2H, CH), 7.03 (s, 2H, CH), 7.11 
(d, J=8.0 Hz, 2H, CH), 7.7S (d, J=8.4 Hz, lH, CH); Oc (100 
65 MHz, dcDMSO) 20.3, 22.1, 2S.4, 26.2, 33.8, 34.4, 43.2, 
49.1, Sl.S, 116.0, 118.4, 120.2, 126.S, 127.4, 131.2, 131.7, 
132.1, 134.1, 139.4, 142.1, 146.7, 146.7, 161.S, 166.6, 171.0; 
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HRMS (ES+) calcd for [C32H38N2 0 6S+H] 613.2366. Found 
613.23S6; HPLC (V) tR=2l.29 min (96.82%), (VI) tR=37.S4 
min (9S.30%). 
99. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N-
methy lbipheny 1-4-y lsulfonamido )acetamido )-2-hy-
droxy-benzoic acid ( 4Sc) 
272 
102. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N-
methylquinoline-8-sulfonamido )acetamido )-2-hy-
droxy-benzoic acid ( 4Sf) 
Benzyl protected Sl was globally deprotected on a 0.29 
mmol scale via General Procedure I to furnish 4Sf (123 mg, 
84%): OH (400 MHz, CDCl3 ) 1.29-1.41 (m, SH, CH2 ), 1.69-
1.86 (m, SH, CH2 ), 2.40-2.S2 (m, lH, CH), 2.77 (s, 3H, CH3 ), 
3.86 (s, 2H, CH2), 4.SS (s, 2H, CH2), 6.SS (t, J=S.O Hz, lH, 
1° CH), 6.61 (d, J=S.O Hz, lH, CH), 6.70 (s, lH, CH), 7.04-7.14 
(m, SH, CH), 7.47 (d, J=S.O Hz, lH, CH), 7.86 (d, J=S.4 Hz, 
lH, CH); Oc (100 MHz, CDCl3 ) 26.7, 34.2, 36.1, 41.S, 44.1, 
S0.6, S3.l, 114.9, 116.9, 119.1, 123.8, 124.8, 126.9, 128.3, 
128.9 (br), 132.2, 133.1, 134.4, 147.7, 162.8, 167.8, 171.9; 
Benzyl protected 49 was globally deprotected on a 0.06 
mmol scale via General Procedure I to furnish 4Sc (34 mg, 
97%): OH (400 MHz, dcDMSO) 1.23-1.38 (m, SH, CH2), 
1.62-1.78 (m, SH, CH2), 2.3S-2.44 (m, lH, CH), 2.08 (s, 3H, 
CH3 ), 3.96 (s, 2H, CH2 ), 4.78 (s, 2H, CH2 ), 6.80 (dd, J=S.4 
and 2.0 Hz, lH, CH), 6.89 (d, J=2.0 Hz, lH, CH), 7.04 (d, 
J=S.O Hz, 2H, CH), 7 .09 ( d, J=S.4 Hz, 2H, CH), 7.44 ( d, J=S.O 
Hz, lH, CH), 7.Sl (t, J=7.6 Hz, 2H, CH), 7.68-7.81 (m, SH, 
CH), 7.86 (d, J=S.4 Hz, 2H, CH); Oc (100 MHz, dcDMSO) 
2S.4, 26.2, 33.7, 3S.8, 43.2, S0.7, Sl.6, llS.9, 118.4, 120.3, 
126.S, 126.9, 127.2, 127.4, 127.S, 128.4, 129.0, 131.3, 134.1, 20 
136.9, 138.3, 144.1, 146.3, 146.8, 161.6, 166.S, 171.1; 
HRMS (ES+) calcd for [C35H36N2 0 6 S+H] 613.2366. found 
613.23S6; HPLC (V) tR=22.09 min (96.S0%), (VI) tR=38.47 
min (89.47%). 
15 HRMS (ES+) calcd for [C32H33N3 0 6S+H] S92.247S. Found 
S92.2467; HPLC (III) tR=23.9S min (100.00%), (IV) 
tR=S3.4l min (100.00%). 
103. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(S-
( dimethy !amino)-N-methy lnaphthalene-1-sulfona-
mido) acetamido )-2-hydroxybenzoic acid ( 4Sg) 
Benzyl protected S2 was globally deprotected on a 0.11 
mmol scale via General Procedure I to furnish 4Sg (71 mg, 
100. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N-
methylnaphthalene-2-sulfonamido )acetamido )-2-
hydroxy-benzoic acid (4Sd) 
25 92% ): OH ( 400 MHz, CDCl3 ) 1.23-1.40 (m, SH, CH2 ), 1.72-
1.83 (m, SH, CH2 ), 2.42-2.46 (m, lH, CH), 3.02 (s, 3H, CH3 ), 
3.33 (s, 6H, CH3 ), 3.92 (s, 2H, CH2 ), 4.78 (s, 2H, CH2 ), 6.43 
(d, J=S.O Hz, lH, CH), 6.S6 (s, lH, CH), 7.04 (d, J=S.O Hz, 
2H, CH), 7.10 (d, J=S.O Hz, 2H, CH), 7.S8-7.6S (m, 3H, CH), 
30 7.70 (t, J=S.O Hz, lH, CH), 8.31 (d, J=7.2 Hz, lH, CH), 8.S9 
( d, J=S.4 Hz, lH, CH), 8.62-8.66 (m, lH, CH); oc (100 MHz, 
CDCl3 ) 26.2, 27.0, 34.S, 36.0, 44.3, 46.8, Sl.3, S3.2, 112.4, 
117.7, 118.9, 126.2, 126.3, 127.2, 127.3, 127.S, 128.6, 130.2, 
130.6, 132.2, 133.S, l3S.7, 140.0, 142.1, 147.2, 147.9, 1S8.2, 
Benzyl protected SO was globally deprotected on a 0.07 
mmol scale via General Procedure I to furnish 4Sd (3S mg, 
87%): OH (400 MHz, dcDMSO) 1.28-1.39 (m, SH, CH2), 
1.62-1.79 (m, SH, CH2), 2.37-2.46 (m, lH, CH), 2.88 (s, 3H, 
CH3 ), 3.9S (s, 2H, CH2 ), 4.76 (s, 2H, CH2 ), 6.80 (dd, J=S.4 
and 2.4 Hz, lH, CH), 6.88 (d, J=2.0 Hz, lH, CH), 7.02 (d, 
J=8.0Hz, 2H, CH), 7.08 (d, J=8.0Hz, 2H, CH), 7.62-7.73 (m, 
3H, CH), 7.79 (d, J=S.4 Hz, lH, CH), 8.04 (d, J=S.4 Hz, lH, 
CH), 8.09 (d, J=S.8 Hz, lH, CH), 8.12 (d, J=8.0Hz, lH, CH), 
8.3S (d, J=l.6 Hz, lH, CH); Oc (100 MHz, dcDMSO) 2S.4, 
40 
26.2, 33.8, 3S.9, 43.2, S0.8, Sl.S, 112.S, 116.0, 118.S, 119.9, 
122.S, 126.S, 127.4, 127.7, 127.8, 128.7, 129.1, 131.3, 131.6, 
134.1, 134.2, 13S.1, 146.3146.8, 161.S, 166.S, 171.l;HRMS 
(ES+) calcd for [C33H34N20 6 S+H] S87.2210. Found 
S87.2196; HPLC (V) tR=20.69 min (98.96%), (VI) tR=3S.Ol 45 
min (9S.03%). 
35 162.7, 166.9, 171.8;HRMS(ES+)calcdfor[C35H39N30 6 S+ 
HJ 630.2632. Found 630.2622; HPLC (III) tR=21.26 min 
(90.39%), (IV) tR=46.32 min (93.61 %). 
104. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N, 
l-dimethyl-lh-imidazole-4-sulfonamido )acetamido )-
2-hydroxybenzoic acid (4Sh) 
Benzyl protected S3 was globally deprotected on a 0.07 
mmol scale via General Procedure I to furnish 4Sh (38 mg, 
98% ): OH ( 400 MHz, CDCl3 ) 1.20-1.38 (m, SH, CH2 ), 1.70-
1.83 (m, SH, CH2 ), 2.39-2.49 (m, lH, CH), 2.91 (s, 3H, CH3 ), 
3.74 (s, 3H, CH3 ), 3.96 (s, 2H, CH2 ), 4.79 (s, 2H, CH2 ), 
6.SS-6.64 (m, lH, CH), 6.67 (s, lH, CH), 7.03-7.10 (m, 4H, 
CH), 7.4S (s, lH, CH), 7.74 (d, J=7.6 Hz, lH, CH); Oc (100 
101. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N-
methylnaphthalene-l-sulfonamido )acetamido )-2-
hydroxy-benzoic acid (4Se) 50 MHz, CDCl3 ) 26.2, 27.0, 34.S, 44.3, S2.l, S3.2, 113.1, 116.7, 
119.0, 127.1, 127.2, 128.6, 132.2, 133.9, 139.2, 139.3, 146.9, 
147.6, 163.0, 167.0, 172.2; HRMS (ES+) calcd for 
[C27H33N4 0 6 S+H] S41.211S. Found S41.2104; HPLC 
tR=19.10 min (100.00%), (IV) tR=42.32 min (100.00%). 
Benzyl protected 62 was globally deprotected on a 0.12 
mmol scale via General Procedure I to furnish 4Se (72 mg, 
94% ): OH ( 400 MHz, CDCl3 ) 1.30-l .4S (m, SH, CH2 ), 1.70-
1.92 (m, SH, CH2 ), 2.42-2.S2 (m, lH, CH), 2.99 (s, 3H, CH3 ), 55 
3.98 (s, 2H, CH2), 4.80 (s, 2H, CH2 ), 6.SS (dd, J=S.O and 2.0 
Hz, lH, CH), 6.70 (d, J=2.0 Hz, lH, CH), 7.04 (d, J=S.O Hz, 
2H, CH), 7.11 (d, J=S.O Hz, 2H, CH), 7.Sl (t, J=S.O Hz, lH, 
CH), 7.S6-7.61 (m, 2H, CH), 7.87 (d, J=S.4 Hz, lH, CH), 
7.89-7.92 (m, lH, CH), 8.04 (d, J=S.O Hz, lH, CH), 8.2S (d, 60 
1=7.2 Hz, lH, CH), 8.61 (d, J=8.0Hz, lH, CH); Oc (lOOMHz, 
CDCl3 ) 2S.9, 26.7, 34.2, 3S.9, 44.1, S0.9, S3.0, 112.8, 117.2, 
119.1, 123.9, 124.9, 126.7, 126.9, 128.0, 128.3, 128.6, 128.7, 
129.6, 132.2, 133.2, 133.7, 134.2, 147.6, 162.8, 167.0, 172.1; 
HRMS (ES+) calcd for [C33H34N2 0 6S+H] S87.2210. Found 65 
S87.2196; HPLC (III) tR=l9.22 min (76.63%), (IV) tR=43.81 
min (79.9S%). 
1 OS. Preparation of 4-(2-( 4-cyano-N-methylphenyl-
sulfonamido )-N-( 4-cyclohexylbenzyl)acetamido )-2-
hydroxy-benzoic acid (4Si) 
Benzyl protected S4 was globally deprotected on a 0.13 
mmol scale via General Procedure I to furnish 4Si (6S mg, 
87%): OH (400 MHz, CDCl3 ) 1.2S-1.41 (m, SH, CH2 ), 1.71-
1.SS (m, SH, CH2 ), 2.43-2.S3 (m, lH, CH), 2.93 (s, 3H, CH3 ), 
3.96 (s, 2H, CH2), 4.78 (s, 2H, CH2 ), 6.61 (dd, J=S.4 and 1.6 
Hz, lH, CH), 6.72 (d, J=l.6 Hz, lH, CH), 7.03 (d, J=S.O Hz, 
2H, CH), 7.13 (d, J=S.O Hz, 2H, CH), 7.77 (d, J=S.4 Hz, 2H, 
CH), 7.89-7.94 (m, 3H, CH); Oc (100 MHz, CDCl3 ) 26.2, 
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94%): OH (400 MHz, dcDMSO) 1.32-1.38 (m, SH, CH2 ), 
1.63-1.78 (m, SH, CH2 ), 2.39-2.49 (m, lH, CH), 2.77 (s, 3H, 
CH3 ), 3.82 (s, 3H, CH3 ), 3.86 (s, 2H, CH2 ), 4.80 (s, 2H, CH2 ), 
6.79 (dd, J=8.4 and 2.0 Hz, lH, CH), 6.87 (d, J=2.0 Hz, lH, 
27.0, 34.S, 36.1, 44.4, Sl.9, S3.4, 111.7, 116.4, 117.3, 117.6, 
119.3, 127.3, 128.3, 128.6, 132.7, 132.8, 133.3, 143.2, 147.9, 
148.2, 163.2, 166.8, 172.7; HRMS (ES+) calcd for 
[C30H31N30 6 S+H] S62.2006. Found S62.1997; HPLC 
tR=8.69 min (92.00%), (IV) tR=4S.44 min (91.69%). 
106. Preparation of 4-(2-(4-bromo-N-methylphenyl-
sulfonamido )-N-( 4-cyclohexylbenzyl)acetamido )-2-
hydroxy-benzoic acid (4Sj) 
5 CH), 7.07 (d, J=8.8 Hz, 4H, CH), 7.13 (d, J=8.0Hz, 2H, CH), 
7.61 (d, J=8.8 Hz, 2H, CH), 7.78 (d, J=8.4 Hz, lH, CH); Oc 
(100 MHz, dcDMSO) 2S.4, 26.2, 33.8, 3S.7, 43.2, S0.8, Sl .6, 
SS.S, 114.2, 1 lS.9, 118.4, 121.3, 126.S, 127.4, 129.0, 131.2, 
131.4, 134.2, 146.3, 146.9, 161.S, 162.3, 166.6, 177.1; 
10 HRMS (ES+) calcd for [C30H34N2 0 7 S+H] S67.2lS9. Found 
S67.2170; HPLC (V) tR=l9.67 min (100%), (VI) tR=33.74 
min (9S.49%). 
Benzyl protected SS was globally deprotected on a 0.12 
mmol scale via General Procedure I to furnish 4Sj (68 mg, 
87% ): OH ( 400 MHz, CDC13 ) 1.24-1.40 (m, SH, CH2 ), 1.68-
1.84 (m, SH, CH2 ), 2.42-2.S l (m, lH, CH), 2.90 (s, 3H, CH3 ), 
3.8S (s, 2H, CH2 ), 4.74 (s, 2H, CH2 ), 6.SO (dd, J=8.4 and 1.6 
Hz, lH, CH), 6.63 (d, J=l.6 Hz, lH, CH), 7.01 (d, J=8.0 Hz, 15 
2H, CH), 7.08 (d, J=8.0 Hz, 2H, CH), 7.S9 (d, J=8.8 Hz, 2H, 
CH), 7.64 (d, J=8.8 Hz, 2H, CH), 7.8S (d, J=8.4 Hz, lH, CH); 
Oc(lOOMHz, CDC13 ) 26.2, 27.0, 34.S, 36.0, 39.S, 44.3, Sl.S, 
S3.l, 113.2, 116.8, 118.8, 126.1, 127.1, 127.6, 129.2, 132.2, 
132.3, 133.8, 138.0, 146.9, 147.7, 163.0, 166.6, 172.0; 20 
HRMS (ES+) calcd for [C29H31 BrN2 0 6S+H] 61S.11S8. 
Found 61S.1132; HPLC (III) tR=23.36 min (86.S2%), (IV) 
tR=S3.43 min (100.00%). 
110. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(N-
methyl-4-nitrophenylsulfonamido )acetamido )-2-
hydroxy benzoic acid ( 4Sn) 
Benzyl protected S9 was globally deprotected on a 0.12 
mmol scale via General Procedure I to furnish 4Sn (S2 mg, 
7S%): OH (400 MHz, dcDMSO) 1.2S-1.42 (m, SH, CH2 ), 
1.63-1.80 (m, SH, CH2 ), 2.38-2.47 (m, lH, CH), 2.90 (s, 3H, 
CH3 ), 4.03 (s, 2H, CH2 ), 4.74 (s, 2H, CH2 ), 6.79 (dd, lH, 6.87 
(d, J=2.0 Hz, lH, CH), 7.02 (d, J=8.0 Hz, 2H, CH), 7.13 (d, 
107. Preparation of 4-(2-(4-chloro-N-methylphenyl-
sulfonamido )-N-( 4-cyclohexylbenzyl)acetamido )-2-
hydroxy-benzoic acid (4Sk) 
Benzyl protected S6 was globally deprotected on a 0.12 
mmol scale via General Procedure I to furnish 4Sk ( 49 mg, 
72%): oH(400MHz, CDC13 ) 1.34 (m, SH, CH2 ), l.7S (m, SH, 
CH2 ), 2.44 (m, lH, CH), 2.84 (s, 3H, CH3 ), 3.96 (s, 2H, CH2 ), 
4.77 (s, 2H, CH2 ), 6.80 ( dd, J=8.4 and 2.0 Hz, lH, CH), 6.89 
25 J=8.0Hz, 2H, CH), 7.78 (d, J=8.4Hz, lH, CH), 7.99 (d, J=8.8 
Hz, 2H, CH), 8.38 (d, J=8.8 Hz, 2H, CH); Oc (100 MHz, 
dcDMSO) 2S.4, 26.2, 33.8, 3S.7, 43.2, S0.8, Sl.7, l lS.6, 
llS.9, 118.2, 124.2, 126.S, 127.4, 128.S, 128.S, 134.0, 144.0, 
146.4, 146.S, 149.S, 161.6, 166.2, 171.0; HRMS (ES+) calcd 
30 for [C29H31N30 8 S+H] S82.1904. Found S98.1878; HPLC 
(V) tR=20.Sl min (97.S8%), (VI) tR=3S.OO min (9S.66%). 
111. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-(2, 
3 ,4,S ,6-pentafluoro-N-methy lphenylsulfonamido) 
acetamido )-2-hydroxybenzoic acid ( 4So) 
Benzyl protected 60 was globally deprotected on a 0.06 
mmol scale via General Procedure I to furnish 4So (37 mg, 
99%): OH (400 MHz, d6-DMSO) 1.27-7.41 (m, SH, CH2 ), 
(d, J=2.0 Hz, lH, CH), 7.04 (d, J=8.0 Hz, 2H, CH), 7.13 (d, 
J=8.0Hz, 2H, CH), 7.64 (d, J=8.8 Hz, 2H, CH), 7.72 (d, J=8.8 
Hz, 2H, CH), 7.78 (d, J=8.4 Hz, lH, CH); Oc (100 MHz, 35 
CDC13 ) 2S.4, 26.2, 33.8, 3S.8, 43.2, S0.8, Sl.6, 112.4, llS.9, 
118.4, 126.S, 127.4, 128.8, 129.1, 131.2, 134.1, 137.1, 137.S, 
146.4, 146.8, 161.S, 166.4, 171.0; HRMS (ES+) calcd for 
[C29H31 CIN2 0 6S+H] S71.1664. Found S71.1682; HPLC (V) 
tR=20.92 min (96.73%), (VI) tR=3S.97 min (97.88%). 40 1.64-1.79 (m, SH, CH2 ), 2.40-2.49 (m, lH, CH), 3.00 (s, 3H, 
CH3 ), 4.13 (s, 2H, CH2 ), 4.77 (s, 2H, CH2 ), 6.74 (dd, J=8.4 
and 2.0 Hz, lH, CH), 6.83 (d, J=2.0 Hz, lH, CH), 7.04 (d, 
J=8.0Hz, 2H, CH), 7.12 (d, J=8.0Hz, 2H, CH), 7.80 (d, J=8.4 
Hz, lH, CH); oc(lOOMHz, d6 -DMSO) 2S.4, 26.2, 33.8, 3S.S, 
108. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-( 4-
fluoro-N-methylphenylsulfonamido )acetamido )-2-
hydroxy benzoic acid ( 4Sl) 
45 43.2, Sl.2, Sl.7, 116.1, 118.4, 118.8, 126.S, 127.S, 131.4, 
133.9, 146.3, 146.S, 161.S, l6S.9, 171.0; HRMS (ES+) calcd 
for [C29H27F5 N20 6 S+H] 627.1S82. Found 627.lSSl; HPLC 
(V) tR=22.71 min (97.47%), (VI) tR=39.92 min (9S.22%). 
Benzyl protected S7 was globally deprotected on a 0.06 
mmol scale via General Procedure I to furnish 4Sl (30 mg, 
8S%): OH (400 MHz, dcDMSO) 1.28-1.39 (m, SH, CH2 ), 
1.62-1.79 (m, SH, CH2 ), 2.37-2.46 (m, lH, CH), 2.88 (s, 3H, 
CH3 ), 3.9S (s, 2H, CH2 ), 4.76 (s, 2H, CH2 ), 6.80 (dd, J=8.4 
and 2.4 Hz, lH, CH), 6.88 (d, J=2.0 Hz, lH, CH), 7.02 (d, 50 
J=8.0Hz, 2H, CH), 7.08 (d, J=8.0Hz, 2H, CH), 7.62-7.73 (m, 
3H, CH), 7.79 (d, J=8.4 Hz, lH, CH), 8.04 (d, J=8.4 Hz, lH, 
CH), 8.09 (d, J=8.8 Hz, lH, CH), 8.12 (d, J=8.0Hz, lH, CH), 
8.3S (d, J=l.6 Hz, lH, CH); oc (100 MHz, d6-DMSO) 2S.4, 
26.2, 33.8, 3S.9, 43.2, S0.8, Sl.S, 112.S, 116.0, 118.S, 119.9, 55 
122.S, 126.S, 127.4, 127.7, 127.8, 128.7, 129.1, 131.3, 131.6, 
134.1, 134.2, 13S.1, 146.3, 146.8, 161.S, 166.S, 171.1; 
HRMS (ES+) calcd for [C33H34N2 0 6S+H] S87.2210. Found 
S87.2196; HPLC (V) tR=l9.62 min (9S.61 %), (VI) tR=33.96 
min (9S.10%). 
109. Preparation of 4-(N-( 4-cyclohexylbenzyl)-2-( 4-
methoxy-N-methy lpheny lsulfonamido )acetamido )-2-
hydroxybenzoic acid ( 4Sm) 
Benzyl protected S8 was globally deprotected on a 0.08 
mmol scale via General Procedure I to furnish 4Sm ( 40 mg, 
65 
112. Molecule Characterization: 4-(N-( 4-cyclohexyl-
benzyl)-2-(N,4-dimethylphenylsulfonamido )aceta-
mido )-2-hydroxybenzoic acid (SFl-066) 
0 
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OH (400 MHz, dcDMSO) 1.14-1.40 (m, SH, CH2 ), 1.64-
1.81 (m, SH, CH2 ), 2.36 (s, 3H, CH3Ar), 2.44 (s (br), lH, 
CH), 2.77 (s, 3H, NCH3 ), 3.86 (s, 2H, COCH2 ), 4.79 (s, 2H, 
CH2Ar), 6.79 (d, J=8.6 Hz, lH, CH (Ar)), 6.86 (s (br), lH, CH 
(Ar)), 7.06 (d, J=7.8 Hz, 2H, 2 CH (Ar)), 7.13 (d, J=7.8 Hz, 5 
2H, 2 CH (Ar)), 7.3S (d, J=8.0 Hz, 2H, 2 CH (Ar)), 7.S4 (d, 
J=8.0 Hz, 2H, 2 CH (Ar)), 7.77 (d, J=8.3 Hz, lH, CH (Ar)), 
11.30 (s (br), lH, OH); oc (400 MHz, d6 -DMSO) 21.2, 2S.l 
(2), 26.6, 34.2, 36.1, 42.3, 43.6, Sl.2, Sl.9, 112.7, 116.3, 
118.9, 126.9, 127.2, 127.8, 129.9, 131.6, 134.S, 13S.3, 143.4, lO 
146.8, 147.3, 161.8, 167.0, 171.S; HRMS (ES+) calcd for 
[C30H35N20 6 S+H] SSl.2223. found SSl.2210; HPLC (I) 
tR=24.3S min (98.11 %), (II) tR=S2.80 min (98.16%). 
HPLC was carried as follows: Analysis by rpHPLC was 
15 
performed using a Microsorb-MV 300 A C18 2SO mmx4.6 
mm colunmrun at 1 ml/min, and using gradient mixtures. The 
linear gradient consisted of a changing solvent composition 
of either (I) 100% H2 0 with 0.1 % TFA for two minutes to 
100% MeCNwith 10% H2 0 and 0.1% TFA (v/v) at 22 min- 20 
utes and UV detectionat2S4nmor(II) 100% H20with0.1 % 
TFA for two minutes to 100% MeCN with 10% H2 0 and 
0.1 % TFA (v/v) at 62 mins and UV detectionat214 nmor(III) 
100% H2 0 (0.01 M NH4 0Ac) for 2 mins to 100% MeOH at 
22 minutes and UV detection at 2S4 nm or (IV) 100% H20 25 
(0.01 M NH4 0Ac) for 2 mins to 100% MeOH at 62 minutes 
and UV detection at 2S4 nm or (V) 100% H2 0 (0.01 M 
NH4 0Ac) for 2 mins to 100% MeOH at 2S minutes and UV 
detection at 2S4 nm or (VI) 100% H20 (0.01 M NH4 0Ac) for 
2 mins to 100% MeOH at 62 mins and UV detection at 2S4 30 
nm, each ending with S mins of 100% B. Percentage purity is 
given in parentheses after the retention time. 
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(97.80%), (II) tR=S9.27 min (100%). HPLC was carried as 
described above for compound SFl-066. 
114. Molecule Characterization: 4-(N-benzyl-2-(N-
(tert-butoxycarbonyl)-4-methylphenylsulfonamido) 
acetamido )-2-hydroxybenzoic acid (SF 1-088) 
OH ( 400 MHz, CDC13 ) 1.31 (s, 9H, 3(CH3 )), 2.41 (s, 3H, 
CH3Ar), 4.47 (s, 2H, COCH2 ), 4.9S (s, 2H, CH2Ar), 6.69 (d, 
J=8.4 Hz, lH, CH (Ar)), 6.81 (s, lH, CH (Ar)), 7.20-7.32 (m, 
7H, CH (Ar)), 7.87 (d, J=8.4 Hz, lH, CH (Ar)), 8.00 (d, J=8.2 
Hz, 2H, 2 CH (Ar)), 10.68 (s (br), lH, OH); oc (400 MHz, 
CDC13 ) 21.6, 27.7, 47.4, S3.3, 84.8, 111.6, 117.2, 119.2, 
127.7, 128.4, 128.S, 128.7, 129.0, 132.3, 136.2, 136.6, 144.2, 
147.7, lS0.6, 162.9, 166.8, 172.6; HRMS (ES+) calcd for 
[C28H31N20 8 S+H] SS7.l6lS. found S77.161S; HPLC (I) 113. Molecule Characterization: 4-(2-(N-(tert-bu-
toxycarbony 1 )-4-methy lphenylsulfonamido )-N-( 4-
cyclohexy l benzyl)acetamido )-2-hydroxybenzoic 
35 tR=2l.67 min (99.02%), (11) tR=46.0S min (98.14%). HPLC 
was carried as described above for compound SFl-066. 
acid (SFl-087) 
OH (400 MHz, CDC13 ) l.22-l.4S (m, 14H), 1.70-1.8S (m, 
SH, CH2 ), 2.42 (s, 3H, CH3 ), 2.46 (s (br), lH, CH), 4.46 (s, 
2H, COCH2 ), 4.91(s,2H, CH2Ar), 6.70 (d, J=8.0Hz, lH, CH 
(Ar)), 6.82 (s (br), lH, CH (Ar)), 7.10-7.lS (m, 4H, 4 CH 
(Ar)), 7.30 (d, J=8.0 Hz, 2H, 2 CH (Ar)), 7.88 (d, J=8.4 Hz, 
lH, 1 CH (Ar)), 8.02 (d, J=8.2 Hz, 2H, 2 CH (Ar)), 10.66 (s 
(br), lH, OH); oc (100 MHz, CDC13 ) 21.6, 26.0, 26.8, 27.7, 
34.3, 44.2, 47.S, S3.l, 84.7, 111.6, 117.2, 119.3, 126.9, 128.3, 
128.8, 129.0, 132.3, 133.S, 136.6, 144.2, 147.S, 147.9, SO.S, 
162.9, 166.7, 172.6; HRMS (ES+) calcdfor [C34H41 N20 8 S+ 
HJ 637.2S47. found 637.2S78; HPLC (I) tR=26.SS min 
40 
45 
11 S. Cells and Reagents 
Normal mouse fibroblasts (NIH3T3) and counterparts 
transformed by v-Src (NIH3T3/v-Src), human epidermal 
growth factor (EGF) receptor (NIH3T3/hEGFR), or v-Ras 
(NIH3T3/v-Ras), the human breast cancer line (MDA-MB-
231) and counterpart expressing inducible KLF8 shRNA 
(231-K8ikd), the murine thymus epithelial stromal cells, the 
human prostate (DU14S), non-small cell lung (AS49), and 
pancreatic (Pane- I) cancer cells have all been previously 
reported (Turkson J, et al. (2001) J. Biol. Chem. 276:4S443-
50 4S4SS, Turkson J, et al. (1998) Mo!. Cell. Biol. l8:2S4S-
2SS2, Wang X, et al. (2011) Oncogene 30:1901-1911, Zhao 
W, Jaganathan S, & Turkson J (2010) J Biol. Chem. 28S: 
3S8SS-3S86S, Zhang, X.; et al. Biochem. Pharmacol. 2010, 
79, 1398-1409). The Stat3-dependent (pLucTKS3) and 
55 Stat3-independent (pLucSRE), and the pLucKLF8 luciferase 
reporters, and the vectors expressing v-Src (pMv-Src) and 
~-galactosidase (~-gal) have been previously reported (27, 
28, 49). The Human Cytokine Array Kit, ARYOOS was pur-
chased from R&D Systems (Minneapolis, Minn.). G-CSF 
60 was purchased from Sigma Aldrich (St. Louis, Mo.) and was 
used at 100 ng/ml. Cells were grown in Dulbecco' s modified 
Eagle's medium (DMEM) containing 10% heat-inactivated 
fetal bovine serum. Antibodies against STAT3, 
pY70SSTAT3, Erkl/2, and pErkl/2 are from Cell Signaling 
65 Technology (Danvers, Mass.). Recombinant human epider-
mal growth factor (rhEGF) was obtained from Invitrogen 
(Carlsbad, Calif.). 
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116. Cloning and Protein Expression 
Coding regions for the murine STAT3 protein and STAT3 
SH2 domain were amplified by PCR and cloned into vectors 
pET-44 Ek/LIC (Novagen) and pET SUMO (Invitrogen), 5 
respectively. The primers used for amplification were: STAT3 
Forward: GACGACGACAAGATGGCTCAGTGGAAC-
CAGCTGC; STAT3 Reverse: GAGGAGAAGCCCGGT-
TATCACATGGGGGAGGTAGCACACT; STAT3-SH2 For-
pY416Src, Src, pErkl/2, Erkl/2, pSTATl, STATl, (Cell Sig-
naling), and antiphosphotyrosine, clone 4G 10 (Upstate Bio-
technology, Lake Placid, N.Y.). Where appropriate, cells 
were stimulated for 12 min by 9 ng/µl rhEGF (12 µl into 3 ml 
culture) prior to preparation ofwhole-cell lysates for immu-
noprecipitation and/or immunoblotting analysis. 
Immunoblotting analysis of whole-cell lysates were per-
formed as previously described (Zhang X, et al. (2010) Bio-
chem Pharmacol79:l398-l409., Zhao W, et al. (20lO)JBiol. 
Chem. 28S:3S8SS-3S86S). Primary antibodies used were 
anti-Stat3, pY70SStat3, pY416Src, Src, pErkl/2, Erkl/2, 
ward: ATGGGTTTCATCAGCAAGGA; STAT3-SH2 10 
Reverse: TCACCTACAGTACTTTCCAAATGC. Clones 
were sequenced to verify the correct sequences and orienta-
tion. His-tagged recombinant proteins were expressed in 
BL21(DE3) cells, and purified on Ni-ion sepharose colunm. 
The molecular cloning, expression, and the purification of 
His-tagged STAT3 is described further in Razgulin AV & 
Mecozzi S (2006) J. Med. Chem. 49:7902-7906 and Zhao W., 
et al. (2010) J Biol. Chem. 28S:3S8SS-3S86S. 
117. Extract Preparation, Gel Shift Assays, and 
Densitometric Analysis 
Nuclear extract preparations and electrophoretic mobility 
shift assay (EMSA) were carried out as previously described 
(Yang J, et al. (200S) Cancer Res. 6S:939-947). The 32P-
labeled oligonucleotide probe used was hSIE (high affinity 
sis-inducible element from the c-fos gene, m67 variant, 
S'-AGCTTCATTTCCCGTAAATCCCTA) that binds Stat3 
(YuH&JoveR(2004)Nat. Rev. Cancer4:97-lOS). For direct 
effect of a test compound on Stat3 DNA-binding activity, 
nuclear extracts were pre-incubated with the agent for 30 min 
at room temperature prior to incubation with the radiolabeled 
probe for 30 min at 30° C. before subjecting to EMSA analy-
sis. Bands corresponding to DNA-binding activities were 
scanned, quantified for each concentration of test compound 
using ImageQuant and plotted as percent of control (vehicle) 
against concentration of compound, from which the IC50 
values were derived, as previously reported (Yue P & Turkson 
pJakl, Jakl, pShc, She, Cyclin Dl, c-Myc, Bcl-xL, Survivin, 
FAK, paxillin, E-cadherin, HDACl, and ~-Actin (Cell Sig-
naling Technology, Danvers, Mass.), KLF8 (36), and VEGF 
15 (Santa Cruz Biotechnolgy, Santa Cruz, Calif.), and EPSTil 
(Sigma Aldrich, St. Louis, Mo.). 
These studies were performed as previously reported (Sid-
diquee KAZ, et al. (2007)ACS Chem. Biol. 2:787-798) using 
whole-cell lysates or nuclear extracts (2SO µg total protein) 
20 
and 2 µg of anti-Stat3, anti-NF I B/p6SRelA, or anti-IkappaB 
polyclonal antibody (Santa Cruz) or S µl of the monoclonal 
anti-Stat3 antibody (Cell Signaling Technology). 
Cells were lysed in lysis buffer (SO mM Tris-HCL, 1 mM 
EDTA, 1%NP-40, 1SOmMNaCl)for30minutesonice, then 
freeze/thaw once at -80° C. and clarified by centrifugation at 
25 12000 g for lS minutes. Proteins were separated by 6.S% to 
lS% sodium dodecyl-polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblotted with the specified anti-
body. Protein bands were visualized using secondary anti-
bodies coupled to horseradish peroxidase and the Chemilu-
30 minescence Reagent Plus (from Perkin Elmer Life Sciences) 
according to the manufacturer's instructions. Anti cMyc was 
from Santa Cruz, anti surviving is from NOVUS Biologicals, 
Anti-Mcl-1, and anti-Bcl-x from BD Biosciences, (Missis-
sauga, ON), anti-phospho STAT3 and STAT3, anti PARP are 
35 from Cell Signaling Technology, (Pickering, ON). 
120. Cell Viability and Proliferation Assay 
J (2009) Targeting STAT3 in cancer: how successful are we? 
Expert Opin Investig Drugs. 18:4S-S6). Cytosolic extract 
preparation from mammalian cells and luciferase assay pre-
40 
viously described (Zhang X, et al. (2010) Biochem Pharma-
col 79: 1398-1409; Turkson J, et al. (1999) Mal. Cell. Biol. 
19:7S19-7S28; Turkson J, et al. (1998) Mal. Cell. Biol. 
Cells in culture in 6-well or 96-well plates were treated 
with or without agents for 24-144 hand subjected to CyQuant 
cell proliferation assay (Invitrogen Corp/Life Technologies 
Corp, Carlsbad, Calif.). IC50 values shown below were 
derived from the plot of viability versus drug concentration. 
Further details of cell viability assay methods are as described 
previously (Zhang X, et al. (2010) Biochem Pharmacol 
l 8:2S4S-2SS2).) 
118. Transient Transfection of Cells 
Transient transfection of cells was carried as previously 
reported (Bromberg J & Darnell J E, Jr. (2000) Oncogene 
19:2468-2473; Bowman T, et al. Oncogene 19:2474-24881; 
Yang J, et al. (200S) Cancer Res. 6S:939-947). Eighteen 
hours following seeding, cells in 12-well plates were tran-
siently co-transfected with 100 ng ~-galactosidase (for nor-
malizing), and 900 ng of pLucTKS3, pLucSRE, or 
pLucKLF8, and with or without SOO ng pMv-Src, where 
appropriate, for 3 h using Lipofectamine plus (Invitrogen) 
and following the manufacturer's protocol. Twelve hours 
after transfection, cells were treated or untreated with a test 
compound (0-60 µM) for 16-24 h, after which they were 
harvested and cytosolic extracts prepared for luciferase assay, 
as previously reported (Bowman T, et al. Oncogene 19:2474-
24881; Yang J, et al. (200S) Cancer Res. 6S:939-947). 
119. Immunoprecipitation and Immunoblotting 
Assay 
45 79:1398-1409). 
To determine whether STATS inhibitors could be cytotoxic 
in cell lines that have constitutive activation of STATS, the 
cell lines KS62 and MV-4-11 were cultured at concentration 
lxl05 , to insure that the cells are at the exponential stage of 
50 growth, and treated with the different synthesized molecules 
at concentrations of 10, 20 and 40 µM. Viability were deter-
mined using Almar Blue (Invitrogen) in 96-well plate over 3 
consecutive days. Fluorescence was quantified using Spectra 
Max MS (Molecular Devices). 
55 
To further test activity of these molecules, a whole-cell 
study involving cancer lines with known abherrant STAT3 
expression was conducted. These human cell lines, including 
prostate cancer (DU14S), breast cancer (MDA468), and pro-
myelocytic leukemia (HL-60) were treated with the peptido-
mimetics and incubated for 72 hours. Disruption of cell 
60 viability was measured by MTS assay and IC50 values for the 
potential inhibitors was determined. OriginPro 8 (Northamp-
ton, Mass.) was used to evaluate EC50 using the dose response 
curve defined as follows: 
Immunoprecipitation, and SDS/PAGE and Western blot- 65 
ting analysis were performed as previously described ( 6, 16). 
Primary antibodies used were anti-STAT3, pY70SSTAT3, 
y = Al + __ (A_2_-_A_l_:_) _ 
( 1 + 1Q((logx0-x)xp)) 
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where y is the fraction of death, xis the log of drug concen-
tration. A2 is the top asymptote, Al is the bottom asymptote, 
logx0 is the center of the curve, and pis the hill slope. IEC50 
is determined by using this relationship: IC50=10Zogxo. 
280 
tion in black 384-flat well micoplates (Coming), and incu-
bated for 15-30 minutes. The MlOOO performed a shaking 
cycle and then read the plates. IC50 's were derived from the 
output using the curve-fitting software OriginPro 8 
121. Apoptosis/Immunoblotting Analysis 
5 (Northampton, Mass.). The FP data was modelled by the 
following equation: 
P1XICso+P2XX 
p(X) = IC so+ X 
where X was the concentration of inhibitor and p was the 
corresponding fluorescence at that concentration. The free 
Apoptosis of compound-treated cells was measured using 
the Annexin V-Flus Staining Kit (Boehringer Mannheim, 
Indianapolis, Ind.). Cell lines were plated at a cell density of 10 
5xl05 cells/mL in IMDM with 5% FCS in the presence of 
inhibitors/DMSO control at the indicated concentrations. 
Cells were harvested after 24 h, washed once in PBS and 
double stained with PI and FITC-conjugated Annexin V as 
per manufacturers instructions. Samples were analyzed on a 
FACSCalibur flow cytometer (BD Biosciences, San Jose, 
Calif.) using Flowjo software (Tree Star. Ashland, Oreg.). 
Human MM cell lines JJN3 and OPM2 were maintained in 
Iscoves modified Dulbecco medium (IMDM) supplemented 
with 5% fetal calf serum (FCS), JJN3 were treated overnight 
with 5 agents. OPM2 were starved overnight and treated with 
15 parameter was half the maximal inhibitory concentration 
(IC50) and the limiting values was the maximal measured 
fluorescence polarization (p 1) and the minimal fluorescence 
polarization (p2 ). Origin curve fitting software utilizes the 
Levenberg-Marquardt algorithm and reduced chi-square cri-
5 compounds for 2 hours before stimulated with 100 ng/ml 
rhIL-6 (R & D Systems) for 10 mins. Representative data 
obtained with representative compounds is shown in FIGS. 
20 terion for convergence. The inhibitor dissociation constant, 
K,, was calculated from the derived IC50 values, as per the 
following formula: 
26 and 27. 
In other assays, K562 cells were treated and used in an 
annexin V/PI assay. Briefly, K562 cells treated with 40 µM of 
BPl-108 for 24 h or untreated were washed twice with PBS 
25 
and then stained consequently with FITC-coupledAnnexin V 
(Becton Dicknson) antibody for 15° and PI (Becton Dickn- 30 
son) for 10°. Then, data were acquired using FacsCaliber® 
and analyzed using Flow Jo® software. 
IC so 
K; = [STAT3] 
1+--
Kd 
where [STAT3]=150 nM and Kd=lOO nM. Further details of 
the fluorescence polarization assay are as described previ-
ously (Zhang X, et al. (201 O)Anovel small-molecule disrupts 
Stat3 SH2 domainphosphotyrosine interactions and Stat3-
dependent tumor processes. Biochem Pharmacol 79: 1398-122. Surface Plasmon Resonance Analysis 
35 1409). 
Surface Plasmon resonance analysis was performed to In other experiments, fluorescence polarization analysis of 
characterize the binding of compounds to STAT3, as previ- other STAT proteins used the following concentrations of 
ously reported (Zhang X, et al. (2010) Biochem Pharmacol protein: 120 nM, 150 nM and 105 nM for Statl, Stat3 and 
79:1398-1409; Zhao W, et al. (2010) J Biol. Chem. 285: Stat5, respectively. Concentrations of inhibitor compounds 
35855-35865). SensiQ and its analysis software Qdat (ICX 40 were varied between 200 to 0.2 µM final concentrations. In 
Technologies, Oklahoma City, Okla.) were used to analyze some experiments, the fluorescent probe was added at a final 
the interaction between agents and the STAT3 protein and to concentration of 10 nM. Protein, inhibitor and probe were 
determine the binding affinity. Purified STAT3 was immobi- combined and incubated for 15 minutes prior to analysis. 
lized on a H is Cap Sensor Chip by injecting 50 µg/ml of Polarized fluorescence was plotted against concentration and 
STAT3 onto the chip. Various concentrations of compounds 45 fitted using a standard dose response curve. 
in running buffer (1 xPBS, 0.5% DMSO) were passed over the 
sensor chip to produce response signals. The association and 
dissociation rate constants were calculated using the Qdat 
software. The ratio of the association and dissociation rate 
constants was determined as the affinity (Kn)· 
123. Fluorescent Polarization Assay 
The fluorescent polarization experiments were performed 
on an Infinite MlOOO (Tecan, Crailsheim, Germany). All 
assays were performed in the same buffer conditions of 50 
mM NaCl, 10 mM Hepes, pH 7.5, 1 mM EDTA, and 2 mM 
dithiothreitol. Fluorescent-labelled peptides were kept at a 
final concentration of 10 nM in buffered solution. 7.5 mL of 
labelled peptides were added to 15 mL of a 300 nM STAT3 
protein solution (provided by SignalChem in 50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM PMSF, 
25% glycerol and stored at -80° C.). Inhibitory molecules 
were dissolved in pure DMSO and diluted using buffer solu-
tion to produce four final concentrations (250 µL, 31.25 µL, 
3.90 µL, 0.49 µL). 7.5 µL of the inhibitory molecule solution 
was mixed with the STAT3 protein and labelled peptide solu-
124. Immunostaining with Laser-Scanning Confocal 
Imaging 
50 Studies are described in details in Supplemental Materials, 
Methods. Cells were grown on glass cover slips in multi-well 
plates, fixed with ice-cold methanol for 15 min, washed 3 
times with lx phosphate buffered saline (PBS), permeabi-
lized with 0.2% Triton X-100 for 10 min, and further washed 
55 3-4 times with PBS. Specimens were then blocked in 1 % 
bovine serum albumin (BSA) for 30 min and incubated with 
anti-pY705Stat3 (Cell Signaling) or anti-pS536NFKB (Cell 
Signaling) antibody at 1:50 dilution (in 0.1 % BSA) at 4° C. 
overnight. Subsequently, cells were rinsed 3 times with PBS 
60 and incubated with two AlexFluor secondary antibodies, 
ALexaFLuor546 (goat anti-mouse) andAlexaFluor488 (don-
key anti-rabbit) (Molecular Probes, Invitrogen) for 
p Y705Stat3 and pS536NFKB/p65 detection, respectively, for 
1 h at room temperature in the dark. Specimens were then 
65 washed 3 times with PBS, mounted on slides with 
VECTASHIELD mounting medium containing DAPI (Vec-
tor Lab, Inc., Burlingame, Calif.), and examined immediately 
US 8,846,707 B2 
281 
under a Leica TCS SPS confocal microscope (Germany). 
Images were captured and processed using the Lei ca TCS SP 
S software. 
l2S. Small-Interfering RNA (siRNA) Transfection 
282 
levels between samples were analyzed by quantitation of 
pixel density in each spot of the array with ImageJ (National 
Institute of Health, Bethesda, Md.). 
129. In Vivo Tumor Studies 
Six-week-old female athymic nude mice were purchased 
from Harlan (Indianapolis, Ind.) and maintained in the insti-
tutional animal facilities approved by theAmericanAssocia-
The Stat3 siRNA smart pool Stat3 (cat #M-003 S44) and the 
control, SiGENOME non-targeting siRNA pool were pur-
chased from Dharmacon RNAi Technologies, Thermo Scien-
tific (Lafayette, Colo.). Transfection into cells was performed 
following manufacturer's protocol and using 200 pmol 
siRNA with 10 µL ofLipofectamine RNAiMAX (Invitrogen 
Corporation, Carlsbad, Calif.) in serum-freeOPTI-MEMcul-
ture medium (S ml) (Invitrogen). 
lO tion for Accreditation of Laboratory Animal Care. All mice 
studies were performed under an Institutional Animal Care 
and Use Committee (IACUC)-approved protocol. Athymic 
nude mice were injected subcutaneously in the left flank area 
with 1xl06 human breast cancer MDA-MB-231 or non-small 
126. Cell Migration Assay: Wound-Healing Assay 
Wounds were made using pipette tips in monolayer cul-
tures of cells in six-well plates. Cells were treated with or 
without increasing concentrations of test compound and 
allowed to migrate into the denuded area for 16 h. Cells was 
visualized at a !Ox magnification using an Axiovert 200 
Inverted Fluorescence Microscope (Zeiss, Gottingen, Ger-
many) and pictures of cells were taken using a mounted 
Canon Powershot A640 digital camera (Canon USA, Lake 
Success, N.Y.). Cells that migrated into the denuded area 
were quantified. 
15 cell lung cancer AS49 cells in 100 µI of PBS. After S to 10 
days, tumors of a 30-100 mm3 volume were established. 
Animals with established tumors were grouped so that the 
mean tumor sizes in all groups were nearly identical and then 
given test compound (in O.OS% DMSO in water) at 1 or 3 
20 mg/kg (i.v.) every 2 or every 3 days or 3 mg/kg (oral gavage, 
100 µ!) every day for 1 S or 20 days. Animals were monitored 
every day, and tumor sizes were measured with calipers and 
body weights taken every 2 or 3 days. Tumor volumes were 
calculated according to the formula V=O.S2xa2 xb, where a, 
25 smallest superficial diameter, b, largest superficial diameter. 
127. Additional Cell Migration/Invasion Assays 
30 
Cell migration/invasion experiments were carried out and 
quantified as previously reported (Turkson J & Jove R (2000) 
Oncogene 19:6613-6626; Turkson J (2004) Expert Op in Ther 
Targets 8(S):409-422; Gough DJ, et al. (2009) Science 324: 
1713-1716) using Bio-Coat migration/invasion chambers 35 
(BD Biosciences, Bedford, Mass.) of 24-well companion 
plates with cell culture inserts containing 8 µm pore size 
filters and following the manufacturer's protocol, with some 
modifications. Briefly, for doxycycline (Dox) induction, cells 
were maintained un-induced, U (in the absence of Dox) or 40 
induced, I (in the presence ofDox) for three days. Cells were 
then resuspended in serum-free medium minus or plus Dox, 
transferred to the top chambers of the 24-well trans-well 
plates, and incubated for 16 h to allow the migration or inva-
sion towards the serum-containing medium in the bottom 45 
chamber, and cells on the lower side were then counted. For 
treatment with test compound ( l S µM), the drug was added to 
both the top and bottom chambers during the 16-h incubation. 
Where appropriate, the migration or invasion rates were nor-
malized to the control, U cells in the absence of serum and in 50 
the bottom chambers. 
128. Cytokine Assays 
Cytokine analysis was performed using the human cytok- 55 
ine array kit and following the manufacturer's (R&D Sys-
tems, Minneapolis, Minn.) instructions. Briefly, following 
treatment of cells with 10 µM BP-1-102 for 48 h, 1 ml samples 
of conditioned culture medium or in the case of tumors, SOO 
ug of tumor tissues lysates in RIPA buffer (SO mM Tris-HCI, 60 
pH7.4, 1 % NP-40, I SO mM NaCL, 2 mM EDTA, 0.1 % SDS) 
were mixed with a cocktail ofbiotinylated detection antibod-
ies. The mixture was incubated with the array membrane for 
antibody binding on the membrane. Membrane was pro-
cessed for signal development using Streptavidin-HRP and 65 
chemilunimescent detection reagents, exposed to X-ray 
films, and then processed. The relative changes in cytokine 
For each treatment group, the tumor volumes for each set of 
measurements were statistically analyzed in comparison to 
the control (non-treated) group using paired t-test. 
130. Plasma and Tumor Tissue Analysis 
Test compound concentrations in mouse plasma and tumor 
tissue lysates were assayed using validated analytical proce-
dure via high-performance liquid chromatography (Shi-
madzu Prominence UHPLC, Shimadzu Scientific Instru-
ments, Columbia, Md.) and LC/MS/MS (API4000 Liner Ion 
Trap Mass Spectrometer, MDS Sciex, Ontario, Canada). The 
mass spectrometer was operated in a product ion scanning 
mode. BP-1-102 solution diluted in methanol was infused 
directly into the MS source at a flow of 10 µI/min. Tuning was 
evaluated in both positive and negative MS modes using both 
turbo ion spray and atmospheric pressure chemical ionization 
sources. The chromatography used a Phenomenx Kinetex 
C18 2.lxSO mm, 1.7µ UHPLC colunm (Phenomenex, Tor-
rance, Calif.) with a flow rate of0.300 ml/min using a S mM 
ammonium acetate (in water) and S mM ammonium acetate 
(in acetonitrile) as mobile phase A and B, respectively. 
131. Statistical Analysis 
Statistical analysis was performed on mean values using 
Prism GraphPad Software, Inc. (La Jolla, Calif.). The signifi-
cance of differences between groups was determined by the 
paired t-test at p<O.OS*, <0.01 **,and <O.OOS***. 
132. Assay oflnhibition oflntracellular STATS, 
STAT3 and STAT! Phosphorylation 
Cells were treated with the potential Stats inhibitors for 6 
hr, then lxl07 were lysed using RIPA buffer. Lysates were 
loaded on SDS-PAGE in order to size-fractionate the pro-
teins. Thereafter, proteins were blotted onto PVDF mem-
brane (PALL Life Sciences). The membrane was blocked 
using S% BSA in PBS containing 0.1% Tween 20 (Sigma) 
and then probed with antibodies against pSTATS, STATS, 
pSTAT3, STAT3 (Cell Signaling) and GAPDH. Secondary 
staining was performed with anti-rabbit IgG coupled with 
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HRP (Amersham Bioecinces) and chemiluminescence reac-
tion was carried out using ECL Plus (Amersham Bio-
sciences). Proteins were quantified using Typhoon 9410 
(Amersham Biosciences). 
133. Real-Time RT-PCR 
Total RNA was isolated using RNeasy kit (Qiagen, Mis-
sissagua, ON, Canada). All RNA samples were treated with 
Dnase during extraction according to the manufacturer's pro-
tocol (Qiagen, Mississagua, ON, Canada). An amount of 2 µg 
284 
kept as an input. Sheared chromatin was incubated with rabbit 
polyclonal Phospho-StatS (Tyr694) Antibody (Cell Signal-
ing, Danvers, Mass., USA) at dilution 1 :SO or rabbit poly-
clonal IgG at appropriate concentration. Incubation was per-
5 formed at 4° C. overnight. The antibody/chromatin complex 
was precipitated using Protein G. Agarose beads. After elu-
tion, the crosslink of protein/DNA was reversed, and DNA 
was purified using Spin Colunms. PCR was performed using 
platinum Taq™ (Invitrogen Canada, Burlington, ON, 
10 Canada). Two sets of primers were designed to amplify two 
DNA segments that contain STATS-binding sites located 
1672 bp and 428 bp upstream the start sites of C-Myc and 
Cyclin-Dl, respectively. The STATS-binding site in the 
C-MYC promoter is characterized by a 4N spacer and has the 
of RNA was reversed transcribed using TaqMan Kit (Applied 
Biosystems, Branchburg, N.J., USA); and 1 µl ofcDNA was 
used for amplification. Real-time RT-PCR was performed 
SYBR® Green PCR Master Mix (Applied Biosystems, War-
rington, UK) and amplification was performed using 96-well 
plate and 7700 Sequence Detection System (Applied Biosys-
tems, Foster City, Calif., USA) according to manufacturer's 
instructions. All amplifications were done in duplicate on one 
plate. A standard curve was established using NB-4 cell line 20 
in order to calculate the PCR efficiency. DLKl levels were 
normalized using GAPDH as an internal standard control and 
then calculated according to li. li. Ct formula. 
15 sequence (ttcccccgaa), whereas the one in the Cyclin Dl 
promoter is characterized by a 3N spacer and has the 
sequence (ttcttggaa). 
l3S. Activity of Substituted 
2-Hydroxy-4-(2-(Phenylsulfonamido)Acetamidobenzoic 
Acid Analogs Compounds 
Substituted 2-hydroxy-4-(2-(phenylsulfonamido )aceta-
mido )benzoic acid analogs were synthesized as described 
134. Chromatin Immunoprecipitation(Chip) 
ChIP assay was performed using EZ ChIP Kit® (Millipore, 
Billerica, Mass., USA) as per manufacturer's instruction. 
Briefly, after crosslinking with formaldehyde (1 % ), cell were 
lysed using SDS Lysis Buffer containing Protease Inhibitor 
Cocktail and nuclear extract were obtained. Then, crosslinked 
DNA was sheared using sonication; sheared DNA size was 
checked on agarose gel and ranged, in all cases, between 
300-SOO bp. An amount of 1ho of the shared chromatin was 
Compound 
25 above. Specific examples of preparation and characterization 
data is provided above for compounds 27E, 27JA-27NH, and 
4SA-4SO. The other compounds in Table 1 were prepared by 
similar methods to those described above. Activity (K; for 
inhibition of binding to STAT3 in a fluorescence polarization 
30 assay and IC50 for inhibition of STAT3 activity in an EMSA) 
was determined as described above, and the data are shown 
below in Table 1. The compound identifier ("ID") corre-
sponds to the number given parenthetically for the prepara-







27E >300 n.d. 
27JA >300 n.d. 
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TABLE I-continued 
Compound ICso K; 
ID Structure (EMSA) (FP) 
27JB >300 n.d. 
27JC >300 n.d. 
27JD >300 n.d. 
27KA 0 >300 n.d. 
0 
OH N~r< 
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>300 18.7 ± 1.4 
>300 n.d. 
>300 n.d. 
50 ± 15 21.5 ± 2.2 
>300 n.d. 
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TABLE I-continued 
Compound ICso K; 
ID Structure (EMSA) (FP) 
27KI 0 >300 n.d. 
ff~, 0 
N u ~ II° N 
~ /'Ni 0 
I o 
27LA 0 OH 191±8 n.d. 
"°' ~ o-.......... II° N 0 /'Ni 0 
I o 
27LB 0 OH 250 ± 23 n.d. 
u ~ ~N II° N 
/'Ni 0 
I o 
27LC 0 OH >300 n.d. 
NH2 "°' ~ II° N /'Ni 0 
I o 
27LD 0 141±10 n.d. 
0 
0/ 
"°' ~ II° N /'Ni 0 
I o 
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TABLE I-continued 
Compound ICso K; 
ID Structure (EMSA) (FP) 
27LE >300 n.d. 
0 
OH 







27LG 0 >300 n.d. 
0 
NH2 




27NA 63 ± 2 n.d. 
0 
o.........._ 
27NB >300 n.d. 
OH 
0 




ID Structure (EMSA) (FP) 
27NC 82 ± 1 n.d. 
CN 
27ND 90 n.d. 
0 
27NE 0 91±17 n.d. 
27NF 0 >300 n.d. 
OH 
27NG CN 74.3 ± 9.3 21.6 ± 0.9 
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TABLE I-continued 
Compound ICso K; 
ID Structure (EMSA) (FP) 
27NH 0 43 ± 1.3 16.7 ± 1.7 
OH 
NH2 
45A 119±1.9 n.d. 
45B 51.9 ± 2.4 n.d. 
45C 100 n.d. 
45D 79.2 ± 11.2 n.d. 




ID Structure (EMSA) (FP) 




45F 24.6 ± 3. 4 41.0 ± 0.4 
45G 28.8 ± 1.9 n.d. 
45H >300 n.d. 
451 126.2 ± 5.3 n.d. 





45J 0 OH 
"''Q ~ I o 




c''Q ~ I o 
~ // N 
/'NIT 0 
I o 
45L 0 OH 




/Ou ~ I o 
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13 ± 0.3 
7.2 ± 2.2 
>50 
33 ± 22 




ID Structure (EMSA) (FP) 
BP2-032 0 n.d. >50 
I 
~ 
() N w-y 
-0-s~o o II 
0 
BP2-033 n.d. 8.9 ± 1.4 
BP2-046 n.d. 8.3 ± 0.3 
BP2-047 0 n.d. 2.6 ± 0.2 
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C~o:m:po=-und --------~ TABLE 1 . ID -----co_n=tJn:u:ed~------
B~P~2-~05~6---------- SwcMe ~~~~~ ICso (EMSA) K; (FP) 
n.d. 0 2.6 ± 0.2 
OH 
BP2-057 n.d. 2.5 ± 1.0 
BP2-061 n.d. 1.8 ± 2.3 











ID Structure (EMSA) (FP) 
BP2-066 n.d. 4.4 ± 0.3 
BP2-067 n.d. 5.3 ± 0.3 
BP2-068 n.d. 4.5 ± 1.9 
F F 
F F 
BP2-086 n.d. 23.3 ± 0.7 




ID Structure (EMSA) (FP) 
BP2-119 OH n.d. 7.7 ± 1.0 
F F 
F 
BP2-120 0 OH n.d. 11.1±0.6 





BP2-121 0 n.d. 11.4±0.4 
F F 
F 




ID Structure (EMSA) (FP) 
BP2-124 n.d. 48.7 ± 14.2 
BP2-125 n.d. 27.9 ± 5.0 
BP2-130 n.d. 25.4 ± 0.8 







US 8,846,707 B2 
313 
TABLE 1 . -contmued 
Structure 
OH 







ul ~ / //'-N~N 
H1N II 0 
# 
OH 
ul ~ / //'-N~N 











5.5 ± 3.7 
6.2 ± 1.6 
12.0 ± 0.5 
2.5 ± 2.2 
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c--::=----------- TABLE 1 . Com,ooo" -contmu«l 











u"° ~ / 
NC'CY//'N~N 



















5.0 ± 6.5 
4.3 ± 0.7 
6.2 ± 0.8 
ll.3 ± 0.8 
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3.0 ± 4.1 
7.9 ± 0.3 
3.8 ± 1.5 
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c--::=----------- TABLE 1 . Com,ooo" -contmu«l 

































4.0 ± 1.1 
4.8 ± 0.6 
4.6 ± 1.6 
3.6 ± 0.5 
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c--::=----------- TABLE 1 . Com,ooo" -contmu«l 











u'°, l //"-N~N 












5.5 ± 0.4 
5.9 ± 0.6 
5.1 ± 0.4 
9.2 ± 0.8 







136. Effect of Substituted 2-Hydroxy-4-(2-(Phenyl-
sulfonamido )Acetamido )Benzoic Acid Analogs on 
Cell Viability 
Using the assay methods described herein, the effect of 
representative compounds on cell viability was determined, 
ICso K; 
(EMSA) (FP) 
n.d. 5.8 ± 0.6 
and the data are shown in Tables 2 and 3 below. The com-
pound identifier ("ID") corresponds to the number given par-
25 








U # II° 
s ITN // "'-N 






94.9 ± 8.8 > 100 





83.1 ± 13.5 
76.7 ± 27.1 68.0 ± 32.8 
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468 145 AMI.2 HL60 
90.5 ± 63.2 >100 >100 82.8 ± 19.0 
96.3±317 . >100 >100 >100 
32.5 ± 15.5 94.4 6.8 58 .4 ± 13.8 37 .4 ± 14.0 
59.6 ± 4.0 90.4 ± 3.1 85.9 ± 0.4 78 .5 ± 1.8 







c2 ~ I!° 





/2XI ~ I 
~ ~ 
~ I I!° 
s TIN // '-N 
a I a 









47.4 ± 6.2 80.0 ± 31.6 95.4 ± 33.7 74.8 ± 28.2 
45.4 ± 23.2 81.0 ± 39.3 93.5 ± 32.2 99.8 ± 15.6 
46.5 ± 12.4 74.5 ± 30.2 33.3 ± 19.8 76.9 ± 50.5 
>100 >100 >100 >100 












--N: I II° N 
~s~ 












~ (! ~N 
// 'N II 0 
I o 
0 
Fu ~ I o 
~ (! ~N 
// 'N II 0 
I o 





OH 27.0 ± 2.7 
19.5 ± 2.0 
29.7 ± 16.7 






69.6 ± 3.4 
45.9 ± 8.6 
67.5 ± 24.2 




8 59.1±11.5 53.5 ± 22. 
1 47.4 ± 8.2 44.9 ± 7. 
0 8 56.3 ± 93 76.4 ± 1 . 










':¢;' ~ I II° ~ 
F s......_ iN 
// N 
F 0 I 
0 
TABLE3 





45c 17 ± 1 
27na 24 ± 2 




77 ± 5 
>80 
80 ± 18 
42 ± 16 
24 ± 3 
IC M 
MDA- DU- OCI-
468 145 AMI.2 HL60 
71.4 ± 13.6 92.7 ± 27.9 >100 >100 
51.7 ± 14.2 >100 96.3 ± 18.5 99.3 ± 62.1 
10.9 ± 3.0 22.7 ± 8.5 10.5 ± 6.2 10.4 ± 1.6 
137. STATS Activity of Substituted 
55 2-Hydroxy-4-(2-(Phenylsulfonamido )Acetamidobenzoic 
Acid Analogs 
The fluorescence polarization assay was as described 
herein was used to assess the STAT isoform selectivity of 
60 representative compounds. Data are given below in Table 4. 
The inhibitor codes given in Table 4 correspond as follows to 
the compound IDs used in Table 1: BP1-075=27na; BP2-
122=27nh; SF2-096=27kg; SF3-005=27ki; BP1-107=45b; 
65 BP1-108=45c; BPl-111 =45k. SFl-066, SFl-087 and SF-088 
correspond to the same named compounds shown above with 
the corresponding compound characterization. 
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Inhibitor R R3 R2 Stat5 Stat3 Stall 
SFl-066 ----0 ----0- ---CH3 >25 15.5 ± 4.7 >25 
BP! -075 ----0- ---CH3 3.8 ± 1.6 2.8 ± 1.1 3.2 ± 1.3 C02Me ----o--0 
BP2-122 ----0--0-< ----o-
NH2 
---CH3 4.8 ± 1.6 8.4 ± 2.4 9.5 ± 2.4 
SF2-096 
0 0-11 - --------CN-~-o-CN ~ ;j 
0 
7.3 ± 0.9 8.4 ± 0.9 >25 
SF3-006 ----CN--0--<o ----0-
NH2 
10.1 ± 1.5 17.6 ± 0.8 27.8 ± 2.2 
BPl-107 ----0 ----o-o---CH3 4.1 ± 0.5 6.2 ± 2.0 8.8 ± 1.6 
BPl-108 ----0 ----9---
2.8 ± 3.2 8.0 ± 2.4 9.7 ± 8.2 
BPl-111 ----0 ----0-Cl 7.9 ± 2.1 11.0 ± 0.2 20.4 ± 2.9 
SFl-087 ----0 ----0- ---Boe 3.4 ± 0.9 7.9 ± 0.1 >25 
SFl-088 ---H ----0- ---Boe 8.3 ± 6.1 >25 >25 
138. Prospective In Vivo Activity 
Generally compounds that inhibit STAT protein activity in 
preclinical animal models of tumor growth and pathology. In 
vivo effects of the compounds described in the preceding 
examples are expected to be show activity in various models 
cancer biology known to the skilled person, such as a mouse 
subcutaneous xenograft model or, alternatively, the mouse 
orthotopic xenograft model. These models are typically con-
65 ducted in an immunocompromised mouse, e.g. athymic nude 
mice, severely compromised immunodeficient (SCID) mice, 
or other immunocompromised mice (see reference (40) 
US 8,846,707 B2 
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above), but may be conducted in other animal species as is 
convenient to the study goals. Alternatively, a genetically 
engineered mouse (GEM) model can be used to assess the 
efficacy of the disclosed compounds on inhibiting tumor 
growth. The genetic profile of GEM mice is altered such that 
one or several genes thought to be involved in transformation 
336 
ties of the test compound. Exemplary vehicles include mix-
tures comprising DMSO, Cremaphor, and vegetable oils, e.g. 
12.5% DMSO, 5% Cremaphor and 82.5% peanut oil; 
polysorbate:ethanol, e.g. 80: 13; cremaphor:ethanol; and nor-
mal saline, e.g. phosphate-buffered saline. Body weight and 
tumor diameter are measured on a suitable schedule, e.g. 
every 3-4 days using calipers, and tumor volume determined 
by calculating the volume of an ellipsoid using the formula: 
lengthxwidth2 x0.5. Antitumor activities can be expressed as 
or malignancy are mutated, deleted or overexpressed; subse-
quently, the effect of altering these genes is studied over time 
and therapeutic responses to these tumors may be followed in 
VIVO. 
10 percent inhibition of tumor growth and percent regression of 
the tumor. 
The subcutaneous xenograft model is frequently used by 
one skilled in the art to assess anti-cancer activity. Briefly, the 
cell-line of choice, e.g. MDA-MB-231, Panc-1, DU 145, or 
NIT3T3/v-Src cells, are grown in vitro in culture flasks, and 15 
then collected with using trypsin (if adherent) or by simple 
centrifugation (if suspension cultures), and then suspended in 
PBS at about 6x 10 7 cells/mL. In one experimental approach, 
about 105 cells are injected in mice subcutaneously on Day 0, 
and the tumors allowed to develop to about 106 cells (about 20 
7-10 days). Suitable mice strains to use in this include nu/nu 
nude mice or CAnN.Cg-Foxnlnu/Cr!Crlj(nu/nu), and are 
readily available from suitable commercial sources (e.g. Har-
lan or Charles River). Drug is administered by a suitable route 
of administration, e.g. intravenous or intraperitoneally, on a 25 
dosing schedule suitable for the compound, e.g. daily for a 
period of five days or every third day for a period of two weeks 
or other schedule as determined from in vitro and in vivo data 
on potency, pharmacokinetics, and metabolism. The vehicle 
choice is determined based on the physical-chemical proper-
<160> NUMBER OF SEQ ID NOS, 5 
<210> SEQ ID NO 1 
<211> LENGTH, 34 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
For example, compounds having a structure represented by 
a Formula I, II, III, or IV, or a pharmaceutically acceptable 
salt, hydrate, solvate, or polymorph thereof, are expected to 
show such in vivo effects. 
For example, compounds having a structure represented by 
a Formula V or VI, or a pharmaceutically acceptable salt, 
hydrate, solvate, or polymorph thereof, are expected to show 
such in vivo effects. 
Moreover, compounds prepared using the disclosed syn-
thetic methods are also expected to show such in vivo effects. 
It will be apparent to those skilled in the art that various 
modifications and variations can be made in the present 
invention without departing from the scope or spirit of the 
invention. Other embodiments of the invention will be appar-
ent to those skilled in the art from consideration of the speci-
fication and practice of the invention disclosed herein. It is 
intended that the specification and examples be considered as 
exemplary only, with a true scope and spirit of the invention 
being indicated by the following claims. 
<223> OTHER INFORMATION, Description of Artificial Sequence, note 
synthetic construct 
<400> SEQUENCE, 1 
gacgacgaca agatggctca gtggaaccag ctgc 
<210> SEQ ID NO 2 
<211> LENGTH, 40 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, note 
synthetic construct 
<400> SEQUENCE, 2 
gaggagaagc ccggttatca catgggggag gtagcacact 
<210> SEQ ID NO 3 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, note 
synthetic construct 
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-continued 
<210> SEQ ID NO 4 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, note 
synthetic construct 
<400> SEQUENCE, 4 
tcacctacag tactttccaa atgc 
<210> SEQ ID NO 5 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
24 
<223> OTHER INFORMATION, Description of Artificial Sequence, note 
synthetic construct 
<400> SEQUENCE, 5 
agcttcattt cccgtaaatc ccta 
What is claimed is: 





wherein R11 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl; 
or a pharmaceutically acceptable salt, hydrate, or poly-
morph thereof. 
2. The compound of claim 1, wherein the compound exhib-
its inhibition ofSTATwith an IC50 ofless than about 300 µM. 
3. The compound of claim 1, wherein the compound exhib-
its inhibition with an K, of less than about 300 µM. 
4. A pharmaceutical composition comprising a therapeuti-
35 cally effective amount of a compound of claim 1 and a phar-
maceutically acceptable carrier. 
5. A method for the treatment of breast cancer or non-small 
cell lung cancer, comprising: administering to a subject in 
need thereof a therapeutically effective amount of a com-
40 pound having a structure represented by a formula: 
wherein mis an integer from 0-3 when R2 is aryl; 
wherein m=O when R2 is non-aryl; 
wherein R2 is selected from C3-C8 alkyl, C3-C8 alkenyl, 45 
C3-C8 alkynyl, C3-C8 haloalkyl, C3-C8 haloalkenyl, 
C3-C8 haloalkynyl, C3-C8 polyhaloalkyl, C3-C8 poly-
haloalkenyl, C3-C8 polyhaloalkynyl; or 
wherein R2 is aryl substituted with 0-5 groups indepen-
dently selected from halo, hydroxyl, amino, nitro, 50 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, 
Cl-C6 alkylthio, Cl-C6 haloalkythio, Cl-C6 polyha-
loalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, 
(Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)- 55 





, and (C=O)NHR11 ; 
wherein R3 is aryl substituted with 0-5 groups indepen- 60 
dently selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 alkyl, Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 poly-
haloalkoxy, Cl-C6 alkylamino, Cl-C6 dialkylamino, 
(Cl-C6)-alk-(Cl-C6)-alkoxy, (Cl-C6)-alk-(Cl-C6)- 65 
haloalkoxy, and (Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy; 
and 
wherein mis an integer from 0-3 when R2 is aryl; 
wherein m=O when R2 is non-aryl; 
wherein R2 is selected from C3-C8 alkyl, C3-C8 alkenyl, 
C3-C8 alkynyl, C3-C8 haloalkyl, C3-C8 halo alkenyl, 
C3-C8 halo alkynyl, C3-C8 polyhaloalkyl, C3-C8 poly-
haloalkenyl, C3-C8 polyhaloalkynyl; or 
wherein R2 is aryl substituted with 0-5 groups indepen-
dently selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 haloalkyl, Cl-C6 polyhaloalkyl, Cl-C6 
alkoxy, Cl-C6 haloalkoxy, Cl-C6 polyhaloalkoxy, 
Cl-C6 alkylthio, Cl-C6 haloalkythio, Cl-C6 polyha-
loalkylthio, Cl-C6 alkylamino, Cl-C6 dialkylamino, 
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(Cl -C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-





, and (C=O)NHR11 ; 
wherein R3 is aryl substituted with 0-5 groups indepen-
dently selected from halo, hydroxyl, amino, nitro, 
cyano, Cl-C6 alkyl, Cl-C6 haloalkyl, Cl-C6 polyha-
loalkyl, Cl-C6 alkoxy, Cl-C6 haloalkoxy, Cl-C6 poly-
haloalkoxy, Cl-C6 alkylamino, Cl-C6 dialkylamino, 10 
(Cl -C6)-alk-( Cl -C6)-alkoxy, (Cl -C6)-alk-( Cl -C6)-
haloalkoxy, and (Cl-C6)-alk-(Cl-C6)-polyhaloalkoxy; 
and 
wherein R11 is selected from hydrogen, Cl-C6 alkyl, 
Cl-C6 haloalkyl, and Cl-C6 polyhaloalkyl; 15 
or a pharmaceutically acceptable salt, hydrate, or poly-
morph thereof. 
6. The method of claim 5, wherein the subject has been 
diagnosed with breast cancer or non-small cell lung cancer 
prior to the administering step. 20 
7. The compound of claim 1, wherein the compound has a 
structure represented by a formula: 
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-continued /oyCY· ... 
0 
and 
u .. __ ~---- y:. 
ClY"n FY] /OY"n 
0----, 0----, 0----, 40 
F 
02N'Y') _ F*I · F v ... and F ~ '•, , . 
F 
8. The compound of claim 1, wherein the compound has a 






wherein R2 is selected from a structure represented by a 
formula: 





9. The compound of claim 1, wherein the compound has a 
structure represented by a formula: 25 





10. The compound of claim 1, wherein the compound is 
selected from: 











~N......._11° N 'n ! I ~ ~ ,,,::::; 
OH 
11. A compound having a structure represented by a for-
mula: 
wherein each of m is 0 and n is O; 






























A __ J. 
N N 
~ N, 
' ' ' ' 
' ' ' ' 
----
' ---



















































wherein R2 is selected from a structure represented by a 40 
formula: 





wherein R3 is selected from a structure represented by a 
formula: 
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-continued v·· .. cf· .. 
CC,:· 
'v··. 




JJ ,-y=: ,-q=: 
F F F 
;o C Co···, r;-··.. v~N ·-.,, 
or a pharmaceutically acceptable salt, hydrate, solvate, or ~ l_ __ ) ,,,? 




~# '•,_, H2Nv~# '•,_, 12. The compound of claim 11, wherein the compound has " - " -
a structure represented by a formula: 




CC'•,,, ~--,, N02 NC,,,v 45 
NCl(Y'',,, cc~ '•,,, 




wherein R2 is selected from a structure represented by a 
formula: 55 











wherein R3 is selected from a structure represented by a 
formula: 




3 is selected from a structure represented by a 
formula: 
20 
25 co. __  
30 /2XI ~I
~ , 
~I ___ _ 
40 ~N NC'O Bru 
-N~---' ~ I ___ , ~ I ___ , 
' ' ' 
/2XI ~I
~I 




0 2NY1 FvYF 
0---- ~· ,,Y----
F 
13. The compound of claim 11, wherein the compound has 
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15. A method for the treatment of breast cancer or non-
small cell lung cancer, comprising: administering to a subject 25 
in need thereof a therapeutically effective amount of a com-




wherein each of m is 0 and n is O; 
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-continued -continued 
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wherein R2 is selected from a structure represented by a 
formula: 
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-continued Cl'Y'n F'Y'n /O'Y'n 
0---,, 0---,, 0---,,5 
F 
FyYF 
~· .,y .... 10 
F 
or a pharmaceutically acceptable salt, hydrate, or poly-
15 
morph thereof. 
16. The method of claim 15, wherein the subject has been 
diagnosed with breast cancer or non-small cell lung cancer 
prior to the administering step. 
* * * * * 
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